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Summary 
 
With the search for potent and selective inhibitors of Mycobacterium tuberculosis thymidine 
monophosphate kinase (TMPKmt), this PhD study describes the development of new anti-
tuberculosis agents.  As TMPKmt is an essential enzyme for the growth of the bacillus, 
inhibitors of this enzyme might be useful as anti-tuberculosis agents.  The X-ray structure of 
the enzyme was determined in 2001.  It shows the way of binding of the natural substrate, 
dTMP and was used to explain and predict the activities of modified thymidine derivatives. 
As this work is a continuation of earlier research in our group, the structure-activity 
relationship derived from earlier synthesized compounds, was a useful tool for further 
development.  The most interesting topics of the initial structure-activity relationship served 
as a starting point for this work. 
The first chapter describes the influence of a F-substituent at the 2’-position on the 
conformational behaviour of the sugar ring and consequently, on TMPKmt activity.  
Synthesis of 2’-F-substituted thymidine derivatives allowed the biological evaluation and 
conformational analysis of those compounds. 
A second important modification considers the discovery of two important new leads, a 2’,3’-
bicyclic nucleoside and a 3’-C-branched dinucleoside.  Optimisation of those compounds led 
to a series of modified 2’,3’-bicyclic thymidine derivatives and a series of 3’-C-branched 
thiourea substituted compounds.  For those two new families of TMPKmt inhibitors, 
modelling, docking and conformational analysis are used to rationally design new 
compounds and to explain the observed activities.  Finally this led to compounds with 
activities in the low micromolecular range with the most active compounds 1-(3-
aminomethyl-3,5-dideoxy-2-O,6-N-(thiocarbonyl)-β-D-ribofuranosyl)thymine (Ki= 2.3 µM) and 
N-(5’-deoxy-α-D-thymidin-5’-yl)-N’-(3-trifluoromethyl-4-chlorophenyl)thiourea (Ki= 0.6 µM), 
with Ki-values, significantly lower than the Km-value of dTMP (4.5 µM).  Next to the good 
TMPKmt-affinities, those compounds showed a high selectivity index compared to the 
human enzyme and no significant toxicity.  Moreover, for the first time, the most active 
TMPKmt-inhibitors showed inhibitory activities against growing Mycobacterium bovis and 
Mycobacterium tuberculosis strains. 
An extension of the biological evaluation of modified thymidine derivatives in the field of 
antiviral agents, revealed the activity of 3’-C-branched thymidine derivatives on 
mitochondrial thymidine kinase 2.   
 
The last chapter of this work describes the use of a 3’-C-branched thymidine derivative, 
obtained earlier as building block in oligonucleotide synthesis.  As oligonucleotides have 
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found their application in DNA diagnosis, the fluorescent pyrene was attached to the 3’-
position of thymidine, before this building block was incorporated in different 
oligonucleotides.  Stability and fluorescence studies showed that those fluorescently labelled 
oligonucleotides are useful tools as nucleoside diagnostics.  The fluorescently silent single 
stranded oligonucleotides emit their fluorescence after binding to a DNA duplex by 
Hoogsteen interactions. 
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Samenvatting 
 
Met de zoektocht naar krachtige en selectieve inhibitoren van het thymidine monophoshate 
kinase van Mycobacterium tuberculosis (TMPKmt), beschrijft dit werk de ontwikkeling van 
nieuwe anti-tuberculose geneesmiddelen.  Aangezien TMPKmt een essentieel enzyme is 
voor de groei van de bacterie, kunnen inhibitoren van dit enzyme verder ontwikkeld worden 
tot anti-tuberculose geneesmiddelen.  De X-stralen structuur van dit enzyme is bepaald in 
2001 and toont de bindingswijze van het natuurlijke substraat dTMP en werd gebruikt om de 
activiteiten van gemodificeerde thymidine derivaten te verklaren en te voorspellen. 
Dit werk kadert in een eerder onderzoek in onze groep en bijgevolg kan de structuur-
activiteitsrelatie die afgeleid werd uit vroeger gesynthesiseerde componenten gebruikt 
worden voor verdere ontwikkeling van nieuwe thymidine derivaten.  De meest interessante 
topics van de reeds gekende structuur-activiteitsrelatie hebben gediend als startpunt van dit 
werk. 
Een eerste belangrijke uitgangspunt betreft de invloed van een F-substituent op de 2’-plaats 
op de conformatie van het suikergedeelte, en bijgevolg ook op de biologische activiteit.  
Synthese van 2’-F gemodificeerde thymidine derivaten lieten de biologische evaluatie en 
conformationele analyse toe van deze verbindingen. 
A tweede belangrijke modificatie volgde uit de ontdekking van twee belangrijke nieuwe lead-
verbindingen, een 2’,3’-bicyclische molecule en een 3’-C-vertakt dinucleoside.  Optimalisatie 
van deze verbindingen gaf aanleiding tot een reeks van gemodificeerde 2’,3’-bicyclische 
thymidine derivaten en een reeks van 3’-C-vertakte thiourea gesubstitueerde componenten.  
Docking, modelling en conformationele analyse werden gebruikt om uitgaande van deze 
deze twee nieuwe families van TMPKmt inhibitoren, op rationele wijze nieuwe componenten 
te ontwikkelen en hun activiteiten te verklaren.  Uiteindelijk heeft dit aanleiding gegeven tot 
verbindingen met activiteiten in lage micromolaire range, zijnde 1-(3-aminomethyl-3,5-
dideoxy-2-O,6-N-(thiocarbonyl)-β-D-ribofuranosyl)thymine (Ki= 2.3 µM) and N-(5’-deoxy-α-D-
thymidin-5’-yl)-N’-(3-trifluoromethyl-4-chlorophenyl)thiourea (Ki= 0.6 µM), met Ki-waarden die 
significant lager zijn dan de Km-waarde van dTMP (4.5 µM).  Naast de goede affiniteiten voor 
TMPKmt, vertoonden deze componenten ook een hoge selectiviteit tegenover het humane 
enzyme en geen significante toxiciteit.  Bovendien werden voor de eerste keer TMPKmt 
inhibitoren ontdekt, die activiteit vertonen tegenover groeiende Mycobacterium bovis en 
Mycobacterium tuberculosis stammen. 
Een uitbreiding van de biologische evaluatie van de gemodificeerde thymidine derivaten 
naar antivirale activiteiten toe, toonden aan dat enkele 3’-C-vertakte thiourea 
gesubstitueerde thymidine derivaten een interessante activiteit vertoonden op het 
mitochondriale thymidine kinase 2. 
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Het laatste hoofdstuk van dit werk beschrijft het gebruik van een 3’-C-vertakte thymidine 
derivaat als bouwsteen in oligonucleotide synthese.  Aangezien oligonucleotiden diagnostica 
hun toepassing hebben gevonden in het oligonucleotide onderzoeksdomein, werd pyrene 
via de 3’-plaats aan de nucleoside bouwsteen verbonden, alvorens deze werd ingebouwd in 
verschillende oligonucleotiden.  Stabiliteits- en fluorescentie studies van triplexen gevormd 
door het gemodificeerde oligonucleotide dat bindt aan dsDNA, tonen aan dat de fluorescent 
gelabelde oligonucleotiden bruikbaar zijn als DNA diagnosticum.   
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1 INTRODUCTION 
 
1.1 GENERAL BACKGROUND 
1.1.1 Tuberculosis on the rise 
More than a century ago, tuberculosis (TB), an infectious disease usually affecting the lungs, 
was ranked among the most feared and dreaded of the numerous diseases afflicting 
mankind.  The discovery of the causative agent of tuberculosis by Robert Koch in 1882 gave 
great hope that this ‘white plague’ would soon be vanquished. 
During the 20th century new antituberculosis drugs were discovered.  In the early 1980’s the 
great majority of patients could be cured by treatment with short-course curative 
chemotherapy that was possible as a consequence of several newly introduced 
antituberculosis drugs. 
Only one decade later, an outbreak of HIV-related multidrug-resistant tuberculosis in New 
York made tuberculosis suddenly the centre of attention.  More than one century after 
Koch’s discovery, far from celebrating the final conquest of tuberculosis, the World Health 
Organization (WHO) declared TB as a global emergency.  Even in the beginning of the 21st 
century tuberculosis remains a major public health issue, killing over 1.6 million people 
annually.1  Especially countries with poverty, like in Africa and Asia suffer from severe TB 
epidemics (Figure 1.1). 
 
 
 
Figure 1.1 Estimated TB incidence per 100.000 inhabitants (2005)1 
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Mycobacterium tuberculosis, the causative agent of TB is a slow-growing bacillus, primarily 
transmitted via the respiratory system.  The WHO estimates that one third of the world’s 
population is infected by this organism, however usually this latent infection is not 
reactivated.  HIV-infection is the major risk factor for converting latent TB into active 
transmissible TB.  At the same time TB-bacteria assist in accelerating the progress of HIV-
infection in the patient.  Since both diseases combined are more destructive than each 
disease alone, the TB- and HIV-epidemics form a vicious circle.  TB is the leading cause 
of death among people who are HIV-positive accounting for 13% of AIDS deaths per year 
worldwide.1,2 
 
Nowadays TB can be cured with DOTS (Directly Observed Treatment Shortcourse) in which 
patients are subjected to standard treatment regimens that consist of an exceedingly 
lengthy therapy of 6-9 months under direct observation, often with a cocktail consisting 
of three or four different drugs.3  Patients following this regimen become non-infectious 
after the first few weeks but the remaining treatment period is crucial to eradicate the slow 
growing bacilli and to allow the host immune system to achieve a clinical cure.  The direct 
observation is needed because in addition to the significant toxicity, the lengthy therapy 
causes poor patient compliance, resulting in the selection of drug resistant and often deadly 
multi-drug-resistant (MDR)-TB bacteria. 
For people infected with these MDR-TB strains, there is a large need for more effective 
drugs acting on novel targets.1  The emergency for new TB-drugs is reflected in the 
amount of publications dealing with TB, which increased significantly during the last 20 years 
(See Figure 1.2). 
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Figure 1.2 Number of publications about TB during the last 30 years4 
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Recently, the complete genome sequence of the best characterised strain of M. tuberculosis 
H37Rv, has been determined.5  This was of great interest for the cloning and overexpression 
of mycobacterial proteins, needed for their structure elucidation via crystallisation and X-ray 
analysis. 
 
1.1.2 Tuberculosis: the disease 
1.1.2.1 The bacillus Mycobacterium tuberculosis 
Human tuberculosis is caused by Mycobacterium tuberculosis, and less frequently by M. 
bovis (usually infecting cows), M. avium (usually infecting birds) or M. africanum, all being 
aerobic rod-shaped organisms. 
The mycobacterial cell consists of cytoplasm surrounded by a plasma membrane and 
containing the single chromosome, tightly wrapped into a nuclear body, but not bounded by 
a nuclear membrane.  Thus, like other bacteria, mycobacteria are prokaryots.  Many 
environmental mycobacteria contain one or more small extrachromosomal elements of DNA 
known as plasmids.  In contrast with M. tuberculosis where plasmids do not seem to occur, 
they have been found frequently in M. avium.   
The main features, distinguishing the mycobacterial cells from other microorganisms, are 
their typical cell wall and the presence of a unique type of iron chelating peptides. 
 
A)  The mycobacterial cell wall   
i) Structure 
A typical characteristic of M. tuberculosis, uniquely found in mycobacteria species, is the 
hardly permeable and complex cell wall with its extremely high lipid content.  Lipids account 
for up to 60% of the cell wall weight and they consist of a wide range of components.  Some, 
for example mycolic acids attached to the peptidoglycan by phosphodiester bonds, are unique 
for mycobacteria.  These mycolic acids are a group of complex branched-chain hydroxy-lipids 
and offer the bacillus an extra layer for adhesion.  The exact structure of the cell wall has not 
been fully elucidated but the generally accepted model6,7 is shown in Figure 1.3.  
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Figure 1.3 Schematic representation of the generally accepted structure of the mycobacterial cell 
wall.8  The cytoplasmic membrane is encapsulated by a layer of peptidoglycan. The peptidoglycan 
backbone is attached to arabinogalactan.  The hexaarabinofuranosyl termini of arabinogalactan are 
esterified to mycolic acids. Another major component associated to the mycobacterial cell wall is the 
immunogenic lipoarabinomannan.  Small and hydrophilic solutes diffuse through water-filled protein 
channels, porins, whereas hydrophobic compounds use the lipid pathway. Proteins are represented 
by solid oval bodies. 
 
 
To produce the typical branched fatty acids, two types of fatty acid synthases are used by 
mycobacteria: a eukaryotic type of fatty acid synthase (FAS I pathway) and a series of 
prokaryotic type of enzymes (FAS II pathway).  The first synthase is a single multifunctional 
enzyme, producing C16 and C24/C26 fatty acids in four steps.  The prokaryotic enzymes 
elongate these acid chains to lengths up to 56 carbons.   
 
The synthesis of those characteristic mycolic acids represents an attractive target for 
developing antituberculosis drugs.  In addition, these fatty acids render the cell wall 
extremely hydrophobic, making the cell highly impermeable.  As a result, mycobacteria 
are resistant against dryness and disinfectants, and the low permeability for nutrients causes 
a very slow growth, with a generation time of 24 hours in synthetic media.  This last feature 
contributes to the chronic nature of the disease requiring long treatments for complete 
sterilisation. 
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ii) Uptake through the mycobacterial cell wall 
The hydrophobic mycobacterial cell wall acts as an efficient permeability barrier.  Despite the 
low permeability of the cell wall, the penetration of small hydrophilic nutrient molecules into 
the cell occurs.   
In Gram-negative bacteria the outer membrane serves as a permeability barrier.  Hydrophilic 
channels are formed by porins across this outer membrane, allowing the transport of 
nutrients and small hydrophilic molecules.  Although mycobacteria are Gram-positive 
organisms, known to lack this specific outer membrane, the extremely thick (10nm, 2.5-fold 
thicker than the one of Gram-negative bacteria), hydrophobic cell wall limits the uptake of 
nutrients significantly. 
In M. chelonae, the presence of a porin in the cell wall was reported.9  This porin forms a 
water-filled channel, allowing the diffusion of hydrophilic molecules through the lipid layers.  
Studies of this channel have shown a cation-selectivity and a strong voltage dependence of 
this channel.10 
A similar porin, allowing the non-specific permeation of small molecules such as sugars and 
amino acids, was found in M. smegmatis.11  In contrast with Gram-negative bacteria, that 
form trimeric porins, M. smegmatis forms a cone-like tetrameric complex of 10 nm in length 
with a single central pore, called MspA.  The length of MspA is sufficient to span the outer 
membrane and contributes, in combination with the tapering end of the pore and the low 
number of pores (about 1000 pores per µm2, 50-fold fewer compared to Gram-negative 
bacteria), to the low hydrophilic permeability of the cell wall.12 
Both M. smegmatis and M. chelonae are fast-growing mycobacteria.  For slow-growing 
bacteria, including M. tuberculosis, no similar porins have yet been described.  A study of 
porins in the cell wall of M. tuberculosis revealed a lower channel-forming activity,13 which 
might explain the slower growth of this strain. 
 
Except for the transport of hydrophilic molecules through porins, other mechanisms for 
uptake through the mycobacterial cell wall are suggested.  For isoniazid (INH), one of the 
currently most important antituberculosis drugs (see 1.1.5.2), the uptake in M. tuberculosis 
has been studied.  This compound is likely to enter the cell by passive diffusion through 
the bacterial envelope.14  
 
So far little information is known about the uptake of compounds into the mycobacterial cell, 
which can be used in the search for new antituberculosis agents.  Still it is very hard to 
develop compounds that are able to penetrate this hydrophobic layer, as on one hand, 
passive diffusion promotes the search for hydrophobic compounds, while on the other hand 
the presence of hydrophilic channels allows the transport of very polar molecules.   
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Concerning these difficulties in drug development, Lipinski identified several 
physicochemical parameters that should be considered for small molecules, intended to be 
orally bioavailable.  These parameters are defined as the ‘Lipinski’s rule of 5’,15 no more than 
one rule should be violated: 
• molecular mass < 500 Daltons 
• number of hydrogen-bond donors < 5 
• number of hydrogen-bond acceptors < 10 
• calculated octanol/water partition coefficient clogP <5  
 
Known antibacterials however, do not generally follow ‘Lipinski’s rule of five’ (Figure 1.4).   
Greater molecular diversity and better understanding of the physicochemical properties that 
are important for antibacterials is necessary. 
 
 
 
Figure 1.4 The chemical diversity of antibacterials is different to other drugs.  A plot of calculated logP 
and molecular mass of marketed drugs for central nervous system disorders compared with marketed 
antibacterial classes. CNS drugs (similar observations for other mammalian target classes; data not 
shown) closely follow Lipinski’s rule of five. Antibacterial molecules are on average more hydrophilic 
and slightly larger.16 
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Similarly to what is observed for all antibacterials, antituberculosis agents are often found not 
to follow the ‘Lipinski’s rule of 5’.  This is illustrated by the recently discovered promising 
diarylquinolones (See 1.1.5.3), which would be flagged in a Lipinski analysis, with a 
molecular weight of 555.5 and a high clogP (7.72).15 
 
 
B) Siderophores 
Despite the very slow growth of mycobacteria and the complexity of their lipid-rich cell wall, 
their nutritional requirements are rather simple, including oxygen, carbon, nitrogen, 
phosphorus, sodium, potassium, sulfur, iron and magnesium.  A wide range of nutrients are 
available for mycobacteria within cells and host tissues.17  Free soluble iron however can 
only be found in a very small amount in lifeless environment and even less in the living host.  
As it is an essential requirement for bacterial growth and metabolism, micro-organisms need 
mechanisms for the capture and solubilisation of iron and for its transport to the interior of 
the cell.  The acquisition of iron by bacteria is mediated by chelating agents, the so 
called ‘siderophores’.  In mycobacteria there are two unique classes of siderophores: 
exochelins and mycobactins.18,19 19  Exochelins are water-soluble low-molecular weight 
peptides, secreted into the environment, while mycobactins are water-insoluble lipids, found 
within the cell wall.  Iron is first solubilised and chelated from the external environment by 
exochelins and then transferred to mycobactin for transport across the cell wall (Figure 1.5). 
 
Environment Cell wall Cytoplasm
Fe
EXO:Fe
EXO
Myc
Myc:Fe
Fe
 
Figure 1.5 The role of exochelins (EXO) and mycobactins (MYC) in the acquisition of iron (Fe) by 
mycobacteria. 
 
As exochelins and mycobactins are specific iron-chelating agents for mycobacteria species, 
they have recently been explored as promising target for antituberculosis agents.19 
 
Chapter 1   
 
12   
1.1.2.2 Infection with M. tuberculosis 
Once a human host is infected with M. tuberculosis, the cell-mediated immunity is activated 
and battles the invading micro-organisms.  The interaction between the human host and M. 
tuberculosis depends on the virulence of the strain, but it is supposed to depend more 
importantly on the specific or non-specific resistance of the host.  Two types of infection 
occur: the primary infection and the postprimary infection (or reinfection). 
During primary infection, the bacteria that reach the lungs after exogenous infection (e.g. 
from droplets containing viable bacteria from people with active pulmonary disease) are 
ingested by macrophages.  As the fusion between phagosome and lysosomes can be 
hindered, the bacilli often survive this first attack of the human immune system.  The 
multiplying bacteria in these macrophages cause a chemotactic response, attracting 
additional macrophages into the area.  This flow of macrophages allows the formation of 
aggregates, called tubercles in which Mycobacterium tuberculosis continues its multiplication 
intracellularly.  After a few weeks, many of the macrophages die, causing the release of TB 
bacteria and liquefying the centre of the tubercle, which is now surrounded by macrophages 
and lymphocytes.  In this stage, the disease can become dormant. 
  
In most cases, tuberculosis infection remains dormant and is usually unapparent.  However, 
in people with a weakened immune system (e.g., HIV-infection, diabetes, malnutrition,…) the 
disease is not sufficiently controlled, leading to enlarging tubercles during liquefaction until 
the tubercle ruptures.  At this point, the bacilli can move into a bronchiole and can then be 
disseminated to other organs in the body.  This acute pulmonary infection can cause 
extensive destruction of lung tissue and can lead to the spread of bacteria to other parts of 
the body and finally to death.  This extrapulmonary tuberculosis can affect the whole body: 
lymph nodes, bones, joints, central nervous system, urinary and genital tracts, abdomen and 
the skin.  Especially in young children this can cause serious extrapulmonary forms, 
including meningitis.  While mostly all cases of pulmonary tuberculosis are treated by 
antituberculosis drugs only, additional procedures are often required (e.g., surgical 
intervention) for extrapulmonary diseases.   
 
 
 
 
  In troduct ion 
    13 
1.1.3 Diagnosis 
Due to the extremely slow growth of M. tuberculosis, diagnosis is not easy.  Consequently, 
many different methods were developed to allow diagnosis and the onset of the required 
therapy as early as possible.  The most relevant methods are described below. 
 
1.1.3.1 Tuberculin skin test 
Tuberculin is a protein factor extracted from M. tuberculosis and is used as an indicator for 
previous immunologically effective contact of the patient with the bacillus.  During this test a 
small amount of tuberculin is intradermally injected.  If the injected person has previously 
been exposed to the bacillus, a localised immune reaction (induration and swelling) 
appears within 1-3 days at the site of injection.  The drawback of this diagnosis method is 
the absence of a difference between active disease or past infection and that past Bacille 
Calmette-Guérin vaccination also results in a positive tuberculin skin test. 20 
 
1.1.3.2 Culture 
Sputum is by far the best material for the diagnosis of pulmonary mycobacterial infections.  
As most specimens submitted for culture growth contain other bacteria and possibly fungi, 
which will rapidly overgrow the medium, it is important to treat the specimens with reagents 
that selectively kill non-acid-fast organisms.  Because of the very specific features of their 
cell wall, mycobacteria are relatively more resistant to acids, alkalis and certain disinfectants 
than other micro-organisms.  Depending on the contamination grade of the specimen, ‘hard’ 
or ‘soft’ decontamination methods are used.  A commonly used method consists of treatment 
of the specimen with 1N NaOH for 30 minutes, followed by neutralisation and inoculation on 
an isolation medium.  Due to the slow growth of M. tuberculosis, it takes several weeks 
before colonies can be observed. 
 
1.1.3.3 Sputum smear microscopy 
As the isolation of M. tuberculosis by standard cultural methods takes several weeks, the 
use of microscopy to obtain early diagnosis is of great importance, especially for the 
detection of open or infectious cases.  Sputum is examined either directly or after 
liquefaction and centrifugation and M. tuberculosis is visualised by the Ziehl-Neelsen 
method, based on carbol fuchsin with methylene blue as a counterstain.21  Nevertheless, 
25% of the smear negative patients appear to be culture positive. 
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1.1.3.4 Radiometric methods 
In order to solve the detection problem of the very slow growing tubercle bacilli, attempts 
have been made to develop rapid methods for the detection of mycobacteria by their growth 
or metabolism.  So far the only rapid method in routine clinical use is radiometry.  In this 
technique, the bacillus uses [14C]-palmitic acid as a nutrient and consequently releases 
radioactive labelled carbon dioxide, which can be detected within two or three days.  
Although this technique is clearly more rapid than conventional methods, the high price 
restricts the use in many countries.22  
 
1.1.3.5 X-ray 
Primary and reactivated tuberculosis have distinct radiographic patterns.  When renewed 
pulmonary infection occurs, it is usually a chronic infection that involves destruction of lung 
tissue, followed by partial healing and slow spread of the lesions within the lungs.  Those 
spots of damaged tissue may be observed by X-ray examination.  However, intercurrent 
pneumonia, pulmonary embolism or supervening carcinoma may be confounding factors.1 
 
1.1.3.6 Susceptibility to antibiotics 
Smear negative patients can be treated with amoxicillin and/or erythromycin.  Patients not 
responding to either of these antibiotics, have a 50-75% (depending on the chosen 
antibiotics) chance of having TB anyway. 
 
1.1.3.7 Symptoms 
Uncomplicated primary disease appears usually without any symptom.  Post-primary 
infection causes local and generalized symptoms.  Localized symptoms include coughing, 
sputum production and pleuritic pain.  Constitutional symptoms include fatigue, fever, weight 
loss and night sweats. 
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1.1.4 Resistance 
Many bacteria are known to acquire drug resistance through plasmid exchange.  Although 
this is not the case for M. tuberculosis, resistance appears very often.  Normal error rates of 
DNA replication make it obvious that even without antibiotic exposure, spontaneous 
mutations give rise to resistant strains. 
Spontaneous mutation leading to isoniazid, streptomycine or ethambutol resistance occurs 
about once in 106 bacteria.  About 1 of 108 bacteria is rifampicin-resistant.  Consequently, 
treatment with a single drug in patients with a high bacterial load leads to suppression of 
only the susceptible bacteria, while the drug-resistant strains continue their growth.  For this 
reason, TB is commonly treated with cocktails of multiple drugs. 
 
1.1.4.1 Drug resistant tuberculosis 
In cases of drug resistant TB, the bacteria are resistant to one or more anti-tuberculosis 
drugs.  Two types can be distinguished.  When resistant bacilli are found in people that have 
been treated before, it is called ‘acquired resistance’.  In most cases, the resurgent 
organisms are resistant to the drug that was used before.  Although especially in developing 
countries, the resurgence of the infection can be caused by several factors: the poor drug 
supply or the prescription of inadequate chemotherapy, combined with interruption of the 
lengthy therapy by the patient, are common reasons for failure of the treatment. 
In patients without prior treatment with antituberculosis drugs, resistant bacilli can be 
observed as a consequence of the high level of acquired resistance in the community.  This 
is called ‘primary resistance’ and occurs less frequently than acquired resistance.  
Moreover it is less severe as it is very commonly restricted to just one drug (streptomycine or 
isoniazid). 
 
1.1.4.2 Multi-drug resistant (MDR) tuberculosis 
TB infections caused by MDR strains are resistant to several antituberculosis drugs, and 
at least to isoniazid and rifampicin.  MDR tuberculosis affects usually patients after failed 
treatment regimens and represents a significant proportion of tuberculosis cases with 
acquired resistance. 
In March 2006, the WHO even agreed to introduce a new “type” of infections: the 
‘extensively drug-resistant (XDR) TB’, now defined as TB cases in persons whose isolates 
are resistant to at least isoniazid and rifampicin (= MDR) and to any fluoroquinolone and at 
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least one of the three injectable second line drugs, such as capreomycin, kanamycin or  
amikacin.1 
Data on the MDR and XDR-TB infections are lacking for many parts of the world, but since 
1990 several outbreaks of MDR-TB associated with HIV have been reported in several 
locations, including London, Milan and New York.  The WHO published some data about 
MDR and XDR-TB cases in March 2006.  In a study of 17690 isolates spread over 49 
countries during 2000-2004, 20% were found to be MDR, and 2% were XDR. 
 
1.1.4.3 Cross-resistance 
Patients showing resistance to one drug often show resistance against other drugs from the 
same family or even drugs from other families as well.  This should be taken into account 
when choosing a drug regimen for a patient with multi-drug resistant TB. 
 
1.1.5 Control and treatment 
1.1.5.1  Chemoprophylaxis and preventive therapy 
As vaccination with the Bacille Calmette-Guérin (BCG) vaccine, the only vaccine in use, 
often fails,23  some more attention needs to be paid to the prevention and treatment of TB. 
Chemoprophylaxis is defined as the treatment of uninfected people who are exposed to risk 
of infection, while preventive therapy refers to the treatment of people who are infected with 
tubercle bacilli but do not show evidence of active disease. 
This preventive therapy is principally used to protect children, especially under the age of 
three, who are at risk to develop serious extrapulmonary forms of tuberculosis. 
For adults, at risk to develop TB, like for example HIV-positive persons, the use of this 
preventive therapy is controversial.  HIV-negative people have a 5% chance of developing 
active TB during their lifetime.  Thus, if preventive chemotherapy is life-long and 100% 
effective, it requires the treatment of 20 patients to prevent the disease in 1 case.  Problems 
of adherence and toxic side effects further limit the usefulness of this preventive approach.24  
For HIV-infected patients, the situation is totally different as their risk for developing active 
TB increases to 50% during their life.  But still, as the problem of adherence is quite large, 
therapy should be supervised, which is almost impossible especially in developing countries.  
This compromises the overall impact of preventive therapy. 
Transplant recipients receiving steroids and other immunosuppressive drugs show a 
reduced immune response and are also at risk of developing active TB.  It has been 
suggested to treat these people with a low dose of antituberculosis drugs.25 
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1.1.5.2 Current chemotherapy 
The mycobacterial population in a patient can be divided into three stages: 
1) freely dividing extracellular bacilli, mainly in the cavity walls; 
2) slowly dividing bacilli within macrophages and in acidic, inflammatory lesions; 
3) dormant and near-dormant bacilli, within cells and in firm caseous material. 
 
The aim of chemotherapy is to cure the patient, and at the same time prevent the 
emergence of drug resistance.  Taking into account the problem of mutations, leading to 
resistance, it is essential to give at least two drugs to which the strain is susceptible as the 
chance of two mutations occurring simultaneously in one cell is almost non-existing.  In 
regions with a high prevalence of drug resistance, a combination of three or more drugs 
should be given. 
The currently used anti-tuberculosis drugs are divided into two categories: the first-line 
drugs, used in patients without drug resistant strains or strains resistant to one or two drugs 
(other than isoniazid and rifampicin) and the second-line drugs, used in cases of MDR 
infections, in combination with first-line drugs.  They are often less effective, more toxic and 
more expensive and they are only used if the standard regimens are not effective anymore. 
 
a) First-line antituberculosis drugs 
The most important features of the first line antituberculosis drugs and their structure are 
shown in Table 1.1. 
  
   
 
Table 1.1 First-line antituberculosis drugs 
Compound Structure Mechanism of action Activity Drawback Resistance 
Streptomycine26 
HO
HO
O
OH
N
O
H2N
H2N
H2N NH2
O
OH
O
OH
HN
OH
OH
O
 
Inhibition of translation of mRNA via interaction with the 
30S ribosomal unit. 
Alkaline: 
bactericidal 
Acidic: 
ineffective 
 
Given by 
injection. 
Mutation on the 
genes coding for 
ribosomal protein 
S12. 
Isoniazid27 
N
H
N NH2O
 
Inhibition of mycolic acid synthesis. 
After activation by catalase-peroxidase, the obtained 
radical reacts with NAD+ to yield an enoyl-ACP 
reductase inhibitor. 
Bactericidal Limited efficacy 
against 
metabolically 
less active bacilli. 
Mutation on the 
gene coding for 
catalase-
peroxidase. 
Rifampicin28 
NH
O
OOH
HO
OAc
O
O
O
OH
OH
OH
N N
N
 
Inhibition of RNA-transcription via interaction with RNA-
polymerase. 
Active against all 3 
stages of bacterial 
population. 
Resistance is 
developed with 
high frequency. 
Mutation on the 
gene coding for 
RNA-polymerase 
β subunit. 
Pyrazinamide29 
 
N
N NH2
O
 
Uncertain. 
After intracellular conversion to pyrazinoic acid by 
pyrazinamidase, an intake of protons leads to complete 
dysfunction of the pH balance. 30 
Pyrazinoic acid might inhibit fatty acid synthetase I. 31, 32 
Alkaline or neutral: 
ineffective 
Acidic: effective. 
Kills semi-dormant 
bacilli 
Toxicity to retinal 
ganglion cells 
and ocular 
tissue. 
Correlated with 
pyrazinamidase 
activity. 
Ethambutol33, 34 
H
N N
H
HO
OH
 
Inhibition of arabinan biosynthesis, via for example 
inhibition of arabinosyl transferase, thereby destroying 
the basis of the cell wall and facilitating the uptake of 
other compounds.35, 36 
Bactericidal No sterilizing 
agent, not very 
effective if used 
alone. 
Mutation on the 
gene coding for 
arabinosyl 
transferase. 
Thioacetazone37 
CH3
O
HN
N NH
S
NH2
 
Not elucidated yet.38 
Probably interfering with mycolic acid synthesis 
Bacteriostatic Low efficacy  
   
  
b) Second-line antituberculosis drugs (Table 1.2)   
 
Table 1.2 Second-line antituberculosis drugs 
Compound Structure Mechanism of action Side effects Resistance 
Aminoglycosides 
(e.g. kanamycine, 
amikacine and 
capreomycin) 26,39 
O O
O
O
HO
HO
NH2
OHHO
NH2
NH2
HO
HO
HO
H2N
Kanamycin
 
Inhibition of translation of mRNA 
via interaction with the 30S 
ribosomal unit. 
Uptake through porins. 
Ototoxicity, reversible 
nephrotoxicity. 
Mutation on the genes coding 
for ribosomal protein S12. 
Thioamides (e.g. 
ethionamide, 
prothionamide) 27 N
NH2S
N
NH2S
Ethionamide Prothionamide
 
Inhibition of mycolic acid synthesis. 
Binds enoyl-ACP reductase at a 
different part of the active site 
compared to isoniazid. 
Nausea, psychotic reactions, 
hypoglycaemia, hepatitis. 
 
Fluoroquinolones 
(e.g. ofloxacin, 
ciprofloxacin) 26 N
F
N
O
COOH
ON
N
F
N
O
COOH
HN
Ofloxacin Ciprofloxacin
 
Inhibition of DNA-gyrase, responsible 
for supercoiling the bacterial DNA. 
Rare. 
Gastrointestinal disturbance, 
dizziness, headache, mood changes. 
Missense mutations in DNA 
gyrase. 
Cycloserine40 
O
H
N O
NH2
 
Inhibition of mycobacterial 
peptidoglycan synthesis by 
inhibition of D-alanine racemase. 
High toxicity. 
Dizziness, convulsions, headache, 
depression. 
 
Para-
aminosalicylic 
acid41 
COOH
OH
NH2
 
Inhibition of DNA-synthesis (mimic 
of p-aminobutyric acid). 
Mechanism unclear. 
Dose related side effects: vomiting, 
diarrhea, hepatotoxicity, fever, 
hypocalcaemia, rash. 
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c) WHO recommended regimens 
In order to shorten the length of the illness, to lower the risk of death and to prevent the 
development of resistant strains, the WHO recommended a regimen known as Directly 
Observed Therapy, Short Course (DOTS).  It focuses on five elements: political obligation, 
microscopic provision, drug supply, monitoring systems and a direct observation of the 
treatment.  When implemented over a long period of time, this approach is expected to give 
a huge reduction in sources of infection and transmission.1 
The fixed patterns as presented by the WHO regimens depend on the type of treatment. 
 
♦ WHO standard first-line regimen 
This regimen is used when a patient is treated for the first time with antituberculosis agents.  
It takes at least 6 months and requires a combination of different antibiotics.  Usually, the 
treatment starts with three drugs: isoniazid, rifampicin and pyrazinamide, often with the 
inclusion of a fourth drug, e.g. ethambutol or streptomycin.  These agents are administered 
daily in combination for two months.  In a continuation phase, isoniazid and rifampicin are 
administered twice a week for 4 to 12 months.  The advantage of using an early intensive 
phase of treatment is the possibility to cure a high proportion of patients resulting in a 
smaller chance of the disease relapsing if the patient absconds before completion of the less 
intensive continuation phase. 
 
♦ WHO standard retreatment regimen 
This retreatment regimen is used for patients returning after premature interruption of the 
first-line treatment and/or relapse.  It combines five drugs for a period of 8 months to 
reduce the risk of failure due to acquired resistance.  During the whole period, isoniazid, 
rifampicine and ethambutol are administered, combined with pyrazinamide during the first 
three months and streptomycine during the first two months.  The vast majority of the 
patients will be cured with this retreatment regimen.  Failures are generally due to the use of 
an incorrect regimen and/or failure to ensure that the regimen is fully administered and 
directly observed. 
 
♦ Therapy of MDR-TB 
Treatment of patients infected with MDR tubercle bacilli involves second-line drugs.  
Unfortunately, these agents are more expensive, less effective and cause more side effects 
compared to the standard drugs.  The treatment consists of a mix of at least four standard 
or second-line drugs, distributed by a specialized unit and, if possible, selected on the 
basis of in vitro susceptibility, or else being likely to be fully sensitive, i.e. not previously used 
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by that patient.  When the patient’s sputum cultures have become negative, one or more 
drugs are withdrawn, preferably weaker drugs which are causing side effects.  In order to 
prevent relapse, the treatment with this slimmed regimen is continued for at least 18 months 
after sputum conversion. 
If therapy fails, the regimen should be revised in the light of repeated in vitro susceptibility 
tests.  Additional drugs should never be added blindly to an ineffective regimen. 
As in some parts of South-Africa, studies concerning extensively drug-resistant (XDR) 
tuberculosis in an HIV-positive population have shown alarmingly high mortality rates, 
alternative and new forms of treatment are urgently required.  
 
d) Surgery 
For patients with bacilli sensitive to only 2 or 3 relatively weak drugs, surgery is considered.  
Nevertheless, for many of these patients the infection has become too severe or the lung 
function has diminished too much for surgery to be possible.  Nowadays, surgery is rarely 
considered in pulmonary tuberculosis but is often important for the diagnosis and 
management of extrapulmonary disease (e.g., bone lesions, lymph nodes,…). 
If the patient has a large localised lesion with little other disease, reasonable lung function 
and only 2 or 3 weak drugs available, surgery can be considered.  To avoid serious and 
potentially fatal TB complications, the operation is performed when the bacterial load is the 
lowest, i.e. after 2 months of intensive treatment.  After surgery, the same drug regimen is 
continued for at least 18 months. 
 
1.1.5.3 Patent developments in small-molecule antimycobacterials 
As the clinical management of patients infected with M. tuberculosis faces difficult problems 
such as the worldwide emergence of multidrug resistant tuberculosis (MDR-TB) and the 
increase of AIDS-associated infections, the development of new drugs with greater or 
distinct antimycobacterial activity than those currently available, is urgently required.  As this 
message is well understood in scientific research area, a large amount of patents have 
been published during the last years discussing the discovery of small-molecule agents that 
appear useful in the treatment of TB.  Three main strategies toward this effort can generally 
be distinguished: structural modification of existing antibiotics, discovery of new targets and 
the identification of natural resources for novel antibiotics.  Some of major remarkable 
developments in recently patented antimycobacterials are described below. 
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a) Derivatives of existing drugs 
♦ Using thioacetazone (1.1) and p-aminosalicylic acid (1.2) as a template, the University 
of Sciences in Philadelphia prepared some halogenated derivatives.42  A 3-fluorinated 
derivative 1.3 emerged as the most active derivative of thioacetazone.  The compound 
showed a MIC-value < 0.1 µg/mL and a selectivity index (SI) > 312.5.  Moreover, it proved 
active against TB strains resistant to isoniazid, rifampicin, ethambutol, kanamycin and 
ciprofloxacin.  Compared to the MIC-value of thioacetazone against M. tuberculosis H37Rv 
(>2.0 µg/mL) this fluorinated derivative is about 20-times more effective. 
In the series of p-aminosalicylic acid derivatives, the 5-fluorinated p-aminosalicylic acid (1.4) 
showed the highest activity with a MIC-value of < 3.13 µg/mL and an SI of > 10.  Tests for 
activity against drug-resistant strains revealed a lower but still significant activity.  Only 
strains resistant to isoniazid are less susceptible (MIC= 25 µg/mL).  Compared with the MIC 
of p-aminosalicylic acid (1.25 µg/mL), this derivative seems less active than the original lead 
compound. 
 
♦ Using ethambutol (1.5) as the lead, a large library of ethylene diamines with a variety of 
amine substituents, as well as substituents in the linker region, has been produced using 
split-and-pool procedures on a solid support.43,44  Initial evaluation of the library was done by 
a high-throughput screening (HTS) assay using bioluminescent reporter strains that produce 
light in response to inhibition of the cell wall synthesis.45  A number of hits resulted from this 
HTS assay.  One of the interesting derivatives, flanked by a 2-adamantyl and a geranyl 
substituent (1.6), gave a MIC-value of 0.2 µM against M. tuberculosis, compared to 9 µM for 
ethambutol in the same BACTEC assay.43  This derivative also proved to be active against 
three MDR patient isolates that were highly resistant to ethambutol and was well tolerated by 
mice in concentrations up to 600 mg/kg.  In vivo assays in mice infected with M. tuberculosis 
H37Rv showed that 10 mg of compound 1.6 had similar activity as 100 mg of ethambutol in 
reducing colony-forming units (CFUs) in the spleen, whereas the same dose had superior 
activity than 100 mg ethambutol in reducing CFUs in lung. 
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Figure 1.6 Derivatives of existing drugs 
 
♦ Rifampicin (1.7), a semisynthetic antimicrobial drug derived from rifamycine, is a front-line 
drug in the treatment of TB.  As it kills persistent semidormant bacilli, it is crucial to achieve 
sterilisation.  Since its introduction in the treatment of susceptible TB in the beginning of the 
70’s, new derivatives have been synthesized and evaluated for the treatment of TB.46  The 
best headway has been made with rifapentine (1.8), a long-acting rifamycin derivative 
characterised by a lower MIC-value (0.06 µg/mL versus 0.25 µg/mL), which was approved 
for the treatment of TB in the US in 1998. 
WOO3O84965 describes N-(3-rifamycinyl)carbamates (1.9) as new substances for treating 
and preventing TB.47  Compounds have been tested ex vivo.  The intracellular activity of 
growth inhibition in mouse macrophages, infected with M. tuberculosis H37Rv, was 
determined by counting the CFU/mL.  The most active compounds (R= ethyl, methyl) exhibit 
an eightfold higher activity than rifampicin. 
WO0400529848 highlights new derivatives of rifabutine Ia (1.10), a spiropiperidyl-rifamycine, 
which has been recommended for HIV-infected TB patients who cannot receive rifampicin 
because of interactions with antiretroviral agents.  Antimycobacterial activity was determined 
against M. avium.  While the known lead displayed a MIC-value of 0.15 µg/mL, the most 
promising derivatives were slightly less active.  Only rifabutin IIIa (1.11) had comparable 
activity to compound 1.10 (MIC-value= 0.2 µg/mL). 
Several patents from Hokuriku Seiyaki are related to novel series of 14-membered macrolide 
derivatives.  Among the 1265 erythromycin analogues disclosed in WO0226753,49 several 
compounds are claimed useful for preventing and/or treating TB.  Analogues 1.13-1.16 
showed MIC-values in the 0.10-0.20 µg/mL range against different M. avium and M. 
intercellulare strains.  Another typical analogue 1.17 showed a MIC-value of 1.56 µg/ml 
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against M. tuberculosis H37Rv and some other M. tuberculosis strains, 50 while 1.12 exhibits 
the same MIC-value against M. avium strains. 
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Figure 1.7 Rifampicin-analogues and macrolide derivatives 
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♦ For a long period, the mechanism of action of isoniazid has remained uncertain.  Now it is 
established that isoniazid first requires activation by Kat G into an unstable intermediate 
which reacts with NAD to give biologically active species as 1.18.  This adduct then binds 
the NAD(H) recognition site of enoyl ACP-reductase and this leads to the antimycobacterial 
effect.  Further analysis and biological evaluation of the adducts arising from the reaction 
between isoniazid, an oxidizing agent and NAD proved that compounds structurally related 
to the generated adducts can also act as ACP-reductase inhibitors.51  Few synthetic 
analogues of NAD bearing a double substitution on the nicotinamide moiety such as 1.19 
have been patented for their antimycobacterial properties.52 
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Figure 1.8 Mechanism of action of isoniazid and derived intermediate-analogue 1.19 
 
 
b) Drugs on known targets 
♦ A Janssen Pharmaceutica patent discloses novel 6-bromoquinoline derivatives with potent 
antimycobacterial activity.53  These so-called diarylquinolines (DARQ) are structurally 
distinct from known broad-spectrum fluoroquinolone antibiotics.  With a MIC-value of 0.01 
µg/ml against M. tuberculosis H37Rv and M. smegmatis strains, one of the four possible 
diastereoisomers of compound 1.20 showed potent antituberculous activity.  Unfortunately, 
the absolute configurations of the two stereocenters were not determined.  A follow-up paper 
of Andries at al., however, attributes the activivity to the (1R,2S) diastereomer (called 
TMC207, previously called R207910).54  This paper further reveals that TMC207 does not 
inhibit M. tuberculosis DNA gyrase, the target for fluoroquinolones.  A gene commonly 
affected in isolated mutants resistant to TMC207 encodes for atpE, a part of the F0 subunit 
of ATP synthase.  This indicates that the atpE gene product (i.e., the proton pump of M. 
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tuberculosis ATP synthase) is inhibited by TMC207. This distinct target of TMC207 implies 
that there is no cross-resistance with existing anti-TB drugs.  Pharmacodynamic studies in 
mice, where TMC207 was used individually or where one of the first-line drugs of the triple 
combination therapy was replaced with 25 mg/kg TMC207, proved that the activity of each 
combination containing TMC207 was significantly better than the standard regimen (e.g. 
culture-negative lungs after two months).  The mouse studies also showed that this new 
compound quickly enters the bloodstream and is actually concentrated in lung cells, which 
harbor the TB bacilli, killing the bacilli soon after they enter the body.  Also, TMC207 lingers 
in the body for days continuing to kill bacilli even when administered only once a week in 
mice.  At this moment, this compound is going into clinical phase II, to evaluate the anti-
bacterial activity, safety and tolerability in subjects with sputum smear-positive pulmonary 
infection with MDR-TB.55 
 
♦ Oxazolidinones represent the first completely new class of synthetic antibacterial agents 
to achieve regulatory approval in over 30 years, as exemplified by linezolid (1.21, Zyvox®).  
In addition to its potent activity against Gram-positive pathogens, this class is of great 
interest because it exerts its antibacterial action by a mechanism distinct from other 
antibacterial agents.  Oxazolidinones inhibit bacterial protein synthesis (translation) at a very 
early step.  They inhibit the formation of a ribosomal initiation complex involving 30S and 
50S ribosomes.  Because of their unique mechanism, the oxazolidinones are not cross-
resistant with any known antibiotic.  Since this class was found to be endowed with 
promising antibacterial properties, many pharmaceutical companies worldwide began 
research programmes in the oxazolidinone area, which resulted in an impressive number of 
patents.56  However, most patents are silent about antimycobacterial activity of the disclosed 
compounds and only a few of the disclosures present compounds that have demonstrated 
potential as antimycobacterials.  A general feature of the oxazolidinone derivatives is the fact 
that only enantiomers with a (5S)-acetamidomethyl configuration are known to exhibit 
antibacterial activity.  Another feature is that almost all oxazolidinones endowed with 
antibacterial activity carry a phenyl ring attached to the nitrogen atom of the oxazolidinone. 
Linezolid forms an attractive starting point to design anti-TB agents, since it displays a MIC-
value of 0.5 µg/ml against M. tuberculosis and it is known that resistant bacterial mutants to 
linezolid arise at low frequency.  Some of the potential side effects associated with extended 
linezolid treatment are toxic optic neuropathy, peripheral neuropathy and myelosuppression.  
Ranbaxy disclosed novel oxazolidinone analogues related to eperezolid.57  All analogues 
have a diazine moiety attached to the phenyloxazolidinone, which is further substituted by a 
heterocyclic or aromatic ring.  Compound 1.22 with a 5-nitrothien-2-yl moiety directly 
  In troduct ion 
  
   27 
attached to the piperazinyl oxazolidinone core was very effective against the different M. 
tuberculosis, M. intracellulare, M. avium and M. bovis strains tested and MIC-values 
compared well with those of established anti-tuberculosis agents.  
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Figure 1.9 Diarylquinolone 1.20 and oxazolidinones 1.21-1.24 
 
♦ A Lupin Patent disclosed 78 novel oxazolidinones as antibiotic agents against M. 
tuberculosis.58  Elongation of the acetamido moiety (as it occurs in linezolid) is common to all 
claimed analogues.  Among the most potent analogues are 1.23 and its N-oxide (MIC-value 
of 0.25 µg /ml for both compared to 0.50 µg /ml for linezolid) and the related 1.24 (MIC-value 
of 0.50 µg /ml).  The latter analogue was also potent against resistant clinical isolates and 
showed a favourable acute toxicity profile (LD0 > 1000 mg/kg P.O.).  When administered at 
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12.5 or 25 mg/kg to mice infected with M. tuberculosis ATCC27294 5 days/week for 4 
weeks, a mean log10 reduction in colony forming units of 0.20 and 2.3 (in lung) and of 0.26 
and 2.49 (in spleen) was observed. The N-oxide derivatives are expected to be highly water 
soluble. 
 
c) Agents with unspecified mechanisms of action 
1'-Acetoxychavicol acetate (1.25) is a natural compound, found in some plants of the 
family Zingiberaceae.  The mechanisms of action of this compound are not clear. It could 
inhibit the function of xanthine oxidase and NADPH oxidase.  These enzymes are involved in 
the production of superoxide anion, which is one of the spontaneously occurring toxic 
substances in the body.  It may also inhibit nitric oxide synthase production.  The MIC of 1'-
acetoxychavicol acetate against M. tuberculosis H37Rv is 0.1 µg/ml (0.1 to 0.5 µg/ml to 30 
clinical isolates), which is well below the toxic concentration against various mammalian 
cells.59 
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Figure 1.10 Agents with unspecified mechanism of action 
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Pleuromutilin (1.26) is a tricyclic diterpenoid and a naturally occurring antibiotic produced 
by the basidiomycetes Pleurotus mutilus and P. passeckerianus.  A number of further 
pleuromutilin derivatives have been claimed by Sandoz.60  The most active derivatives, e.g., 
Valnemulin (1.27), displayed MIC-values in the range of 0.5 to 8 µg/ml depending on the M. 
tuberculosis strain considered. 
By using the existing lead BM212,61 researchers at Lupin have discovered novel substituted 
pyrroles endowed with antimycobacterial activity.62  Compared to the plethora of pyrrole 
derivatives reported earlier and reviewed in this patent, several of the ca. 90 disclosed 
derivatives possess higher antimycobacterial activity against clinically sensitive as well as 
resistant strains.  The MIC-value of compound 1.28, the most active derivative, against M. 
tuberculosis 27294 is 0.125 µg/ml.  When assayed in vivo in Swiss albino mice that were 
challenged with the same strain, 1.28 compared favourably (on a mg/kg basis) with isoniazid 
in reducing CFUs in lung and spleen, while its LD0 was > 2000 mg/kg, compared to a 
reported LD50 of isoniazid of 139 mg/kg in mice. 
US6268393 contains disclosures on the synthesis and the antimycobacterial activity of 
calanolide analogues.63  (+)-Calanolide A (1.29), a known anti-HIV agent which was 
originally isolated from the rain forest tree Calophyllum lanigerum, was moderately active 
(MIC-value of 3.13 µg/ml against M. tuberculosis H37Rv). 
In WO03042186, Medac revealed dithiocarbamate derivatives endowed with activity against 
different Mycobacterium species.  The most active agent is 4-dimethylamino-6-
tetramethylenedithiocarbamoyl-5-nitropyrimidine (1.30) with a MIC-value of 3.12 µg/ml 
against M. tuberculosis.64 
 
1.1.5.4 Nucleosides as anti- tuberculosis agents 
Whereas nucleoside derivatives are used to treat HIV, so far no nucleosides are registered 
as antibacterial or antituberculosis drugs.  Nevertheless, during the last years, some 
interesting nucleosides were discovered with potent activity against M. tuberculosis. 
Almost all nucleoside antibiotics have non-specific antibacterial activity because nucleoside 
and nucleotide metabolism are essential for DNA and RNA biosynthesis in all organisms.   
A simple nucleoside named toyocamycin (1.31)65 is isolated from the fermentation broth of 
Streptomyces toycaensis and shows good antibacterial activity against Mycobacterium 
tuberculosis H37Rv (MIC-value = 2.0 mg/mL).  Next to this promising activity, it has many 
other biological activities such as antitumor, antivirus and herbicidal activities, but it is also 
cytotoxic against eukaryotic cells and showed toxicity in mouse, thus limiting their use as 
specific antibiotic.  
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Aldrich et al.66,67 described the rational development of compounds inhibiting the growth of 
M. tuberculosis H37Rv under iron-limiting conditions, with the most active compounds 1.32 
(MIC99= 0.29 µM) and 1.33 (MIC99 = 0.19 µM) (See Figure 1.11).  These compounds target 
MbtA, the enzyme that initiates the biosynthesis of mycobactins, essential iron-chelating 
siderophores.  The main drawback of these compounds is their hydrolysis to 5’-O-
(sulfamoyl)adenosine, an extremely cytotoxic compound.  Thus further exploration for 
compounds with similar activities but with lower toxicities is required. 
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Figure 1.11 Nucleosides as antituberculosis agents 
 
 
Kumar et al.68,69 explored a large family of 5-substituted alkynylpyrimidine nucleosides 
1.34 (Figure 1.11).  5-Decynyl, 5-dodecynyl and 5-tetradecynyl derivatives showed the 
highest antimycobacterial potency against M. bovis with MIC90-values below 10 µg/mL.  Next 
to normal ribose and 2’-ribose sugars, also acyclic compounds have been synthesized and 
evaluated for their activity.  The target of these nucleosides remains unknown. 
Very recently, a series of modified adenine derivatives was reported as potent 
antimycobacterial agents.70  Based on earlier results, this paper starts from the isomeric 
pyrazolo [3,4-d]pyrimidine nucleus and explores a large amount of S- and N-alkylations, to 
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end up with a very potent compound 1.35 with a MIC-value of 0.5-1 µg/mL.  As is the case 
for the 5-alkylated pyrimidines, no target is known for this new class of antituberculosis 
agents. 
 
Caprazamycins (CPZs) 1.36 were isolated from a culture broth of the Actinomycete strain 
Streptomyces sp. MK730-62F2.71  Different CPZs were isolated, each with a different fatty 
acyl side chain (R).  Caprazamycin B (with R= 11-methyl-dodecyl) showed excellent anti-
mycobacterial activity in vitro against drug-susceptible Mycobacterium tuberculosis H37Rv 
(MIC= 3 µg/mL) and multi-drug resistant strains (MIC= 6.25-12.5 µg/mL).  Furthermore, CPZ 
B proved equipotent as clarithromycin in inhibiting M. avium growth and did not show any 
toxicity in mice.  Caprazamycins are believed to disrupt the formation of the bacterial cell 
wall peptidoglycan by strong inhibition of phosphor-MurNAc-pentapeptide translocase 
(MraY, translocase I).  Being one of the key enzymes for peptidoglycan biosynthesis, MraY 
is essential for the growth of bacteria.72 
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Figure 1.12 Caprazamycins and A-500359A 
 
 
In 2003, A-500359A (1.37) was isolated from the fermentation broth of Streptomyces griseus 
446-S3 by Sankyo Co. Ltd.73  It consists of a 3’-O-methylated uridine coupled to a 
dehydrohexopyranuronate and a caprolactam fragment and strongly inhibits MraY (IC50= 
0.010 µg/mL).  Due to its cell wall biosynthesis inhibiting activity, it showed potent 
antibacterial activity against Mycobacterium smegmatis (MIC = 9 µg/mL) as well as 
Mycobacterium avium (MIC = 2 µg/mL) and Mycobacterium intracellulare (MIC = 6.25 
µg/mL).  Efforts were made to increase the lipophilic nature of this compound by introducing 
an acyl group at the 2’-position to enhance uptake through the lipophilic cell wall.74  An A-
500359A derivative possessing a decanoyl group at the 2’-position exhibited far superior 
activity against M. avium (MIC < 0.063 µg/mL) and M. intracellulare, despite a strongly 
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decreased MraY inhibitory activity (IC50= 0.55 mg/mL).  Most probably, the 2’-decanoyl 
substituted compound acts as a prodrug of A-500359A. 
A more detailed overview of nucleoside-derived antibiotics is given in several reviews.75  
 
1.1.5.5 Modified nucleosides as therapeutic agents 
Especially in the antiviral field synthetic nucleoside analogues have found clinical 
applications.  Most therapeutically useful nucleosides are based on the structure of natural 
β-D-nucleosides (i.e. AZT, d4T). 
However also a significant number of L-nucleosides such as 3TC (1.38; Lamivudine, β-L-
2’,3’-dideoxy-3’-thiacytidine)76, FTC (1.39; Emtricitabine, β-L-2’,3’-dideoxy-5-F-3’-
thiacytidine),77 L-d4FC (1.40; Elvucitabine, β-L-2',3'-didehydro-2',3'-dideoxy-5-
fluorocytidine)78 and β-L-2',3'-didehydro-2',3'-dideoxy-2’-F-4’-thio-cytidine (1.41)79, have been 
discovered as potent antiviral agents.  All compounds show activity against Human 
Immunodeficiency Virus-1 (HIV-1) and hepatitis B virus (HBV).  These nucleosides are in 
fact prodrugs that need to be converted to their triphosphorylated forms to achieve 
pharmacological activity.  3TC and FTC are both phosphorylated by deoxycytidine kinase, 
indicating that this enzyme possesses the ability to phosphorylate nucleosides with unnatural 
L-chirality.80  3TC, also known as Lamivudine was found to be the first drug active against 
HBV.  Its D-isomer proved less active and more cytotoxic.  Several of these L-nucleosides 
belong to nowadays antiviral therapy.  
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Figure 1.13 L-nucleosides with potent antiviral activity 
 
While the above mentioned L-nucleosides are very well studied, only few reports were made 
on pharmacologically active α-nucleoside analogues.81,82  α-L-lyxofuranosyl benzimidazoles 
showed no activity against HIV-1, but proved active against human cytomegalovirus 
(HCMV).  However, while those reports date from 1998, no further explorations have been 
published in this area, indicating that only little success was obtained with those compounds. 
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Figure 1.14 α-L-lyxofuranosyl benzimidazoles and α-D-thymidine derivatives 
 
Schmidt et al. described the synthesis of 5’-azido (1.44) and 5’-fluoro (1.45) substituted α-D-
thymidine.  No antiviral (HIV-1 and HSV-1) activity was observed for those compounds.83 
Remarkably, while variation between D- or L- sugars of modified nucleosides proved 
possible while retaining antiviral activity, modification of the stereochemistry at the anomeric 
centre, from β to α, is generally associated with complete loss of bioactivities of the modified 
nucleosides.  So far, α-nucleosides are solely well-known for their recognition of 
complementary DNA and RNA sequences forming stable parallel stranded duplexes.84,85 
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1.2 THYMIDINE MONOPHOSPHATE KINASE 
 
A prerequisite for a valuable target enzyme in antibiotic research is that it is essential for 
bacterial growth and intracellular survival.  Consequently it should catalyze a reaction 
necessary for growth and survival of the micro-organisms, which can not succeed without 
the presence of only this enzyme. 
For antiviral and anticancer chemotherapy, classical molecular targets are often key 
enzymes involved in the salvage and de novo pathways of DNA synthesis, such as DNA 
polymerase, dihydrofolate reductase, thymidylate synthetase, ribonucleotide reductase and 
2’-deoxynucleoside kinases.86,87  Despite the fact that prokaryotes rely on the same 
pathways for DNA synthesis,88 antibiotics targeting enzymes of these pathways have hardly 
been discovered.  Except for trimethoprim, an antibiotic targeting dihydrofolate reductase,89 
no antibiotics targeting other enzymes of the DNA synthesis-pathways have entered the 
clinical stage. 
For the use of 2’-deoxynucleosides, as antibiotics, two strategies can be followed.  Similar to 
the anti-HIV drug AZT,86 activation into its triphosphate by three successive kinases (TK, 
TMPK and TDPK) could yield a toxic 2’-deoxynucleoside triphosphate, serving as a DNA-
polymerase inhibitor or resulting in a disruption in the DNA-duplex when built in, thus leading 
to cell death.  Alternatively, 2’-deoxynucleosides could serve as an inhibitor of one of the 
kinases instead of being recognized as a substrate, in this way causing its toxic effect. 
So far, substrates or inhibitors specifically targeting bacterial TKs or TMPKs have not yet 
been developed for therapeutic purposes. 
 
1.2.1 Mycobacterium tuberculosis TMPK: An  ideal target 
Thymidine monophosphate kinase (TMPK) is one of the many nucleoside monophosphate 
kinases responsible for important steps during DNA-synthesis.  With ATP as its preferred 
phosphoryl donor, it catalyzes the reversible conversion of thymidine monophosphate 
(dTMP) to thymidine diphosphate (dTDP), as important intermediate for DNA-building 
blocks.90 
  TMPK 
   dTMP   +   ATP      dTDP   +   ADP 
 
TMPK lies at the junction of the de novo and salvage pathway of the thymidine 
triphosphate (dTTP) metabolism (Figure 1.15) and it is the last specific enzyme for its 
synthesis, making it an attractive target for drug design. 
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Figure 1.15 Salvage and de novo pathway of dTTP metabolism. 
 
In TMPK-deficient Saccharomyces cerevisiae cells, Jong et al. proved that yeast TMPK is 
essential for DNA-replication and thus for cellular growth.91,92  Moreover, a correlation 
between thymidylate kinase activity and the rate of DNA-synthesis during rapid growth has 
been documented, while in non-proliferating tissues, enzyme activity is barely detectable.93 
Although the global folding of this enzyme is similar to that of the human TMPK (TMPKh), 
there is only 22% of sequence identity between the human and the mycobacterial 
isozyme.  This strongly supports the possibility to design inhibitors which are selective for 
the mycobacterial enzyme, thereby reducing or excluding toxicity for human cells and side 
effects.  The first selective competitive inhibitor found to bind to mycobacterial TMPK 
(TMPKmt) was AZTMP.94  By now, several nucleoside- and nucleotide-derivatives have 
been found to selectively inhibit mycobacterial TMPK. 
 
1.2.2 The structure of TMPKmt 
In 2001, Li de la Sierra et al.95 described the crystal structure of TMPKmt on a 1.95 Å 
resolution X-ray image.  This structure shows TMPKmt, bound to its natural substrate dTMP, 
with a sulphate ion mimicking for the β-phosphoryl group of ATP. 
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1.2.2.1 Primary, secondary, tertiary and quaternary structure 
TMPKmt has a molecular mass of 24 kDa and consists of 214 amino acid residues.  It is a 
homodimer in solution, with each monomer having nine α-helices surrounding a five-
stranded β-sheet core.  At the interface of the dimer, three pairs of helices are kept together 
through hydrophobic interactions and an ion pair between Glu50 and Arg127.95 
The global folding of TMPKmt is similar to that of other TMPKs.  Nevertheless only a low 
similarity of their amino acid sequences is found: 
- 26% with TMPK of E. coli 
- 25% with TMPK of yeast 
- 22% with TMPKh 
 
During binding of the substrate into the active site of TMPKmt, large conformational changes 
can be observed.  In the absence of substrate, the enzyme appears in the open 
conformation.  This changes to a partially closed conformation in the presence of one 
substrate, and finally to a fully closed and active conformation when both substrates are 
available (dTMP and ATP). 
 
Within the 214 amino acid residues, the essential residues for the function of the TMPKmt 
can be found in three regions: 
 
♦ The P-loop motif  (Gly X1X2X3X4 Gly Lys X5)96 
This motif of 8 amino acid residues is responsible for the positioning of the phosphoryl 
groups of the phosphate donor.  Through interactions between the amide backbone 
hydrogens and the phosphate oxygen atoms, it binds and positions the α- and β-phosphoryl 
groups.  Unique for TMPKs is an interaction between the P-loop and the phosphoryl 
acceptor dTMP.  This is achieved through a hydrogen bond between the 3’-hydroxyl group of 
dTMP and a carboxylic acid residue at position X2 of the P-loop motif (Asp9 in TMPKmt).  
Although the exact function of this acidic amino acid is still unclear, it appears to be crucial 
for the catalytic mechanism of TMPK.  Any mutation of this residue in the yeast, human or E. 
coli enzyme disables the phosphoryl transfer activity.97 
 
♦ The DR(Y/H/F) motif 
This region contains a strictly conserved arginine residue acting as a clip which favourably 
orients the phosporyl donor and acceptor via an interaction with the phosphate group of 
dTMP and the γ-phosphate of ATP. 
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♦ The LID region 
Upon binding of the phosporyl donor to the enzyme, the LID region closes as a flexible 
stretch.  Important conformational changes appear when ATP is fixed onto the enzyme.  At 
the same moment, there is a transition from a coil to a helical conformation in the LID region.  
Phosphoryl groups of both substrates interact with arginine side chains in the LID region, 
revealing the importance of these residues in catalysing phosphoryl transfer.95 
 
The presence of those three important amino acid regions is an important feature of all 
TMPKs.  Uniquely in the mycobacterial TMPK, a magnesium ion binds the enzyme 
transiently during catalysis, establishing a link between the P-loop (Asp9) and the LID region 
(Glu166).  Giving rise to a strong electrostatic potential, the γ-phosphate of the phosphoryl 
donor ATP is attracted very close the α-phosphate of dTMP, thereby acting as a clamp 
between phosphor donor and acceptor.  For the human enzyme, one magnesium ion binding 
site has been reported, located further away along the ATP-binding site, between the β- and 
γ-phosphate groups.  For the yeast and the E. coli enzyme, no magnesium atoms have been 
reported.  Next to its unique presence in TMPKmt, the essential role of this magnesium ion 
during catalysis, makes it an attractive target to destabilise it in order to disturb catalysis. 
 
a) The dTMP-binding site 
In order to design competitive inhibitors for TMPKmt in a rational way, the main interactions 
with its substrate have to be taken into account.  Substrate derivatives envisioned to interact 
more strongly with the active site than the substrate itself, can in this way be constructed, 
synthesized and generate interesting lead compounds for enzyme inhibition.  As observed 
by the X-ray structure of TMPKmt, the main bonding forces between dTMP and the enzyme 
are the following: 
- A stacking interaction between the pyrimidine nucleobase and Phe70; 
- A hydrogen bond between O-4 of thymine and the Arg74 side-chain.  This results 
in greater affinity for the thymidine compared to cytidine; 
- A hydrogen bond between Asn100 and N-3 of the thymine ring; 
- A hydrogen bond between 3’-hydroxyl of dTMP and the terminal carboxyl of 
Asp9, that in its turn interacts with the magnesium ion, responsible for positioning 
the phosphate oxygen of dTMP; 
- Hydrogen bonds and ionic interaction between the 5’-O-phosphoryl and Tyr39, 
Phe36, Arg95 and Mg2+ respectively; 
- The presence of Tyr 103 close to the 2’-position is believed to render the enzyme 
catalytically selective for 2’-deoxy-nucleotides versus ribo-nucleotides. 
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Figure 1.16 The active pocket of TMPKmt 
 
In order to obtain selective inhibition, the differences with other TMPK’s have to be taken into 
account: 
- The hydrogen bond between the N-3 atom of the pyrimidine ring with the Asn100 
sidechain (corresponding to a glycine in the yeast and human enzyme and to a 
threonine in the E. coli enzyme); 
- The Tyr39 residue makes two polar contacts with dTMP: one with the phosphate 
oxygen atom and the other with the oxygen atom at the 5’-position.  Arginine and 
glycine residues replace this tyrosine in the human and yeast enzymes 
respectively; 
- The 3’-hydroxyl group of the ribose moiety makes three polar contacts: one with 
water molecule involved in the Mg2+-coordination and two others with Asp9.95 
 
b) The ATP binding site 
The crystal structure of TMPKmt, co-crystallised as a complex with dTMP and SO42-, in the 
absence of ATP, is similar to those observed for yeast and E. coli enzymes, where ATP is 
fixed at its donor position.  This indicates that this crystal structure represents the closed 
conformation, Arg149 and Thr15 interacting with the adenine ring of ATP, accommodating it 
at the correct position for enzyme activity.95 
TMPKmt has broader substrate specificity for nucleoside triphosphates than other nucleotide 
monophosphates kinases.  The reaction rates with ATP or dATP as phosphate donors are 
similar.  ITP, GTP, CTP and UTP also serve as efficient phosphate donors (order of efficacy: 
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ITP > GTP > CTP > UTP).  Even dGTP, dCTP and dTTP can act as phosphate donors, 
although less efficient (1% for dTTP, 8% for dCTP and 35% for dGTP compared to ATP).93 
 
1.3 RATIONAL DRUG DESIGN 
While in the past drugs were discovered rather than being developed, the scientific evolution 
afforded several helpful tools that changed the general drug discovery process significantly.  
First of all, numerous target structures have been elucidated by X-ray or NMR, clarifying the 
requirements for effective binding to the enzyme, which can be useful to improve the 
potency and specificity of new lead compounds.  In addition to providing structural 
information, computer models are used to simulate the binding mode of ligands to the known 
targets.  In this way, new ligands with a higher probability of effectively binding a target can 
be predicted and synthesized.  Combined with combinatorial chemistry, computer-aided 
molecular design is now routinely used in lead identification and optimisation. 
In cases where the target of a series of compounds is unknown or a reliable structure of a 
target is not available yet, molecular modelling is a useful tool to analyse the structure-
activity relationship of a series of ligands.  This can lead to more active compounds.  A 
technique implementing this strategy is the Quantitative Structure-Activity Relationship 
(QSAR), which is based on a set of analogues of a biologically active compound.  By the use 
of descriptors (e.g. MW, log P,…), the physicochemical properties of a compound are 
identified and quantified.  A correlation is determined between these descriptors and the 
corresponding activities, which is then used for the prediction of the activities of new 
analogues. 
Based on 47 earlier synthesized thymidine derivatives, Aparna et al.98 performed a 3D-
QSAR study for TMPKmt inhibitors.  From this study, the following structural requirements 
for strong TMPKmt inhibition could be concluded: 
- C-5: Moderately bulky substituents, preferably electronegative groups are favored. 
- C-2’: A hydrogen bond donor at this position may lead to drop in activity. 
- C-3’: Moderately bulky substituents are favored. 
- C-5’: Either hydrogen bond acceptors or donors can be accommodated.  Bulky and 
highly polar substituents are favored. 
 
Both strategies are used in this work in order to find new potent TMPKmt inhibitors in a 
rational way. 
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To illustrate the relevance of structure based drug design, the successful development of 
HIV-protease inhibitors, based on crystal structures of inhibitor/HIV protease complexes is a 
textbook example.  Several papers99,100 describe the rational design of protease inhibitors, 
which even resulted in compound 1.38, a protease inhibitor with a Ki in the low picomolar 
range (4.5 pM) and active against drug-resistant HIV.101 
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Figure 1.17 HIV-protease inhibitor 1.38, the result of successful rational design 
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1.4 INITIAL STRUCTURE ACTIVITY RELATIONSHIP 
 
Earlier evaluation of thymidine analogues, synthesized in our lab as inhibitors of TMPKmt 
has generated useful information about their structure-activity relationship (SAR).   
 
The generally accepted numbering system for nucleosides is as depicted in Figure 1.18: 
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Figure 1.18 Generally used numbering system for nucleosides 
  
The ribofuranose ring numbering can be distinguished from the pyrimidine numbering by the 
use of the prime after the numbers.   
 
1.4.1 Base-modifications 
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Figure 1.19 Base modifications 
 
♦ 5-position 
The thymine nucleobase has been modified at its 5- and 2-position.  Modifying the 5-methyl 
into several halogens, resulted in TMPKmt-substrates with the 5-Br-dUMP (1.46) being the 
most active one (Km= 30 µM).95  Other halogens at this position like iodine or fluorine 
extremely decreased the affinity for the enzyme.  Complete removal of the methyl group 
(dUMP) affected the affinity even more, resulting in a 50-fold increase in the Km-value.  The 
difference in kinetic parameters between the different 5-substituted dUMP-analogues 
seemed related to the ability of the differently sized halogen atoms to fill a cavity.102  Later, 
larger substituents at the 5-position have been introduced in an effort to form stacking 
interactions with Phe36 (e.g. furanyl, thienyl or benzyloxymethyl) or ionic interactions with 
Arg74 (5-hydroxymethyl).  In contrast to the previously synthesized 5-halogen substituted 
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compounds, none of these derivatives behaved as a substrate for TMPKmt.  Moreover, 
since 5-hydroxymethyl (1.47) and 5-furan-2-yl dUMP were the most active compounds with 
Ki-values of 110 and 140 µM respectively, it was concluded that the volume of this cavity 
cannot be stretched too much, limiting further explorations at this position.103 
 
♦ 2-position 
At the 2-position of the pyrimidine ring, modifications have been introduced in order to 
enhance the inhibitory activity on the enzyme, which resulted in 5-methyl-iso-dCMP (1.48) as 
a competitive inhibitor with a Ki of 130 µM.95 
 
1.4.2 Sugar modifications 
♦ 3’-position 
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Figure 1.20 3’-modified thymidine derivatives 
 
The first reported selective competitive inhibitor of TMPKmt is AZTMP (1.49), having an 
azide at the 3’-position instead of a hydroxyl in the natural substrate.  While TMPKs from 
eukaryotes and other prokaryotes recognize it as a substrate, AZTMP showed a Ki of 10 µM 
for TMPKmt.95  The complex of the natural substrate dTMP to TMPKmt is characterized by 
an important hydrogen bond between 3’-OH and the carboxylic acid of Asp9.  In the case of 
AZTMP however, no stabilizing hydrogen bond can be formed.  The X-ray structure of 
TMPKmt complexed with AZTMP demonstrated that binding of AZTMP prevents the 
positioning of Mg2+ in the active site and consecutive LID-closure.  Moreover a direct 
interaction between the azidofunction and Asp9 causes an inadequate positioning of this 
important amino acid residue.  As a result, catalysis abolishes.104 
Considerable efforts to find strong inhibitors were directed towards a strong ionic interaction 
between a 3’-substituent and the carboxylic acid of Asp9.  Despite the fact that modelling 
pointed towards a 3’-amino group, 3’-aminothymidine monophosphate (1.50) showed only 
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disappointing inhibitory activity (Ki= 235 µM).  Replacement of a 3’-OH by a 3’-F afforded 
analogue 1.51 that behaved as a substrate with a Km of 30 µM.105 
As it was anticipated that the 3’-NH2 group was unable to approach Asp 9 close enough to 
establish the envisaged interaction, a series of 3’-branched-chain nucleotides was 
synthesized, i.e. 3’-C-azidomethyl (1.52; Ki= 12 µM), 3’-aminomethyl (1.53; Ki= 10.5 µM), 3’-
fluoromethyl (1.54; Ki= 15 µM) and 3’-hydroxymethyl derivatives (1.55; Ki= 29 µM) of dTMP.  
Their activities indicated the possibility of the enzyme to accommodate sterically more 
demanding substituents at the 3’-position.  Since no significant difference in Ki-values 
among these 3’-C-branched chain analogues was obtained, it remained uncertain if the 3’-
CH2NH2 was really involved in an ionic interaction with Asp9.106 
In an attempt of Veerle Vanheusden to synthesize 3’-aminomethyl-3’-deoxythymidine, 
Barton deoxygenation of a 2’-O-phenylthionocarbonate substituted 3’-azidomethyl-
ribothymidine, resulted in three peculiar nucleoside analogues, being two bicyclic 
nucleosides 1.56 and 1.57 (discussed later) and one dinucleoside 1.58.107   
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Scheme 1.1 Serendipitous discovery of three potent TMPKmt inhibitors 
 
As the X-ray structure of TMPKmt did not point towards the presence of a binding site for a 
second nucleoside at the 3’-position, the activity of the dinucleoside (Ki= 37 µM) was very 
surprising.  Modelling experiments in GOLD showed that the sugar ring of the first monomer 
I binds the TMP-pocket upside down, allowing the hydrogen of its 5’-hydroxyl to interact with 
Asp9 (Figure 1.21).  This binding mode permits the sugar ring of the second monomer (II) to 
be directed towards the outside of the enzyme where the phosphoryl donor normally binds 
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and opened new possibilities for the design of much larger inhibitors for TMPKmt than 
explored earlier. 
 
Figure 1.21 Predicted binding mode of dinucleoside 1.58 with TMPKmt 
 
♦ 5’-position 
At the onset of our research group’s search for TMPKmt inhibitors, the aim was to 
synthesize modified nucleoside 5’-O-phosphates that were not prone to further 
phosphorylation in order to avoid cell toxicity.  A main disadvantage of this approach 
however, concerned the uptake of 5’-O-phosphorylated analogues in cells, generally 
accepted to be very difficult.  Normally, nucleosides cross the cell membrane barrier in the 
non-phosphorylated form and are then phosphorylated by intracellular kinases.  However, in 
this particular case, intracellular activation is not possible, as no gene coding for TK can be 
identified in the M. tuberculosis genome. 
Fortunately, previous work by Vanheusden et al. demonstrated that certain non-
phosphorylated thymidine analogues (1.52-1.55) were equally active compared to their 
phosphorylated analogues.  At the same time, these analogues showed only a low affinity for 
the human enzyme resulting in selective TMPKmt inhibitors.106  Our research will 
consequently be directed toward the synthesis of non-phosphorylated TMPKmt inhibitors. 
 
Other 5’-modified dT-analogues showed a positive influence of the functional groups at the 
5’-position on the interaction between inhibitor and the enzyme.  The Ki-value of 5’-NH2dT 
(1.59) and 5’-N3dT (1.60) are 12 and 7 µM respectively, both close to the Km of the natural 
substrate.  For this reason, azido- and amino-modifications seem to be attractive 
substitution patterns to result in potent inhibitors.108 
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Figure 1.22 5’- and 2’- modified dT and dTMP analogues 
 
 
♦ 2’-position 
As described earlier, in the active site of the enzyme Tyr103 is responsible for a sterical 
hindrance at the 2’-position resulting in a higher activity for 2’-deoxynucleosides 
compared to their ribo analogues.  Only in the case of a 3’-amino modification, the 2’-
ribonucleotide (Ki= 45 µM) proved more active than its 2’-deoxy analogue (Ki= 235 µM).104 
Surprisingly, the introduction of halogens appeared to be better tolerated than a hydroxyl 
group at this position.  2’-Chloro-dTMP (1.61), for example, showed a Ki of 19 µM for the 
mycobacterial enzyme. 105  Modelling indicated that the introduction of a chlorine influenced 
the puckering of the sugar.  This allowed the chlorine to occupy the pocket where the 3’-
hydroxyl group normally resides.   
Van Rompaey et al.109 described the synthesis and conformational analysis of 2’- and 3’- 
modified thymidine analogues.  This study showed that ribo- configured halogens at the 2’-
position limited the conformational freedom of the nucleoside and forced it into a 
Northern conformation which is opposite to the conformation of the natural substrate, 
explaining the low affinity for the enzyme.  A more detailed explanation of the sugar 
puckering is discussed below. 
 
♦ 1’-position 
The natural substrate dTMP has the nucleobase at the 1’-position above the sugar plane, 
which makes it, like most natural nucleosides, a β-nucleoside.  Earlier, an undesired α-
anomer (3’-azidomethyl-α-thymidine) had been synthesized and tested for TMPKmt affinity.  
It showed an unexpected high affinity for the enzyme with a Ki of 29 µM compared to 40 
µM for its β-derivative.  At that time, no efforts were made to further explore this interesting 
observation.107  
 
♦ Bicyclic nucleosides (2’-3’-substituted) 
The two bicyclic nucleosides, thiocarbamate 1.56 and carbamate 1.57 were found to be very 
potent inhibitors of TMPKmt.  With a Ki of 3.5 µM, the thiocarbamate showed the highest 
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TMPKmt inhibitory activity at that time.  Moreover, these compounds showed a very high 
selectivity.107 
Due to the extra space needed to fit the bicyclic compounds in the active site, the high 
activity of these compounds was unexpected.  Modelling indicated that the 2’,3’-substituted 
6-membered ring forces the 6’-nitrogen into the most appropriate position for interaction with 
the Asp9 residue in the enzyme cavity.  The sulfur atom, in its turn, forms hydrophobic 
interactions with Tyr103 and Tyr165 residues.  The smaller oxygen in the carbamate 
compound fills the 3’-cavity less efficiently, which resulted in a lower affinity for the enzyme.  
However, despite their high affinities for the enzyme both bicyclic nucleosides failed to inhibit 
the growth of M. tuberculosis H37Rv strain, limiting further potential of these compounds as 
antituberculosis agents.  Nevertheless we believed these hits were valuable starting points 
for further optimisation. 
 
♦ Sugar puckering 
Apart from the substitution pattern of the sugar, the conformational behaviour of 
nucleosides is considered to be of great importance for their interaction with target 
proteins and hence for their biological activity.110  As a planar furanose conformation is 
energetically highly unfavourable, the ring atoms are displayed out of the plane, giving rise to 
ring puckering.   
The complete definition of the conformation of a nucleoside involves the determination of 
three principal structural parameters: (1) the glycosyl torsion angle χ, which determines the 
relative position of the base to the sugar moiety (syn or anti); (2) the torsion angle γ, 
determining the orientation of the 5’-OH with respect to C3’; and (3) the puckering of the 
furanose ring (pseudorotation P) and its deviation from planarity (maximum out-of-plane 
pucker νmax).111  In the present study the most important determinant is the ring puckering 
because it is able to influence the χ- and γ-angle and it is established that TMPKmt prefers 
to bind its substrate and related analogues with the thymine moiety in the anti-position and 
prefers a specific rotamer (γ-angle) around the C4’-C5’- bond upon binding.  By convention, 
a pseudorotation angle P = 0° corresponds to the ab solute Northern conformation (C2’-exo-
C3’-endo), whereas the Southern conformation (C2’-endo-C3’-exo) is represented by P= 
180°. 112  The sugar puckering of natural ribo- and deoxyribonucleosides in solution appears 
to be a dynamic equilibrium between those two major conformers, the North (N) and the 
South (S) type, with a very low energy barrier between the N- and the S-state.  These two 
conformations are depicted in the pseudorotational cycle, shown in Figure 1.23. 
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Figure 1.23 Pseudorotational cycle 
 
In the solid state, one of the two solution conformations is usually present, determined 
mainly by crystal packing forces.  The activity on the enzyme is mainly determined by the 
adopted sugar puckering of the nucleoside in solution.  The more this puckering corresponds 
to the conformation in which the nucleoside binds to the enzyme, the easier this nucleoside 
fits into the active site.   
Additionally, other structural features of nucleosides like rotamers about C1’-N1 and C4’-C5’ 
and C5’-O5’ bonds affect the affinity for the enzyme.  As a result, conformation-activity 
studies based exclusively on solid-state conformational parameters are often not very 
significant. 
Since the X-ray analysis of the dTMP-TMPKmt complex indicates that the substrate adopts 
a Southern conformation with the base in an equatorial orientation,95 one would expect 
that nucleoside analogues that exhibit a similar S-type conformation would have an optimal 
affinity for TMPKmt.109 
Each of the substituents influences the conformation of the sugar which complicates the 
prediction of the preferred conformation of new nucleoside analogues.  Additionally, the 
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sugar has a constant conformational mobility between a North and South configuration.  This 
makes it first of all difficult to determine the general conformation of a molecule in solution, 
and when the energy needed to change between the two conformations is very low, this 
diminishes the influence of the conformation on activity.  Moreover, the amino acid chains in 
the active site have some flexibility, allowing the enzyme to be favourable for one certain 
conformation for one type of modification and to be disadvantageous for another one.  This 
is illustrated by the activity of the earlier described 3’-C-branched chain nucleosides.  
Modelling indicated that these nucleosides bind to TMPKmt in the N- (northern, 2’-exo-3’-
endo) conformation.  While this conformation is known to be the opposite of the natural 
substrate binding to the enzyme, in this case it is favourable as it enables interactions 
between the 3’-C-substituent and Asp9.  Thus, although the conformational behaviour of 
nucleosides is an important feature, it renders the prediction of binding affinities of 
nucleoside analogues difficult.   
For this reason, conformationally restrained nucleosides have been synthesized in which an 
extra ring locks the conformation in one preferred conformation.  This makes it possible to 
predict and determine this one conformation, and to study the influence of the conformation 
on the biological activity. 
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1.5 OBJECTIVES  
 
1. Rational design of TMPKmt inhibitors 
 
By making use of different techniques of rational drug design, described in 1.3, we aimed to 
synthesize potent and selective inhibitors of TMPKmt.  Both modelling, docking and 
Quantitative Structure-Activity-Relationship analysis were used throughout this work to 
facilitate the search for interesting TMPKmt inhibitors. 
 
2. Profound understanding of enzyme binding 
 
As the X-ray structure of the enzyme is known, the way of binding of new inhibitors can be 
studied in detail.  By making use of docking techniques, clear and innovative design 
hypotheses could be stated, and consequently be tested and proven by the synthesis of 
thymidine derivatives. 
 
3. Applicability as useful drugs 
 
The overall ambition of this thesis goes beyond enzyme inhibition.  Although bacterial uptake 
puts an extra challenge on molecule synthesis, our clear goal was to integrate and 
incorporate the different aspects of useful drug design.  For this reason, we focused not only 
the inhibitory activity and selectivity, but also the low toxicity and bacterial uptake were taken 
into account.  
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1.6 STRUCTURE OF THIS THESIS 
 
In chapter 2 a number of hybrid nucleosides were designed, based on modifications that 
were earlier discovered as favourable for good affinity for TMPKmt, i.e. 5’-amino-3’-azido 
and 2’-fluoro-2’-deoxy-arabino thymidine analogues.  
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Figure 1.24 Target molecules, described in chapter 2 
 
As described in the initial structure-activity relationship, the presence of sterically more 
demanding nitrogen containing substituents at the 3’-position resulted in good activities.   
Moreover some interesting compounds have been discovered recently, two bicyclic 
compounds and a dinucleoside, all showing a good inhibitory activity, and characterized by 
an extra carbon atom at the 3’-position. Some extra attention will therefore be paid to the 
introduction of an extra carbon at this position and is described in chapter 3. 
 
 
Two interesting recently discovered potent TMPKmt inhibitors are the 2’-3’-bicyclic 
nucleosides.  The synthesis of alternative fused 5- and 6-membered rings intends the 
optimisation of those compounds and can yield a better understanding of the binding mode 
of those compounds. 
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Figure 1.25 Alternative 2’,3’-fused 5- and 6-membered bicyclic thymidine derivatives, described in 
chapter 4. 
The discovery of dinucleoside 1.51 as TMPKmt inhibitor illustrated the possibility of TMPKmt 
to accommodate sterically more demanding substituents at the 3’-position.  In order to 
explore the feasibility to replace the second nucleoside, a series of 3’-branched thiourea 
substituted derivatives was envisaged.  Modelling and the studied structure-activity 
relationship can be used to develop new modifications in a rational way. 
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Figure 1.26 Exploration of dinucleoside 1.58, described in chapter 5 
 
Finally, the synthesized compounds were tested for their activity against other kinases than 
TMPK, which is described in Chapter 6. 
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2 SYNTHESIS AND BIOLOGICAL EVALUATION OF  
5’-AMINO AND 2’-FLUORO SUBSTITUTED  
3’-AZIDO-3’-DEOXYTHYMIDINE DERIVATIVES 
 
2.1 OBJECTIVE 
Combining modifications at different positions of the thymidine scaffold, individually leading 
to potent inhibitors, may result in more active compounds.  Consequently, the introduction of 
a 5’-amino function (as in 2.4) together with a 3’-azido group (as in AZT) on thymidine, was 
proposed as an interesting target molecule.  Apart from the expected synergistic activity of 
the two modifications, the 5’-amino-3’-azido-substituted nucleoside opens interesting 
perspectives for further modifications at the 5’-position (e.g. amideformation, ureum, 
carbamates,…). 
 
Table 2.1 Kinetic parameters of TMPKmt with compounds 2.4-2.6 
O
R3
N NH
O
O
R2 R1
 
Compound R1 R2 R3 Ki (µM) TMPK mt 
dTMP H OH OPO32- 4.5 a 
AZT H N3 H 28 
2.4108 H OH NH2 12 
2.5109 F N3 OH 118 
2.6109 F NH2 OH 190 
a
 Km-Value 
 
 
A second objective is based on the influence of fluorine on the conformation of a furanose 
ring.  Fluorine is known to serve as a hydroxyl mimic and to participate in hydrogen 
bonding.113  Its van der Waals radius (1.47 Å) is intermediate between that of hydrogen (1.2 
Å) and oxygen (1.6 Å) and its electronegativity is similar to that of hydroxyl, making it act as 
a H-bond acceptor.  Replacing a 2’-H atom by a fluorine has a significant influence on the 
resulting nucleoside.  Such modification not only stabilizes the glycosidic bond,114 it also 
influences the conformation of the furanose ring.115 
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The two main influences which affect the conformation of the furanose ring are the gauche 
effect and an additive anomeric effect. 
The anomeric effect favours the pseudoaxial position of an electronegative ligand at the C1’ 
position.  For the β-D-nucleosides, a pseudoaxial position at the C1’ position forces the 
sugar to adopt the North conformation (Figure 2.1).  Additionally, the anomeric effect is 
influenced by other effects like the stereo-electronic competition at the anomeric centre116 
and the influence of the chemical nature of nearby substituents on the anomeric strength.117 
The gauche effect causes the tendency of two vicinal electronegative ligands on a C-C 
bond to adopt a gauche conformation along this C-C bond.  This effect drives the sugar to 
the South conformation. 
As described earlier, a 2’-fluoro substituent in the ribo configuration (3.5 and 3.6) locks the 
sugar pucker in the North or C3’-endo conformation.  In a 2’-fluoro-ara-nucleoside, the 
gauche effect opposes the much weaker anomeric effect, resulting in a favourable South 
conformation.114 
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Figure 2.1 Conformational equilibrium for 2’-F-ribo and 2’-F-arabino thymidine.  The anomeric effect 
in the 2’-F-ribo configuration dominates, leading to a preferred North conformation.  For the 2’-F-
arabino configuration, the gauche effect opposes the weaker anomeric effect, resulting in a favourable 
South conformation. 
 
 
As dTMP binds TMPKmt in the South conformation, this conformation is expected to be 
preferable for compounds to exhibit a good binding affinity for the enzyme.  The opposite 
was illustrated by the weak activity of 3’-NH2 and 3’-N3 substituted derivatives containing a 
2’-F in ribo configuration (2.5 and 2.6).  Conformational analysis based on NMR coupling 
constants proved these compounds to be biased in North conformation in solution, which 
explains their moderate activity.109 
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Consequently, we considered the synthesis of analogues that combine a 3’-NH2 or 3’-N3 
modification and a 2’-F-ara-substituent an interesting objective. 
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Figure 2.2 Target molecules 
 
2.2 CHEMISTRY  
For the synthesis of 5’-amino-3’-azido-3’,5’-dideoxythymidine (See Scheme 2.1), we 
selected the natural nucleoside β-D-thymidine as a starting compound.  The main difficulty is 
the presence of two different nitrogen-substituents in the target analogue, a 5’-amino group 
and a 3’-azido function.  An azido group can be introduced rather easily and is inert to a lot 
of reaction conditions.  It is often used as a protected amine that can be ‘deprotected’ easily 
by Staudinger reduction or hydrogenolysis.  Regioselective azido reduction however is not 
possible, and consequently the two nitrogen containing substituents need to be introduced 
separately into this molecule.   
Based on the work of McGuigan et al.118 we used a tandem Mitsunobu reaction.  
Triphenylphosphine combines with DEAD to generate a phosphonium intermediate that 
binds to the 3’- and 5’-alchohol oxygen, activating them as a leaving group.  The 3’-leaving 
group immediately leads to 2,3’-O-anhydrothymidine, while the 5’-leaving group is 
substituted by phtalimide.  Opening of this 2,3’-O-anhydroring with NaN3 and subsequent 
deprotection of the 5’-phtalimide with hydrazine gave final compound 2.1 in an overall yield 
of 31%. 
HO
O
HO
N NH
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O
N
O N
NO OO
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O N NH
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Scheme 2.1, reagents and conditions: (a) phtalimide, Ph3P, DEAD, THF, rt, 16h, 60%; (b) NaN3, 
DMF, benzoic acid, 150 °C, 2h, 70%; (c) hydrazine, EtOH, 28 °C, 2d, 73%. 
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For the 2’-fluoro arabino compounds, the starting material of the synthesis was the 1,2-O-
isopropylidene-α-D-xylofuranose 2.8. 
The synthetic pathway depicted in Scheme 2.2 proved high-yielding and straight forward. 
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Scheme 2.2 , reagents and conditions: (a) TsCl, CH2Cl2, rt, 1h, 94%; (b) Na0, BnOH, 100 °C, 16h, 
78%; (c) (i) Tf2O, CH2Cl2, pyridine, 0 °C, 1h, (ii) TMGA, DMF, rt, 16h, 59%; (d) (i) HOAc/H2O 3:1, 80 
°C, 16h (ii) Ac2O, pyridine rt, 3h, 95%; (e) silylated thymine, TMSOTf, (CH2)2Cl2, 40 °C, 5h, 90%; (f) 
BOMCl, DBU, DMF, 0 °C, 40 min, 91%; (g) 1N NH3 in methanol, rt, 3h, 98%; (h) DAST, toluene, 
pyridine, 50 °C, 3h, 61%; (i) 1M BCl3, CH2Cl2 -78 °C, 15 min, 89%; (j) 10% Pd/C, MeOH, rt, 4h, 94%.  
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The most limiting step for an overall high yield is the introduction of the azidogroup on the 3-
position of the ribose-sugar.  Due to the antiperiplanar position of the triflate leaving group 
and the proton at the 4-position, elimination competes with SN2-substitution (See Scheme 
2.3), especially when the poorly soluble NaN3 is used.  In order to enlarge the amount of the 
desired 2.11, the better soluble N,N,N’,N’-tetramethylguanidinium azide was used.  As a 
result of faster substitution, a lower amount of elimination product is obtained. 
 
HO
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Scheme 2.3, reagents and condititons: (a) Tf2O, CH2Cl2, pyridine, -78 °C, 1h; (b) TMGA, DMF, rt, 
16h, 59% from 2.13. 
 
Deprotection of the 1,2-O-isopropylidene group in 75% acetic acid and subsequent 
protection of the alcohol functionalities resulted in the formation of the 3’-azido sugar building 
block, which after Vorbrüggen coupling, afforded 2’-O-acetyl-3’-azido-5’-O-benzyl- 
substituted thymidine in 90% yield.   
Deacetylation was performed with 1N ammonia in methanol.  The fluorine-atom is introduced 
by the fluorinating agent diethylaminosulfur trifluoride (DAST).  During this reaction, DAST is 
introduced as a leaving group at the free alcohol function, which can then be substituted by 
the fluorine anion.  In pyrimidine nucleosides however, a good leaving group at the 2’-ribo 
position is known to stimulate the intramolecular attack of the O-2 of the nucleobase, 
resulting in 2,2’-O-anhydrothymidine 2.17 (Scheme 2.4). 
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Scheme 2.4 Undesired 2,2’-anhydrothymidine formation 
 
For this reason, the N-3 of thymine was protected with a benzyloxymethyl group, thereby 
preventing anhydro formation.  Treatment of compound 2.15 with DAST resulted in the 2’-
arabino F-substituted compound.  After simultaneous deprotection of the benzyl and the 
benzyloxymethyl groups, the 3’-azido (2.2) and 3’-amino (2.3) substituted compounds were 
obtained.  
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2.3 BIOLOGICAL EVALUATION 
The three synthesized derivatives were tested for their affinity for TMPKmt via a reported 
spectrometric assay. 119 
In this spectrophotometric assay, the formation of thymidine diphosphate is coupled to 
reactions catalyzed by pyruvate kinase (PK) and lactate dehydrogenase (LDH) in the 
presence of phosphoenolpyruvate (PEP) and NADH, using NADH as indicator.  Each mole 
of transferred phosphoryl group generates two moles NDP (ADP and TDP) and 
consequently two moles of NADH are oxidised to NAD+. 
 
          TMPK 
        ATP   +   TMP                           ADP   +   TDP 
           PK 
 ADP   +   TDP   +   2 PEP               ATP   +   TTP   +   2 pyruvate 
             LDH 
 2 pyruvate + 2 (NADH + H+)            2 lactate + 2 NAD+ 
 
However, as the reactivity of various NDP’s towards PK can vary a lot, the coupling system 
may become rate limiting, which leads to underestimation of the phosphorylation rate.  
Adding NDP-kinase, with broad substrate specificity circumvents this problem. 
 
          TMPK 
        ATP   +   TMP                           ADP   +   TDP 
                                           NDPK 
        ATP   +   TDP                           ADP   +   TTP 
           PK 
      2 ADP   +   2 PEP                    2 ATP   +  2 pyruvate 
             LDH 
 2 pyruvate + 2 (NADH + H+)            2 lactate + 2 NAD+ 
 
From the spectrometrically measured decrease in NADH, the phosphorylation rate can be 
calculated.  In case the synthesised compounds are no substrates, their inhibitory capacity is 
determined.  At a fixed concentration of dTMP, the decrease in phosphorylation rate was 
measured, allowing the calculation of the Ki-value. 
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According to this biological assay, compounds 2.1, 2.2 and 2.3 were tested for their 
inhibitory activity against TMPKmt.  Their activities are shown in Table 2.2. 
 
 
a
 Km-Value 
 
Compound 2.1 can be considered as a hybrid structure of AZT (Ki = 28 µM) and 5’-NH2-5’-
deoxythymidine (2.4; Ki = 12 µM).  The combination of these two beneficial modifications 
however leads to a compound with only weak inhibitory activity (Ki = 152 µM).  One 
modification probably limits the good positioning of the other modification, thereby preventing 
this compound to optimally interact with the enzyme. 
 
Compounds 2.2 and 2.3, containing a 2’-F-substituent in the arabino configuration were 
designed to force the sugar into the South conformation.  The activities of 2.2 and 2.3 
appeared to be very weak.  To explain these disappointing results, a conformational analysis 
was performed. 
For each compound, three vicinal proton-proton and two vicinal proton-fluor coupling 
constants were measured at 500 MHz in DMSO at four different temperatures in a 298-328 
K range (See Table 2.3). 
 
 
 
 
 
 
 
 
 
 
Table 2.2 Kinetic parameters of TMPKmt with compounds 2.1-2.3 
O
R3
N NH
O
O
R2
R1
 
Compound R1 R2 R3 Ki (µM) TMPK mt 
Dtmp 
 
 
 4.5 a 
2.1 H N3 NH2 152 
2.2 F N3 OH 157 
2.3 F NH2 OH > 2000 
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Table 2.3 3JH,H and 3JH,F coupling constants (Hz) of 2.2 and 2.3 at four different 
temperatures 
 
3J1’2’ 3J2’3’ 3J3’4’ 3J1’F 3J3’F 
2.2 
     
298 1.76 4.60 8.79 19.12 23.26 
308 1.82 4.65 8.64 19.22 23.00 
318 1.85 4.70 8.63 19.27 22.71 
328 1.95 4.76 8.63 19.37 22.48 
2.3 
     
298 1.60 5.49 8.78 21.24 23.61 
308 1.73 5.44 8.80 21.18 23.11 
318 1.73 5.55 8.74 21.06 22.91 
328 1.78 5.61 8.73 21.06 22.81 
3JH,H recorded at 300 MHz in DMSO.  XS is the mole fraction in South conformation at 30 °C 
 
Subsequently, in collaboration with the Lab for NMR and structural analysis of the UGent, 
the Matlab graphical user interface for 5-membered rings was used to calculate the best fit 
for the coupling constants at the different temperatures for 2.2 and 2.3.  For both 
compounds, a best fit was found for a North conformation (P ~ 320, νm~70) and an East 
conformation (P ~ 90; νm= 90).   
For five-membered ring systems, this νm is normally between 30 and 60 degrees.  A value of 
90 degrees, obtained for the East conformation is physically impossible, which indicates that 
the used system is underdetermined.  This can be explained by the fact that not enough 
coupling constants are available for a reliable result. 
To answer this uncertainty, a systematic scan of the full pseudorotational cycle is performed 
(see Figure 2.3).  This scan shows the regions of the conformations for which a good 
similarity between the experimental and calculated coupling constants can be found.  This 
indicates that the Northern and Eastern part of the cycle enclose the regions that contain the 
most probable conformations of compounds 2.2 and 2.3, which is in agreement with the 
calculations of the graphical user interphase.  Most probably, the North and East 
conformation appear, but with different νm values as those calculated above.  The calculated 
ratio North/East is 63/37 for 2.2 and 50/50 for compound 2.3. 
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Figure 2.3 Pseudorotational mapping of compound 2.2 (left) and compound 2.3 (right); the red areas 
contain the conformations for which there is a very small difference between the expected and 
calculated NMR-data. 
 
 
While a 2’-F-arabino-substitution on β-D-thymidine is known to force the sugar into a South 
conformation, our results show that the additional influence of an N-containing substituent on 
the 3’-position dominates the effect of the 2’-F-substitution, leading to compounds with a 
furanose in the less preferable North and East conformations, which might explain the low 
affinities of compounds 2.2 and 2.3 for TMPKmt. 
 
2.4 CONCLUSION 
This chapter describes the synthesis and biological activities of compounds 2.1, 2.2 and 2.3. 
Compound 2.1 combines two beneficial substituents at the 3’- and 5’- position in an attempt 
to optimise the TMPKmt inhibitory activity.  This compound, however, showed only a 
moderate activity with a Ki of 152 µM, indicating that the two individually interesting 
modifications do not act synergistically. 
Compounds 2.2 and 2.3, which combine an amino or azido function at the 3’-position, with a 
2’-F-arabino group, intend to force the sugar ring in the preferable South conformation. 
Conformational analysis, however, indicated that these analogues did not adopt the intended 
conformation in solution.  Apparently, the presence of an additional N-containing substituent 
at the 3’-position favours the North or East conformation, which might explain the poor 
activities observed for 2.2 and 2.3. 
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2.5 EXPERIMENTAL PART 
Nucleoside nomenclature 
Since IUPAC nomenclature does not allow rapid visualisation of modified nucleosides, the 
typical nucleoside notation starts from the name of the natural nucleoside, to which the 
chemical modifications at the different positions are added.  This nomenclature is generally 
accepted in the nucleoside chemistry and is therefore generally used throughout this work.  
When an extra carbon is introduced at the 3’-position, it is described as C-6’.   
As these conventions can lead to misinterpretations if changes on the nucleoside structure 
modify the parent nucleoside too much, sometimes the IUPAC nomenclature should be 
used.  This is the case for the 2’,3’-bicyclic thymidine derivatives, described in chapter 4 
which differ too much from the natural nucleoside. 
 
Synthesis 
General 
NMR spectra were obtained with a Varian Mercury 300 spectrometer.  Chemical shifts are 
given in ppm (δ) relative to the residual solvent peak, in the case of DMSO-d6 2.54 ppm for 
1H and 40.5 ppm for 13C, in the case of CDCl3 7.26 ppm for 1H and 77.4 ppm for 13C.  All 
signals assigned to hydroxyl groups were exchangeable with D2O.  Mass spectra and exact 
mass measurements were performed on a quadrupole/orthogonal-acceleration time-of-flight 
(Q/oaTOF) tandem mass spectrometer (qT of 2, Micromass, Manchester, U.K.) equipped 
with a standard electrospray ionization (ESI) interface.  Samples were infused in a 2-
propanol/water (1:1) mixture at 3µL/min.  Precoated Merck silica gel F254 plates were used 
for TLC and spots were examined under UV light at 254 nm and revealed by sulfuric acid-
anisaldehyde spray.  Column chromatography was performed on ICN silica gel (63-200 µm, 
ICN, Asse Relegem, Belgium). 
 
Spectrophotometric binding assay 
The in vitro tests were conducted with recombinant enzymes overexpressed in E. coli: 
TMPKmt and TMPKh.  TMPKmt and TMPKh activity was determined using the coupled 
spectrophotometric assay described by Blondin et al.119 at 334 nm in an Eppendorf ECOM 
6122 photometer.  The reaction medium (0,5 ml final volume) contained 50 mM Tris-HCl pH 
7.4, 50 mM KCl, 2 mM MgCl2, 0.2 mM NADH, 1 mM phosphoenol pyruvate kinase and 2 
units each of lactate dehydrogenase, pyruvate kinase and nucleoside diphosphate kinase.  
The concentrations of ATP and dTMP were kept constant at 0.5 mM and 0.05 mM 
respectively, whereas the concentrations of the analogues varied between 0.01 and 2 mM. 
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Pseudorotational analysis 
Compounds 2.2 and 2.3 were dissolved in DMSO and high resolution 1D 1H spectra were 
recorded on a Bruker Avance 500MHz spectrometer on the standard TXI-probe.  Spectra 
were recorded at four temperatures between 298 and 328 K.  
 
For the calculation of the pseudorotational parameters, the Karplus equation as described by 
Donders et al.120 was used.  The group electronegativity-values used in this equation are 
shown below. 
 
 
1’- 2’ 0.68 1.37 0.56 1.40 
2’- 3’ 1.24 0.68 1.37 0.68 
3’- 4’ 1.40 0.68 0.65 1.24 
 
 
The pseudorotational analysis was performed using the Matlab graphical user interface for 
five-membered rings, at the Laboratory for NMR and structural analysis at UGent (Prof. 
Martins). 
 
 
2’,3’-O-Anhydro-5’-N-phtalimidyl-5’-deoxy-β-D-thymidine (2.7) 
To a solution of thymidine (300 mg, 1.24 mmol), phtalimide (200 mg, 1.36 mmol) and 
triphenylphosphine (357 mg, 1.36 mmol) in THF (8 mL), was added 
diisopropylazodicarboxylate (536 µL, 2.72 mmol) at 0 °C.  The reaction mixture was stirred 
at room temperature overnight.  Water (20 mL) was added and the reaction mixture was 
extracted with ethylacetate (3 x 20 mL).  The combined organic layers were dried over 
MgSO4, evaporated and purified by column chromatography (CH2Cl2/MeOH 95:5) to yield 
compound 2.7 (264 mg, 60 %) as a slightly yellow solid. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.79 (3H, d, 5-CH3), 2.48 (1H, m, H-2’), 
2.58 (1H, d, J= 12.9 Hz, H-2”), 3.71 (1H, dd, J= 8.7 and 14.4 Hz, H-5’), 
3.87 (1H, dd, J= 4.8 and 14.4 Hz, H-5”), 4.51 (1H, m, H-4’), 5.36 (1H, s, 
H-3’), 5.77 (1H, d, J= 3.6 Hz, H-1’), 7.55 (1H, s, H-6), 7.84 (4H, m, arom-
H). 
 
 HRMS (ESI-MS) for C18H16N3O5 [M+H]+ found, 354.1096; calcd, 354.1089. 
  
 
N
O N N
O
OO
O
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3’-Azido-3’,5’-dideoxy-5’-N-phtalimidyl-β-D-thymidine (2.8) 
A mixture of 2.7 (160 mg, 0.45 mmol) and NaN3 (146 mg, 2.25 mmol) was dissolved in DMF 
(3 mL) and heated to 150 °C.  After the addition of benzoic acid (55 mg, 0.45 mmol), the 
reaction was refluxed for 2 hours.  The reaction was quenched with water (10 mL) and the 
reaction mixture was extracted with ethylacetate (3 x 10 mL).  The combined organic layers 
were dried over MgSO4 and evaporated to dryness.  The residue was purified by column 
chromatography (CH2Cl2/MeOH 95:5), affording 2.8 (124 mg, 70%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.64 (3H, d, 5-CH3), 2.29 (1H, m, H-
2’), 2.48 (1H, m, H-2”), 3.89 (2H, m, H-5’ and H-5”), 3.98 (1H, m, H-
4’), 4.43 (1H, m, H-3’), 6.04 (1H, t, J= 6.3 Hz, H-1’), 7.44 (1H, s, H-6), 
7.84 (4H, m, arom-H). 
 
 
HRMS (ESI-MS) for C18H16N6O5Na [M+Na]+ found, 419.1084; calcd, 419.1080. 
 
 
5’-Amino-3’-azido-3’,5’-dideoxy-β-D-thymidine (2.1) 
Compound 2.8 (100 mg, 0.25 mmol) was dissolved in ethanol (3 mL) and hydrazine 
monohydrate (49 µl, 1 mmol) was added.  The reaction mixture was stirred at 28 °C during 2 
days, evaporated to dryness and purified by column chromatography (CH2Cl2/MeOH 90:10) 
to afford final compound 2.1 (48 mg, 73%) as a white solid. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.77 (3H, d, 5-CH3), 2.23 (1H, m, H-2’), 
2.37 (1H, m, H-2”), 2.75 (2H, d, J= 5.1 Hz, H-5’ and H-5”), 5.69 (1H, dd, J= 
5.1 and 9.9 Hz, H-3’), 4.39 (1H, m, H-4’), 6.05 (1H, t, J= 6.9 Hz, H-1’), 7.64 
(1H, s, H-6). 
 
HRMS (ESI-MS) for C10H15N6O3 [M+H]+ found, 267.1198; calcd, 267.1205. 
 
13C NMR (75 MHz, DMSO-d6): δ 12.57 (5-CH3), under DMSO (C-2’), 41.39 (C-5’), 61.37 (C-3’), 85.61 
(C-1’), 86.84 (C-4’), 110.79 (C-5), 138.56 (C-6), 151.11 (C-4), 164.82 (C-2). 
 
 
1,2-O-Isopropyl-5-tosyl-α-D-xylofuranose (2.9) 
1,2-O-isopropyl-α-D-xylofuranose (10 g, 53 mmol) was dissolved in pyridine (53 mL) and 
cooled to 0 °C.  A solution of para-toluenesulfonyl chloride (10.11 g, 53 mmol) in CH2Cl2 (25 
mL) was added.  After warming up to room temperature, the reaction was allowed to stir for 
1 h.  H2O (0.2 mL) was added and the obtained mixture was stirred for 30 minutes.   After 
the reaction mixture was evaporated in vacuo, the residue was partitioned between H2O 
N
O N NH
O
OO
O N3
H2N
O N NH
O
O
N3
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(100 mL) and CH2Cl2 (100 mL), and the aqueous layer was extracted with CH2Cl2 (4 x 100 
mL).  The combined organic layers were washed with water and brine, dried over MgSO4 
and concentrated in vacuo.  The resulting solid was washed with ether and filtered to afford 
2.9 (17.22 g, 94%) as a white powder. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.21 (3H, s, CH3), 1.33 (3H, s, CH3), 2.42 (3H, 
s, CH3Ph), 4.02 (2H, m, H-5 and H-5’), 4.13 (1H, m, H-3), 4.24 (1H , dd, J= 3.2 
and 10.5 Hz, H-4), 4.37 (1H, m, H-2), 5.41 (1H, d, J= 4.5 Hz, 3-OH), 5.81 (1H, 
d, J= 4.5 Hz, H-1), 7.49 (2H, d, J= 8.1 Hz, 2 ar H), 7.79 (2H, d, J= 8.1 Hz, 2 ar 
H); 
 
Exact mass (ESI-MS) for C15H21O7S [M+H]+ found, 345.1011; calcd, 345.1008. 
 
 
5-O-Benzyl-1,2-O-isopropyl-α-D-xylofuranose (2.10) 
Sodium metal (6.9 g, 300 mmol) was dissolved in benzyl alcohol (190 mL) at 100 °C and 
solid 2.9 (17.22 g, 50 mmol) was added.  The reaction mixture was heated at 100 °C 
overnight, cooled to room temperature and treated with H2O and glacial acetic acid till pH= 7.  
The mixture was partitioned between ether (150 mL) and H2O (100 mL).  The organic layer 
was washed twice with H2O (100 mL), dried over MgSO4, and evaporated.  The oily residue 
was purified by column chromatography (pentane/ethylacetate 85:15) to yield 2.10 (11 g, 
78%) as a white crystalline powder. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.23 (3H, s, CH3), 1.37 (3H, s, CH3), 3.52 (1H, 
dd, J= 7.1 and 10.5 Hz, H-5), 3.68 (1H, dd, J= 3.4 and 10.5 Hz, H-5’), 3.98 (1H, 
m, H-3), 4.14 (1H, m, H-4), 4.38 (1H, m, H-2), 4.50 (2H, s, CH2Ph), 5.22 (1H, d, 
J= 4.5 Hz, 3-OH), 5.82 (1H, d, J= 4.1 Hz, H-1), 7.33 (5H, m, CH2Ph). 
 
Exact mass (ESI-MS) for C15H21O5 [M+H]+ found, 281.1388; calcd, 281.1389. 
 
 
3-Azido-5-O-benzyl-1,2-O-isopropyl-α-D-ribofuranose (2.11) 
Compound 2.10 (6g, 20 mmol) was dissolved in CH2Cl2 (70 mL) and pyridine (5.5 mL).       
At -78 °C, triflic anhydride (4 mL, 24 mmol) was added slowly.  The reaction was allowed to 
warm up to 0 °C.  After 1 hour, the reaction was quenched with saturated NaHCO3-solution 
(75 mL) and extracted with CH2Cl2 (3 x 100 mL).  The combined organic layers were dried 
over MgSO4, evaporated to dryness and used immediately in the next reaction. 
The crude compound was dissolved in DMF (50 mL) and N,N,N’,N’-tetramethylguanidium 
azide was added (6.32 g, 40 mmol).  The reaction was stirred overnight, evaporated to 
HO
O
TsO
O
O
HO
O
O
OBnO
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dryness and purified by column chromatography (hexane/ethylacetate 97:3) to obtain 3.79 g 
(59%) of the pure compound 2.11 as a white solid. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.27 (3H, s, CH3), 1.43 (3H, s, CH3), 3.57 (2H, 
m, H-5a and H-3), 3.67 (1H, dd, J= 2.6 and 11.1 Hz, H-5b), 4.06 (1H, m, H-4), 
4.51 (2H, s, CH2Ph), 4.77 (1H, app t, J= 4.1 Hz, H-2), 5.78 (1H, d, J= 3.9 Hz, H-
1), 7.32 (5H, m, CH2Ph). 
 
HRMS (ESI-MS) for C15H20N3O4 [M+H]+ found, 306.1449; calcd, 306.1454. 
 
Elimination procuct: 
 
1H NMR (300 MHz, CDCl3): δ 1.47 (3H, s, CH3), 1.50 (3H, s, CH3), 4.83 (2H, s, H-
5a and H-5b), 5.31 (2H, m, H-2 and H-3), 4.51 (2H, s, CH2Ph), 6.13 (1H, d, J= 4.1 
Hz, H-1), 7.37 (5H, m, CH2Ph). 
 
HRMS (ESI-MS) for C15H18O4 [M+H]+ found, 263.1289; calcd, 263.1283. 
 
 
1,2-Di-O-acetyl-3-azido-5-O-benzyl-α-D-ribofuranose (2.12) 
A solution of 2.11 (3.48 g, 10.83 g) in acetic acid/water (3:1, 120 mL) was heated overnight 
at 80 °C.  The reaction mixture was evaporated to dryness and coevaporated with toluene 
(2x 15 mL).  The obtained compound was dissolved in pyridine (40 mL) and acetic anhydride 
(13 mL) was added.  This reaction was stirred for 3 hours under nitrogen atmosphere.  After 
evaporation, no further purification was needed to obtain the pure compound 2.12 (3.76 g, 
95%) as a white solid. 
 
 
1H NMR (300 MHz, DMSO-d6): δ 1.94 (3H, s, COCH3), 2.10 (3H, s, COCH3), 
3.59 (2H, m, H-5a and H-5b), 4.09 (1H, m, H-4), 4.42 (1H, dd, J= 4.8 and 7.8 
Hz, H-3), 4.54 (2H, s, CH2Ph), 5.31 (1H, d, J= 4.5 Hz, H-2), 5.97 (1H, s, H-1), 
7.33 (5H, m, CH2Ph). 
 
HRMS (ESI-MS) for C16H20N3O6 [M+H]+ found, 350.1354; calcd, 350.1352. 
 
 
2’-O-Acetyl-3’-azido-5’-O-benzyl-β-D-thymidine (2.13) 
Chlorotrimethylsilane (1.04 mL, 8.2 mmol) was added to a suspension of thymine (1.43 g, 
11.32 mmol) in HMDS (120 mL) and pyridine (10 mL).  The suspension was heated 
overnight at 130 °C.  The clear solution was cooled to room temperature, evaporated to 
dryness and coevaporated with toluene (2x 10 mL).  The silylated base was then dissolved 
N3
O
O
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in dry dichloroethane (40 mL).  Compound 2.12 was dissolved in 45 mL dichloroethane and 
added to the silylated base, followed by the dropwise addition of TMSOTf.  The clear 
solution was stirred at 40 °C for 5 hours.  After cooling down to room temperature, the 
reaction mixture was extracted with a saturated NaHCO3-solution (50 mL).  The water layer 
was extracted three times with CH2Cl2 (50 mL).  The organic layers were dried over MgSO4, 
evaporated and purified by column chromatography (hexane/ethylacetate 65:35) yielding 
3.85 g (90%) pure nucleoside 2.13 as a white foam. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.79 (3H, s, 5-CH3), 2.09 (3H, s, COCH3), 
3.67 (1H, dd, J= 3.3 and 11.1 Hz, H-5’), 3.78 (1H, dd, J= 2.5 and 11.1 Hz, 
H-5”), 4.06 (1H, m, H-4’), 4.59 (2H, s, CH2Ph), 4.62 (1H, app t, J= 5.5 Hz, 
H-3’), 5.47 (1H, app t, J= 5.5 Hz, H-2’), 5.91 (1H, d, J= 4.8 Hz, H-1’), 7.32 
(5H, m, CH2Ph), 7.53 (1H, s, H-6), 11.39 (1H, s, N(3)H). 
 
HRMS (ESI-MS) for C19H22N5O6 [M+H]+ found, 416.1572; calcd, 416.1569. 
 
 
2’-O-Acetyl-3’-azido-5’-O-benzyl-3-N-benzyloxymethyl-β-D-thymidine (2.14) 
Compound 2.13 (830 mg, 2 mmol) was dissolved in anhydrous DMF (20 mL).  DBU (301 µL, 
2 mmol) was added, followed by the addition of benzyloxymethylchloride (334 µl, 2.4 mmol) 
at 0 °C.  After stirring at this temperature for 40 minutes, the reaction was quenched with 
saturated NaHCO3-solution (25 mL) and extracted three times with CH2Cl2 (30 mL).  After 
drying over MgSO4 and evaporation, the crude material was purified by column 
chromatography (hexane/ethylacetate 85:15) yielding 974 mg 2.14 (91%) as a white foam. 
 
1H NMR (300 MHz, CDCl3): δ 1.55 (3H, d, J= 1.2 Hz, 5-CH3), 2.11 
(3H, s, COCH3), 3.66 (1H, dd, J= 2.2 and 11.0 Hz, H-5’), 3.89 (1H, 
dd, J= 2.2 and 11.0 Hz, H-5”), 4.11 (1H, m, H-4’), 4.35 (1H, app t, 
J= 5.7 Hz, H-3’), 4.68 and 4.64 (4H, 2 x s, 2 x CH2Ph), 5.34 (2H, s, 
NCH2O), 5.46 (1H, d, J= 0.9 Hz, H-2’), 6.09 (1H, d, J= 4.2 Hz, H-
1’), 7.33 (10H, m, 2 x CH2Ph), 7.44 (1H, d, J= 1.2 Hz, H-6). 
 
HRMS (ESI-MS) for C27H30N5O7 [M+H]+ found, 536.2142; calcd, 536.2145. 
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3’-Azido-5’-O-benzyl-3-N-benzyloxymethyl-β-D-thymidine (2.15) 
Compound 2.14 (970 mg, 1.81 mmol) was dissolved in 1N NH3 in methanol (20 mL).  The 
reaction was stirred at room temperature during 3 hours, evaporated to dryness and purified 
by column chromatography (hexane/ethylacetate 80:20) to yield 875 mg 2.15 (98%) as a 
slightly yellow foam. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.51 (3H, d, J= 0.9 Hz, 5-CH3), 
3.66 (1H, dd, J= 3.1 and 10.9 Hz, H-5’), 3.79 (1H, dd, J= 2.7 and 
10.8 Hz, H-5”), 4.08 (1H, m, H-4’), 4.18 (1H, app t, J= 5.3 Hz, H-3’), 
4.44 (1H, m, H-2’), 4.58 and 4.55 (4H, 2 x s, 2 x CH2Ph), 5.30 (2H, 
d, J= 1.8 Hz, NCH2O), 5.81 (1H, d, J= 5.2 Hz, 2’-OH), 6.21 (1H, d, 
J= 5.1 Hz, H-1’), 7.33 (10H, m, 2 x CH2Ph), 7.56 (1H, d, J= 1.1 Hz, 
H-6). 
 
 HRMS (ESI-MS) for C25H28N5O6 [M+H]+ found, 494.2032; calcd, 494.2039. 
 
 
1-(3-Azido-5-O-benzyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)3-N-benzyloxymethyl 
thymine (2.16) 
A solution of 2.15 (200 mg, 0.41 mmol) in toluene (4 mL) and pyridine (0.4 mL) was treated 
with DAST (201 µl, 1.52 mmol).  The reaction was stirred at room temperature during 2 
hours before heating it at 50 °C for 3 additional hours.  Ethylacetate (10 mL) was added to 
the reaction and the organic layer was washed with a saturated NaHCO3-solution (15 mL)  
and water (10 mL).  After drying over MgSO4, the combined organic layers were evaporated 
to dryness and purified by column chromatography (hexane/ethylacetate 80:20) to yield 126 
mg pure 2.16 (61%) as a white foam. 
 
 
1H NMR (300 MHz, DMSO-d6): δ 1.50 (3H, d, J= 1.1 Hz, 5-CH3), 
3.68 (1H, dd, J= 3.3 and 11.7 Hz, H-5’), 3.88 (1H, dd, J= 2.1 and 
11.7 Hz, H-5”), 4.18 (1H, m, H-4’), 4.32-4.45 (1H, ddd, J= 4.5, 9.0 
and 24.0 Hz, H-3’), 4.54 and 4.58 (4H, s and d, J= 2.4 Hz, 2 x 
CH2Ph), 5.28 (2H, s, NCH2O), 5.29-5.48 (1H, dd, J= 4.5 and 52.2 
Hz, H-2’), 5.92 (1H, d, J= 17.7 Hz, H-1’), 7.29 (10H, m, 2 x CH2Ph), 
7.57 (1H, d, J= 1.1 Hz, H-6). 
 
HRMS (ESI-MS) for C25H27N5O5F [M+H]+ found, 496.1991; calcd, 496.1996. 
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1-(3-Azido-2-deoxy-2-fluoro-β-D-arabinofuranosyl)thymine (2.2) 
Compound 2.16 (126 mg, 0.26 mmol) was dissolved in anhydrous CH2Cl2 (10 mL) and at -78 
°C a 1M BCl3 in CH2Cl2 (2.07 mL) was added dropwisely.  After 15 minutes, the reaction was 
quenched with methanol (10 mL).  The resulting mixture was evaporated to dryness and 
purified by column chromatography (CH2Cl2/MeOH 97:3 to 95:5) yielding 66 mg pure 
compound 2.2 (89%) as a white foam. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.72 (3H, d, J= 1.0 Hz, 5-CH3), 3.58 (1H, 
d, J= 12.3 Hz, H-5’), 3.78 (1H, d, J= 12.3 Hz, H-5”), 3.97 (1H, m, H-4’), 4.22-
4.35 (1H, ddd, J= 4.5, 8.7 and 23.4 Hz, H-3’), 5.30-5.50 (1H, ddd, J= 1.5, 
4.5 and 53.1 Hz, H-2’), 5.42 (1H, br s, (5’-OH), 5.87 (1H, dd, J= 1.5 and 17.7 
Hz, H-1’), 7.57 (1H, d, J= 1.1 Hz, H-6), 11.45 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.76 (5-CH3), 58.67 (J= 15.6 Hz, C-3’), 59.76 (C-5’), 81.58 (C-4’), 
88.38 (J= 34.6 Hz, C-2’), 94.68 (J= 186.4 Hz, C-1’), 110.10 (C-5), 136.89 (C-6), 150.84 (C-4), 164.52 
(C-2). 
 
19F NMR (300 MHz, DMSO-d6): δ -197.65. 
 
HRMS (ESI-MS) for C10H13N5O4F [M+H]+ found, 286.0955; calcd, 286.0952. 
 
 
1-(3-Amino-2-deoxy-2-fluoro-β-D-arabinofuranosyl)thymine (2.3) 
Compound 2.2 (47 mg, 0.16 mmol) was dissolved in methanol (5 mL) and after the addition 
of 10% Pd/C (5 mg), the reaction was stirred under H2-atmosphere for 4 hours.  After 
filtration over a celite path, the filtrate was evaporated to dryness and the crude residue was 
purified by column chromatography (CH2Cl2/MeOH 93:7) to yield 40 mg 2.3 (94%) as a white 
foam. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.73 (3H, s, 5-CH3), 3.61 (1H, m, H-5’), 
3.78 (1H, m, H-5”), 4.06 (1H, m, H-4’), 4.35 (1H, app t, J= 4.8 H-3’), 5.30-
5.50 (1H, dd, J= 4.6 and 52.4 Hz, H-2’), 5.31 (1H, br s, (5’-OH), 5.80 (1H, d, 
J= 21.0 Hz, H-1’), 7.70 (1H, s, H-6), 8.16 (2H, br s, 3’-NH2), 11.44 (1H, br s, 
N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.82 (5-CH3), 51.63 (J= 18.2 Hz, C-3’), 59.59 (C-5’), 84.88 (C-4’), 
88.36 (J= 35.7 Hz, C-2’), 96.88 (J= 180.5Hz, C-1’), 109.57 (C-5), 136.82 (C-6), 150.82 (C-4), 164.51 
(C-2). 
 
 
HRMS (ESI-MS) for C10H15N3O4F [M+H]+ found, 260.1048; calcd, 260.1046. 
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3 SYNTHESIS OF 3’-C-BRANCHED CHAIN THYMIDINE 
INTERMEDIATES
 
 
 
Many of the envisaged analogues in this work are structurally derived from a couple of hits, 
which are characterized by a 3’-CH2-X moiety (cf. supra).  As a consequence, 3’-C-
branched thymidine and ribo-thymidine constitute precious intermediates for the 
synthesis of these analogues.  As illustrated in Figure 3.1, 3’-aminomethyl ribothymidine and 
its 2’-deoxy analogue constitute important building blocks throughout this work.  Therefore, 
this chapter is devoted to possible strategies for the stereoselective introduction of a 3’-C-
branching on pyrimidine nucleosides.   
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Figure 3.1 Application of 3’-C-branched thymidine derivatives in this work 
 
 
3.1 NUCLEOSIDE SYNTHESIS 
The intense search for clinically useful nucleoside derivatives has resulted in a wealth of 
approaches for their synthesis.  In general, two main strategies for the synthesis of 
nucleoside analogues are followed.  In a first approach, the natural and readily available 
nucleoside is used to introduce the intended modifications.  Unfortunately, the reaction 
conditions required to introduce the desired modifications are not always compatible with the 
nucleoside.  Sometimes one does not profit from starting from the natural nucleoside.  In 
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these cases a second approach is followed, generally consisting of the glycosylation of a 
suitable sugar synthon with the desired nucleobase. 
A critical feature of the glycosylation step is stereoselectivity.  Generally, attack of the 
nucleobase from the β-side of the sugar, resulting in the formation of a β-nucleoside, is 
desirable.  A method developed by Vorbrüggen, uses silylated nucleobases and strong 
Lewis acids and provides reproducibly high yields of ribofuranose derivatives with reliable 
and predictable stereochemical outcome.121  As depicted in Scheme 3.1, the mechanism of 
the Vorbrüggen coupling method involves the conversion of a 1,2-diacetylated ribofuranosyl 
sugar 3.1 into a stable 1,2-acetyloxonium salt 3.3 by both assistance of the 2’-acetate group 
and a Lewis acid catalyst, trimethylsilyl triflate (3.2).  The resulting triflate anion reacts with 
the persilylated nucleobase to regenerate trimethylsilyl triflate, along with the simultaneous 
attack of the thymine from the β-face of the electrophilic ‘ribofuranose cation’ to afford 
exclusively the β-nucleoside 3.4.122 
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Scheme 3.1 The Vorbrüggen coupling reaction for the formation of β-ribonucleosides 
 
As the esterified 2’-OH-group contributes to the stereoselectivity, Vorbrüggen’s method can 
only be used for the synthesis of ribonucleosides. 
For the preparation of 2’-deoxynucleosides, where the driving force in the 
stereoselectivity of the glycosylsation is lacking, a different strategy is needed.  If attainable, 
starting from an available 2’-deoxynucleoside is the method of choice.  An alternative 
strategy involves the glycosylation of 2’-deoxyribose derivatives.  A major drawback of this 
approach is that it often produces hardly separable mixtures of α- and β-nucleosides.   
With the synthesis of ribo- as well as 2’-deoxy-3’-branched-thymidine analogues in view, 
strategies towards either type will be described in the following part. 
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3.2 SYNTHESIS OF 3’-C-BRANCHED RIBONUCLEOSIDES 
3.2.1 Synthesis of 3-C-branched ribofuranose  
Different methods for the formation of a 3-α-oriented carbon-containing substituent on 
ribofuranose have been reported.123,124,125  We will discuss the two most interesting 
procedures.  Both methods start from the commercially available or readily available 1,2-O-
isopropylidene-α-D-xylofuranose (2.8), which needs to be protected at the 5-position (3.5) 
(Scheme 3.2) prior to oxidation (Swern or Cr(VI)O3) of the 3-alcohol function to afford the 
pentofuranos-3-ulose 3.6.  In a first method the 3-keto group of 3.6 is converted into an 
exocyclic 3-methylene moiety (3.7) using a Wittig reaction.  Due to the sterical hindrance of 
the 1,2-O-isopropylidine protecting group, hydroboration of this methylene intermediate 3.7, 
selectively generates a 3-α-hydroxymethylated derivative 3.8 in an overall yield of 55%, 
starting from 2.8.123 
A second method124 relies on the stereoselective addition of KCN to the 3-keto function, 
leading to the xylo cyanoisomer 3.9.  Barton deoxygenation proved effective to obtain the 3-
α-cyano-sugar 3.10.  Next to the much lower yield described for this reaction pathway 
(22%), Filichev et al. also reported the presence of the 3-β-epimer, leading to hardly 
separable mixtures.124 
Consequently we chose to synthesize the sugar building block of 3’-azidomethyl-3’-
deoxythymidine according to the first method. 
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Scheme 3.2 Synthesis of 3’-branched ribofuranose: overview of two discussed methods 
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3.3 SYNTHESIS OF 3’-C-BRANCHED 2’-DEOXYNUCLEOSIDES 
3.3.1 Earlier observations 
For 2’-deoxynucleosides, which are lacking the 2’-OH, the stereoselective Vorbrüggen 
coupling is excluded.  Previous attempts in our laboratory to convert a 3’-azidomethyl-
ribonucleoside into a 2’-deoxynucleoside proved problematic.  During attempted Barton 
deoxygenation of a 2’-phenylthionocarbonate substituted 3’-azidomethyl-thymidine, no 
trace of the desired 2’-deoxygenated compound could be detected.  Instead, 
rearrangements gave rise to three unexpected nucleoside analogues, being two bicyclic 
nucleosides and one dinucleoside (See Scheme 1.1).107  This eliminates the use of Barton 
deoxygenation on 3’-azidomethyl substituted nucleosides. 
Vanheusden et al.106 described a divergent synthesis which utilizes a p-anisyl group to 
protect the 3-hydroxymethyl group of compound 3.8.  Coupling of this suitably protected 
sugar, afforded the ribo-thymidine derivative 3.11, for which uncomplicated 2’-deoxygenation 
proved feasible (Scheme 3.3).   
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Scheme 3.3 Barton deoxygenation on suitably protected 3’-C-branched ribothymidine 
 
An interesting feature of this reaction sequence was that it gave access to both thymidine 
and ribo-thymidine derivatives.  However this synthetic route proved very laborious.  Due to 
the introduction and removal of different protecting groups, 12 steps were required to obtain 
intermediate 3.12, which, we felt, is a major drawback of this approach.   
For this reason, Vorbrüggen coupling followed by 2’-deoxygenation was not considered as a 
convenient method to obtain 3’-C-branched thymidine analogues. 
 
In search for an alternative synthesis, we carried out a literature survey, from which the most 
interesting methods are described below. 
 
  Synthes is  of 3 ’-C-branched nuc leos ides 
  79 
3.3.2 Reported methods 
3.3.2.1 De novo sugar synthesis 
One of the oldest methods reported is the synthesis of Samuelsson starting from 1,4-
butenediol (Scheme 3.4).126  This method is not starting from a naturally available nucleoside 
and consequently it is not a method of first choice.  As it is a generally known old method 
and it illustrates the major drawback of non-stereoselective glycosylation of a 2’-
deoxynucleoside, it is described in this part. 
The furanose part was constructed using de novo sugar synthesis involving Sharpless 
epoxidation (3.13),127 regioselective alkylation of a 2,3-epoxy alcohol using allylmagnesium 
bromide (3.14), followed by oxidative cleavage of the double bond (3.16).  The resulting 
protected furanose derivative was condensed with silylated base, which after deprotection 
and separation of α- and β-isomers, provided the nucleoside analogues (3.17).  Although 
this route was explored for the synthesis of 3’-C-branched nucleosides, it is obvious that the 
poor stereoselectivity observed in the late-stage glycosylation step (1.4:1 α:β) prevents 
efficient preparation of 3’-C-branched β-nucleosides.128 
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Scheme 3.4, reagents and conditions: (a) (i) RBr, NaH, THF, TBAI, rt, 15h; (ii) Ti(O-iPr)4, 
diisopropyltartrate, tert-butyl hydroxyperoxide, -20 °C, 16h; (b) AllylMgBr, Et2O, -50 °C, 30 min; (c) 
BzCl, pyridine, 0 °C, 15 min; (d) (i) OsO4, NMNO, THF/H2O, rt, 16h; (ii) NaIO4, THF/H2O, rt, 30 min; 
(iii) Na, NH3, rt, 30 min; (e) silylated base, TBDMSOTf, CH2Cl2, rt, 24h. 
 
To circumvent problems associated with non-stereoselective glycosylation using 2’-deoxy 
sugars, we decided to use the 2’-deoxynucleoside thymidine with intrinsic β-
stereochemistry at the anomeric position as starting material.   
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3.3.2.2 Substitution of 3’-mesylate or 3’-triflate ester or opening of 2,3’-O-anhydro with 
cyanide 
Substitution of the β-oriented 3’-triflate (3.19) or 3’-mesylate esters of 2’-deoxynucleosides 
(3.20) with azide, amine and few carbon nucleophiles (e.g. cyano-anion) or opening of 2,3’-
O-anhydro-derivative (3.18) of 2’-deoxynucleosides with amines or azides has proven 
successfull.129  The synthesis of compounds 3.19 and 3.20 requires the inversion of the 
stereochemistry at the 3’-position, which is performed over 2,3’-O-anhydro derivative 3.18 
(Scheme 3.5). 
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Scheme 3.5, Reagents and conditions: (a) RCl; (b) MsCl, pyridine, 0 °C, 2h; (c) DBU, acetonitrile, 
reflux, 16h; (d) NaOH, EtOH/H2O, THF, rt, 4h; (e) MsCl or (CF3SO2)2O 
 
Although Schreiber130 reported the reaction of a 3’-triflate ester with NaCN to provide 3’-
cyano thymidine 3.21 along with the 2’,3’-olefin 3.22 in 71% yield (3.21:3.22 in a ratio 3:2), 
this method seemed not reproducible.128  Others131 tried to perform the same reaction using 
NaCN or Et4NCN but obtained only the undesired 2’,3’-didehydronucleoside 3.22. 
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Scheme 3.6 Strategy for nucleophilic attack of a cyanide ion 
 
Saha132 reported the reaction of anhydronucleoside 3.18 with CuCN in the presence of 
MeOTf to provide 3.23, the nitrile addition product being hydrolyzed to the carboxylic acid in 
the presence of cuprous ion (Scheme 3.7).  According to Faul et al. this reaction was not 
reproducible.128 
 
  Synthes is  of 3 ’-C-branched nuc leos ides 
  81 
aO N
NO O
RO
3.18
O T
HOOC
RO
3.23
 
Scheme 3.7, Reagents and conditions: (a) MeOTf, CuCN, rt 
 
As conflicting results were published concerning those reactions, compounds 3.20 and 3.18, 
obtained as intermediates during other synthesis pathways (see further), were used to 
repeat those reactions.  Compound 3.18 was reacted with trimethylsilyl cyanide in DMF.  
Neither heating, nor the addition of acid or Lewis acids appeared successful in the opening 
of the 2,3’-O-anhydro ring.  Compound 3.20 was treated with tetrabutylammonium cyanide in 
acetonitrile.  Elimination resulted in complete conversion to 3.22. 
From these results it coulcarbd be concluded that the cyanide appeared to be too weak as 
carbon nucleophile to open 2,3’-O-anhydrothymidine or to attack 3’-mesylated or triflated 
compounds.    
 
3.3.2.3 Metal-catalyzed hydroformylation of 2’,3’-didehydro-2’,3’-dideoxynucleosides 
A very direct approach involves the functionalization of 2’,3’-didehydro-2’,3’-
dideoxynucleoside 3.24 by hydrometalation-carbonylation, which provides the extra carbon 
at the 3’-position in one single step.128  Moreover, compound 3.24 can very easily be 
obtained from the antiviral drug d4T, which is commercially available and very cheap ($136/ 
50g).133  The major problem however is the regioselectivity.  As the obtained aldehydes are 
easily equilibrated to the desired erythro-isomer, the facial selectivity is less important. 
Using Rh(CO)2acac.PPh3 as a catalyst in the case of a uracil base regiomers 3.25 and 3.26 
were obtained in a 2.7:1 ratio in a total yield of 37%.  For cytidine counterpart a 3.2:1 ratio of 
3.25 and 3.26 was achieved in 42% yield. 
Although this reaction efficiently introduces the desired extra carbon, the resulting 
regioisomers are difficult to purify.  Not only the regioisomers need to be separated.  The 
presence of a very small amount of the unwanted epimers (<5%) further complicates the 
resolution of the reaction mixture.  
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Scheme 3.8 Hydrometalation-carbonylation 
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3.3.2.4 Free radical introduction of a 3’-substituent of 2’-deoxynucleosides 
A third method described in the literature uses a 3’-iodo or a 3’-phenoxythiocarbonyl 
substituted nucleoside, which is activated to a free radical after treatment with 2,2’-
azobisisobutyronitrile (AIBN) in benzene. 
It was demonstrated that β-tributylstannylstyrene-mediated C-C bond formation was able to 
generate a 3’-formyl functionality in ribonucleosides.134  Also the isocyanide radical can be 
used as the C-containing radical reagent, attacking the 3’-position.135 
The sterical hindrance of the selected 5’-O-protecting group as well as the nucleobase 
favours the radical attack from below, resulting in the desired erythro-configuration. 
The two different methods will be used in this work.  Reduction of the 3’-cyano compound 
leads to 3’-aminomethyl-3’-deoxythymidine, while 3’-styrene-3’-deoxythymidine can be 
converted to 3’-hydroxymethyl-3’-deoxythymidine by successive cis-dihydroxylation, 
periodate cleavage and final reduction.  For both procedures, the yield of the free radical 
reaction is around 60%. 
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Scheme 3.9 Radical introduction of a 3’-carbon 
 
 
3.4 RESULTS AND DISCUSSION 
3.4.1 3’-C-branched ribonucleosides 
For the synthesis of 3’-azidomethyl-3’-deoxythymidine, we started from 1,2-O-isopropyl-α-D-
xylofuranose (Scheme 3.10).  Reaction of the primary alcohol with TsCl gave 3.27, which 
was treated with the sodium salt of benzyl alcohol at 100 °C to afford 3.28, presumably via 
the intermediate oxetane.  At 70 °C only the intermediate oxetane was formed.  As this 
compound is volatile, the in situ conversion to the benzylated 3.28 at 100 °C is highly 
recommended.   
On this 5-protected sugar a 3-C-branching was introduced by successive Swern and Wittig 
reaction, followed by hydroboration.  After conversion of the 3-hydroxymethyl to an 
azidofunction by substituting the corresponding mesylate ester with NaN3 in DMF, the sugar 
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was prepared for Vörbruggen coupling, using a one-pot conversion of the 1,2-
isopropylidene-protected sugar into the 1,2-O-diacetylated protected sugar.  Coupling with 
persilylated thymine to afford compound 3.32 was realized in 95 % yield.  This precious ribo-
intermediate will be used in Chapter 4, for the synthesis of a series of 2’,3’-bicyclic 
nucleosides. 
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Scheme 3.10, reagents and conditions: (a)  (COCl)2, CH2Cl2, DMSO, -78 °C, 2h, then, TEA, rt, 2.5 
h; (b) CH3P(C6H5)3Br, NaH, DMSO, 70%, rt, 2.5h, 70% from 2.10; (c) 1M Borane/THF, 2N NaOH, 
35% H2O2, rt, 1.5 h, 79%; (d) i) CH3SO2Cl, pyridine, 0 °C, 1h; ii) NaN3, DMF, 60 °C, 16h, 77%; (e) i) 
75% CH3COOH, 80 °C, 16h; ii) (CH3CO)2O, rt, 3h, 74%; (f) silylated base, trimethylsilyltriflate, 
(CH2)2Cl2, 40 °C, 5h, 95%. 
 
3.4.2 3’-C-branched 2’-deoxynucleosides 
3.4.2.1 Radical cyanation 
We tried to reproduce the free radical introduction of a 3’-substituent.  The synthesis starts 
with protection of the 5’-hydroxyl function of β-D-thymidine, followed by iodination of the 3’-
hydroxyl function in 3.33 with methyltriphenoxyphosphonium iodide. 
Although a yield of around 60% has been described for the free radical reaction, in our 
hands compound 3.35 was only obtained in 32% yield.  This intermediate can further be 
reduced to obtain the 3’-aminomethyl substituted compound, used in chapter 5. 
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Scheme 3.11 , reagents and conditions: (a) TrCl, DMAP, pyridine, 65 °C, 16h, 83%; (b) 
CH3(PhO)3P+I-, DMF, rt, 16h, 60%; (c) t-BuNC, AIBN, (CH3)6Sn2, benzene, 80 °C, 13h, 32%. 
 
 
While Parkes et al. described stereoselective formation of the erythro-isomer,135 other 
groups reported the presence of the threo-isomer during this reaction.136  In our hands, the 
threo-isomer was not isolated, but as the reaction mixture contained several side products, it 
is not possible to exclude its formation.  A more polar compound was isolated in a 14% yield.  
NMR and mass spectroscopy elucidated that this compound was amide 3.36.  A possible 
mechanism for its formation is proposed in Scheme 3.12.  After the radical attack of tert-
butylisonitrile, the radical on the cyano-carbon is captured by water (during workup), or by 
radicals present in the reaction mixture, leading to amide 3.36 during workup of the reaction. 
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Scheme 3.12 Mechanism of the formation of the main side product 3.36 during radical cyanation 
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3.4.2.2 Radical introduction of β-styrene 
We followed the method of Shangvi et al.134 to generate a 3’-C-formyl functionality via an 
intermolecular radical C-C bond formation reaction.  The synthesis started from β-D-
thymidine.  Reaction of the primary alcohol with tert-butyldiphenylsilyl chloride gave 3.37, 
which was treated with phenylchlorothionoformate in acetonitrile to afford compound 3.38.  
Treatment with β-tributylstannyl styrene and 2,2’-azobisisobutyronitrile in benzene gave 
3.39.  A two-step one pot reaction involving cis-dihydroxylation with osmium tetroxide and 4-
methylmorpholine N-oxide as cooxidans, followed by sodium periodate cleavage of the diol, 
resulted in an unstable aldehyde, which was immediately reduced with sodium borohydride 
in aqueous ethanol to afford 3.40.  This compound forms an alternative strategy for the 
synthesis of 3’-C-branched thymidine derivatives in Chapter 5. 
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Scheme 3.13 , Reagents and conditions: (a) TBDPSCl, imidazole, DMF, rt, 16h, 80%; (b) 
PhOCSOCl, DMAP, acetonitrile, rt, 16h, 64%; (c) β-Bu3SnCH=CHPh, AIBN, benzene, reflux, 72h, 
24%; (d) (i) 4-NMO, OsO4, dioxane, rt, 16h; (ii) NaIO4, rt, 2h; (iii) NaBH4, EtOH/H2O, rt, 2h, 59%; 
 
 
3.4.2.3 Attempted opening of 2,3’-O-anhydrothymidine by 1,3-dithiane 
1,3-Dithiane acts as a sulfur-stabilized acyl anion equivalent and has been widely used as a 
masked nucleophilic acylating agent.137 
Treatment of 1,3-dithiane with n-BuLi, results in the formation of the (p,d)pi-stabilized anion.  
After reaction with an electrophile, hydrolysis of the dithioacetal moiety provides the 
corresponding aldehyde.  
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A review describing the use of dithiane in natural product synthesis illustrates the utility of 
epoxides, alkyl halides, sulphonates and triflates as ideal electrophiles to react with the 1,3-
dithiane anion.138  Since the use of triflates and sulphonates was anticipated to give 
elimination products, we decided to explore the use of the 2,3’-O-anhydrothymidine 
derivative 3.42 as electrophile ( 
Scheme 3.14). 
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Scheme 3.14 , Reagents and conditions: (a) TBDMSCl, DMAP, pyridine, 0 °C, 2h, 88%; (b) (i) 
MsCl, pyridine, 0 °C, 2h; (ii) DBU, acetonitrile, reflux, 16h, 95%; (c) 1,3-dithiane, n-BuLi, DMPU, THF, 
-20 °C to rt, 16h; (d) MeI, CaCO3, acetonitrile, H2O; (e) 1,3-dithiane, n-BuLi, BF3.etherate, THF, 
CH2Cl2, -20 °C to -10 °C, 2h. 
 
Unfortunately, no reaction could be observed.  Attempts to activate the anhydroring by the 
addition of Lewis acids (e.g. BF3) or metals (e.g. CuSO4) and the use of different solvents all 
failed. 
Interestingly, in case CH2Cl2 was used as solvent and BF3 as activating agent, the 
anhydroring was opened by a chloride anion, resulting in the undesired 3’-chloro substituted 
compound 3.45. 
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3.5 CONCLUSION 
So far, no short, high-yield procedure is known for the synthesis of nucleosides with an 
additional carbon at the 3’-position.  For the synthesis of a suitable 3’-C-branched chain 
ribonucleoside building block, we first constructed the sugar part, which was coupled with 
silylated thymine under Vorbrüggen conditions. 
2’-Deoxynucleosides were synthesized from β-D-thymidine using a radical introduction of a 
3’-C-containing substituent.  Attempts to use the 1,3-dithiane-anion to open 2,3’-O-
anhydrothymidine remained unsuccessful.    
 
 
3.6 EXPERIMENTAL PART 
 
5-O-Benzyl-3-deoxy-1,2-O-isopropylidene-3-methylene-α-D-ribofuranose (3.28) 
To a solution of oxalyl chloride (1.24 mL, 14.5 mmol) in CH2Cl2 (15 mL) at -78 °C, DMSO 
(2.06 mL, 29 mmol) in CH2Cl2 (9 mL) was added.  After stirring for 15 minutes, compound 
2.10 (3.9 g, 13.2 mmol) in CH2Cl2 (29 mL) was added dropwise.  The reaction was stirred at 
-78 °C for 2 h.  Triethylamine (3.54 mL, 43.4 mmol) was added and the reaction mixture was 
warmed to room temperature, stirred for 2.5 h, then poured into H2O (75 mL) and extracted 
with CH2Cl2 (3 x 75 mL).  The organic layer was washed with brine (50 mL), dried over 
MgSO4 and evaporated to dryness.  The crude ketone 3.27 was used in the next step 
without any further purification. 
 
A suspension of NaH (1.1 g, 46.3 mmol) in DMSO (60 mL) was heated at 65 °C under 
nitrogen atmosphere until all the sodium hydride was dissolved.  The solution was cooled to 
room temperature and methyltriphenylphosphonium bromide (18.2 g, 51 mmol) was added 
while stirring.  After 1.5 h, compound 3.27 (13.2 mmol) in DMSO (20 mL) was added and the 
mixture was stirred for 2.5 h.  The mixture was then poured into ice water (450 mL) and 
extracted with pentane (5 x 300 mL).  The organic layer was dried over MgSO4 and 
evaporated to give a syrup, which was purified by column chromatography 
(pentane/ethylacetate 97:3) to afford compound 3.28 (2.5 g, 70%) as a slightly yellow oil. 
 
1H NMR (300 MHz, CDCl3): δ 1.37 (3H, s, CH3), 1.50 (3H, s, CH3), 3.55 (1H, dd, 
J= 5.2 and 10.5 Hz, H-5), 3.66 (1H, dd, J= 3.5 and 10.5 Hz, H-5’), 4.57 (2H, s, 
CH2Ph), 4.87 (1H, m, H-4), 4.89 (1H, d, J= 4.1 Hz, H-2), 5.18 (1H, m, H-6), 5.41 
(1H, m, H-6’), 5.86 (1H, d, J= 4.1 Hz, H-1), 7.24-7.33 (5H, m, CH2Ph). 
 
Exact mass (ESI-MS) for C16H20O4Na [M+Na]+ found, 299.1261; calcd, 299.1259. 
H2C
O
O
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6
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5-O-Benzyl-3-hydroxymethyl-1,2-O-isopropyl-α-D-ribofuranose (3.29) 
To a solution of compound 3.28 (2.2 g, 7.9 mmol) in THF (16 mL) at 0 °C, a 1M borane/THF-
solution (17 mL) was added under vigorous stirring.  The solution was stirred at room 
temperature for 1.5 h.  After cooling to 0 °C, the mixture was subsequently treated with 
THF/H2O (8.1 mL, 1:1, v/v), 2 N NaOH (24.4 mL) and 35% H2O2 (10.5 mL).  The turbid 
mixture was stirred at room temperature for 1h.  Ether (50 mL) was added to the reaction 
mixture, which was then washed twice with ice water (30 mL) and brine (30 mL).  After 
drying over MgSO4, the solvents were evaporated and the residue was purified by column 
chromatography (CH2Cl2/MeOH 99:1) to yield compound 3.29 (1.83 g, 79%) as a white solid. 
 
1H NMR (300 MHz, CDCl3): δ 1.32 (3H, s, CH3), 1.51 (3H, s, CH3), 2.17 (1H, m, 
H-3), 3.59 (1H, dd, J= 6.6 and 10.6 Hz, H-6), 3.76-3.83 (3H, m, H-6’, H-5, H-5’), 
4.21 (1H, m, H-4), 4.59 (2H, s, CH2Ph), 4.75 (1H, dd, J= 3.5 and 4.2 Hz, H-2), 
5.81 (1H, d, J= 3.5 Hz, H-1), 7.28-7.35 (5H, m, CH2Ph). 
 
Exact mass (ESI-MS) for C16H22O5Na [M+Na]+ found, 317.1362; calcd, 317.1365. 
 
Next to desired compound 3.29, 10 %  (230 mg) of compound 3.29b was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.12 (3H, s, CH3), 1.17 (3H, s, CH3), 1.32 (3H, 
s, CH3), 3.46 (1H, dd, J=7.8 and 11.1 Hz, H-5), 3.62 (1H, dd, J= 5.4 and 11.2 
Hz, H-5’), 3.82 (1H, m, H-4), 4.10 (1H, d, J= 3.6, H-2), 4.47 (2H, s, CH2Ph), 4.97 
(1H, d, J= 0.6 Hz, 3-OH), 5.76 (1H, d, J= 3.5 Hz, H-1), 7.28-7.35 (5H, m, 
CH2Ph). 
 
 
3-Azidomethyl-5-O-benzyl-1,2-O-isopropyl-α-D-ribofuranose (3.30) 
To a solution of 3.29 (8.35 g, 28.4 mmol) in pyridine (100 mL) at 0 °C, methanesulfonyl 
chloride (5.7 mL, 73.8 mmol) was added.  The reaction mixture was stirred for 1 h at 0 °C.  
CH2Cl2 (75 mL) was added, and the organic layer was washed with NaHCO3 (75 mL) and 
H2O (75 mL), dried over MgSO4 and evaporated.   
A solution of the crude mesylated compound (28.4 mmol) and NaN3 (18.4 g, 284 mmol) in 
DMF (70 mL) was heated at 60 °C overnight.  The reaction mixture was evaporated in 
vacuo.  The residue was resolved in CH2Cl2 (75 mL), and washed with H2O (3 x 75 mL).  
The organic layer was dried over MgSO4, evaporated and purified by column 
chromatography (pentane/ethylacetate 95:5) to afford compound 3.30 (9.1 g, 77%) as a 
colourless oil. 
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1H NMR (300 MHz, DMSO-d6): δ 1.27 (3H, s, CH3), 1.39 (3H, s, CH3), 2.85 (1H, 
m, H-3), 3.38 (1H, m, H-6), 3.49 (2H, m, H-6’ and H-5), 3.62 (1H, m, H-5’), 3.88 
(1H, m, H-4), 4.48 (2H, s, CH2Ph), 4.69 (1H, dd, J= 2.7 and 3.6 Hz, H-2), 5.67 
(1H, d, J= 3.7 Hz, H-1), 7.31 (5H, m, CH2Ph).  
 
Exact mass (ESI-MS) for C16H21N3O4Na [M+Na]+ found, 342.1436; calcd, 342.1430. 
 
 
1,2-Di-O-acetyl-3-azidomethyl-5-O-benzyl-α-D-ribofuranose (3.31) 
A solution of 3.30 (1.19 g, 3.73 mmol) in acetic acid/H2O (3:1, 40 mL) was heated at 80 °C 
overnight.  The reaction mixture was evaporated to dryness and coevaporated twice with 
toluene (20 mL). 
The obtained residue was dissolved in pyridine (29 mL).  Acetic anhydride (4.44 mL) was 
added and the reaction was allowed to stir for 3 h at room temperature.  The resulting 
mixture was evaporated and purified by column chromatography (CH2Cl2/MeOH, 99:1) to 
obtain 3.31 (1.00 g, 74%) as a mixture of two anomers. 
 
NMR of the most polar anomer:  
1H NMR (300 MHz, CDCl3): δ 1.96 (3H, s, CH3), 2.17 (3H, s, CH3), 2.78 (1H, m, 
H-3), 3.52 (1H, dd, J= 6.6 and 12.4 Hz, H-6), 3.65 (1H, dd, J= 8.5 and 12.4 Hz, 
H-6’), 4.33-4.60 (3H, m, H-4, H-5 and H-5’), 4.54 (2H, s, CH2Ph), 5.29 (1H, d, J= 
4.7 Hz, H-2), 6.14 (1H, s, H-1), 7.31 (5H, m, CH2Ph). 
 
Exact mass (ESI-MS) for C17H21N3O6Na [M+Na]+ found, 386.1332; calcd, 386.1328. 
 
 
2’-O-Acetyl-3’-azidomethyl-5’-O-benzyl-β-D-thymidine (3.32) 
Thymine (2.22 g, 17.62 mmol) was dissolved in HMDS (100 mL) and pyridine (15.87 mL).  
TMSCl (1.61 mL) was added and the mixture was heated at 130 °C overnight.  After cooling 
of the clear reaction mixture, it was evaporated to dryness and coevaporated twice with 
toluene. 
The obtained silylated base was dissolved in dry (CH2)2Cl2 (10 mL).  Compound 3.31 was 
dissolved in (CH2)2Cl2 (10 mL) and added to the base.  TMS triflate (479 µL) was added and 
the clear solution was stirred at 40 °C during 5 h.  The reaction mixture was then extracted 
with CH2Cl2 (3 x 50 mL) and NaHCO3 (50 mL).  The organic layer was dried and evaporated 
to dryness.   The dry residue was purified by column chromatography to yield compound 
3.32 (6.88 g, 95%) as a white foam. 
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1H NMR (300 MHz, DMSO-d6): δ 1.53 (3H, s, CH3), 2.07 (3H, s, COCH3), 
2.79 (1H, m, H-3’), 3.48 (1H, m, H-6’), 3.61 (2H, m, H-6” and H-5’), 3.80 
(1H, m, H-5”), 4.11 (1H, m, H-4’), 4.55 (2H, s, CH2Ph), 5.39 (1H, m, H-2’), 
5.67 (1H, m, H-1’), 7.33 (5H, m, CH2Ph), 7.55 (1H, s, H-6), 11.29 (1H, br 
s, N(3)H). 
 
Exact mass (ESI-MS) for C20H24N5O6 [M+H]+ found, 430.1729; calcd, 430.1726. 
 
 
5’-O-Trityl-β-D-thymidine (3.33) 
To a solution of β-D-thymidine (5 g, 21.1 mmol) in anhydrous pyridine (50 mL) was added 
DMAP (2.8 g, 23.2 mmol) and trityl chloride (6.9 g, 24.8 mmol).  The mixture was heated to 
65 C and stirred overnight.  The reaction mixture was then diluted with CH2Cl2 (50 mL), 
washed with saturated aqueous NaHCO3 (3 x 100 mL), and dried over anhydrous MgSO4.  
The solvent was removed under reduced pressure and the resulting residue was purified by 
column chromatography (CH2Cl2/MeOH 98:2), affording 3.33 as a white foam (8.3 g, 83 %). 
 
1H NMR (300 MHz, CDCl3): δ 1.43 (3H, s, 5-CH3), 2.25-2.35 (1H, m, H-2’), 
2.40-2.51 (1H, m, H-2’’), 3.36 (2H, m, H-5’ and H-5’’), 4.09 (1H, d, J= 2.2 
Hz, H-3’), 4.58 (1H, t, J= 2.7, H-4’), 6.44 (1H, dd, J= 6.2 and 7.4 Hz, H-1’), 
7.21-7.41 (15H, m, Ph), 7.60 (1H, s, H-6). 
 
Exact mass (ESI-MS) for C29H28N2O5Na [M+Na]+ found, 507.1899; calcd, 507.1896. 
 
 
3’-Deoxy-3’-iodo-5’-O-trityl-β-D-thymidine (3.34) 
To a solution of 3.33 (3.1 g, 6.29 mmol) in 25 mL anhydrous DMF, methyltriphenoxy- 
phosphonium iodide (3.7 g, 8.18 mmol), freshly washed with EtOAc and subsequently dried, 
was added slowly.  The mixture was stirred at room temperature for 16 h.  The reaction was 
cooled to 0 °C and treated with 20 mL 10% aqueous Na2S2O3.  Addition of water was 
needed to effect separation of an oil.  The solvent was carefully decanted.  The residual oil 
was dissolved in 30 mL CH2Cl2 and washed three times with 75 mL water.  The water layer 
was extracted with CH2Cl2 and the combined organic layers were dried (MgSO4) and 
crystallised from CH2Cl2/MeOH 2/1, yielding pure compound 3.34 (2.24 g, 60%). 
 
1H NMR (300 MHz, CDCl3): δ 1.47 (3H, d, J= 0.8 Hz, 5-CH3), 2.77-2.82 
(2H, m, H-2’ and H-2’’), 3.47-3.60 (2H, m, H-5’ and H-5’’), 4.30 (1H, dt, J= 
2.0 and 8.6 Hz, H-4’), 4.48 (1H, dd, J= 8.5 and 8.8 Hz, H-3’), 6.15 (1H, dd, 
J= 4.2 and 5.9 Hz, H-1’), 7.24-7.45 (15H, m, Ph), 7.68 (1H, d, J= 0.9 Hz, H-
6), 9.63 (1H, br s, NH). 
 
Exact mass (ESI-MS) for C29H27N2O4INa [M+Na]+ found, 617.0919; calcd, 617.0915. 
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3’-Cyano-3’-deoxy-5’-O-trityl-β-D-thymidine (3.35) 
To a solution of 3.34 (3.00 g, 5.05 mmol) in benzene (120 mL) was added tert-butyl 
isocyanide (5.46 g, 65.65 mmol) and hexamethylditin (1.65 g, 5.05 mmol).  Before adding 
AIBN (415 mg, 2.53 mmol) to the reaction mixture, 40 mL of benzene was distilled under 
argon and removed.  The reaction mixture was heated at 80 °C for 13 hours.  After cooling, it 
was concentrated and purified by column chromatography (cyclohexane/ethylacetate 70:30) 
to give 800 mg of the pure 3.35 (32%). 
 
1H NMR (300 MHz, CDCl3): δ 1.57 (3H, s, 5-CH3), 2.60 (1H, m, H-2’), 2.74 
(1H, m, H-2’’), 3.42-3.64 (3H, m, H-3’, H-5’ and H-5’’), 4.28 (1H, m, H-4’), 
6.18 (1H, dd, J= 4.2 and 7.0 Hz, H-1’), 7.26-7.46 (16H, m, Ph and H-6), 
9.61 (1H, br s, NH). 
 
 
13C NMR (300 MHz, CDCl3): δ 12.02 (5-CH3), 28.12 (C-3’), 36.58 (C-2’), 61.88 (C-5’), 81.86 (C-4’), 
85.36 (CPh3), 87.60 (C-1’), 111.38 (C-5), 118.05 (CN), 127.61, 128.18, 128.52 (CPh3), 135.11 (C-6), 
142.97 (CPh3), 150.19 (C-2), 163.87 (C-4).  
 
Exact mass (ESI-MS) for C30H27N3O4Na [M+Na]+ found, 516.1905; calcd, 516.1899. 
 
 
3’-tert-Butylcarbamate-3’-deoxy-5’-O-trityl-β-D-thymidine (3.36) 
Compound 3.36 was obtained as an impurity of radical cyanation reaction in a yield of 14%. 
 
1H NMR (300 MHz, CDCl3): δ 1.21 (9H, s, (C(CH3)3)), 1.54 (3H, s, 5-CH3), 
2.25-2.35 (1H, m, H-2’), 2.77-2.88 (1H, m, H-2’’), 3.10 (1H, m, H-3’), 3.27 
(1H, dd, J= 3.0 and 10.9 Hz, H-5’), 3.66 (1H, dd, J= 2.7 and 11.2 Hz, H-5’’), 
4.22 (1H, dt, J= 2.7 and 9.0 Hz, H-4’), 6.13 (1H, dd, J= 3.0 and 7.2 Hz, H-
1’), 7.26-7.46 (15H, m, Ph), 7.65 (1H, s, H-6), 8.69 (1H, br s, NH). 
 
 
13C NMR (300 MHz, CDCl3): δ 12.05 (5-CH3), 28.60 (C-3’), 28.61 (C(CH3)3), 36.95 (C-2’), 45.01 
(C(CH3)3), 62.40 (C-5’), 83.08 (C-4’), 85.79 (CPh3), 87.18 (C-1’), 110.51 (C-5), 127.49, 128.08, 128.59 
(CPh3), 135.75 (C-6), 143.24 (CPh3), 150.02 (C-2), 163.76 (C-4), 169.13 (NHC=O). 
 
Exact mass (ESI-MS) for C34H37N3O5 [M+Na]+ found, 590.2000; calcd, 590.2631. 
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5’-O-tert-Butyldiphenylsilyl-β-D-thymidine (3.37) 
To a mixture of β-D-thymidine (12 g, 42.9 mmol) and imidazole (8.76 g, 128.7 mmol) in dry 
DMF (75 mL) was added slowly tert-butyldiphenylsilyl chloride (11.16 mL, 42.9 mmol).  The 
reaction was stirred at room temperature overnight and evaporated to dryness.  The organic 
residue was resolved in water (150 mL) and extracted with ethyl acetate (3 x 150 mL).  The 
combined organic layers were dried over MgSO4, filtered and concentrated.  The residue 
was purified by column chromatography (CH2Cl2/MeOH 97:3) to yield 3.37 (16.9 g, 80%) as 
a white foam. 
 
1H NMR (300 MHz, DMSO-d6): δ 0.99 (9H, s, tert-butyl), 1.48 (3H, s, 5-
CH3), 2.14 (2H, m, H-2’ and H-2”), 3.77 (1H, dd, J= 5.1 and 12.6 Hz, 
H-5’), 3.86 (2H, m, H-4’ and H-5”), 4.32 (1H, app s, H-3’), 5.33 (1H, 
app s, 3’-OH), 6.19 (1H, t, J= 6.9 Hz, H-1’), 7.37-7.46 (7H, m, 6 ar-H 
and H-6), 7.58-7.62 (4H, m, ar-H), 11.35 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C26H32N2O5SiNa [M+Na]+ found, 503.1979; calcd, 503.1978. 
 
 
5’-O-tert-Butyldiphenylsilyl-3’-deoxy-3’-O-(phenoxythiocarbonyl)-β-D-thymidine (3.38) 
To a solution of 3.37 (10.39 g, 21.61 mmol) and DMAP (5.28 g, 43.22 mmol) in dry 
acetonitrile (100 mL) at 0 °C was added dropwise phenylchlorothionoformate (5 g, 29 mmol).  
The reaction mixture was stirred at room temperature for 16 hours.  The next day, 
acetonitrile was removed in vacuo and the residue was purified by column chromatography 
(hexane/ethyl acetate 75:25) to afford 3.38 (8.5 g, 64%). 
 
1H NMR (300 MHz, DMSO-d6): δ 0.98 (9H, s, tert-butyl), 1.48 (3H, d, J= 
0.9 Hz, 5-CH3), 2.49-2.64 (2H, m, H-2’ and H-2”), 3.94 (2H, m, H-5’ and 
H-5”), 4.33 (1H, m, H-4’), 5.82 (1H, d, J= 6.0 Hz, H-3’), 6.22 (1H, dd, J= 
5.7 and 9.0 Hz, H-1’), 7.16-7.19 (2H, m, 2 ar-H), 7.32-7.46 (10H, m, 9 
ar-H and H-6), 7.59-7.62 (4H, m, ar-H), 11.35 (1H, br s, N(3)H). 
 
 
Exact mass (ESI-MS) for C33H36N2O6SSiNa [M+Na]+ found, 639.1957; calcd, 639.1961. 
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5’-O-tert-Butyldiphenylsilyl-3’-deoxy-3’-O-((E)-phenylethenyl)-β-D-thymidine (3.39) 
To a solution of carbonothioate 3.38 (7.3 g, 11.85 mmol) in benzene (40 mL) was added β-
tributylstannylstyrene (11.64 g, 29.62 mmol) in 20 mL benzene.  The resulted solution was 
degassed twice with nitrogen during 30 minutes (1 x at room temperature; 1 x at 45 °C).  
2,2’-azo-bis-isobutyronitrile (AIBN; 583 mg, 3.56 mmol) was added and the solution was 
refluxed for 2 h.  A second portion of AIBN (583 mg, 3.56 mmol) was added after cooling the 
reaction mixture to 40 °C.  The reaction mixture was refluxed again for 2 h.  This procedure 
was repeated 10 times over a period of 72 hours (total amount of AIBN: 6.99 g).  After 
evaporation of the solvent, the residue was purified by column chromatography 
(hexane/ethyl acetate 85:15) to give 3.39 as an oil (1.8 g, 24%). 
 
 
1H NMR (300 MHz, CDCl3): δ 1.05 (9H, s, tert-butyl), 1.54 (3H, s, 5-
CH3), 2.22-2.40 (2H, m, H-2’ and H-2”), 3.26 (1H, m, H-3’), 3.85 (1H, m, 
H-4’), 4.10 (2H, m, H-5’ and H-5”), 5.98 (1H, dd, J= 8.4 and 15.9 Hz, 
CH-6’), 6.19 (1H, dd, J= 3.3 and 7.2 Hz, H-1’), 6.50 (1H, d, J= 15.6 Hz, 
CH-Ph), 7.25-7.41 (11H, m, 11 ar-H), 7.55 (1H, d, J= 1.2 Hz, H-6), 7.67 
(4H, m, ar-H), 8.21 (1H, br s, N(3)H). 
 
 
Exact mass (ESI-MS) for C34H38N2O4SiNa [M+Na]+ found, 589.2492; calcd, 589.2499. 
 
 
5’-O-tert-Butyldiphenylsilyl-3’-deoxy-3’-(hydroxymethyl)-β-D-thymidine (3.40) 
To a mixture of 3.39 (1.8 g, 3.11 mmol) and 4-methylmorpholine N-oxide (546 mg, 4.66 
mmol) in dioxane (50 mL) was added an aqueous solution of OsO4 (1 mL, 0.16 mmol, 1% in 
water).  After stirring overnight at room temperature under light protection, the reaction was 
completed.  Sodium periodate (1.33 g, 6.22 mmol) was added and after 2 h the oxidative 
cleavage was completed.  The mixture was diluted with ethyl acetate, filtered through a celite 
path and solids were washed with ethyl acetate.  The combined filtrates were washed with 
brine, dried over MgSO4 and evaporated under reduced pressure.  To the crude resulting 
aldehyde dissolved in ethanol/water (4:1, 45 mL) at 0 °C was added NaBH4 (540.8 mg, 14.3 
mmol) in small portions.  After 2 h at room temperature, the reaction mixture was diluted with 
ethyl acetate and washed with water.  The organic layer was dried over MgSO4 and 
concentrated to dryness.  After purification by column chromatography (CH2Cl2/MeOH 97:3), 
compound 3.40 (900 mg, 59% from 3.39) was isolated as a white foam. 
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1H NMR (300 MHz, DMSO-d6): δ 1.00 (9H, s, tert-but), 1.49 (3H, s, 5-
CH3), 2.03-2.19 (2H, m, H-2’ and H-2”), 2.48 (under DMSO-signal, H-
3’), 3.43 (2H, d, J= 5.1 Hz, H-6’ and H-6”), 3.77 ( 1H, dd, J= 4.2 and 
10.5 Hz, H-5’), 3.86-3.95 (2H, m, H-4’ and H-5”), 4.77 (1H, br s, 6’-OH), 
6.03 (1H, dd, J= 5.4 and 6.6 Hz, H-1’), 7.37-7.44 (7H, m, 6 ar-H and H-
6), 7.61-7.64 (4H, m, 4 ar-H), 11.23 (1H, br s, N(3)H). 
 
 Exact mass (ESI-MS) for C27H34N2O5SiNa [M+Na]+ found, 517.2139; calcd, 517.2134. 
 
 
5’-O-tert-Butyldimethylsilyl-β-D-thymidine (3.41) 
β-D-thymidine (13.47 g, 55.6 mmol) and DMAP (1.7 g, 13.9 mmol) were dissolved in pyridine 
(110 mL).  Tert-butyldimethylsilyl chloride (7.96 g, 52.8 mmol) was added at 0 °C and the 
reaction was stirred at this temperature for 2 hours.  10 mL of water was added to quench 
the reaction.  The reaction mixture was evaporated to dryness, resolved in ethylacetate (75 
mL), and washed with water (75 mL).  After drying over MgSO4, the organic layer was 
evaporated and the crude oil was purified by column chromatography (CH2Cl2/MeOH 95:5) 
to obtain compound 3.41 (19.82 g, 88%) as a white foam. 
 
1H NMR (300 MHz, DMSO-d6): δ 0.00 (6H, s, 2x CH3), 0.92 (9H, s, tert-
butyl), 1.73 (3H, s, 5-CH3), 2.04 (2H, m, H-2’ and H-2”), 3.73 (3H, m, H-
4’, H-5’ and H-5”), 4.16 (1H, app s, H-3’), 5.26 (1H, app s, 3’-OH), 6.13 
(1H, t, J= 6.9 Hz, H-1’), 7.44 (1H, d, J= 1.2 Hz, H-6), 11.31 (1H, br s, 
N(3)H). 
 
Exact mass (ESI-MS) for C16H28N2O5SiNa [M+Na]+ found, 379.1663; calcd, 379.1665. 
 
 
  
5’-O-tert-Butyldimethylsilyl-2,3’-anhydro-β-D-thymidine (3.42) 
To an ice-cooled solution of 3.41 (1g, 2.8 mmol) in pyridine (7.5 mL) was added 
methanesulfonyl chloride (326 µl, 4.2 mmol).  The reaction mixture was stirred for 2 hours, 
quenched with NaHCO3 (15 mL) and extracted with ethyl acetate (3 x 25 mL).  The 
combined organic layers were dried over MgSO4, evaporated to dryness and the obtained 
white foam was dissolved in acetonitrile (12 mL).  After the addition of DBU (453 µL, 3.0 
mmol) the reaction was refluxed overnight.  The reaction mixture was evaporated to dryness 
and purified by column chromatography (CH2Cl2/MeOH 97:3) to yield 3.42 (899 mg, 95%) as 
a white foam. 
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1H NMR (300 MHz, DMSO-d6): δ 0.00 (6H, s, 2x CH3), 0.83 (9H, s, 
tert-butyl), 1.73 (3H, d, J= 1.2 Hz, 5-CH3), 2.44 (1H, ddd, J= 2.7 and 
12.9 Hz, H-2’), 2.53 (1H, ddd, J= 1.5 and 12.9 Hz, H-2”), 3.66 (2H, m, 
H-5’ and H-5”), 4.22 (1H, ddd, J= 2.4 and 6.3 Hz, H-4’), 5.21 (1H, d, J= 
2.1 Hz, H-3’), 5.81 (1H, d, J= 3.9 Hz, H-1’), 7.55 (1H, d, J= 1.2 Hz, H-
6). 
 
Exact mass (ESI-MS) for C16H26N2O4SiNa [M+Na]+ found, 361.1555; calcd, 361.1560; 
 
 
Attempted opening of 3.42 with 1,3-dithiane 
To a stirred solution of dithiane (254 mg, 2.11 mmol) in anhydrous THF (4 mL) at -20 °C, n-
BuLi (1.26 mL, 2.01 mmol) was added over a period of 30 minutes.  This mixture was stirred 
for 2 hours, while the temperature increased to -15 °C.  DMPU (506 mL, 4.2 mmol) was 
added, followed by the dropwise addition of 3.42 (150 mg, 0.42 mmol) in anhydrous THF (5 
mL).  The reaction was stirred at -10 °C for 10 hours and then at room temperature 
overnight.  No reaction could be observed. 
 
When performing this reaction in CH2Cl2 with the addition of BF3.etherate, a product was 
isolated which arose from opening of the anhydroring by a chlorine anion (3.45). 
 
1H NMR (300 MHz, CDCl3): δ 0.00 (6H, s, 2x CH3), 0.80 (9H, s, tert-
butyl), 1.79 (3H, s, 5-CH3), 2.32 (1H, m, H-2’), 2.48 (1H, m, H-2”), 3.85 
(1H, dd, J= 2.2 and 16.0 Hz, H-5’), 3.95 (1H, dd, J= 2.1 and 15.8 Hz, 
H-5”), 4.21 (1H, m, H-4’), 4.30 (1H, m, H-3’), 6.35 (1H, t, J= 6.3 Hz, H-
1’), 7.47 (1H, s, H-6), 8.17 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C16H27N2O4SiClNa [M+Na]+ found, 397.1326; calcd, 397.1326. 
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4 SYNTHESIS AND BIOLOGICAL EVALUATION OF BICYCLIC 
NUCLEOSIDES
 
 
 
4.1 OBJECTIVE 
 
As described in the initial structure-activity relationship, two interesting bicyclic nucleosides 
with promising TMPKmt inhibitory potency have been discovered.  The structure of these 
nucleosides is shown in Figure 4.1.  The second ring is fused to the sugar ring involving its 
2’,3’-bond.  The fused six-membered ring is built up as a thiocarbamate (4.1) or a carbamate 
(4.2).  Except for their high affinity for the mycobacterial TMPK, they also show only a low 
affinity for the human enzyme, resulting in a very selective activity. 
 
4.1. X= S 
Ki(TMPKmt) = 3.5 µM
Ki(TMPKh) = 700 µM
4.2. X= O
Ki(TMPKmt) = 13.5 µM
Ki(TMPKh) = 1100 µM
O N NH
O
O
HO
HN
O
X
 
Figure 4.1 Bicyclic TMPKmt inhibitors, used as leads in this chapter 
 
The present synthetic work was directed towards functional, structural and conformational 
variations of these bicyclic derivatives to gain further insight into their binding mode and to 
improve inhibitory activity.   
First, a series of bicyclic six-membered derivatives 4.3, 4.4 and 4.5 (Figure 4.2) was 
envisaged in which the thiourethane moiety of 4.1 was replaced by a thiourea, a urea and a 
guanidine function respectively.  The goal of introducing a guanidine functionality was to 
investigate if delocalisation of a positive charge might account for an optimal interaction with 
the carboxylate residue of Asp 9, which is one of the important amino acids in the active site 
of TMPKmt.95  A second modification consisted of a ring contraction, resulting in five-
membered bicyclic nucleosides 4.6 and 4.7. 
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4.3: R = S
4.4: R = O
4.5: R= NH
HN
O N NH
O
O
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4.6: R = S
4.7: R = O
O N NH
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O
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O
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S
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Figure 4.2 Overview of the synthesized bicyclic nucleosides 
 
To investigate the influence of a different sugar puckering on binding the enzyme, an 
analogue with inverted configuration at C-2’ (4.8) was considered. 
Despite the fact that compound 4.1 is a potent inhibitor of TMPKmt, it failed to inhibit the 
growth of the M. tuberculosis H37Rv strain.  As described earlier, an important hurdle in drug 
development for TB is the very low permeability of the cell wall.  Hence, a more apolar 
derivative (4.9) was designed in order to penetrate the lipophilic bacterial cell wall more 
easily.  This 5’-deoxy analogue also allows to further investigate the contribution of the 5’-
hydroxyl group on enzyme affinity.  Munier-Lehmann et al.139 already demonstrated that 
removal of the 5’-OH group of thymidine improved the affinity for TMPKmt. 
As mentioned before, the conformational behaviour of nucleosides is considered to be of 
great importance for their interactions with target proteins and thus for their biological 
activity.110 
Conformation-activity studies based exclusively on solid-state conformational parameters 
are often not very significant.  This explains why the evaluation of conformationally 
restrained nucleosides can be very useful, as they adopt certain restricted, geometrical 
shapes.140  Kifli et al.141 described the synthesis and conformational analysis of bicyclic 
nucleosides related to those reported here. 
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4.2 CHEMISTRY  
4.2.1 Synthesis of six-membered bicyclic nucleosides 4.3, 4.4 and 4.5 
The synthesis of the bicyclic nucleosides 4.3, 4.4 and 4.5 started from compound 3.32, 
which was synthesized as described in chapter 3, starting from 1,2-O-isopropyl-α-D-
xylofuranose. 
 
O N NH
O
O
BnO
OAc
N3
O N NH
O
O
BnO
OH
N3
O N N
O
BnO
N3
O
O N NH
O
O
BnO
N3
N3
O N NH
O
O
BnO
NH2
NH2
O N NH
O
O
HO
HN
NH
R
O N NH
O
O
BnO
HN
NH
S
O N NH
O
O
BnO
N
NH
SMe
O N NH
O
O
HO
HN
NH
NH
d
4.11
c
4.12 4.13
4.3: R = S
4.4: R = O
g h, f
4.16 4.17 4.5
a b
3.32 4.10
f
O N NH
O
O
BnO
HN
NH
R
e
4.14: R= S
4.15: R= O
 
 
Scheme 4.1, Reagents and conditions: (a) NH3, MeOH, rt, 4h, 95%; (b) TfCl, DMAP, CH2Cl2 , rt, 2h, 
93%; (c) NaN3, benzoic acid, DMF, reflux, 7h, 74%; (d) Pd/C, H2, MeOH, rt, 5h, 90%;  (e) for 4.14: 
thiocarbonylimidazole, THF, rt, 1.5h, 60%; for 4.15: carbonyldiimidazole, THF, rt, 3h, 60%; (f) BCl3, 
CH2Cl2, -78 °C, 15 min,  47% (4.3), 60% (4.4) and 38% (4.5); (g) MeI, MeOH, rt, 8h, 78%; (h) NH3, 
MeOH, 100 °C, 16h, 50%. 
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The 5’-O-benzyl protected compound 3.32 was deacetylated and converted into 
anhydronucleoside 4.11 upon treatment with trifluoromethanesulfonyl chloride and DMAP.  
Opening of the anhydro ring with NaN3 afforded the bis-azido derivative 4.12.  Reduction of 
both azido groups was accomplished by hydrogenolysis (Pd/C), without loss of the 5’-benzyl 
group.  Ring closure was realized by reacting 4.13 with 1,1’-carbonyldiimidazole or its 
thiocarbonyl analogue in THF.  Finally, deprotection with boron trichloride gave the desired 
bicyclic nucleosides 4.3 and 4.4. 
The thiourea compound 4.3 also served as a starting point to prepare the guanidine 
analogue 4.5 by subsequent methylation using iodomethane, substitution with ammonia in 
MeOH at 100 °C and removal of the benzyl groups. 
 
4.2.2 Synthesis of five-membered bicyclic nucleosides 4.6 and 4.7 
The synthesis of the five-membered bicyclic nucleosides (Scheme 4.2) started from 2.13 
(obtained from 1,2-O-isopropylidene-α-D-xylofuranose as described in chapter 2 with an 
overall yield of 37%). 
Deacetylation and subsequent azidoreduction led to compound 4.19 that was used to 
synthesize two five-membered bicyclic analogues. 
Ring closure and final deprotection were carried out following the same procedures as 
described for the six-membered rings.  
 
O N NH
O
O
BnO
O N NH
O
BnO
O
O N NH
O
O
HO
c
4.19
4.20: R = S
4.21: R = O
4.6: R = S
4.7: R = O
d
HN O
R
HN O
R
H2N OHN3
O N NH
O
O
BnO
OH
4.18
b
N3
O N NH
O
O
BnO
OAc
a
2.13
 
Scheme 4.2, reagents and conditions: (a) 1N NH3 in MeOH, rt, 3h, 98%; (b) Pd/C, H2, MeOH, rt, 
3h, 96%;  (c) for 4.20: 1,1’-TCDI, THF, 50 °C, 16h, 50%; for 4.21: 1,1’-CDI, THF, 50 °C, 16h, 72%; (d) 
BCl3, CH2Cl2, -78 °C, 15 min, 70%. 
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4.2.3 Synthesis of nucleoside 4.8 
The synthesis of compound 4.8, with a reversed configuration at the 2’-position, started from 
the previously used 2,2’-O-anhydronucleoside 4.11 (Scheme 4.3).  The anhydro ring was 
opened under basic conditions to afford the arabino sugar 4.22.  Reduction of the azide then 
gave compound 4.23.  Ring closure with 1,1’-thiocarbonyldiimidazole was sluggish but gave 
access to the desired compound 4.8 after final debenzylation. 
 
O N N
O
BnO
N3
O
O N NH
O
O
BnO
N3
OH
O N NH
O
O
HO
HN
O
S
O N NH
O
O
BnO
NH2
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a
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d
4.23
b
4.8
O N NH
O
O
BnO
HN
O
S
4.24
c
 
Scheme 4.3, Reagents and conditions: (a) NaOH, dioxane, EtOH/H20, rt, 3h, 92%; (b) Pd/C, H2, 
MeOH, rt, 5h; (c) 1,1’-TCDI, THF, rt, 3h, 43%; (d) BCl3, CH2Cl2, -78 °C, 15 min, 38%. 
 
4.2.4 Synthesis of 5’-deoxygenated nucleoside 4.9 
Several attempts to convert 4.1 to its 5’-deoxy analogue remained unsuccessful.  After 
introduction of a p-toluenesulphonyl group at the 5’-position of compound 4.25, substitution 
by iodine and subsequent reduction should lead to the 5’-deoxygenated compound.  
However this intended synthesis failed, as the first step in this pathway, the introduction of 
the p-toluenesulponyl-group, could not be achieved, most likely due to the poor sterical 
availability of the 5’-hydroxygroup.   
Therefore we were forced to perform the deoxygenation step before the ring closure.  5’-
deprotection was therefore performed on the earlier obtained compound 3.32.  During 
removal of the 5’-O-benzylgroup with BCl3 under standard conditions (15 minutes, -78 °C), 
partial removal of the 2’-O-acetyl group occurred.  Extension of the reaction time to 30 
minutes resulted in complete 2’-deacetylated compound 4.26.   
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O
BnO
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N3
O N NH
O
O
HO
OAc
N3
O N NH
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O
HO
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N3
  +
3.32 4.25 4.26
a
 
Scheme 4.4, Reagents and conditions: (a) BCl3, CH2Cl2, -78 °C, 15 min, 4.25: 30% and 4.26: 45%. 
 
5’-Tosylation and iodination of 5’-tosylate using NaI, gave the 5’-iodinated compound 4.28.  
However, during simultaneous reduction of the 6’-azido function and the 5’-iodine, 
acylmigration resulted in the N-6’-acylated derivative 4.30. 
 
O
HO
N NH
O
O
N3
OAc
O
OTs
N NH
O
O
N3
OAc
O
I
N NH
O
O
N3
OAc
OH3C N NH
O
O
NH2
OAc
OH3C N NH
O
O
NH
OH
CH3
O
4.25 4.27
4.28
4.29
a b
c
4.30
 
Scheme 4.5, Reagents and conditions: (a) p-toluenesulfonyl chloride, pyridine, rt, 2d, 87%; (b) NaI, 
acetone, 60 °C, 16h, 97%; (c) Pd/C, H2, MeOH, TEA, rt, 3h, 98%. 
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Several attempts were made to reduce selectively the 5’-iodine without 6’-azidoreduction.  
The use of NaBH4 resulted in 2’-deacetylation without reduction of 5’-iodine.  The use of 
NaCNBH3 or LiAlH3 both remained unsuccesfull.   
For this reason, the completely deprotected compound 4.26 was used.  Selective tosylation 
of the primary alcohol of 4.26,142 followed by nucleophilic displacement of the tosylate with 
sodium iodide gave the 5’-iodo analogue 4.32.  Simultaneous reduction of the azide and the 
iodide using catalytic hydrogenation at atmospheric pressure led to compound 4.33, which 
gave target compound 4.9 after ring closure. 
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HO
N NH
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c d
 
Scheme 4.6, Reagents and conditions: (a) p-toluenesulfonyl chloride, pyridine, rt, 2d, 46%; (b) NaI, 
acetone, TBAI, 60 °C, 16h, 100%; (c) Pd/C, H2, MeOH, TEA, rt, 16h, 69%; (d) 
thiocarbonyldiimidazole, THF, rt, 5h, 43%. 
 
 
4.3 BIOLOGICAL EVALUATION  
All compounds were tested for TMPKmt inhibition as described in the experimental section 
of chapter 3.  This series of bicyclic thymidine derivatives revealed several potent inhibitors. 
(See Table 4.1)  The rationalisation of the observed structure-activity relationship involving 
molecular modelling and conformational analysis is described in the following part. 
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The compounds with the highest inhibitory activity on the enzyme (i.e. 4.6 and 4.9) were 
evaluated for their in vitro inhibitory activity against Mycobacterium bovis BCG.  While 
compound 4.6 showed 100% inhibition of bacterial growth at 500 µg/mL, derivative 4.9 
displayed a stronger inhibitory activity: no growth was observed at 100 µg/mL.  No 
compound demonstrated toxicity against VERO cell lines in a 0-500 µg/mL concentration 
range. 
Since compound 4.1 failed to show any inhibition of bacterial growth at 64 µg/mL, the activity 
of 4.9 represents a significant progress in our search for new anti-tuberculosis agents.   
 
 
4.4 STRUCTURE-ACTIVITY RELATIONSHIP (S.A.R.) AND MODEL BUILDING 
Compared to the bicyclic nucleosides 4.1 and 4.2, isosteres 4.3 and 4.4, with the 2’ oxygen 
replaced by a 2’-NH, showed a significant drop in affinity.  Modelling experiments indicate a 
repulsion between 2’-NH and the aromatic ring of Tyr 103. 
The five-membered bicyclic derivatives 4.6 and 4.7 are 2-fold less active than the 
corresponding leads 4.1 and 4.2.  This result confirms earlier observations that a 3’-
branching enhances the interaction with the enzyme.107  Upon superimposition of the five- 
and six-membered bicyclic (thio)urethane derivatives, differences in binding TMPKmt 
Table 4.1 Kinetic parameters of TMPKmt with bicyclic sugar derivatives. 
O N NH
O
O
R
HN
X
Y
n
O N NH
O
O
HO
HN
O
S
4.84.1-4.7, 4.9
 
Compound X Y R N Ki (µM) TMPKmt IC99 Myc. Bovis  
4.1 O S OH 1 3.5106  
4.2 O O OH 1 13.5106  
4.3 NH S OH 1 21  
4.4 NH O OH 1 59  
4.5 NH NH OH 1 46  
4.6 O S OH 0 8 500 µg/mL 
4.7 O O OH 0 27  
4.8 (arabino) O S OH 1 150  
4.9 O S H 1 2.3 100 µg/mL 
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become perceptible, i.e. the H-bond between 3’-NH and Asp 9 is weaker in the five-
membered ring derivative.  In both series the distance between NH and the O-atoms of Asp 
9 is very small (<3.5 Å), which is a requirement for a strong H-bonding.  In the five-
membered ring derivatives, however, the angle of the H-bond is too large.  For a strong H-
bond the angle between the N-H-bond and the O-H-bonds should be smaller than 35 
degrees.143  For compound 4.1 this angle is 23 degrees, for compound 4.6 139 degrees, 
thus explaining the weakness of the H-bond in compounds 4.6 and 4.7 (Figure 4.3).   
 
 
Figure 4.3 Superimposition of compounds 4.1 and 4.6 in their predicted binding modes to the enzyme 
 
Comparison of all final compounds shows that the sulfur-derivatives are consistently more 
active than the corresponding oxygen-derivatives.  Presumably, the large lipophylic sulfur 
atom gives a stronger hydrophobic interaction with the enzyme. 
Compound 4.8 was synthesized in order to gain insight on the influence of the puckering of 
the sugar on binding affinity.  Conformational analysis provides an explanation for the low 
binding affinity of this compound (Ki = 150 µM), as will be explained further. 
Deletion of 5’-OH, the only hydroxyl function in compound 4.1, strongly reduces polarity.  As 
deoxygenation comes with the loss of a strong H-bonding between 5’-OH and Tyr 39, a 
lower binding affinity for this compound was expected.  Surprisingly this 5’-deoxy derivative 
4.9 was almost twice as active as compound 4.1 toward inhibition of TMPKmt.  The same 
phenomenon was observed for the 5’-methyl derivative of dT accompanied by a 6-fold 
increase in binding affinity.139  This higher activity can be explained by a higher hydrophobic 
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interaction between 5’-CH3 and Pro 37 (See Figure 4.4 for a modelled binding mode of 
compound 4.9 and the LIGPLOT interaction map in Figure 4.5).  
 
Figure 4.4 The modeled binding mode of compound 4.9 to TMPKmt. 
 
 
 
Figure 4.5 LIGPLOT interaction map of compound 4.9. 
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4.5 CONFORMATIONAL ANALYSIS OF COMPOUNDS 4.6 AND 4.9 
The solution state conformation of compounds 4.6 and 4.9 was analyzed using Pseurot 
6.2.144  Consequently, vicinal proton-proton coupling constants (3J1’,2’, 3J2’,3’ and 3J3’,4’) of 4.6 
and 4.9 were accurately measured at 500 MHz in D2O using the Selective Refocussing 
(SERF) technique145 at five different temperatures ranging from 293 K to 325 K.  In the case 
of compound 4.6, the J values were virtually unaffected within the temperature interval 
studied.  This observation can be explained by assuming that the sugar adopts one peculiar 
conformation independent of temperature.  Alternatively, an equilibrium might exist between 
two conformations, which are already present in their T∞ ratio at the lowest temperature, 
indicating a small conformational energy barrier.  The latter scenario proved the only 
satisfactory one with the following conformations found: one with P equal to 77° and a νmax of 
about 18° (O4’ endo), the other with P of – 88° and  a νmax of about 17° (O4’ exo).  These 
results extend a previously reported conformational analysis of the thymine congener of 4.6 
using Macromodel potential energy calculations, which only pointed towards a single O4’-
endo-C4’-exo puckering.141 
Pseurot analysis of 4.9 reveals a predominant sugar puckering with P value of 40° and a 
νmax of 39°, corresponding to a puckering between C4’ ex o and C3’ endo.  Although this 
puckering is very similar to the one deduced from modelling of compound 4.8, the inverted 
configuration at C2’ probably excludes a favourable interaction of the fused ring of 4.8 with 
TMPKmt.  
Since the X-ray analysis of the dTMP-TMPKmt complex indicates that the substrate adopts a 
Southern conformation with the base in an equatorial orientation,95 one would expect that 
nucleoside analogues exhibiting a similar S-type conformation would have an optimal affinity 
for TMPKmt.110  In the present case, however, the extra ring fused to the sugar part via 2’ 
and 3’ seems to exclude such conformation.  The established rigidification in compound 4.9 
seems to contribute to its enhanced affinity for TMPKmt by allowing favourable interactions 
with Asp9 and Arg95.  
 
4.6 CONCLUSIONS 
This chapter describes the synthesis, the biological and conformational analysis of a series 
of bicyclic sugar nucleosides as inhibitors of TMPKmt.  Most compounds showed an 
inhibitory potency in the low micromolar range, with compound 4.9 being the most active one 
(Ki = 2.3 µM).  With an IC99 of 100 µg/mL, this compound gives a strong indication to be 
capable of inhibiting M. tuberculosis growth, promoting TMPKmt as an attractive target for 
further inhibitor design. 
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4.7 EXPERIMENTAL PART 
3’-Azidomethyl-5’-O-benzyl-β-D-thymidine (4.10) 
Compound 2.35 (810 mg, 1.89 mmol) was dissolved in 7N NH3 in MeOH (20 mL) and was 
stirred at room temperature during 4 hours.  The reaction mixture was evaporated, 
suspended in H2O (20 mL) and extracted with CH2Cl2 (3 x 25 mL).  The organic layer was 
dried and evaporated to dryness.  The residue was purified by column chromatography 
(CH2Cl2/MeOH 95/5) to afford compound 4.10 (700 mg, 95%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.41 (3H, d, 5-CH3), 2.44 (1H, m, H-3’), 
3.64 (2H, m, H-6’ and H-6”), 3.86 (1H, dd, J= 2.4 and 11.1 Hz, H-5’), 4.08 
(1H, m, H-5”), 4.20 (1H, m, H-4’), 4.56 (2H, s, CH2Ph), 5.65 (1H, d, J= 2.1, 
H-2’), 5.91 (1H, d, 4.8 Hz, H-1’), 7.31 (5H, m, CH2Ph), 7.64 (1H, d, J= 1.2 
Hz, H-6). 
 
Exact mass (ESI-MS) for C18H21N5O5Na [M+Na]+ found, 410.1445; calcd, 410.1441. 
 
 
2,2’-O-Anhydro-1-(3-azidomethyl-3-deoxy-5-O-benzyl-β-D-arabinofuranosyl)thymine 
(4.11) 
A solution of 4.10 (3.00 g, 7.74 mmol) and DMAP (3.78 g, 30.96 mmol) in dichloromethane 
(77 mL) was stirred at room temperature.  After 30 minutes the mixture was cooled to 0 °C 
and trifluoromethanesulfonyl chloride (1.65 mL, 15.50 mmol) was added.  After stirring for 2 
hours at room temperature, the reaction mixture was quenched with water.  The mixture was 
partioned between CH2Cl2 and a saturated NaHCO3-solution.  The aqueous layer was 
washed with CH2Cl2 and the combined organic layers were dried over MgSO4, filtered and 
evaporated to dryness.  The residue was purified by column chromatography (CH2Cl2/MeOH 
98:2), affording 4.11 (2.86 g, 93%) as a white foam. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.79 (3H, d, J= 1.2 Hz, 5-CH3), 2.66 (1H, 
m, H-3’), 3.19 (1H, dd, J= 6.6 and 10.2 Hz, H-5’), 3.35 (1H, dd, J= 3.9 and 
10.5 Hz, H-5”), 3.63 (2H, m, H-6’/H-6”), 4.21 (1H, m, H-4’), 4.31 (2H, s, 
CH2Ph), 5.28 (1H, dd, J= 2.1 and 5.4 Hz, H-2’), 6.20 (1H, d, J= 6.0 Hz, H-
1’), 7.26 (5H, m, CH2Ph), 7.74 (1H, d, J= 1.5 Hz, H-6). 
 
Exact mass (ESI-MS) for C18H20N5O4 [M+H]+ found, 370.1512; calcd, 370.1515. 
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1-(2-Azido-3-azidomethyl-2,3-dideoxy-5-O-benzyl-β-D-ribofuranosyl)thymine (4.12) 
A solution of 4.11 (2.46 g, 6.66 mmol), NaN3 (2.16 g, 33 mmol) and benzoic acid (0.813 g, 
6.66 mmol) in DMF (40 mL) was heated to 150 °C.  The reaction mixture was refluxed for 7 
h and evaporated to dryness.  The residue was partitioned between water and CH2Cl2.  The 
organic layer was dried over MgSO4, filtered and evaporated.  Further purification by column 
chromatography (CH2Cl2/MeOH 99:1) yielded 4.12 (2.01 g, 74%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.40 (3H, d, J= 1.2 Hz, 5-CH3), 2.63 (1H, 
m, H-3’), 3.43 (1H, dd, J= 6.6 and 12.6 Hz, H-6’), 3.60 (2H, m, H-6” and H-
5’), 3.88 (1H, dd, J= 2.1 and 11.4 Hz, H-5”), 4.01 (1H, m, H-4’), 4.57 (2H, s, 
CH2Ph), 4.55 (1H, d, J= 1.5 Hz, H-2’), 5.79 (1H, d, J= 1.8 Hz, H-1’), 7.32 
(5H, m, CH2Ph), 7.62 (1H, d, J= 0.9 Hz, H-6), 11.34 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C18H20N8O4Na [M+Na]+ found, 435.1508; calcd, 435.1505. 
 
 
1-(2-Amino-3-aminomethyl-2,3-dideoxy-5-O-benzyl-β-D-ribofuranosyl)thymine (4.13) 
A solution of 4.12 (200 mg, 0.48 mmol) in methanol (12 mL) was hydrogenated at 
atmospheric pressure for 5 h in the presence of 10% Pd/C (20 mg).  The catalyst was 
removed by filtration through a celite path and the filtrate was evaporated.  The residue was 
purified by column chromatography (CH2Cl2/MeOH 85:15) to give compound 4.13 (155 mg, 
90%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.45 (3H, s, 5-CH3), 2.14 (1H, m, H-3’), 
2.56 (1H, dd, J= 6.0 and 12.6 Hz, H-6’), 3.71 (1H, dd, J= 7.5 and 12.3 Hz, 
H-6”), 3.41 (1H, dd, J= 3.6 and 6.9 Hz, H-2’), 3.56 (1H, dd, J= 3.6 and 11.1 
Hz, H-5’), 3.79 (1H, dd, J= 2.4 and 11.4 Hz, H-5”), 4.07 (1H, m, H-4’), 4.55 
(2H, s, CH2Ph), 5.55 (1H, d, J= 3.6 Hz, H-1’), 7.32 (5H, m, CH2Ph), 7.64 
(1H, d, J= 1.2 Hz, H-6). 
 
Exact mass (ESI-MS) for C18H25N4O4 [M+H]+ found, 361.1871; calcd, 361.1875. 
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1-[2-Amino-3-aminomethyl-2,3-dideoxy-2-N,6-N-(thiocarbonyl)-5-O-benzyl-β-D-
ribofuranosyl]thymine (4.14) 
A solution of 4.13 (200 mg, 0.56 mmol) and 1,1’-thiocarbonyldiimidazole (109 mg, 0.61 
mmol) in THF (6 mL) was stirred at room temperature for 1.5 h.  The mixture was 
evaporated to dryness and purified by column chromatography (CH2Cl2/MeOH 95:5) to give 
compound 4.14 (135 mg) in 60 % yield. 
1H NMR (300 MHz, DMSO-d6): δ 1.50 (3H, d, J= 0.9 Hz, 5-CH3), 2.48 (1H, 
m, H-3’), 3.06 (1H, dd, J= 9.3 and 12.0 Hz, H-6’), 3.32 (1H, m, H-6”), 3.63 
(1H, dd, J= 3.3 and 10.5 Hz, H-5’), 3.75 (1H, dd, J= 3.0 Hz and 11.1 Hz, H-
5”), 3.86 (1H, m, H-2’), 4.03 (1H, dd, J= 3.0 and 6.3 Hz, H-4’), 4.56 (2H, s, 
CH2Ph), 5.79 (1H, d, J= 6.3 Hz, H-1’), 7.33 (5H, m, CH2Ph), 7.47 (1H, d, J= 
1.2 Hz, H-6), 8.33 (2H, m, N(2’)H and N(6’)H), 11.27 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C19H23N4O4S [M+H]+ found, 403.1447; calcd, 403.1439. 
 
 
1-[2-amino-3-aminomethyl-2,3-dideoxy-2-N,6-N-(carbonyl)-5-O-benzyl-β-D-
ribofuranosyl]thymine (4.15) 
A solution of 4.13 (150 mg, 0.41 mmol) and 1,1’-carbonyldiimidazole (73 mg, 0.45 mmol) in 
THF (4 mL) was stirred at room temperature for 3 h.  The mixture was evaporated to dryness 
and purified by column chromatography (CH2Cl2/MeOH 95:5) to give compound 4.15 (95 
mg) in 60 % yield. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.50 (3H, d, J= 0.9 Hz, 5-CH3), 2.52 (1H, 
m, H-3’), 3.07 (1H, m, H-6’), 3.21 (1H, m, H-6”), 3.63 (1H, dd, J= 3.3 and 
10.5 Hz, H-5’), 3.75 (1H, dd, J= 3.0 Hz and 11.1 Hz, H-5”), 3.86 (1H, m, H-
2’), 4.06 (1H, m, H-4’), 4.56 (2H, s, CH2Ph), 5.74 (1H, d, J= 5.4 Hz, H-1’), 
6.45 (1H, br s, N(2’)H), 6.55 (1H, br s, N(6’)H), 7.33 (5H, m, CH2Ph), 7.51 
(1H, d, J= 1.2 Hz, H-6), 11.29 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C19H22N4O5Na [M+Na]+ found, 409.1488; calcd, 409.1498. 
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1-[2-Amino-3-aminomethyl-2,3-dideoxy-2-N,6-N-(thiocarbonyl)-β-D-
ribofuranosyl]thymine (4.3) and 1-[2-amino-3-aminomethyl-2,3-dideoxy-2-N,6-N-
(carbonyl)-β-D-ribofuranosyl]thymine (4.4) 
To a solution of 4.14 or 4.15 (1 eq) in dry CH2Cl2 (40 mL/mmol), a 1 M BCl3 solution in 
CH2Cl2 was added (4 eq) at -78 °C.  After 15 minutes the reaction was quenched with 
methanol, the mixture was evaporated and the residue was purified by column 
chromatography (CH2Cl2/MeOH 95:5) to yield final compounds 4.3 (47%) and 4.4 (60%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 1.2 Hz, 5-CH3), 2.43 (1H, 
m, H-3’), 3.04 (1H, dd, J= 9.6 and 12.3 Hz, H-6’), 3.25 (1H, m, H-6”), 3.60 
(2H, m, H-5’ and H-5”), 3.85 (2H, m, H-4’ and H-2’), 5.18 (1H, t, J= 5.1 Hz, 
5’-OH), 5.76 (1H, d, J= 6.3 Hz, H-1’), 7.71 (1H, d, J= 1.2 Hz, H-6), 8.31 (2H, 
br s, N(6’)H and N(2’)H), 11.27 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.94 (5-CH3), 33.14 (C-3’), 37.58 (C-6’), 57.28 (C-5’), 62.71 (C-2’), 
82.50 (C-4’), 89.08 (C-1’), 110.12 (C-5), 137.04 (C-6), 151.40 (C-4), 164.64 (C-2), 177.18 (C=S). 
 
Exact mass (ESI-MS) for C12H17N4O4S [M+H]+ found, 313.0986; calcd, 313.0970; Anal. 
(C12H16N4O4S) C, H, N, S. 
 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 0.9 Hz, 5-CH3), 2.45 (1H, 
m, H-3’), 3.05 (1H, m, H-6’), 3.19 (1H, m, H-6”), 3.54 (1H, m, H-5’), 3.65 (1H, 
m, H-5”), 3.85 (2H, m, H-4’ and H-2’), 5.18 (1H, t, J= 5.1 Hz, 5’-OH), 5.71 
(1H, d, J= 5.7 Hz, H-1’), 6.42 (1H, br s, N(6’)H), 6.55 (1H, br s, N(2’)H), 7.74 
(1H, d, J= 0.9 Hz, H-6), 11.29 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.93 (5-CH3), 34.96 (C-3’), hidden by DMSO-signal (C-6’), 57.51 (C-
5’), 62.57 (C-2’), 82.22 (C-4’), 90.02 (C-1’), 109.90 (C-5), 137.02 (C-6), 151.39 (C-4), 156.49 (C=O), 
164.56 (C-2). 
 
Exact mass (ESI-MS) for C12H16N4O5Na [M+Na]+ found, 319.1015; calcd, 319.1018; Anal. 
(C12H16N4O5) C, H, N. 
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1-[2-Amino-3-aminomethyl-2,3-dideoxy-2-N,6-N-(methylthiomethylidyne)-5-O-benzyl-β-
D-ribofuranosyl]thymine (4.16) 
To a solution of compound 4.14 (778 mg, 1.93 mmol) in methanol (60 mL), MeI (168 µL, 
2.71 mmol) was added and the solution was stirred for 8 h.  The reaction mixture was 
evaporated to dryness and the residue was purified by column chromatography 
(CH2Cl2/MeOH 98:2) yielding 4.16 (630 mg, 78 %). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.46 (3H, s, 5-CH3), 2.61 (1H, m, H-3’), 
3.18 (1H, m, H-6’), 3.41 (1H, dd, J= 4.8 and 12.9 Hz, H-6”), 3.66 (3H, s, S-
CH3), 3.79 (1H, d, J= 2.4 Hz, H-5’), 3.83 (1H, d, J=2.7 Hz, H-5”), 3.96 (1H, 
m, H-2’), 4.06 (1H, m, H-4’), 4.58 (2H, s, CH2Ph), 5.74 and 5.81 (1H, 2 
tautomers, d, J= 2.7 and 4.8 Hz, H-1’), 7.32 (5H, m, CH2Ph), 7.61 and 7.65 
(1H, 2 tautomers, s, H-6), 11.32 and 11.36 (1H, 2 tautomers, s, N(3)H). 
 
Exact mass (ESI-MS) for C20H25N4O4S [M+H]+ found, 417.1589; calcd, 417.1596. 
 
 
1-[2-Amino-3-aminomethyl-2,3-dideoxy-2-N,6-N-(imine)-5-O-benzyl-β-D-
ribofuranosyl]thymine (4.17) 
Compound 4.16 (189 mg, 0.45 mmol) was dissolved in 7N NH3 in methanol (20 mL).  The 
solution was allowed to stir overnight at 100 °C.  The reaction mixture was evaporated to 
dryness.  The residue was purified by column chromatography (CH2Cl2/MeOH 95:5), 
affording 4.17 (86 mg, 50 %). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.47 (3H, d, J= 1.2 Hz, 5-CH3), 2.71 (1H, 
m, H-3’), 3.22 (1H, dd, J= 7.5 and 12.9 Hz, H-6’), 3.43 (1H, dd, J= 5.4 and 
13.2 Hz, H-6”), 3.67 (1H, dd, J= 3.0 and 11.1 Hz, H-5’), 3.82 (1H, dd, J= 2.7 
and 10.8 Hz, H-5”), 4.04 (1H, t, J= 5.1 Hz, H-2’), 4.12 (1H, m, H-4’), 4.58 
(2H, s, CH2Ph), 5.77 (1H, d, J= 4.5 Hz, H-1’), 7.04 (1H, br s, NH), 7.32 (5H, 
m, CH2Ph), 7.57 (1H, d, J= 1.2 Hz, H-6), 7.99 (1H, br s, N(6’)H), 8.24 (1H, 
br s, N(2’)H), 11.40 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C20H24N4O4 [M+H]+ found, 386.1817; calcd, 386.1953. 
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1-[2-Amino-3-aminomethyl-2,3-dideoxy-2-N,6-N-(imine)-β-D-ribofuranosyl]thymine (4.5) 
The title compound was synthesized from 4.17 (72 mg, 0.19 mmol) using the same 
procedure as described for the deprotection of 4.14, in a yield of 21 mg or 38 %. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.76 (3H, s, 5-CH3), 2.65 (1H, m, H-3’), 
3.22 (1H, dd, J= 6.9 and 13.2 Hz, H-6’), 3.41 (1H, dd, J= 5.1 and 13.5 Hz, 
H-6”), 3.61 (1H, d, J= 11.7 Hz, H-5’), 3.72 (1H, d, J= 11.7 Hz, H-5”), 3.93 
(1H, m, H-4’), 4.03 (1H, m, H-2’), 5.41 (1H, s, 5’-OH), 5.74 (1H, d, J= 3.6 Hz, 
H-1’), 7.23 (1H, br s, C=NH), 7.75 (2H, br s, N(6’)H and N(2’)H), 7.88 (1H, s, 
H-6). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.97 (5-CH3), 33.19 (C-6’), 36.89 (C-3’), 56.42 (C-2’), 61.50 (C-5’), 
82.58 (C-4’), 89.46 (C-1’), 109.76 (C-5), 136.58 (C-6), 151.29 (C-4), 154.31 (C=NH), 164.52 (C-2). 
 
Exact mass (ESI-MS) for C13H18N4O4 [M+H]+ found, 296.1366; calcd, 296.1358; Anal. 
(C13H17N4O4·H2O) C, H, N. 
 
 
3’-Azido-5’-benzyl-β-D-thymidine (4.18) 
Compound 3.11 (3.02 g, 7.27 mmol) was dissolved in 1N NH3 in methanol (70 mL) and 
stirred at room temperature during 3 hours.  The solvent was removed and the resulting 
crude residue was dissolved in CH2Cl2 (50 mL) and extracted with water (50 mL).  The water 
layer was washed three times with CH2Cl2 (50 mL).  Further workup of the organic layers 
(drying and evaporation) resulted in 2.66 g pure compound 4.18 (98%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.48 (3H, d, J= 1.0 Hz, 5-CH3), 3.63 (1H, 
dd, J= 3.1 and 10.8 Hz, H-5’), 3.73 (1H, dd, J= 2.8 and 10.8 Hz, H-5”), 4.02 
(1H, m, H-4’), 4.21 (1H, app t, J= 4.8 Hz, H-3’), 4.43 (1H, m, H-2’), 4.56 
(2H, d, J= 2.1 Hz, CH2Ph), 5.77 (1H, d, J= 6.0 Hz, H-1’), 6.14 (1H, d, J= 4.8 
Hz, 2’-OH), 7.33 (5H, m, CH2Ph), 7.47 (1H, d, J=1.2 Hz, H-6), 11.32 (1H, s, 
N(3)H). 
 
Exact mass (ESI-MS) for C17H20N5O5 [M+H]+ found, 374.1456; calcd, 374.1465. 
 
 
3’-Amino-5’-benzyl-β-D-thymidine (4.19) 
A solution of 4.18 (852 mg, 2.28 mmol) and 10% Pd/C (85 mg) in methanol was 
hydrogenated under atmospheric pressure during 3 hours.  The Pd/C was removed from the 
solution by filtration over celite.  After evaporation, 826 mg (96%) of compound 4.19 was 
obtained. 
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1H NMR (300 MHz, DMSO-d6): δ 1.43 (3H, d, J= 1.0 Hz, 5-CH3), 3.27 (1H, 
dd, J= 5.5 and 7.7 Hz, H-3’), 3.64 (1H, dd, J= 3.4 and 10.8 Hz, H-5’), 3.73 
(1H, ddd, J= 2.1, 3.3 and 7.8 Hz, H-4’), 3.80 (1H, dd, J= 1.9 and 10.9 Hz, 
H-5”), 3.86 (1H, dd, J= 2.5 and 5.1 Hz, H-2’), 4.55 (2H, s, CH2Ph), 5.69 (1H, 
d, J= 2.7 Hz, H-1’), 7.33 (5H, m, CH2Ph), 7.59 (1H, d, J=1.2 Hz, H-6). 
 
Exact mass (ESI-MS) for C17H22N3O5 [M+H]+ found, 348.1559; calcd, 348.1559. 
 
 
1-(3-Amino-3-deoxy-2-O,3-N-(thiocarbonyl)-5-O-benzyl-β-D-ribofuranosyl)thymine 
(4.20) 
Compound 4.19 (410 mg, 1.10 mmol) and 1,1’-thiocarbonyldiimidazole (215 mg, 1.21 mmol) 
in THF (18 mL) were stirred at 50 °C overnight.  The reaction mixture was evaporated to 
dryness, and the residue was purified by column chromatography (CH2Cl2/MeOH 97:3) to 
yield 4.20 (228 mg, 50%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.65 (3H, d, J= 1.2 Hz, 5-CH3), 3.59 (1H, 
dd, J= 5.4 and 10.8 Hz, H-5’), 3.67 (1H, dd, J= 3.9 and 11.1 Hz, H-5”), 4.21 
(1H, m, H-4’), 4.50 (2H, d, CH2Ph), 4.54 (1H, d, J= 3.9 Hz, H-3’), 5.59 (1H, 
dd, J= 3.0 and 8.7 Hz, H-2’), 5.92 (1H, d, J= 2.7, H-1’), 7.31 (5H, m, 
CH2Ph), 7.51 (1H, d, J= 1.2 Hz, H-6), 10.56 (1H, br s, N(3’)H), 11.39 (1H, 
br s, N(3)H). 
 
 
Exact mass (ESI-MS) for C18H20N3O5S [M+H]+ found, 390.1123; calcd, 390.1123. 
 
 
1-(3-Amino-3-deoxy-2-O,3-N-(carbonyl)-5-O-benzyl-β-D-ribofuranosyl)thymine (4.21) 
Compound 4.19 (325 mg, 0.87 mmol) and 1,1’-carbonyldiimidazole (156 mg, 0.96 mmol) in 
THF (14 mL) were stirred at 50 °C overnight.  The reaction mixture was evaporated to 
dryness, and the residue was purified by column chromatography (CH2Cl2/MeOH 97:3) to 
yield 4.21 (250 mg, 72%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.65 (3H, d, J= 1.2 Hz, 5-CH3), 3.59 (1H, 
dd, J= 5.4 and 10.8 Hz, H-5’), 3.67 (1H, dd, J= 3.6 and 10.8 Hz, H-5”), 4.13 
(1H, dd, J= 5.4 and 9.3 Hz, H-4’), 4.25 (1H, dd, J= 4.8 and 8.4 Hz, H-3’), 
4.51 (2H, d, CH2Ph), 5.20 (1H, dd, J= 3.3 and 8.7 Hz, H-2’), 5.90 (1H, d, J= 
3.3, H-1’), 7.32 (5H, m, CH2Ph), 7.49 (1H, d, J= 1.2 Hz, H-6), 8.27 (1H, br s, 
N(3’)H), 11.42 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C18H20N3O6 [M+H]+ found, 374.1354; calcd, 374.1351. 
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1-(3-Amino-3-deoxy-2-O,3-N-(thiocarbonyl)-β-D-ribofuranosyl)thymine (4.6) and 1-(3-
Amino-3-deoxy-2-O,3-N-(carbonyl)-β-D-ribofuranosyl)thymine (4.7) 
These compounds were synthesized from 4.20 (250 mg, 0.67 mmol) and 4.21 (215 mg, 0.52 
mmol) using the same procedure as described for the deprotection of 4.14, to yield 4.6 (103 
mg, 70 %) and 4.7 (140 mg, 70%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.74 (3H, d, J= 0.9 Hz, 5-CH3), 3.54 (2H, 
m, H-5’ and H-5”), 3.97 (1H, dd, J= 4.5 and 9.3 Hz, H-4’), 4.45 (1H, dd, J= 
4.5 and 8.7 Hz, H-3’), 5.09 (1H, t, J= 5.1 Hz, 5’-OH), 5.35 (1H, dd, J= 3.0 
and 8.7 Hz, H-2’), 5.90 (1H, d, J= 3.0, H-1’), 7.58 (1H, d, J= 0.9 Hz, H-6). 
 
 
 
13C NMR (75 MHz, DMSO-d6): δ 12.75 (5-CH3), 56.60 (C-3’), 61.71 (C-5’), 87.96 (C-4’), 88.85 (C-2’), 
91.87 (C-1’), 110.34 (C-5), 138.25 (C-6), 150.99 (C-4), 164.51 (C-2), 187.56 (C=S). 
Exact mass (ESI-MS) for C11H14N3O5S [M+H]+ found, 300.0659; calcd, 300.0654; Anal. 
(C11H13N3O5S) C, H, N, S. 
 
 
1H NMR (300 MHz, DMSO-d6):  δ 1.74 (3H, d, J= 0.6 Hz, 5-CH3), 3.56 (2H, 
m, H-5’ and H-5”), 3.90 (1H, dd, J= 4.5 and 9.3 Hz, H-4’), 4.18 (1H, dd, J= 
4.8 and 8.7 Hz, H-3’), 5.08 (1H, s, 5’-OH), 5.15 (1H, dd, J= 3.6 and 8.7 Hz, 
H-2’), 5.87 (1H, d, J= 3.3, H-1’), 7.56 (1H, d, J= 0.9 Hz, H-6), 8.24 (1H, br s, 
N(3’)H), 11.42 (1H, br s, N(3)H). 
 
 
13C NMR (75 MHz, DMSO-d6): δ 12.79 (5-CH3), 56.85 (C-3’), 61.69 (C-5’), 82.24 (C-4’), 88.08 (C-2’), 
91.27 (C-1’), 110.41 (C-5), 138.06 (C-6), 151.01 (C-4), 157.90 (C=O), 164.48 (C-2). 
 
Exact mass (ESI-MS) for C11H13N3O6Na [M+Na]+ found, 306.0709; calcd, 306.0702; Anal. 
(C11H13N3O6) C, H, N. 
 
 
1-(3-Azidomethyl-3-deoxy-5-O-benzyl-β-D-arabinofuranosyl)thymine (4.22) 
A solution of 4.11 (530 mg, 1.43 mmol), 1 M NaOH (4.24 mL), dioxane (58 mL) and 
EtOH/H2O 1:1 (58 mL) was allowed to stir for 3 h at room temperature.  The resulting 
mixture was extracted with CH2Cl2 (3 x 100 mL).  The organic layer was dried over MgSO4, 
filtered and evaporated, and the crude material was purified by column chromatography 
(CH2Cl2/MeOH 98:2) to yield 4.22 (509 mg, 92%). 
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1H NMR (300 MHz, DMSO-d6): δ 1.46 (3H, d, J= 0.9 Hz, 5-CH3), 2.27 (1H, 
m, H-3’), 3.48 (1H, dd, J= 6.9 and 12.6 Hz, H-6’), 3.66 (2H, m, H-5’ and H-
6”), 3.82 (2H, m, H-4’ and H-5”), 4.16 (1H, dd, J= 6.0 and 12.6 Hz, H-2’), 
4.55 (2H, s, CH2Ph), 5.62 (1H, d, J= 5.4 Hz, 2’-OH), 5.95 (1H, d, J= 5.7 Hz, 
H-1’), 7.33 (5H, m, CH2Ph), 7.47 (1H, d, J= 1.2 Hz, H-6), 11.22 (1H, br s, 
N(3)H). 
 
Exact mass (ESI-MS) for C18H21N4O5Na [M+Na]+ found, 435.1508; calcd, 435.1505. 
 
 
1-(3-Aminomethyl-3-deoxy-5-O-benzyl-β-D-arabinofuranosyl)thymine (4.23) 
A solution of 4.22 (195 mg, 0.50 mmol) in methanol (12 mL) was hydrogenated at 
atmospheric pressure for 5 hours in the presence of 10 % Pd/C (20 
mg).  The catalyst was removed by filtration through a celite path 
and the filtrate was evaporated.  The residue was used in the next 
step without further purification. 
1-(3-Aminomethyl-3-deoxy-2-O,6-N-(thiocarbonyl)-5-O-benzyl-β-
D-arabinofuranosyl)thymine (4.24) 
Compound 4.23 (43 mg, 0.12 mmol) was dissolved in THF (6 mL), and the resulting solution 
was slowly added to a solution of 1,1’-thiocarbonyldiimidazole (64 mg, 0.36 mmol) in THF (2 
mL).  After 1 hour, 5 mL THF was added, and the solution was allowed to stir another 2 h.  
Evaporation of the solvent and purification of the residue by column chromatography 
(CH2Cl2/MeOH 97:3) gave 4.24 (20 mg, 43%). 
  
1H NMR (300 MHz, DMSO-d6): δ 1.43 (3H, d, J= 0.6 Hz, 5-CH3), 2.40 (1H, 
m, H-3’), 3.70 (1H, dd, J= 3.9 and 11.3 Hz, H-6’), 3.81 (1H, dd, J= 3.3 and 
11.1 Hz, H-6”), 3.88 (3H, m, H-4’, H-5’ and H-5”), 4.19 (1H, m, H-2’), 4.55 
(2H, s, CH2Ph), 5.98 (1H, d, J= 6.3 Hz, H-1’), 7.32 (5H, m, CH2Ph), 7.45 
(1H, d, J= 1.2 Hz, H-6), 11.23 (1H, br s, N(3)H). 
 
 
Exact mass (ESI-MS) for C19H21N3O5SNa [M+Na]+ found, 426.1093; calcd, 426.1099. 
 
 
 
 
 
 
 
 
 
 
O N NH
O
O
BnO
N3
OH
O N NH
O
O
BnO
NH2
OH
O N NH
O
O
BnO
HN
O
S
   2 ’,3 ’-Bicyc l ic  thymidine der ivat ives 
  119 
1-(3-Aminomethyl-3-deoxy-2-O,6-N-(thiocarbonyl)-β-D-arabinofuranosyl)thymine (4.8) 
This compound was synthesized from 4.24 using the same procedure as described for the 
deprotection of 4.14, in a yield of 38 % (15 mg). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.72 (3H, d, J= 0.9 Hz, 5-CH3), 2.99 (1H, 
m, H-3’), 3.59 (1H, m, H-6’), 2.67 (2H, m, H-5’ and H-6”), 3.88 (2H, m, H-4’ 
and H-5”), 4.17 (1H, m, H-2’), 5.18 (1H, app s, 5’-OH), 5.66 (1H, d, J= 6.0 
Hz, H-1’), 7.67 (1H, d, J= 0.9 Hz, H-6), 11.22 (1H, br s, N(3)H). 
 
 
 
13C NMR (75 MHz, DMSO-d6): δ 12.99 (5-CH3), 31.38 (C-3’), 33.31 (C-6’), 60.04 (C-5’), 79.82 (C-4’), 
80.14 (C-2’), 81.07 (C-1’), 109.16 (C-5), 136.63 (C-6), 150.90 (C-4), 164.38 (C-2), 186.61 (C=S). 
Exact mass (ESI-MS) for C12H15N3O5SNa [M+Na]+ found, 336.0630; calcd, 336.0636; Anal. 
(C12H15N3O5S) C, H, N. 
 
 
1-(2-O-Acetyl-3-azidomethyl-3-deoxy-β-D-ribofuranosyl)thymine (4.25)  
1-(3-Azidomethyl-3-deoxy-β-D-ribofuranosyl)thymine (4.26)  
To a solution of 2.19 (1.515 g, 3.91 mmol) in dry CH2Cl2 (156 mL), a 1 M BCl3 solution in 
CH2Cl2 was added at -78 °C. After 15 minutes the reaction was quenched with methanol, 
evaporated and purified by column chromatography (CH2Cl2/MeOH 98:2) to yield 
compounds 4.25 (399 mg, 30%) and 4.26 (518 mg, 45%). 
 
 
1H NMR (300 MHz, DMSO-d6): 1.76 (3H, d, 5-CH3), 2.08 (3H, s, COCH3), 
2.70 (1H, m, H-3’), 3.50-3.59 (3H, m, H-6’, H-6’’ and H-5’), 3.71 (1H, d, 
J=12.4, H-5’’), 3.92 (1H, m, H-4’), 5.17 (1H, t, OH-5’), 5.35 (1H, m, H-2’), 
5.77 (1H, d, J= 3.3 Hz, H-1’), 7.75 (1H, d, J= 1.2, H-6), 11.31 (1H, br s, 
N(3)H). 
 
Exact mass (ESI-MS) for C13H18N5O6 [M+H]+ found, 340.1263; calcd, 340.1257 
 
 
1H NMR (300 MHz, DMSO-d6): 1.74 (3H, d, 5-CH3), 2.35 (1H, m, H-3’), 3.34-
3.38 (1H, m, H-6’), 3.51-3.64 (2H, m, H-6’’ and H-5’), 3.73-3.80 (1H, m, H-
5’’), 3.89 (1H, m, H-4’), 4.18 (1H, m, H-2’), 5.19 (1H, t, OH-5’), 5.65 (1H, d, 
J=2.1 Hz, OH-2’), 5.88 (1H, d, J= 5.1 Hz, H-1’), 7.92 (1H, d, J= 1.2, H-6), 
11.26 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C11H16N5O5 [M+H]+ found, 298.1146; calcd, 298.1151 
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1-(2-O-Acetyl-3-azidomethyl-3-deoxy-5-O-tosyl-β-D-ribofuranosyl)thymine (4.27) 
To a solution of 4.25 (340 mg, 1.00 mmol) in pyridine (3 mL) at 0 °C, p-toluenesulfonyl 
chloride (381 mg, 2.00 mmol) was added. The reaction mixture was stirred at room 
temperature over 2 days. The reaction mixture was evaporated in vacuo to remove pyridine 
and partitioned between CH2Cl2 and H2O. This mixture was extracted three times, dried over 
MgSO4 and evaporated. The residue was purified by column chromatography 
(CH2Cl2/MeOH 99:1) to give compound 4.27 (430 mg, 87%). 
 
1H NMR (300 MHz, CDCl3): 1.87 (3H, d, 5-CH3), 2.09 (3H, s, COCH3), 2.46 
(3H, s, PhCH3), 2.74 (1H, m, H-3’), 3.38 (1H, dd, J= 7.2  and 12.6, H-6’), 
3.57 (1H, dd, J=6.3 and 12.6, H-6’’), 4.16-4.24 (2H, m, H-5’ and H-4’), 4.41-
4.45 (1H, m, H-5’’), 5.40 (1H, dd, J= 3.0 and 6.9, H-2’), 5.78 (1H, d, J= 3.0 
Hz, H-1’), 7.37 (2H, m, ar H), 7.81 (2H, m, ar H), 7.93 (1H, s, H-6).  
 
 
Exact mass (ESI-MS) for C20H23N5O9SNa [M+Na]+ found, 532.1114; calcd, 532.1114 
 
 
1-(2-O-Acetyl-3-azidomethyl-3,5-dideoxy-5-iodo-β-D-ribofuranosyl)thymine (4.28) 
A mixture of tosylate 4.27 (430 mg, 0.87 mmol), NaI (640 mg, 4.27 mmol) and a catalytic 
quantity of tetra-n.butylammonium iodide (5 mg) in acetone (34.8 mL) was refluxed at 60 °C 
overnight. Ice-cold water was poured into the reaction mixture. This mixture was extracted 
with CH2Cl2, dried over MgSO4 and evaporated. The obtained residue was purified by 
column chromatography (CH2Cl2/MeOH: 99:1) to yield compound 4.28 (381 mg, 97%).  
 
1H NMR (300 MHz, CDCl3): 1.88 (3H, d, 5-CH3), 2.09 (3H, s, COCH3), 2.61 
(1H, m, H-3’), 3.35-3.41 (2H, m, H-6’ and H-5’), 3.52-3.61 (2H, m, H-6’’ and H-
5’’), 3.75 (1H, m, H-4’), 5.37 (1H, dd, J= 3.9 and 7.8, H-2’), 5.72 (1H, d, J= 3.6 
Hz, H-1’), 7.25 (1H, m, H-6), 7.97 (1H, br s, N(3)H).   
 
 
Exact mass (ESI-MS) for C13H16N5O5INa [M+Na]+ found, 472.0099; calcd, 472.0096 
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1-(3-Acetaminomethyl-3-deoxy-4-methyl-β-D-ribofuranosyl)thymine (4.30) 
A mixture of 4.28 (41 mg, 0.091 mmol) and triethylamine (30 µL) in methanol (3 mL) was 
hydrogenated at atmospheric pressure for 3 hours in the presence of 10% Pd/C (12.3 mg). 
The catalyst was removed by filtration through celite and the filtrate was evaporated. The 
residue was purified by column chromatography (CH2Cl2/MeOH 95:5) to give the final 
compound 4.30 (31 mg, 98%). 
 
1H NMR (300 MHz, CDCl3): 1.44 (1H, m, 5’-CH3), 1.92 (3H, d, 5-CH3), 1.93-
2.00 (1H, m, H-3’), 2.00 (3H, s, COCH3), 3.12-3.21 (2H, m, H-6’ and H-6’’), 
4.14 (1H, m, H-4’), 4.31 (1H, m, H-2’), 4.95 (1H, d, J= 2.9 Hz, H-1’), 5.59 (1H, 
d, J= 0.88 Hz, 2’-OH), 6.13 (1H, br t, NH-3’), 7.27 (1H, m, H-6), 8.85 (1H, br 
s, N(3)H).   
 
 
Exact mass (ESI-MS) for C13H20N3O5 [M+H]+ found, 297.1328; calcd, 297.1325. 
 
 
1-(3-Azidomethyl-3-deoxy-5-O-tosyl-β-D-ribofuranosyl)thymine (4.31) 
To a solution of 4.26 (398 mg, 1.34 mmol) in pyridine (3.2 mL) cooled at 0 °C, p-
toluenesulfonyl chloride (307 mg, 1.61 mmol) was added. The reaction mixture was stirred at 
room temperature during 2 days and evaporated in vacuo to remove pyridine.  The residue 
was partitioned between CH2Cl2 (10 mL) and H2O (10 mL), separated, and the aqueous 
layer was extracted two times more with 15 mL of CH2Cl2.  The combined organic layers 
were dried over MgSO4, filtered and evaporated. The residue was purified by column 
chromatography (CH2Cl2/MeOH 97:3) to yield compound 4.31 (280 mg, 46%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.77 (3H, d, J= 1.2 Hz, 5-CH3), 2.29 (1H, 
m, H-3’), 2.41 (3H, s, PhCH3), 3.31 (1H, m, H-6’), 3.58 (1H, dd, J= 5.7 and 
12.3, H-6’’), 4.06 (1H, m, H-4’), 4.20 (2H, m, H-5’ and H-2’), 4.36 (1H, dd, 
J= 2.1 and 11.1, H-5’’), 5.62 (1H, d, J= 2.4 Hz, H-1’), 5.90 (1H, d, J= 5.4 Hz,  
2’-OH), 7.36 (1H, d, J= 1.5, H-6), 7.45 (2H, m, arom H), 7.77 (2H, m, arom 
H), 11.31 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C18H22N5O7S [M+H]+ found, 452.1240; calcd, 452.1239. 
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1-(3-Azidomethyl-3,5-dideoxy-5-iodo-β-D-ribofuranosyl)thymine (4.32) 
A mixture of 4.31 (342 mg, 0.76 mmol), NaI (557 mg, 3.71 mmol) and a catalytic amount of 
tetra-n.butylammonium iodide (5 mg) in acetone (30 mL) was refluxed at 60 °C overnight. 
Ice-cold water (5 mL) was poured into the reaction mixture. This mixture was extracted with 
CH2Cl2.  The organic layer was dried over MgSO4, filtered and evaporated, and the residue 
was purified by column chromatography (CH2Cl2/MeOH: 97:3) to yield compound 4.32 (311 
mg, 100%).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.79 (3H, d, J= 1.8 Hz, 5-CH3), 2.26 (1H, m, 
H-3’), 3.45 (2H, m, H-6’ and H-5’), 3.62 (2H, m, H-6’’ and H-5’’), 3.80 (1H, m, 
H-4’), 4.35 (1H, m, H-2’), 5.43 (1H, d, J= 3.6 Hz, H-1’), 5.88 (1H, d, J= 5.1 Hz, 
2’-OH), 7.48 (1H, d, J= 1.2, H-6), 11.34 (1H, br s, N(3)H). 
 
 
Exact mass (ESI-MS) for C11H14N5O7INa [M+Na]+ found, 429.9999; calcd, 429.9990. 
 
 
1-(3-Aminomethyl-3,5-dideoxy-β-D-ribofuranosyl)thymine (4.33) 
A mixture of 4.32 (311 mg, 0.764 mmol) and triethylamine (250 µL) in methanol (20 mL) was 
hydrogenated at atmospheric pressure overnight in the presence of 10% Pd/C (95 mg). The 
catalyst was removed by filtration through a celite path, and the filtrate was evaporated. The 
residue was purified by column chromatography (CH2Cl2/MeOH 85:15 to 80:20) to give 
compound 4.33 (134 mg, 69%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.32 (3H, d, J= 6.0 Hz, 5’-CH3), 1.79 (3H, d, 
J= 1.2 Hz, 5-CH3), 2.03 (1H, m, H-3’), 2.76 (1H, dd, J= 5.1 and 12.6, H-6’), 
2.95 (1H, m, H-6’’), 3.96 (1H, m, H-4’), 4.29 (1H, dd, J= 2.1 and 6.0 Hz, H-2’), 
5.60 (1H, d, J= 2.1 Hz, H-1’), 7.32 (1H, d, J= 1.2 Hz, H-6). 
 
 
 Exact mass (ESI-MS) for C11H18N3O4 [M+H]+ found, 256.1294; calcd, 256.1297. 
 
 
1-(3-Aminomethyl-3,5-dideoxy-2-O,6-N-(thiocarbonyl)-β-D-ribofuranosyl)thymine (4.9) 
A solution of 4.33 (127 mg, 0.497 mmol) and 1,1’-thiocarbonyldiimidazole (97.47 mg, 0.547 
mmol) in THF (7 mL) was stirred at room temperature for 5 h. The mixture was evaporated 
to dryness and the residue was purified by column chromatography (CH2Cl2/MeOH 97:3) to 
give compound 9 (64 mg, 43%) as a white solid. 
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1H NMR (300 MHz, DMSO-d6): δ 1.40 (3H, d, J= 6.3 Hz, 5’-CH3), 1.80 (3H, s, 
5-CH3), 2.61 (1H, m, H-3’), 3.16 (1H, d, J= 4.2 Hz, H-6’), 3.46 (1H, dd, J= 5.7 
and 13.8 Hz, H-6’’), 3.96 (1H, m, H-4’), 5.02 (1H, d, J= 5.7, H-2’), 5.80 (1H, s, 
H-1’), 7.37 (1H, s, H-6), 9.85 (1H, br s, N(6’)H), 11.40 (1H, br s, N(3)H). 
 
 
 
13C NMR (300 MHz, DMSO-d6): δ 12.83 (5-CH3), 18.67 (C-5’), 37.18 (C-6’), 38.52 (C-3’), 77.83 (C-4’), 
84.14 (C-2’), 90.36 (C-1’), 110.24 (C-5), 136.54 (C-6), 150.88 (C-2), 164.49 (C-4), 184.70 (6-NHCS). 
 
Exact mass (ESI-MS) for C12H16N3O4S [M+H]+ found, 298.0858; calcd, 298.0861; Anal. 
(C12H15N3O4S) C, H, N. 
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5 RATIONAL DESIGN OF 3’-BRANCHED-THIOUREA SUBSTITUTED β-
THYMIDINE DERIVATIVES AND 5’-THIOUREA SUBSTITUTED α-
THYMIDINE ANALOGUES
 
 
 
5.1 OBJECTIVE 
 
Simultaneously with the discovery of the 2’,3’-bicyclic thymidine derivatives, described in 
chapter 4, an unusual dinucleoside 5.1 (Ki= 37 µM) was revealed as TMPKmt inhibitor.107  
The second thymidine monomer attached to the 3’-position suggested the possibility to 
introduce large substituents at this position to fit in the dTMP-pocket.  Next to its surprisingly 
inhibitory activity, compound 5.1 did not inhibit human TMPK (TMPKh) at 1 mM, indicating 
that further explorations of this type of analogues might result in potent and selective 
TMPKmt inhibitors.  
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Figure 5.1 Dinucleoside 5.1 (Ki= 37 µM) 
 
 
5.2 3’-C-BRANCHED THIOUREA SUBSTITUTED β-THYMIDINE DERIVATIVES 
5.2.1 Rational design 
Starting from the structure of dinucleoside 5.1, we investigated the possibility to replace one 
thymidine monomer by substituted phenyl groups.  Concurrently, thiocarlide,146 a drug that 
formerly proved efficient in treating TB,147,148 inspired us to replace the connecting urea 
group by a thiourea linker, resulting in 3’-C-branched thiourea substituted β-thymidine 
derivatives.  
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By carefully selecting a limited set of compounds based on the Topliss’ tree, 149 we aimed to 
assess the relative importance of the lipophilic, electronic and sterical properties of the aryl 
substituents.  
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Figure 5.2 Dinucleoside 5.1 and envisaged derivatives 
 
5.2.2 Chemistry 
The synthesis of a series of 3’-branched-β-thiourea-derivatives started from β-D-thymidine.  
As depicted in chapter 2, different methods are described for the synthesis of 3’-branched 
nucleosides.  A radical introduction of a β-styrene residue, followed by cis-dihydroxylation, 
oxidative cleavage and reduction resulted in compound 2.43.  After mesylation of the primary 
alcohol, the azido group was introduced using sodium azide in DMF.  Hydrogenation of 5.35 
with Pd/C gave amine 5.36.  This precursor was reacted with different isothiocyanates in a 
parallel fashion to give target compounds 5.2-5.8 after final deprotection of the silyl group. 
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5.6: R1  = Cl; R2 = Cl
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Scheme 5.1, Reagents and conditions: (a) (i) MsCl, pyridine, 0 °C, 1h; (ii) NaN3, DMF, 60 °C, 7h, 
97%; (b) Pd/C, H2, MeOH, rt, 3h, 99%; (c) 3-R2-4-R1-phenylisothiocyanate, DMF, 0 °C, 1h, 70-88%; 
(d) TBAF, THF, rt, 1h, 87-92%. 
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5.2.3 Biological evaluation 
All compounds were tested for TMPKmt inhibition as described in the experimental section 
of chapter 3.  The results of the β-derivatives are shown in Table 5.1. 
 
Table 5.1 Kinetic parameters of TMPKmt with compounds 5.1-5.8 
O
O T
HN
HO
OT
NH
OH
O
HO
N NH
O
O
NH
H
N
S
R1
R2
5.2-5.85.1
 
Compound R1 R2 
Ki (µM) 
TMPK mt 
Ki (µM) 
TMPK h 
MCC (µM) 
Vero cell culturesb 
dTMP 
  4.5 a 5.0 a  
5.1 
  37.0 NI 1mM  
5.2 H H 69.0   
5.3 Cl H 21.0  > 100 
5.4 OCH3 H 46.0  > 100 
5.5 CH3 H 36.0  > 100 
5.6 Cl Cl 7.2  > 100 
5.7 OCH2Ph H 12.0  > 100 
5.8 Cl CF3 5.0 NI 1mM > 100 
a
 Km-Value 
b Minimum cytotoxic concentration in Vero cell cultures, i.e. the concentration required to cause 
microscopically detectable alteration of normal cell morphology. 
 
 
For the 3’-C-branched-β-thymidine derivatives, the thiourea analogue 5.2 with an 
unsubstituted phenyl ring showed a Ki-value of 69.0 µM.  This value indicates a 
weaker binding to the enzyme than dinucleoside 5.1 (Ki= 37 µM) and the natural 
substrate (Km = 4.5 µM).  However, this result suggests that this analogue can still be 
accommodated in the active pocket.  In order to optimize the potency of this phenyl 
analogue, Topliss’ scheme149 (Figure 5.3) was used.   
This decision tree is based on the concept, pioneered by Hansch,150 that principally the 
lipophilic, electronic and steric properties of the introduced substituent influence the 
activity.   
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Figure 5.3 Topliss’ tree 
 
 
A 4-chloro-substitution of the phenyl ring (5.3) resulted in a 3-fold increased activity.  
According to Topliss’ decision tree, this increase confirms the positive effect of lipophilic and 
electron withdrawing substituents on the inhibitory activity.  This trend was validated by 
further improvement of the activity with a 3,4-dichloro-substitution pattern (5.6) which further 
increased activity by another 3-fold (Ki= 7.2 µM).  On the other hand, a 4-methoxy- (5.4) or 
4-methyl-substituent (5.5) resulted in a decreased activity.  To further validate electron 
withdrawing properties, compound 5.8 was synthesized, while 5.7 should indicate if sterically 
more demanding substituents were also allowed.  Compound 5.8 with a 3-CF3-4-Cl-
substitution pattern was found to be the most potent inhibitor of this series with a Ki-value of 
5.0 µM, indicating that mainly the electronic features of the substituents positively influenced 
the inhibitory activity. 
 
The good affinity observed among these β-thiourea derivatives suggests a binding mode 
analogous to that described for dinucleoside 5.1107 with the arylthiourea moiety occupying 
the phosphoryl donor binding site.  
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5.3 5’-O-PHOSPHORYLATED α-THYMIDINE 
5.3.1 Rational design 
Modelling studies on the binding mode of dinucleoside 5.1 to its target suggested that the 
second monomer binds to the area where normally the phosphoryl donor binds, in this way 
forcing the sugar ring to tilt over 180° compared t o the natural substrate dTMP.  Similarly, 
the envisaged β-thiourea derivatives are expected to bind the dTMP-pocket upside down, 
positioning the aromatic 3’-substituent into the phosphoryl donor binding area, and the 
nucleobase below the sugar plane. 
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Figure 5.4 Suggested inverse sugar binding of 3’-C-arylthiourea-modified β-thymidines and 
anticipated similar relative orientation of the coloured moieties in 5’-deoxy-5’-arylthiourea modified α-
thymidines. 
 
As depicted in Figure 5.4, we hypothesized that the relative orientation of the nucleobase 
and the arylthiourea moiety in these β-thiourea derivatives might be imitated by 5’-
substituted α-thymidine analogues. 
In order to sustain this hypothesis, 5’-O-phosphorylated α-thymidine was synthesized to 
assess if it can be accepted by TMPKmt as a substrate.  
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5.3.2 Chemistry 
For the synthesis of α-D-thymidine 5’-O-monophosphate 5.9, 3’,5’-O-diacetyl-β-D-thymidine 
was first anomerized to its α-anomer 5.44 according to the procedure of Ward et al.,151 
followed by deprotection and conversion to the 5’-monophosphate using classical 
phosphorylation conditions.  
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Scheme 5.2, Reagents and conditions: (a) Ac2O, Pyridine, rt, 2h, 99%;  (b) H2SO4, Ac2O, 
acetonitrile, rt, 2h, 45%; (c) NH3, MeOH, rt, 16h, 98%; (d) POCl3, P(OMe)3, 0 °C, 4h then rt, 0.5h, 
62%. 
 
5.3.3 Biological evaluation 
The reported spectrophotometric assay119 confirmed that α-thymidine monophosphate was 
accepted as a substrate by TMPKmt (Km= 450 µM, Vm= 0.77 U/mg), thereby competing with 
dTMP (Ki= 15.0 µM).  Compared to the natural substrate however, the binding constant of 
this anomer was 10 times higher and its maximum velocity (Vm) only 7.5% of that of dTMP.  
The same broad stereoisomeric substrate specificity has been observed for mitochondrial 
thymidine kinase (TK2), deoxyguanosine kinase (dGK) and deoxycytosine kinase (dCK), 
which proved able to recognize β-D and β-L, as well as α-D and α-L nucleosides as a 
substrate.152 
The fact that 5’-O-phosphorylated α-thymidine was accepted by TMPKmt as a substrate 
confirmed that α-nucleosides proved able to adopt the proposed binding mode, which incited 
us to synthesize the readily accessible 5’-deoxy-5’-N-arylthiourea α-thymidine derivatives. 
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5.4 5’-THIOUREA SUBSTITUTED α-THYMIDINE DERIVATIVES 
5.4.1 Objective 
As discussed above, the validation of 5’-O-phosphorylated α-D-thymidine monophosphate 
as a TMPKmt substrate, combined with the encouraging results obtained with the 3’-
branched β-thymidine series opened interesting perspectives for the synthesis of 5’-thiourea 
substituted α-nucleosides. 
A detailed exploration of the 5’-thiourea substituent pattern was envisaged, followed by a 
study about the importance of the deoxyribofuranose moiety by the synthesis of 2’,3’-
dideoxy, 2’,3’-dideoxydidehydro- and acyclic derivatives. 
Very recently,153,154 a series of 5’-modified adenosine derivatives has been discovered as 
potent siderophore biosynthesis inhibitors.  Some of these analogues showed MIC99-values 
against M. tuberculosis H37Rv comparable to that of isoniazid, suggesting the presence of 
active adenosine-uptake mechanisms.  In an attempt to use adenosine to enhance the 
uptake in the mycobacterial cell, a dinucleoside was designed, consisting of a α-thymidine 
monomer connected to adenosine by a thioureum linker. 
The synthesis and biological evaluation of those compounds allows the determination of a 
detailed structure-activity relationship. 
  
5.4.2 Chemistry 
The synthesis of 5’-substituted α-thymidine derivatives started from α-thymidine (5.45) which 
was converted to the 5’-deoxy-5’-(thio)urea-derivatives 5.10-5.27 as depicted in Scheme 5.3.  
Amide 5.30 (Table 5.2) was isolated as a side product upon treatment of 5.47 with 
benzoylisothiocyanate. 
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Scheme 5.3, Reagents and conditions: (a) (i) MsCl, Pyridine, 0 °C, 1h (ii) NaN3, DMF, 60 °C, 16h, 
68%; (b) H2, Pd/C, MeOH, rt, 6h, 98%; (c) suitable iso(thio)cyanate, DMF, 71-91%; or: suitable amine, 
1,1’-TCDI, DMF, rt, 3h, 75-82%. 
 
 
3’-Deoxygenation was performed by converting the 3’-hydroxyl group to its mesylate ester 
(Scheme 5.4). Upon treatment with base, elimination yielded the unsaturated sugar in 
nucleoside 5.49. Hydrogenation over Pd/C gave the 2’,3’-dideoxy-analogue 5.50, while 
Staudinger reduction selectively converted the azide, affording the unsaturated amine 5.51. 
Final treatment of these amines with 3-CF3-4-Cl-isothiocyanate afforded derivatives 5.28 and 
5.29. 
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Scheme 5.4, Reagents and conditions: (a) MsCl, Pyridine, 0 °C, 2h, 81%; (b) DBU, THF, 80 °C, 
16h, 95%; (c) H2, Pd/C, MeOH, rt, 5h, 95%; (d) PPh3, Pyridine, rt, 3h, 92% (e) 3-CF3-4-Cl-
isothiocyanate, DMF, rt, 3h, 78%. 
 
 
Acyclic derivatives were synthesized following a procedure as reported for uridine-
derivatives by Danel et al.155 (see Scheme 5.5). The primary alcohol of 5.52 was converted 
to different thiourea-compounds as described above. 
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Scheme 5.5, Reagents and conditions: (a) Silylated thymine, TMSOTf, acetonitrile, -45 °C, 2h then 
rt, 16h, 76 %; (b) (i) MsCl, Pyridine, 0 °C, 2h (ii) NaN3, DMF, 60 °C, 16h, 96%; (c) Pd/C, H2, MeOH, rt, 
16h, 99%; (d) ) 3-R2-4-R2 isothiocyanate, DMF, rt, 3h, 83-86%. 
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For the preparation of the adenosine-conjugate 5.33, adenosine was protected with a 2’,3’-
isopropylidene group, followed by mesylation and azido-substitution to compound 5.56.  This 
compound was reduced to obtain 5’-amino-2’,3’-isopropylidene adenosine.156  Upon 
treatment with 1,1’-thiocarbonyldiimidazole, 5’-amino-2’,3’-isopropylidene adenosine 5.56 
was converted in situ to the isothiocyanate, which was further reacted with  5’-amino-α-
thymidine to afford the envisaged dinucleoside after deprotection of the acetonide. 
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Scheme 5.6, Reagents and conditions: (a) Dimethoxypropane, Acetone, PTSA, rt, 1h, 77%; (b) (i) 
MsCl, Pyridine, 0 °C, 1h, (ii) NaN3, DMF, 60 °C, 16h, 71%; (b) Pd/C, H2, MeOH, rt, 16h; (c) (i) 5’-NH2-
α-thymidine, TCDI, DMF, rt, 2h; (ii) 50% TFA, rt, 2h, 73%. 
 
5.4.3 Biological evaluation 
The biological activities of the synthesized α-thymidine derivatives are represented in Table 
5.2.  In analogy to our observations for the 3’-C-branched β-thymidine thiourea analogues, 
lipophilic and electronic withdrawing substituents favour high activity.  With a Ki of 0.6 µM, 
analogue 5.15 (R1=Cl, R2= CF3) proved to be the most potent TMPKmt inhibitor reported so 
far.  
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Table 5.2: Kinetic parameters of TMPKmt with compounds 5.9-5.33 and 5.46-5.47 
HO
O
NH N NH
O
OH
N
X
5.30, 5.46-5.47
HO
O
R N NH
O
O
5.10-5.29,5.33
R
H
N
N
OO
O
NH
H
NR
S
5.31-5.32
 
Comp 
N° 
R X 
Ki (µM) 
TMPKmt 
Ki (µM) 
TMPKh 
SI 
MIC99 
(µg/ml) 
 (M. bovis) 
% Inh  
(M. tub 
H37Rv)d 
MCC µM 
Vero cell 
culturese 
Dtmp 
  4.5 a 5.0 a     
Α-Dtmp 
  15.0      
5.10 Phenyl S 16.0     > 100 
5.11 4-Cl-phenyl S 3.2 > 
1000 
    
5.12 4-MeO-phenyl S 10.0      
5.13 4-Me-phenyl S 7.8      
5.14 3,4-diCl-phenyl S 1.0 274 270 25 38% > 100 
5.15 3-CF3-4-Cl-phenyl S 0.6 362 600 20 39% > 100 
5.16 4-morpholinophenyl S 19.2      
5.17 1-adamantyl S 15.0     > 100 
5.18 3-pyridyl S 18.0      
5.19 Fluoresceinyl S 5.4   > 150   
5.20 Phenylmethyl S 5.4      
5.21 Benzhydryl S 4.9 > 500    > 100 
5.22 Benzoyl S 7.2      
5.23 3-CF3-4-Cl-phenylmethyl S 2.6 50 20 40  > 100 
5.24 Phenylethyl S 3.8 > 800    > 100 
5.25 3,4-diCl-phenylethyl S 2.2 79 40 50  > 100 
5.26 3,4-diClphenyl O 1.1 116 105 40 (MIC50) 41%  
5.27 3-CF3-4-Cl-phenyl O 1.9 166 90 40 (MIC50) 49%  
5.28 b 3-CF3-4-Cl-phenyl S 2.3 > 500  40 34%  
5.29c 3-CF3-4-Cl-phenyl S 3.8 190 50 100 55%  
5.30 Benzamido  35      
5.31 Phenyl  260     > 100 
5.32 3-CF3-4-Cl-phenyl  37.0    34% 100 
5.33 
5’-deoxy-β-D-adenosin-
5’-yl 
S 26 280 10    
5.46 N3  26.5      
5.47 NH2  16.0   > 40   
a
 Km-Value; b 3’-deoxy-ribonucleoside; c 3’-deoxy-2’,3’-didehydronucleoside; d inhibition at 6.25 µg/mL; 
e Minimum cytotoxic concentration in Vero cell cultures, i.e. the concentration required to cause 
microscopically detectable alteration of normal cell morphology. 
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As the corresponding α- and β-thiourea derivatives were designed to bind in a similar 
fashion, a comparison between the corresponding activities is presented in Figure 5.5. 
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Figure 5.5 Comparison of the parallel synthesized alpha- and beta- thiourea derivatives; 
(■ β-derivatives, ■ α-derivatives) 
 
The graph shows that the α-derivatives are consistently (~ 4- to 5-fold) more active than the 
β-congeners, and clearly reveals a similar trend in both series, further supporting our design 
hypothesis. 
To illustrate the binding mode of the two main series of inhibitors, docking of two 
representative compounds 5.2 (β) and 5.10 (α) was performed.  This experiment resulted in 
50 conformations, mainly containing two different orientations: one with the nucleobase 
stacking with Phe 70 and one with the aromatic tail stacking to Phe 70.  As opposed to the 
former, the latter conformations preclude certain amino acids (e.g., Arg 74, Asn 100) to form 
H-bonds and were therefore rejected.  This rejection is justified as docking showed that the 
space close to Phe 70 is too small to accommodate bulky substituents like a Cl or a CF3 
group.  Moreover the docked conformations with the aromatic ring occupying the base site 
are shifted, reducing the stacking interaction and thus drastically limiting the number of 
meaningful conformations found.  
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Figure 5.6 Compound 5.2 (left) and compound 5.10 (right) docked in the active site of TMPKmt: All 
residues interacting with the inhibitors (hydrophobic contact) are shown as well as the hydrogen 
bonds (calculated using Ligplot and HBPlus.157, 158 Drawings created using Molscript.159 
 
When comparing corresponding analogues from both series such as 2 and 10 (Figure 5.6), 
both the nucleobase and the arylthiourea-moiety occupy the same areas.  For the α-
derivatives, the pyrimidine ring and Phe 70 are arranged in a more parallel fashion 
compared to the β-derivatives, resulting in a stronger stacking.  Moreover compound 5.10 is 
more favourably positioned to form an extra H-bond with Asp 9 through a nitrogen of its 
thiourea function, which may contribute to the higher affinity of the α-analogues for TMPKmt. 
 
Further structural modifications elucidated that small structural changes, such as introduction 
of an alkyl chain of 1 or 2 carbon atoms between the thioureum and phenyl, are well 
tolerated by TMPKmt, yet not enhancing the affinity for the enzyme.  
It is found that the tail of molecules 5.10 and 5.24 points to the outside of the enzyme 
through a channel, the same orientation as dinucleoside 5.1.107  This exit channel is 
surrounded by residues Arg14, Ala35, Phe36, Pro37, Tyr39, Arg160 (Figure 5.7).  Adding 
functional groups in para- and meta-position on the phenyl ring seems to improve the 
activity, by increasing hydrophobic contact with these residues.  However since longer 
chains extend more out of the enzyme into the solvent (Figure 5.7), this indicates that no 
further improvement can be obtained by increasing the linker length. 
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Figure 5.7 Docking and superposition of α-derivatives 5.10 (green carbons) and 5.24 (grey carbons) 
in the active site of TMPKmt, 5.24 having a longer linker (n=2). The phenyl tails of the inhibitors point 
to the front and seem to exit the enzyme through a channel lined up by residues Arg14, Ala35, Phe36, 
Pro37, Tyr39, Arg160. The “channel” residues are coloured blue. Picture created using, Molscript,160 
Bobscript,161 Raster3D.162 
 
 
Surprisingly, sterically demanding substituents as in 5.19 and 5.21 cause almost no change 
in inhibitory activity, so most likely a large pocket around the phosphoryl donor area is 
available for the inhibitor to interact with.  The activity of the fluoresceine-labelled compound 
5.19 opens interesting perspectives for its use in the enzymatic activity determination or in 
mycobacterial uptake-studies.  The lower activity of compounds 5.16 and 5.17 suggests a 
role for the aromatic moieties to stabilize the enzyme-inhibitor complex. 
 
To check the importance of the hydrophobic sulfur of the thiourea linkage, urea derivatives 
5.26 and 5.27 were synthesized.  As those compounds retain their good affinity for the 
enzyme, a larger structural freedom for the linkage between the aromatic moiety and the 
nucleobase seems to be tolerated. 
Only a small drop in affinity was observed upon removal of the 3’-hydroxyl (5.28) or upon 
additional introduction of a double bond between 2’ and 3’ (5.29).  We therefore conclude 
that the most important feature for TMPKmt inhibition of this series is the relative orientation 
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of the nucleobase and the 5’-substituent, combined with the ability for the 5’-substituent to 
interact with the enzyme active pocket. 
This led us to synthesize acyclic derivatives 5.31 and 5.32, which exhibited only a very weak 
affinity for the enzyme.  Despite the fact that the number of bonds between the thymine and 
the aromatic moiety is retained in these structures, the higher entropy changes required to 
form the complex are likely to be unfavourable for binding.  
 
The selectivity of the most potent TMPKmt vis-à-vis the human isozyme was investigated.  
Most tested compounds proved highly selective for the mycobacterial enzyme.  Especially 
compound 5.15, the most active compound of the series, showed a selectivity index of 600, 
indicating that the inverse binding mode of the sugar is not tolerated by the human enzyme. 
 
Consequently, we assessed the potential of the most promising analogues to restrain 
mycobacterial growth.  Whereas compound 5.15 proved to be the most potent TMPKmt 
inhibitor, it also proved superior in a M. bovis growth inhibition assay.  Selected compounds 
were also tested for their capability to reduce M. tuberculosis H37Rv growth at a 
concentration of 6.25 µg/mL, showing an inhibition of bacterial growth between 34 and 55% 
at this concentration. 
For the first time, TMPKmt inhibitors proved capable to inhibit the growth of both M. bovis 
and M. tuberculosis, confirming that TMPKmt indeed represents a valuable target for 
designing antituberculosis drugs.  Moreover, the compounds were found non-toxic in Vero 
cell cultures at 100 µM and also devoid of appreciable inhibitory activity against a broad 
variety of viruses including herpes simplex virus type 1 (KOS) and type 2 (G), vaccinia virus, 
vesicular stomatitis virus, Sindbis virus, reovirus-1, parainfluenza virus-3, Coxsackie B4, 
respiratory syncytial virus, Punta Toro virus, feline coronavirus, influenza virus A (H1N1 and 
H3N1) and influenza virus B.  This lack of activity further points to the highly selective activity 
of several compounds against mycobacteria. 
 
Very recently, a series of 5’-modified adenosine derivatives has been discovered as powerful 
siderophore biosynthesis inhibitors.153,154  Some of these analogues showed MIC99-values 
against M. tuberculosis H37Rv comparable to that of isoniazid, suggesting the presence of 
active adenosine-uptake mechanism.  For this reason, conjugate 5.33 was synthesized to 
exploit this proposed adenosine uptake mechanism to enhance antimycobacterial activity.  
While still showing moderate TMPKmt inhibitor activity, dinucleoside 5.33 failed to inhibit 
mycobacterial growth. 
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Finally, all compounds tested in Vero cell cultures where devoid of cytotoxicity at 100 µM, 
while another assay proved 5.15 to have a minimum cytotoxic concentration of 300-400 
µg/mL, which is more than 10 times the concentration needed to kill M. bovis.  The urea 
analogues (5.26 and 5.27) of the most active compounds (5.14 and 5.15), which lack the 
thiourea moiety, earlier described as the perpetrator of toxicity,163 showed nearly equal 
inhibitory activity against TMPKmt, while still retaining a sufficient selectivity versus the 
human enzyme (with SI= 90-105) and interesting activity on the growing M. bovis and M. 
tuberculosis strains. 
 
 
5.5 QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS 
As explained in the introduction (See 1.3) Quantitative Structure-Activity Relationship 
(QSAR) analysis, is a technique developed to design new active compounds in a rational 
way.  As the target is not considered in this method, QSAR can also be used for compounds 
for which the target enzyme remains unknown.  This technique is based on a set of 
analogues of a biologically active compound for which the physicochemical properties are 
identified and quantified by making use of descriptors (e.g. MW, log P).  A correlation is 
determined between these descriptors and the corresponding activities, which is then used 
for the prediction of the activities of new analogues. 
 
 
In collaboration with the laboratory for Quantum Chemistry of Ugent (Prof. P. Bultinck) a 
dataset of 22 thiourea derivatives (involving both α− and β-nucleosides) was submitted to a 
QSAR analysis.  For this study it is important that all Ki-values are obtained using the same 
assay method, and the pKi-values should span a sufficiently wide range from 2 to 6.  As the 
analysis was not performed in our group, only a brief result is described, without detailed 
description of the methods used. 
 
 
A good correlation could be obtained for a model with the following 5 descriptors: 
- Log P: Partition coefficient between octanol and water (positively correlated). 
- Electrophilicity/TPSA (= Total Polar Surface Area) (positively correlated). 
- QmaxO: maximum charge on an oxygen atom according to mulliken population analysis 
(positively correlated). 
- Alpha: alpha- or beta-substituted compounds (positively correlated). 
- Simi: similarity with dTMP calculated on quantumchemical level (negatively correlated). 
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The fitting between the observed and predicted activity, obtained with this model, is shown in 
Figure 5.8, in which the crossing of the axes lies at the -log(Ki)-value of dTMP.  With a R2 >> 
0.75, the model gives a good fitting, resulting in a high predictability. 
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Figure 5.8 Fitting between observed and predicted activity as obtained with the 5-descriptor model 
 
Unfortunately, when this model was extended with a wider range of earlier synthesized 
compounds, the good correlation as observed for the thiourea analogues disappeared.  In 
attempt to build a new model with a good fitting between observed and predicted activities, 
only models with a low predictability and based on meaningless descriptors (e.g. the 
difference in mass between atoms on a distance of 3 bonds from each other) could be 
obtained, further limiting the use of QSAR to develop new compounds. 
 
5.6 CONCLUSION 
Based on the structure of the recently discovered dinucleoside 5.1 as a selective TMPKmt 
inhibitor, this chapter describes the synthesis and biological evaluation of a series of 3’-C-
aryl thiourea derivatives of β-D-thymidine.  Optimisation of the aryl thiourea led to analogue 
5.7 that, with a Ki-value of 5.0 µM, clearly surpassed 5.1 in inhibitory activity. 
Modelling experiments suggested a distinct binding mode for these analogs, as compared to 
the natural substrate: the sugar moiety binds the active site upside down.  The acceptance 
of α-thymidine-5’-phosphate as a substrate for TMPKmt supported the synthesis of 5’-
substituted α-thymidine thiourea derivatives, mainly characterized by a similar relative 
orientation of the 5’-aryl moiety and the nucleobase.   
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This led to the discovery of compound 5.15 as the most promising compound of this series 
with a Ki-value of 0.6 µM, a selectivity index (TMPKh) of 600, and a good inhibitory activity 
on the growing M. bovis (MIC99 = 20 µg/mL) and M. tuberculosis (39% inhibition at 6.25 
µg/mL) strains. 
Next to the relative orientation between the aryl moiety and the nucleobase, structural 
exploration of the α-thymidine derivatives, revealed the positive impact of electronic 
withdrawing and lipophilic substituents on the 5’-aryl moiety and the need for aromatic 
residues at this 5’-position.  
 
In conclusion, we have designed, synthesized, and evaluated a series of nucleoside 
inhibitors of M. tuberculosis TMPK, which resulted in the identification of 5’-arylthiorea α-
thymidine analogues endowed with significant inhibitory activity against M. tuberculosis and 
M. bovis growth and low cytotoxicity.  This strategy represents a promising approach for the 
development of a new class of antibiotics effective for the treatment of TB.  
 
In a broader sense, this study opens interesting perspectives for using sugar-modified α-
nucleosides as readily accessible scaffolds for the rational design of biologically important 
tool compounds acting on kinase targets or in other areas in chemical biology. 
 
 
5.7 EXPERIMENTAL SECTION 
Biological assays on Mycobacterium bovis (BCG) 
The different compounds were assayed for their inhibitory potency on Mycobacterium bovis 
var. BCG growth in vitro.164  A micro-method of culture was performed in 7H9 Middlebrook 
broth medium containing 0.2% glycerol, 0.5% Tween 80 and supplemented with oleic acid, 
albumin, dextrose and catalase (Becton-Dickinson). Serial two fold dilutions of each 
compound were prepared directly in 96 well plates.  The bacterial inoculum was prepared 
previously at concentration in the range of 107 bacteria (M. bovis BCG 1173P2) in 7H9 
medium and stored at -80 °C until used.  The bacteria, adjusted at 105 per ml, were 
delivered under a volume of 100µl per well.  The covered plates were sealed with Parafilm 
and incubated at 37 °C in plastic boxes containing humidified normal atmosphere.  At day 8 
of incubation, 30 µl of a resazurin (Sigma) solution at 0.01% (wt/vol) in water were added to 
each well.  After overnight at 37 °C the plates were assessed for colour development using 
the optical density difference at 570 nm and 630nm on a ELISA reader.  The change from 
blue to pink indicates reduction of resazurin and therefore bacterial growth.  The lowest 
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compound concentration that prevented the colour change determined the MIC for the 
assayed compound. 
 
Biological assays on Mycobacterium tuberculosis H37Rv 
Antimycobacterial data were provided by the Tuberculosis Antimicrobial Acquisition and 
Coordinating Facility (TAACF) through a research and development contract with the U.S. 
National Institute of Allergy and Infectious Diseases.  
The screening test against M. tuberculosis H37Rv was conducted at 6.25 mg/mL in 
BACTEC 12B medium using the Microplate Alamar Blue Assay (MABA).165 
 
Cytotoxic activity of test compounds in Vero cell cultures 
To monolayers of confluent Vero cell cultures in 96-well microtiter plates were added serial 
dilutions of the test compounds (total volume of compound-containing culture medium: 200 
µl).  After 3 days of incubation at 37 °C in a humidified CO2-controlled atmosphere, the cell 
cultures were microscopically inspected for morphological alteration.  The MCC was defined 
as the compound concentration required to cause a microscopical alteration of the mock-
infected cell cultures at day 3 post compound administration. 
 
Molecular Modelling 
The published X-ray structure of the TMPKmt (PDB entry 1G3U)95 was used in all docking 
experiments.  The inhibitors 5.2 and 5.10 were drawn using JChemPaint166 and BUILD3D.167  
The molecular geometry was fed into gamess for geometry optimization using the AM1 force 
field.168  The sugar conformation in 5.2 was modelled as C2’-endo with the base in an 
equatorial orientation by replacing the sugar and base by the sugar-base fragment in 
thymidine monophosphate from the pdb file 1G3U.169  The sugar-base in 5.10 was replaced 
by the sugar-base in CSD170 entry LEDRIV171 having the base in alpha position and 
equatorial orientation.  Polar hydrogen atoms were added to the enzyme and inhibitor 
structures using autodocktools.172  The compounds were docked in the cavity close to Tyr-70 
by means of the Autodock 3.05 software.173  The top 50 of docked ligand conformations was 
examined and a manual selection procedure was used to validate the docked conformations.  
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Synthesis 
 
3’-(Azidomethyl)-5’-O-tert-butyldiphenylsilyl-3’-deoxythymidine (5.34)  
Methanesulfonyl chloride (0.366 mL, 4.73 mmol) was added to a solution of 2.43 (900 mg, 
1.82 mmol) in pyridine (10 mL) at 0 °C.  The reaction was stirred at 0 °C during 1 h.  The 
mixture was diluted with CH2Cl2 (25 mL), washed with saturated aqueous NaHCO3 and dried 
over MgSO4.  The solvent was evaporated in vacuo to give the crude mesylate.  The 
obtained residue was dissolved in DMF (50 mL) and treated with NaN3 (1.18 g, 18.2 mmol) 
at 60 °C.  After 7 h the reaction was completed.  The reaction mixture was evaporated to 
dryness and the residue was dissolved in CH2Cl2 (25 mL).  The organic layer was washed 
with water, dried over MgSO4 and evaporated to give a syrup which was purified by column 
chromatography (CH2Cl2/MeOH 99:1) yielding 5.34 (915 mg, 97%) as a white foam. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.00 (9H, s, tert-but), 1.50 (3H, d, J= 
0.6 Hz, 5-CH3), 2.15 (2H, m, H-2’ and H-2”), 2.62 (1H, m, H-3’), 3.42-
3.57 (2H, m, H-6’ and H-6”), 3.77-3.85 (2H, m, H-4’ and H-5’), 3.93 (1H, 
m, H-5”), 6.06 (1H, t, J= 6.6 Hz, H-1’), 7.36-7.45 (7H, m, 6 ar-H and H-
6), 7.61-7.65 (4H, m, 4 arom H), 11.28 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C27H33N5O4SiNa [M+Na]+ found, 542.2197; calcd, 542.2199. 
 
 
3’-(Aminomethyl)-5’-O-tert-butyldiphenylsilyl-3’-deoxythymidine (5.35) 
A solution of 5.34 (915 mg, 1.76 mmol) in methanol (50 mL) was hydrogenated under 
atmospheric pressure for 5 hours in the presence of 10 % Pd/C (90 mg).  The catalyst was 
removed by filtration through celite and the filtrate was evaporated to give pure compound 
5.35 (860 mg, 99%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.00 (9H, s, tert-but), 1.48 (3H, d, J= 
0.9 Hz, 5-CH3), 2.03-2.19 (2H, m, H-2’ and H-2”), 2.32 (1H, m, H-3’), 
2.57 (2H, dd, J= 3.9 and 5.7 Hz, H-6’ and H-6”), 3.74-3.85 (2H, m, H-4’ 
and H-5’), 3.93 (1H, dd, J= 2.4 and 10.8 Hz, H-5”), 6.02 (1H, dd, J= 5.1 
and 6.9 Hz, H-1’), 7.37-7.43 (7H, m, 6 arom H and H-6), 7.61-7.65 (4H, 
m, 4 arom H). 
 
Exact mass (ESI-MS) for C27H36N2O4Si [M+H]+ found, 494.2478; calcd, 494.2474. 
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N-[(5’-O-tert-Butyldiphenylsilyl-3’-deoxythymidin-3’-yl)methyl]-N’-phenylthiourea (5.36) 
To a solution of 5.35 (55 mg, 0.11 mmol) in DMF (1 mL), phenylisothiocyanate (15 mg, 0.11 
mmol) in 1 mL DMF was added at 0 °C.  The reaction mixture was stirred during 1 h.  The 
solvent was evaporated to dryness and the residue was purified by column chromatography 
(CH2Cl2/MeOH 98:2) affording thiourea 5.36 (48 mg) in 70% yield. 
 
 
1H NMR (300 MHz, DMSO-d6): δ 0.99 (9H, s, tert-but), 1.45 (3H, s, 5-
CH3), 2.17 (2H, m, H-2’ and H-2”), 2.83 (1H, m, H-3’), 3.51-3.67 (2H, 
m, H-6’ and H-6”), 3.80-3.93 (3H, m, H-5’, H-4’ and H-5”), 6.08 (1H, t, 
J= 5.4, H-1’), 7.10 (1H, t, J= 7.2 Hz, 1 arom H), 7.26-7.43 (11H, m, 10 
arom H and H-6), 7.61-7.66 (4H, m, 4 arom H), 7.93 (1H, br s, 
N(6’)H), 9.55 (1H, br s, N(ar)H), 11.27 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C34H41N4O4SSi [M+H]+ found, 629.2618; calcd, 629.2617. 
 
 
N-[(5’-O-tert-Butyldiphenylsilyl-3’-deoxythymidin-3’-yl)methyl]-N’-(4-chlorophenyl)- 
thiourea (5.37) 
Thiourea 5.37 was synthesized from 5.35 (138 mg, 0.28 mmol) using the same procedure as 
described for the synthesis of 5.36.  The solid 4-chlorophenylisothiocyanate (52 mg, 0.3 
mmol) was dissolved in DMF (1 mL) before adding it to the reaction mixture at 0 °C.  After 
purification, compound 5.37 (143 mg) was obtained in 77% yield. 
 
1H NMR (300 MHz, DMSO-d6): δ 0.99 (9H, s, tert-but), 1.45 (3H, 
d, J= 0.6 Hz, 5-CH3), 2.17 (2H, m, H-2’ and H-2”), 2.83 (1H, m, H-
3’), 3.51-3.67 (2H, m, H-6’ and H-6”), 3.80 (1H, dd, J= 3.3 and 
10.8 Hz, H-5’), 3.88-3.96 (2H, m, H-4’ and H-5”), 6.08 (1H, t, J= 
5.4, H-1’), 7.31-7.43 (11H, m, 10 arom H and H-6), 7.61-7.66 (4H, 
m, 4 arom H), 8.04 (1H, br s, N(6’)H), 9.63 (1H, br s, N(ar)H), 
11.28 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C34H40N4O4SClSi [M+H]+ found, 663.2230; calcd, 663.2227. 
 
 
N-[(5’-O-tert-Butyldiphenylsilyl-3’-deoxythymidin-3’-yl)methyl]-N’-(4-methoxyphenyl) - 
thiourea (5.38) 
Compound 5.38 was synthesized from 5.35 (130 mg, 0.26 mmol) using the same procedure 
as described for the synthesis of 5.36.  The solid 4-methoxyphenylisothiocyanate (48 mg, 
0.29 mmol) was dissolved in DMF (1 mL) before adding it to the reaction mixture at 0 °C.  
After purification, compound 5.38 (150 mg) was obtained in 88% yield. 
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1H NMR (300 MHz, DMSO-d6): δ 0.99 (9H, s, tert-but), 1.45 (3H, 
d, J= 0.6 Hz, 5-CH3), 2.15 (2H, m, H-2’ and H-2”), 2.83 (1H, m, 
H-3’), 3.48-3.65 (2H, m, H-6’ and H-6”), 3.71 (3H, s, OCH3), 
3.80 (1H, dd, J= 3.6 and 10.8 Hz, H-5’), 3.86-3.95 (2H, m, H-4’ 
and H-5”), 6.07 (1H, t, J= 5.7, H-1’), 6.86 (2H, m, 2 arom H), 
7.17 (2H, m, 2 arom H), 7.34-7.46 (7H, m, 6 arom H and H-6), 
7.63-7.67 (4H, m, 4 arom H), 7.73 (1H, br s, N(6’)H), 9.38 (1H, 
br s, N(ar)H), 11.28 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C35H43N4O5SSi [M+H]+ found, 659.2726; calcd, 659.2723. 
 
 
N-[(5’-O-tert-Butyldiphenylsilyl-3’-deoxythymidin-3’-yl)methyl]-N’-(4-methylphenyl)- 
thiourea (5.39) 
Compound 5.39 was synthesized from 5.35 (160 mg, 0.32 mmol) using the same procedure 
as described for the synthesis of 5.36.  The solid 4-methylphenylisothiocyanate (53 mg, 0.36 
mmol) was dissolved in DMF (1 mL) before adding it to the reaction mixture at 0 °C. After 
purification, compound 5.39 (164 mg) was obtained in 79% yield. 
 
1H NMR (300 MHz, DMSO-d6): δ 0.99 (9H, s, tert-but), 1.44 (3H, 
d, J= 0.9 Hz, 5-CH3), 2.17 (2H, m, H-2’ and H-2”), 2.25 (3H, s, ar-
CH3), 2.87 (1H, m, H-3’), 3.48-3.65 (2H, m, H-6’ and H-6”), 3.77-
3.94 (3H, m, H-4’, H-5’ and H-5”), 6.08 (1H, t, J= 5.7, H-1’), 7.09 
(2H, d, J= 9.2 Hz, 2 arom H), 7.21 (2H, d, J= 9.2 Hz, 2 arom H), 
7.34-7.44 (7H, m, 6 arom H and H-6), 7.62-7.67 (4H, m, 4 arom 
H), 8.05 (1H, br s, N(6’)H), 9.69 (1H, br s, N(ar)H), 11.31 (1H, br 
s, N(3)H). 
 
Exact mass (ESI-MS) for C35H43N4O4SSi [M+H]+ found, 643.2776; calcd, 643.2774. 
 
 
N-[(5’-O-tert-Butyldiphenylsilyl-3’-deoxythymidin-3’-yl)methyl]-N’-(3,4-
dichlorophenyl)thiourea (5.40) 
Compound 5.40 was synthesized from 5.35 (172 mg, 0.35 mmol) using the same procedure 
as described for the synthesis of 5.36.  After purification, compound 5.40 (192 mg) was 
obtained in 79% yield. 
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1H NMR (300 MHz, DMSO-d6): δ 0.98 (9H, s, tert-but), 1.44 (3H, 
s, 5-CH3), 2.19 (2H, m, H-2’), 2.85 (1H, m, H-3’), 3.50-3.69 (2H, 
m, H-6’ and H-6”), 3.80 (1H, dd, J= 3.9 and 12.2 Hz, H-5’), 3.89-
3.96 (2H, m, H-4’ and H-5”), 6.09 (1H, t, J= 5.7, H-1’), 7.34-7.44 
(8H, m, arom H), 7.52 (1H, d, J= 8.7 Hz, arom H), 7.63-7.67 (4H, 
m, 4 arom H), 7.89 (1H, s, H-6), 8.38 (1H, br s, N(6’)H), 9.97 (1H, 
br s, N(ar)H), 11.31 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C34H39N4O4SCl2Si [M+H]+ found, 697.1838; calcd, 697.1838. 
 
 
N-(4-(Benzyloxy)phenyl)-N’-[(5’-O-tert-butyldiphenylsilyl-3’-deoxythymidin-3’-
yl)methyl]thiourea (5.41) 
Compound 5.41 was synthesized from 5.35 (95 mg, 0.19 mmol) using the same procedure 
as described for the synthesis of 5.36.  The solid 4-(benzyloxy)phenylisothiocyanate (51 mg, 
0.36 mmol) was dissolved in DMF (1 mL) before adding it to the reaction mixture at 0 °C.  
After purification, compound 5.41 (116 mg) was obtained in 83% yield. 
 
1H NMR (300 MHz, DMSO-d6): δ 0.99 (9H, s, tert-but), 1.44 
(3H, d, J= 0.6 Hz, 5-CH3), 2.17 (2H, m, H-2’), 2.88 (1H, m, H-
3’), 3.46-3.64 (2H, m, H-6’ and H-6”), 3.79-3.89 (3H, m, H-4’, 
H-5’ and H-5”), 5.07 (2H, s, CH2Ph), 6.07 (1H, t, J= 5.7, H-1’), 
6.94 (2H, dd, J= 2.4 and 7.2 Hz, 2 arom H), 7.10 (2H, dd, J= 
2.4 and 6.9 Hz, 2 arom H), 7.25-7.37 (12H, m, arom H and H-
6), 7.56-7.63 (4H, m, arom H), 7.76 (1H, br s, N(6’)H), 9.43 
(1H, br s, N(ar)H), 11.26 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C41H47N4O5SSi [M+H]+ found, 735.3047; calcd, 735.3036. 
 
 
N-[(5’-O-tert-Butyldiphenylsilyl-3’-deoxythymidin-3’-yl)methyl]-N’-(3-chloro-4-
trifluoromethylphenyl)thiourea (5.42) 
Compound 5.42 was synthesized from 5.35 (90 mg, 0.18 mmol) using the same procedure 
as described for the synthesis of 5.36.  After purification, compound 5.42 (100 mg) was 
obtained in 75% yield. 
 
1H NMR (300 MHz, DMSO-d6): δ 0.99 (9H, s, tert-but), 1.44 (3H, 
s, 5-CH3), 2.17 (2H, m, H-2’), 2.87 (1H, m, H-3’), 3.52-3.68 (2H, 
m, H-6’ and H-6”), 3.80-3.96 (3H, m, H-4’, H-5’ and H-5”), 6.09 
(1H, t, J= 5.7, H-1’), 7.34-7.48 (9H, m, 9 arom H), 7.63-7.74 (4H, 
m, 4 arom H), 8.06 (1H, s, H-6), 8.24 (1H, br s, N(6’)H), 9.97 (1H, 
br s, N(ar)H), 11.23 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C35H39N4O4SCl2F3Si [M+H]+ found, 731.2103; calcd, 731.2101. 
O
TBDPSO
N NH
O
O
NH
H
N
S
Cl
Cl
O
TBDPSO
N NH
O
O
HN
H
N O
H2
C
S
O
TBDPSO
N NH
O
O
NH
H
N
S
Cl
F3C
Chapter 5  
150   
N-[(3’-Deoxythymidin-3’-yl)methyl]-N’-phenylthiourea (5.2) 
Compound 5.36 (48 mg, 0.08 mmol) was dissolved in THF (4 mL).  A solution of 1 M tetra-
nbutylammonium fluoride in THF (4 mL) was added.  After 1 h at room temperature the 
reaction was completed.  The solvent was evaporated, and the dry residue was purified by 
column chromatography (CH2Cl2/MeOH 97:3) to give pure compound 5.2 (27 mg) in 87% 
yield. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, s, 5-CH3), 2.11 (2H, m, H-
2’ and H-2”), 2.57 (1H, m, H-3’), 3.51-3.78 (5H, m, H-4’, H-5’, H-5”, H-
6’ and H-6”), 5.10 (1H, t, J= 5.1 Hz, 5’-OH), 5.99 (1H, t, J= 4.8, H-1’), 
7.09 (1H, t, J= 7.2 Hz, arom H), 7.30 (2H, t, J= 7.5 Hz, 2 arom H), 
7.38 (2H, d, J= 7.5 Hz, 2 arom H), 7.85 (1H, s, H-6), 7.95 (1H, br s, 
N(6’)H), 9.60 (1H, br s, N(ar)H), 11.22 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6):δ 12.99 (5-CH3), 36.73 (C-2’), 38.10 (C-3’), 45.85 (C-6’), 62.09 (C-5’), 
84.57 and 84.63 (C-4’ and C-1’), 109.38 (C-5), 124.02 (arom C), 125.03 (arom C), 129.34 (arom C), 
137.03 (C-6), 139.76 (arom C), 151.07 (C-4), 164.54 (C-2), 181.39 (C=S). 
 
Exact mass (ESI-MS) for C18H22N4O4SNa [M+Na]+ found, 413.1246; calcd, 413.1259. 
 
 
N-(4-Chlorophenyl)-N’-[(3’-deoxythymidin-3’-yl)methyl]thiourea (5.3) 
Compound 5.37 (143 mg, 0.22 mmol) was deprotected using the same procedure as 
described for the synthesis of compound 5.2 to afford analogue 5.3 (81 mg) in 89% yield. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 0.9 Hz, 5-CH3), 
2.12 (2H, m, H-2’ and H-2”), 2.57 (1H, m, H-3’), 3.51-3.65 (2H, m, 
H-6’ and H-6”), 3.67-3.78 (3H, m, H-4’, H-5’ and H-5”), 5.10 (1H, t, 
J= 5.1 Hz, 5’-OH), 6.00 (1H, t, J= 4.5, H-1’), 7.32-7.45 (4H, m, 4 
arom H), 7.85 (1H, d, J= 1.2 Hz, H-6), 7.93 (1H, br s, N(6’)H), 9.57 
(1H, br s, N(ar)H), 11.22 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6):δ 12.97 (5-CH3), 36.74 (C-2’), 38.08 (C-3’), 45.84 (C-6’), 62.07 (C-5’), 
84.54 and 84.64 (C-4’ and C-1’), 109.38 (C-5), 125.55 (arom C), 128.73 (arom C), 129.12 (arom C), 
137.00 (C-6), 138.90 (arom C), 151.07 (C-4), 164.51 (C-2), 181.51 (C=S). 
 
Exact mass (ESI-MS) for C18H21N4O4SClNa [M+Na]+ found, 447.0864; calcd, 447.0869. 
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N-[(3’-Deoxythymidin-3’-yl)methyl]-N’-(4-methoxyphenyl)thiourea (5.4) 
Compound 5.38 (150 mg, 0.23 mmol) was deprotected using the same procedure as 
described for the synthesis of compound 5.2 to afford analogue 5.4 (87 mg) in 91% yield. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, s, 5-CH3), 2.09 (2H, 
m, H-2’ and H-2”), 2.57 (1H, m, H-3’), 3.51-3.62 (2H, m, H-6’ and 
H-6”), 3.66-3.78 (6H, m, OCH3, H-4’, H-5’ and H-5”), 5.11 (1H, t, 
J= 5.1 Hz, 5’-OH), 5.99 (1H, t, J= 4.5, H-1’), 6.93 (2H, d, J= 8.7 
Hz, 2 arom H), 7.20 (2H, dd, J= 2.7 and 9.0 Hz, 2 arom H), 7.70 
(1H, br s, N(6’)H), 7.86 (1H, s, H-6), 9.40 (1H, br s, N(ar)H), 
11.25 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6):δ 12.94 (5-CH3), 36.73 (C-2’), 38.10 (C-3’), 45.78 (C-6’), 55.93 (OCH3), 
62.20 (C-5’), 84.55 and 85.36 (C-4’ and C-1’), 109.42 (C-5), 120.30 (arom C), 126.91 (arom C), 
132.19 (arom C), 135.86 (arom C), 137.03 (C-6), 150.37 (C-4), 164.54 (C-2), 181.78 (C=S). 
 
Exact mass (ESI-MS) for C19H25N4O5S [M+H]+ found, 421.1539; calcd, 421.1545. 
 
 
N-[(3’-Deoxythymidin-3’-yl)methyl]-N’-(4-methylphenyl)thiourea (5.5) 
Compound 5.39 (164 mg, 0.26 mmol) was deprotected using the same procedure as 
described for the synthesis of compound 5.2 to afford analogue 5.5 (95 mg) in 92% yield. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, s, 5-CH3), 2.11 (2H, 
m, H-2’), 2.26 (3H, s, ar-CH3), 2.57 (1H, m, H-3’), 3.51-3.62 (2H, 
m, H-6’ and H-6”), 3.66-3.78 (3H, m, H-4’, H-5’ and H-5”), 5.11 
(1H, t, J= 5.1 Hz, 5’-OH), 5.99 (1H, t, J= 4.5, H-1’), 7.12 (2H, d, 
J= 8.1 Hz, 2 arom H), 7.21 (2H, d, J= 8.1 Hz, 2 arom H), 7.76 
(1H, br s, N(6’)H), 7.86 (1H, d, J= 1.2 Hz, H-6), 9.45 (1H, br s, 
N(ar)H), 11.25 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6):δ 12.99 (5-CH3), 21.18 (ar-CH3), 36.67 (C-2’), 38.16 (C-3’), 45.86 (C-
6’), 62.13 (C-5’), 84.56 and 84.63 (C-4’ and C-1’), 109.39 (C-5), 124.62 (arom C), 1298.89 (arom C), 
134.47 (arom C), 137.03 (C-6), 151.08 (C-4), 164.54 (C-2), 181.42 (C=S). 
 
Exact mass (ESI-MS) for C19H25N4O4S [M+H]+ found, 405.1586; calcd, 405.1596. 
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N-(3,4-Dichlorophenyl)-N’-[(3’-deoxythymidin-3’-yl)methyl]thiourea (5.6) 
Compound 5.40 (192 mg, 0.28 mmol) was deprotected using the same procedure as 
described for the synthesis of compound 5.2 to afford analogue 5.6 (109 mg) in 87% yield. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 1.2 Hz, 5-CH3), 
2.12 (2H, m, H-2’), 2.58 (1H, m, H-3’), 3.51-3.62 (2H, m, H-6’ and 
H-6”), 3.66-3.79 (3H, m, H-4’, H-5’ and H-5”), 5.12 (1H, t, J= 5.1 
Hz, 5’-OH), 6.00 (1H, t, J= 4.5, H-1’), 7.35 (1H, dd, J= 2.4 and 8.7 
Hz, arom H), 7.53 (1H, d, J= 8.7 Hz, arom H), 7.86 (2H, m, H-6 
and arom H), 8.16 (1H, br s, N(6’)H), 9.78 (1H, br s, N(ar)H), 11.23 
(1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6):δ 12.99 (5-CH3), 36.82 (C-2’), 37.93 (C-3’), 45.81 (C-6’), 61.98 (C-5’), 
84.55 and 84.64 (C-4’ and C-1’), 109.37 (C-5), 123.58 (arom C), 124.74 (arom C), 130.98 (arom C), 
131.22 (arom C), 137.00 (C-6), 140.29 (arom C), 151.07 (C-4), 164.53 (C-2), 181.41 (C=S). 
 
Exact mass (ESI-MS) for C18H20N4O4SCl2Na [M+Na]+ found, 481.0480; calcd, 481.0487. 
 
 
N-(4-(benzyloxy)phenyl)-N’-[(3’-deoxythymidin-3’-yl)methyl]thiourea (5.7) 
Compound 5.41 (116 mg, 0.16 mmol) was deprotected using the same procedure as 
described for the synthesis of compound 5.2 to afford analogue 5.7 (69 mg) in 88% yield. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 1.2 Hz, 5-CH3), 
2.10 (2H, m, H-2’), 2.56 (1H, m, H-3’), 3.49-3.60 (2H, m, H-6’ and 
H-6”), 3.64-3.79 (3H, m, H-4’, H-5’ and H-5”), 5.07 (2H, s, CH2Ph), 
5.09 (1H, t, J= 5.1 Hz, 5’-OH), 5.98 (1H, t, J= 4.5, H-1’), 6.95 (2H, 
dd, J= 2.4 and 7.2 Hz, 2 arom H), 7.20 (2H, dd, J= 2.4 and 6.9 Hz, 
2 aromH), 7.31-7.45 (5H, m, CH2Ph), 7.76 (1H, br s, N(6’)H), 7.85 
(1H, d, J= 1.2 Hz, H-6), 9.42 (1H, br s, N(ar)H), 11.22 (1H, br s, 
N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.99 (5-CH3), 36.66 (C-2’), 38.18 (C-3’), 45.92 (C-6’), 62.17 (C-5’), 
70.06 (CH2Ph), 84.60 (C-4’ and C-1’), 109.37 (C-5), 115.52 (arom C), 126.64 (arom C), 128.35 (arom 
C), 128.52 (arom C), 129.13 (arom C), 132.52 (arom C), 137.02 (C-6), 137.80 (arom C), 151.09 (C-4), 
156.34 (arom C), 164.53 (C-2), 181.69 (C=S). 
 
Exact mass (ESI-MS) for C25H28N4O5S [M+H]+ found, 497.1851; calcd, 497.1858. 
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N-(3-Chloro-4-trifluoromethylphenyl)-N’-[(3’-deoxythymidin-3’-yl)methyl]thiourea (5.8) 
Compound 5.42 (100 mg, 0.14 mmol) was deprotected using the same procedure as 
described for the synthesis of compound 5.2 to afford analogue 5.8 (60 mg) in 89% yield. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 0.9 Hz, 5-CH3), 
2.13 (2H, m, H-2’), 2.58 (1H, m, H-3’), 3.51-3.63 (2H, m, H-6’ and 
H-6”), 3.68-3.79 (3H, m, H-4’, H-5’ and H-5”), 5.11 (1H, s, 5’-OH), 
6.00 (1H, t, J= 5.4, H-1’), 7.61 (1H, d, J= 8.7 Hz, arom H), 7.71 
(1H, dd, J= 1.2 and 8.7 Hz, arom H), 7.86 (1H, s, arom H), 8.07 
(1H, s, H-6), 8.24 (1H, br s, N(6’)H), 9.90 (1H, br s, N(ar)H), 11.23 
(1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.93 (5-CH3), 36.81 (C-2’), 37.95 (C-3’), 45.78 (C-6’), 61.98 (C-5’), 
84.52 and 84.69 (C-4’ and C-1’), 109.41 (C-5), 110.00 (CF3), 121.58 (arom C), 122.15 (arom C), 
125.20 (arom C), 126.77 (arom C), 128.28 (arom C), 132.34 (arom C), 137.00 (C-6), 139.78 (arom C), 
151.06 (C-4), 164.56 (C-2), 181.62 (C=S). 
 
Exact mass (ESI-MS) for C19H21N4O4SClF3 [M+H]+ found, 493.0920; calcd, 493.0924. 
  
 
3’-5’-Di-O-acetyl-β-D-thymidine (5.43) 
β-thymidine (4 g, 16.5 mmol) was dissolved in pyridine (70 mL) and acetic acid anhydride 
(70 mL).  The reaction mixture was stirred at room temperature during 2 h, evaporated to 
dryness, and coevaporated with toluene to obtain pure compound 5.43 in a 99% yield (5.3 
g). 
 
1H NMR (300 MHz, CDCl3): δ 1.94 (3H, d, J= 1.2 Hz, 5-CH3), 2.11 (3H, s, 
COCH3), 2.13 (3H, s, COCH3), 2.12 (1H, dd, J= 6.6 and 8.4 Hz, H-2’), 2.43-
2.51 (1H, ddd, J= 2.1, 5.7 and 14.1 Hz, H-2”), 4.24 (1H, m, H-4’), 4.35 (2H, 
m, H-5’ and H-5”), 5.21 (1H, dt, J= 2.1 and 6.6 Hz, H-3’), 6.31 (1H, dd, J= 
5.7 and 8.7, H-1’), 7.29 (1H, d, J= 1.2 Hz), 8.62 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C14H19N2O7 [M+H]+ found, 327.1194; calcd, 327.1192.  
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3’-5’-Di-O-acetyl-α-D-thymidine (5.44) 
To a solution of compound 5.43 (10 g, 41,28 mmol) in 20 mL dry acetonitrile, was added the 
freshly prepared solution, containing 0.710 mL H2SO4 and 2.70 mL acetic acid anhydride in 
20 mL dry acetonitile.  After 2 h, the mixture was quenched with saturated NaHCO3-solution, 
and extracted with ethylacetate three times.  The alpha anomer was crystallised from this 
mixture, giving 4.535 g (45%) pure 5.44, and 5.1 g of an anomeric mixture. 
 
1H NMR (300 MHz, CDCl3): δ 1.95 (3H, d, J= 1.2 Hz, 5-CH3), 2.05 (3H, s, 
COCH3), 2.12 (3H, s, COCH3), 2.21-2.28 (1H, ddd, J= 1.8 and 15.6 Hz, H-
2’), 2.81 (1H, dt, J= 6.9 and 15.1 Hz, H-2”), 4.19 (2H, m, H-5’ and H-5”), 
4.59 (1H, m, H-4’), 5.23 (1H, dt, J= 1.6 and 6.4 Hz, H-3’), 6.26 (1H, dd, J= 
2.4 and 7.2 Hz, H-1’), 7.30 (1H, d, J= 1.2 Hz), 8.62 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C14H19N2O5 [M+H]+ found, 327.1195; calcd, 327.1192.  
 
 
α-D-Thymidine (5.45) 
3’-5’-Di-O-acetyl-α-thymidine (4.54 g, 13.91 mmol) was dissolved in 150 mL NH3 in MeOH 
(7N solution).  The reaction mixture was stirred at room temperature overnight.  The solvent 
was evaporated to dryness, the residue was dissolved in ethylacetate and extracted with 
water three times, yielding 3.30 g of the pure compound 5.45 (98%). 
 
 
1H NMR (300 MHz, DMS0): δ 1.78 (3H, d, J= 1.2 Hz, 5-CH3), 1.84-1.91 (1H, 
ddd, J= 3.0 and 14.4 Hz, H-2’), 2.48-2.60 (1H, m, H-2”), 3.39 (2H, t, J= 5.2 
Hz, H-5’ and H-5”), 4.13 (1H, m, H-3’), 4.23 (1H, m, H-4’), 4.81 (1H, t, J= 5.7 
Hz, 5’-OH), 5.30 (1H, d, J= 3.0 Hz, 3’-OH), 6.12 (1H, dd, J= 3.3 and 7.5 Hz, 
H-1’), 7.75 (1H, d, J= 1.2 Hz), 11.20 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C10H15N2O5 [M+H]+ found, 243.0975; calcd, 243.0981. 
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α-D-Thymidine 5’-monophosphate (5.9) 
A solution of α-D-thymidine (150 mg, 0.62 mmol) in trimethyl phosphate (6.2 mL) was cooled 
to 0 °C, POCl3 (369 µL, 4.03 mmol) was added dropwise and the mixture was stirred for 4 
hours at 0 °C and for 30 minutes at room temperature.  The mixture was poured into ice-
water (12 mL), neutralised with concentrated NH4OH and evaporated to dryness.  The 
resulting residue was purified by column chromatography (iPrOH/NH4OH/H2O 77.5:15:2.5).  
Further purification was performed by HPLC (C-18, CH3CN/MeOH/0.05% HCOOH in H2O 
45:45:10, 3 mL/min).  After lyophilisation of the collected pure fractions compound 5.9 was 
obtained (123 mg, 62%) as a white powder. 
 
 1H NMR (300 MHz, D2O-d6): δ 1.81 (3H, d, J= 0.9 Hz, 5-CH3), 2.02-2.09 
(2H, ddd, J= 3.0 and 14.7 Hz, H-2’), 2.66-2.76 (1H, m, H-2”), 3.78 (2H, 
app t, J= 5.1 Hz, H-5’ and H-5”), 4.43 (2H, m, H-3’ and H-4’), 6.12 (1H, 
dd, J= 3.0 and 7.2 Hz, H-1’), 7.68 (1H, d, J= 0.9 Hz, H-6). 
 
31P-NMR (500 MHz, D20): δ 2.97. 
 
13C NMR (75 MHz, D2O-d6): δ 11.73 (5-CH3), 39.49 (C-2’), 64.67 (C-5’), 71.20 (C-3’), 87.38 and 87.81 
(C-4’ and C-1’), 110.75 (C-5), 138.39 (C-6), 151.76 (C-4), 166.97. 
 
Exact mass (ESI-MS) for C10H14N2O8PNa [M+Na]+ found, 345.0477; calcd, 345.0464; Anal. 
(C10H14N2O8P) C, H, N. 
 
 
5’-Azido-5’-deoxy-α-D-thymidine (5.46) 
To a solution of α-thymidine 5.45 (886 mg, 3.66 mmol) in pyridine (13.5 mL) at -78 °C, 
methanesulfonylchloride (256 µL, 0.41 mmol) was added.  The reaction mixture was stirred 
for 1 h at 0 °C.  The reaction was quenched with saturated aqueous NaHCO3-solution and 
extracted with CH2Cl2 three times, dried over MgSO4 and evaporated.  The residue was 
purified by column chromatography (CH2Cl2/MeOH 98:2) to give the mesylated compound 
(916 mg, 78%). 
 
1H NMR (300 MHz, DMSO-d6): 1.75 (3H, s, 5-CH3), 1.95 (1H, m, H-2’), 2.55 
(1H, m, H-2”), 3.19 (3H, s, CH3SO2), 4.12-4.26 (3H, m, H-5’, H-5” and H-3’), 
4.33 (1H, m, H-4’), 5.58 (1H, br s, 3’-OH), 6.12 (1H, dd, J= 4.4 and 7.6 Hz, 
H-1’), 7.73 (1H, s, H-6), 11.27 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C11H17N2O7S [M+H]+ found, 321.0759; calcd, 321.0756. 
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A solution of 5’-mesylated α-D-thymidine (916 mg, 2.88 mmol) and NaN3 (1.87 g, 29 mmol) 
in DMF (50 mL) was heated to 60 °C overnight.  The reaction mixture was evaporated in 
vacuo.  The residue was resolved in CH2Cl2 and washed with H2O.  The organic layer was 
dried over MgSO4, evaporated and purified by column chromatography (CH2Cl2/MeOH 98:2) 
to afford compound 5.46 (672 mg, 87%).  
 
1H NMR (300 MHz, DMSO-d6): 1.76 (3H, s, 5-CH3), 1.93 (1H, m, H-2’), 2.51 
(1H, m, H-2”), 3.49 (2H, m, H-5’ and H-5”), 4.12 (1H, dd, H-3’), 4.24 (1H, m, H-
4’), 5.50 (1H, br s, 3’-OH), 6.13 (1H, dd, J= 4.5 and 7.5 Hz, H-1’), 7.72 (1H, s, 
H-6), 11.26 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C10H14N5O4 [M+H]+ found, 268.1045; calcd, 268.1046. 
 
 
5’-Amino-5’-deoxy-α-D-thymidine (5.47) 
A solution of azide 5.46 (531 mg, 1.99 mmol) in methanol (30 mL) was hydrogenated under 
atmospheric pressure for 6 hours in the presence of 10% Pd/C (53.1 mg).  The catalyst was 
removed by filtration through celite and the filtrate was evaporated to yield pure compound 
5.47 (471 mg, 98%). 
 
1H NMR (300 MHz, DMSO-d6): 1.74 (3H, s, 5-CH3), 1.85 (1H, m, H-2’), 2.49 
(1H, m, H-2”), 3.43 (2H, m, H-5’ and H-5”), 4.02 (1H, m, H-3’), 4.14 (1H, m, 
H-4’), 5.27 (1H, br s, 3’-OH), 6.05 (1H, dd, J= 3.3 and 7.5 Hz, H-1’), 7.69 
(1H, s, H-6), 11.24 (1H, br s, N(3)H).  
 
Exact mass (ESI-MS) for C10H16N3O4 [M+H]+ found, 242.1134; calcd, 242.1141.  
 
 
N-(5’-Deoxy-α-D-thymidin-5’-yl)-N’-phenylthiourea (5.10) 
For the synthesis of compound 5.10, compound 5.47 (54 mg, 0.22 mmol) was dissolved in 
DMF (2 mL).  At 0 °C, phenyl isothiocyanate (36 mg, 0.26 mmol) was added and the 
reaction mixture was allowed to stir at room temperature during 3 h.  After completion of the 
reaction, the reaction mixture was evaporated to dryness and the residue was purified by 
column chromatography (CH2Cl2/MeOH 97:3) to obtain the pure final compound 5.10 (69 
mg, 83%). 
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1H NMR (300 MHz, DMSO-d6): δ 1.77 (3H, d, J= 1.2 Hz, 5-CH3), 
1.89-1.98 (1H, ddd, J= 3.3 and 14.1 Hz, H-2’), 2.53-2.63 (1H, m, H-
2”), 3.49 (1H, m, H-5’), 3.64 (1H, m, H-5”), 4.22 (1H, m, H-3’), 4.34 
(1H, m, H-4’), 5.47 (1H, d, J= 3.3 Hz, 3’-OH), 6.18 (1H, dd, J= 3.6 
and 8.1, H-1’), 7.10 (1H, t, J= 7.2 Hz, arom H), 7.32 (2H, t, J= 7.5 
Hz, 2 arom H), 7.77 (2H, d, J= 1.2 Hz, H-6 + N(5’)H), 9.63 (1H, br s, N(ar)H), 11.26 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 13.03 (5-CH3), under DMSO (C-2’), 46.18 (C-5’), 71.58 (C-3’), 85.40 
(C-1’), 86.57 (C-4’), 109.51 (C-5), 123.83 (arom C), 124.97 (arom C), 129.29 (arom C), 137.68 (C-6), 
139.84 (arom C), 151.21 (C-4), 164.55 (C-2), 181.41 (C=S). 
 
Exact mass (ESI-MS) for C17H21N4O4S [M+H]+ found, 377.1279; calcd, 377.1283; Anal. 
(C17H20N4O4S) C, H, N, S. 
 
 
N’-(4-Chlorophenyl)- N-(5’-Deoxy-α-D-thymidin-5’-yl)thiourea (5.11) 
Compound 5.11 was synthesized from 5.47 (49 mg, 0.20 mmol) and 4-chlorophenyl 
isothiocyanate (40 mg, 0.24 mmol) using the same procedure as described for the synthesis 
of 5.10.  After purification by column chromatography (CH2Cl2/MeOH 97:3), compound 5.11 
(66 mg, 81%) was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.76 (3H, d, J= 0.9 Hz, 5-
CH3), 1.88-1.95 (1H, ddd, J= 3.0 and 14.4 Hz, H-2’), 2.53-2.63 
(1H, m, H-2”), 3.48 (1H, m, H-5’), 3.65 (1H, m, H-5”), 4.22 (1H, 
m, H-3’), 4.33 (1H, m, H-4’), 5.48 (1H, d, J= 3.3 Hz, 3’-OH), 
6.19 (1H, dd, J= 3.3 and 7.8, H-1’), 7.34 (2H, dd, J= 2.4 and 
8.7 Hz, 2 arom H), 7.48 (2H, dd, J= 2.4 and 9.3 Hz, 2 arom H), 7.77 (1H, d, J= 1.2 Hz, H-6), 7.93 (1H, 
br s, N(5’)H), 9.77 (1H, br s, N(ar)H), 11.25 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 13.01 (5-CH3), under DMSO (C-2’), 46.13 (C-5’), 71.59 (C-3’), 85.43 
(C-1’), 86.45 (C-4’), 109.56 (C-5), 125.41 (arom C), 128.73 (arom C), 129.10 (arom C), 137.69 (C-6), 
138.92 (arom C), 151.22 (C-4), 164.60 (C-2), 181.50 (C=S). 
 
Exact mass (ESI-MS) for C17H20N4O5SCl [M+H]+ found, 411.0889; calcd, 411.0893; Anal. 
(C17H19N4O5S) C, H, N, S. 
 
 
N-(5’-Deoxy-α-D-thymidin-5’-yl)-N’-(4-methoxyphenyl)thiourea (5.12) 
Compound 5.12 was synthesized from 5.47 (57 mg, 0.24 mmol) and 4-methoxyphenyl 
isothiocyanate (47 mg, 0.29 mmol) using the same procedure as described for the synthesis 
of 5.10.  After purification by column chromatography (CH2Cl2/MeOH 97:3), compound 5.12 
(84 mg, 86%) was obtained. 
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1H NMR (300 MHz, DMSO-d6): δ 1.78 (3H, d, J= 0.9 Hz, 5-
CH3), 1.88-1.93 (1H, ddd, J= 3.0 and 14.1 Hz, H-2’), 2.53-
2.63 (1H, m, H-2”), 3.44-3.60 (2H, m, H-5’ and H-5”), 3.72 
(3H, s, OCH3), 4.22 (1H, m, H-3’), 4.33 (1H, m, H-4’), 5.45 
(1H, d, J= 3.0 Hz, 3’-OH), 6.16 (1H, dd, J= 3.0 and 7.5, H-1’), 
6.87 (2H, dd, J= 2.1 and 9.0 Hz, 2 arom H), 7.23 (2H, dd, J= 2.1 and 8.7 Hz, 2 arom H), 7.64 (1H, br 
s, N(5’)H), 7.76 (1H, d, J= 1.5 Hz, H-6), 9.51 (1H, br s, N(ar)H), 11.22 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 13.05 (5-CH3), 43.02 (C-2’), 46.22 (C-5’), 55.92 (OCH3), 71.52 (C-3’), 
85.41 (C-1’), 86.69 (C-4’), 109.45 (C-5), 114.60 (arom C), 126.56 (arom C), 132.37 (arom C), 137.69 
(C-6), 151.21 (C-4), 157.26 (arom C), 164.55 (C-2), 181.74 (C=S). 
 
Exact mass (ESI-MS) for C18H23N4O5S [M+H]+ found, 407.1389; calcd, 407.1389; Anal. 
(C18H22N4O5S) C, H, N, S.  
 
 
N-(5’-Deoxy-α-D-thymidin-5’-yl)-N’-(4-methylphenyl)thiourea (5.13) 
Compound 5.13 was synthesized from 5.47 (56 mg, 0.23 mmol) and 4-methoxyphenyl 
isothiocyanate (41 mg, 0.27 mmol) using the same procedure as described for the synthesis 
of 5.10.  After purification by column chromatography (CH2Cl2/MeOH 97:3), compound 5.13 
(74 mg, 82%) was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.78 (3H, d, J= 1.2 Hz, 5-
CH3), 1.89-1.96 (1H, ddd, J= 3.0 and 14.1 Hz, H-2’), 2.27 (3H, 
s, ar-CH3), 2.54-2.64 (1H, m, H-2”), 3.49 (1H, m, H-5’), 3.63 
(1H, m, H-5”), 4.23 (1H, m, H-3’), 4.36 (1H, m, H-4’), 5.47 (1H, 
d, J= 3.3 Hz, 3’-OH), 6.19 (1H, dd, J= 3.3 and 7.5, H-1’), 7.13 
(2H, d, J= 8.1 Hz, 2 arom H), 7.27 (2H, d, J= 8.7 Hz, 2 arom H), 7.67 (1H, br s, N(5’)H), 7.78 (1H, d, 
J= 1.2 Hz, H-6), 9.55 (1H, br s, N(ar)H), 11.28 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.93 (5-CH3), 21.16 (p-CH3), under DMSO (C-2’), 46.17 (C-5’), 
71.55 (C-3’), 85.42 (C-1’), 86.63 (C-4’), 109.49 (C-5), 124.30 (arom C), 129.82 (arom C), 134.38 
(arom C), 137.07 (arom C), 137.68 (C-6), 151.21 (C-4), 164.57 (C-2), 181.44 (C=S). 
 
Exact mass (ESI-MS) for C18H23N4O4S [M+H]+ found, 391.1431; calcd, 391.1439; Anal. 
(C18H22N4O4S) C, H, N, S. 
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N-(5’-Deoxy-α-D-thymidin-5’-yl)-N’-(3,4-dichlorophenyl)thiourea (5.14) 
Compound 5.14 was synthesized from 5.47 (80 mg, 0.33 mmol) and phenyl isothiocyanate 
(82 mg, 0.40 mmol) using the same procedure as described for the synthesis of 5.10.  After 
purification by column chromatography (CH2Cl2/MeOH 97:3), compound 5.14 (147 mg, 82%) 
was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.77 (3H, d, J= 1.2 Hz, 5-
CH3), 1.89-1.97 (1H, ddd, J= 3.0 and 14.1 Hz, H-2’), 2.54-2.63 
(1H, m, H-2”), 3.48 (1H, m, H-5’), 3.65 (1H, m, H-5”), 4.21 (1H, 
m, H-3’), 4.33 (1H, m, H-4’), 5.48 (1H, d, J= 3.3 Hz, 3’-OH), 
6.19 (1H, dd, J= 3.6 and 7.8, H-1’), 7.36 (1H, dd, J= 2.7 and 
8.7 Hz, arom H), 7.53 (1H, d, J= 8.7 Hz, arom H), 7.77 (1H, d, J= 1.2 Hz, H-6), 7.94 (1H, d, J= 2.1 Hz, 
arom H), 8.02 (1H, br s, N(5’)H), 9.83 (1H, br s, N(ar)H), 11.26 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.96 (5-CH3), under DMSO (C-2’), 46.15 (C-5’), 71.61 (C-3’), 85.52 
(C-1’), 86.31 (C-4’), 109.62 (C-5), 123.51 (arom C), 124.65 (arom C), 124.67 (arom C), 130.96 (arom 
C), 131.23 (arom C), 137.73 (C-6), 140.21 (arom C), 151.21 (C-4), 164.73 (C-2), 181.40 (C=S). 
 
Exact mass (ESI-MS) for C17H19N4O4SCl2 [M+H]+ found, 445.0503; calcd, 445.0503; Anal. 
(C17H18N4O5) C, H, N.  
 
N-(5’-Deoxy-α-D-thymidin-5’-yl)-N’-(3-trifluoromethyl-4-chlorophenyl)thiourea (5.15) 
Compound 5.15 was synthesized from 5.47 (59 mg, 0.25 mmol) and 4-chloro-3-
trifluoromethylphenyl isothiocyanate (70 mg, 0.29 mmol) using the same procedure as 
described for the synthesis of 5.10.  After purification by column chromatography 
(CH2Cl2/MeOH 97:3), compound 5.15 (107 mg, 91%) was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.78 (3H, d, J= 0.9 Hz, 5-
CH3), 1.91-1.99 (1H, ddd, J= 3.3 and 14.4 Hz, H-2’), 2.56-2.66 
(1H, m, H-2”), 3.50 (1H, m, H-5’), 3.69 (1H, m, H-5”), 4.23 (1H, 
m, H-3’), 4.36 (1H, m, H-4’), 5.49 (1H, d, J= 3.0 Hz, 3’-OH), 
6.21 (1H, dd, J= 3.6 and 7.8, H-1’), 7.63 (1H, d, J= 9.0 Hz, 
arom H), 7.74 (1H, dd, J= 2.7 and 8.9 Hz, arom H), 7.79 (1H, d, J= 1.2 Hz, H-6), 8.17 (2H, br s, arom 
H and N(5’)H), 10.05 (1H, br s, N(ar)H), 11.27 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 13.01 (5-CH3), under DMSO (C-2’), 46.23 (C-5’), 71.63 (C-3’), 85.37 
(C-1’), 86.25 (C-4’), 109.58 (C-5), 116.26 (CF3), 121.59 (arom C), 121.92 (arom C), 125.20 (arom C), 
128.00 (arom C), 132.33 (arom C), 137.63 (C-6), 139.85 (arom C), 151.22 (C-4), 164.55 (C-2), 181.47 
(C=S). 
 
Exact mass (ESI-MS) for C18H19N4O4SClF3 [M+H]+ found, 479.0766; calcd, 479.0767; Anal. 
(C18H18N4O4SClF3) C, H, N, S. 
 
HO
O
NH N NH
O
OH
N
S
Cl
F3C
HO
O
NH N NH
O
OH
N
S
Cl
Cl
Chapter 5  
160   
N-(5’-Deoxy-α-D-thymidin-5’-yl)-N’-(4-morpholinophenyl)thiourea (5.16) 
Compound 5.16 was synthesized from 5.47 (100 mg, 0.42 mmol) and morpholinophenyl 
isothiocyanate (110 mg, 0.50 mmol) using the same procedure as described for the 
synthesis of 5.10.  After purification by column chromatography (CH2Cl2/MeOH 98:2), 
compound 5.16 (152 mg, 80%) was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.78 (3H, d, J= 1.2 Hz, 5-
CH3), 1.89-1.96 (1H, ddd, J= 3.2 and 14.4 Hz, H-2’), 2.53-
2.63 (1H, m, H-2”), 3.07 (4H, t, J = 5.3 Hz, 2x CH2N), 3.49 
(1H, m, H-5’), 3.59 (1H, m, H-5”), 3.73 (4H, t, J = 5.1 Hz, 
2x CH2O), 4.23 (1H, m, H-3’), 4.45 (1H, m, H-4’), 5.44 (1H, 
d, J= 3.0 Hz, 3’-OH), 6.17 (1H, dd, J= 3.3 and 7.7, H-1’), 6.90 (2H, d, J = 9.0 Hz, 2 arom H), 7.20 (2H, 
d, J = 9.0 Hz, 2 arom H), 7.55 (1H, br s, N(5’)H), 7.77 (1H, J = 1.2 Hz, H-6), 9.42 (1H, br s, N(ar)H), 
11.21 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 13.03 (5-CH3), 46.22 (C-2’), 46.32 (CH2N), 49.32 (C-5’), 66.80 
(CH2O), 71.53 (C-3’), 85.40 (C-1’), 86.73 (C-4’), 109.43 (C-5), 115.93 (arom C), 125.93 (arom C), 
131.13 (arom C), 137.68 (C-6), 149.16 (arom C), 151.20 (C-4), 164.51 (C-2), 181.57 (C=S). 
 
Exact mass (ESI-MS) for C21H28N5O5S [M+H]+ found, 462.1803; calcd, 462.1732; Anal. 
(C21H27N5O5S) C, H, N, S. 
 
 
N-(Adamant-1-yl)- N’-(5’-deoxy-α-D-thymidin-5’-yl)thiourea (5.17) 
Compound 5.17 was synthesized from 5.47 (120 mg, 0.50 mmol) and 4-methoxyphenyl 
isothiocyanate (114 mg, 0.60 mmol) using the same procedure as described for the 
synthesis of 5.10.  After purification by column chromatography (CH2Cl2/MeOH 99:1), 
compound 5.17 (178 mg, 82%) was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.60 (6H, m, CH and CH2), 1.76 
(3H, d, J = 1.2 Hz, 5-CH3), 1.86-1.94 (1H, ddd, J= 3.1 and 14.1 
Hz, H-2’), 2.00 (2H, m, 2.53-2.63, CH2), 2.12 (5H, m, CH and 
CH2), 2.49 (1H, m, H-2”), 3.38 (1H, m, H-5’), 3.56 (1H, m, H-5”), 
4.19 (2H, m, H-3’ and H-4’), 5.42 (1H, d, J= 2.8 Hz, 3’-OH), 6.16 
(1H, dd, J= 3.4 and 7.6, H-1’), 7.14 (1H, br s, N(ar)H), 7.30 (1H, t, 
J = 5.4 Hz, N(5’)H), 7.75 (1H, J = 1.2 Hz, H-6), 11.21 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.96 (5-CH3), 29.67, 36.62, 41.82 (CH and CH2), 45.36 (C-2’), 53.46 
(C-5’), 71.59 (C-3’), 85.42 (C-1’), 87.10 (C-4’), 109.58 (C-5), 137.66 (C-6), 151.22 (C-4), 164.61 (C-2), 
181.49 (C=S). 
 
Exact mass (ESI-MS) for C21H31N4O4S [M+H]+ found, 435.2065; calcd, 435.2065; Anal. 
(C21H30N4O4S) C, H, N, S. 
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N-(5’-Deoxy-α-D-thymidin-5’-yl)-N’-(3-pyridyl)thiourea (5.18) 
Compound 5.18 was synthesized from 5.47 (40 mg, 0.17 mmol) and 3-pyridyl isothiocyanate 
(27 mg, 0.20 mmol) using the same procedure as described for the synthesis of 5.10.  After 
purification by column chromatography (CH2Cl2/MeOH 95:5), compound 5.18 (52 mg, 83%) 
was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.79 (3H, d, J= 0.9 Hz, 5-CH3), 
1.90-1.99 (1H, ddd, J= 3.0 and 14.1 Hz, H-2’), 2.54-2.64 (1H, m, H-
2”), 3.50 (1H, m, H-5’), 3.65 (1H, m, H-5”), 4.23 (1H, m, H-3’), 4.34 
(1H, m, H-4’), 5.47 (1H, d, J= 3.3 Hz, 3’-OH), 6.19 (1H, dd, J= 3.6 
and 7.8, H-1’), 7.32 (1H, dd, J= 4.5 and 8.7 Hz, arom H), 7.77 (1H, 
d, J= 1.2 Hz, H-6), 7.95 (1H, d, J= 8.1 Hz, arom H), 8.08 (1H, br s, N(5’)H), 8.27 (1H, dd, J= 1.5 and 
4.5 Hz, arom H), 8.55 (1H, d, J= 2.4 Hz, arom H), 9.80 (1H, br s, N(ar)H), 11.22 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 13.02 (5-CH3), 44.30 (C-2’), 46.33 (C-5’), 71.64 (C-3’), 85.39 and 
86.44 (C-1’ and C-4’), 109.56 (C-5), 123.86 (arom C), 125.16 (arom C), 135.26 (arom C), 136.95 
(arom C), 137.65 (C-6), 145.61 (arom C), 151.23 (C-4), 164.53 (C-2), 182.11 (C=S). 
 
Exact mass (ESI-MS) for C16H20N5O4S [M+H]+ found, 378.1229; calcd, 378.1235; Anal. 
(C16H19N5O4S) C, H, N, S. 
 
 
N-(5’-Deoxy-α-D-thymidin-5’-yl)-N’-(fluoresceinyl)thiourea (5.19) 
Compound 5.19 was synthesized from 5.47 (70 mg, 0.29 mmol) and fluoresceine 
isothiocyanate (135 mg, 0.35 mmol) using the same procedure as described for the 
synthesis of 5.10.  After purification by column chromatography (CH2Cl2/MeOH 95:5), 
compound 5.19 (129 mg, 71%) was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.78 (3H, d, J= 0.9 Hz, 5-
CH3), 1.92-2.00 (1H, ddd, J= 3.3 and 14.4 Hz, H-2’), 2.57-
2.68 (1H, m, H-2”), 3.57 (1H, m, H-5’), 3.72 (1H, m, H-5”), 
4.27 (1H, m, H-3’), 4.38 (1H, m, H-4’), 5.53 (1H, d, J= 3.0 
Hz, 3’-OH), 6.23 (1H, dd, J= 3.3 and 7.2 H-1’), 6.54-6.66 
(1H, m, 6 arom H), 7.18 (1H, d, J= 8.4 Hz, arom H), 7.75 
(1H, d, J= 6.6 Hz, arom H), 7.80 (1H, d, J = 1.2 Hz, H-6), 
8.19 (1H, br s, N(5’)H), 8.31 (1H, s, arom H), 10.12 (1H, br s, N(ar)H), 11.23 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 13.10 (5-CH3), 42.96 (C-2’), 46.87 (C-5’), 72.74 (C-3’), 82.84 and 
89.14 (C-1’ and C-4’), 84.91 (COPh3), 103.29 (arom C), 106.30 (arom C), 110.98 (C-5), 115.49 (arom 
C), 123.86 (arom C), 123.97 (arom C), 126.36 (arom C), 129.32 (arom C), 133.76 (arom C), 139.95 
(arom C), 136.65 (C-6), 151.69 (C-4), 152.15 (arom C), 152.94 (arom C), 153.29 (arom C), 164.33 (C-
2), 181.18 (C=S). 
 
Exact mass (ESI-MS) for C31H27N4O9S [M+H]+ found, 631.1498; calcd, 631.1498; Anal. 
(C31H26N4O9S) C, H, N, S. 
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N-Benzyl- N’-(5’-deoxy-α-D-thymidin-5’-yl)thiourea (5.20) 
Compound 5.20 was synthesized from 5.47 (100 mg, 0.42 mmol) and benzyl isothiocyanate 
(74 mg, 0.50 mmol) using the same procedure as described for the synthesis of 5.10.  After 
purification by column chromatography (CH2Cl2/MeOH 97:3), compound 5.20 (120 mg, 74%) 
was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.78 (3H, d, J= 1.2 Hz, 5-CH3), 
1.87-1.96 (1H, ddd, J= 3.0 and 14.5 Hz, H-2’), 2.49-2.60 (1H, m, H-
2”), 3.49 (1H, m, H-5’), 3.60 (1H, m, H-5”), 4.21 (1H, m, H-3’), 4.28 
(1H, m, H-4’), 4.66 (2H, d, J= 4.8 Hz, CH2NH), 5.43 (1H, d, J= 3.0 
Hz, 3’-OH), 6.17 (1H, dd, J= 3.6 and 7.7 Hz, H-1’), 7.21-7.35 (5H, 
m, 5 arom H), 7.58 (1H, br s, N(5’)H), 7.76 (1H, d, J= 1.2 Hz, H-6), 7.98 (1H, br s, CH2NH), 11.23 (1H, 
br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 13.01 (5-CH3), 36.45 (CH2NH), 46.24 (C-2’), 47.77 (C-5’), 71.56 (C-
3’), 85.42 (C-1’), 87.03 (C-4’), 109.48 (C-5), 127.54 (arom C), 127.98 (arom C), 128.96 (arom C), 
137.61 (C-6), 139.86 (arom C), 151.19 (C-4), 164.51 (C-2), 181.91 (C=S). 
 
Exact mass (ESI-MS) for C18H23N4O4S [M+H]+ found, 391.1440; calcd, 391.1439; Anal. 
(C18H22N4O4S) C, H, N, S. 
 
 
N-(Benzhydryl)-N-(5’-deoxy-α-D-thymidin-5’-yl)thiourea (5.21) 
Compound 5.21 was synthesized from 5.47 (70 mg, 0.29 mmol) and benzhydryl 
isothiocyanate (78 mg, 0.35 mmol) using the same procedure as described for the synthesis 
of 5.10.  After purification by column chromatography (CH2Cl2/MeOH 97:3), compound 5.21 
(114 mg, 84%) was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.76 (3H, s, 5-CH3), 1.87-1.94 
(1H, ddd, J= 3.4 and 14.2 Hz, H-2’), 2.52-2.61 (1H, m, H-2”), 3.47 
(1H, m, H-5’), 3.66 (1H, m, H-5”), 4.17 (1H, m, H-3’), 4.25 (1H, m, 
H-4’), 5.42 (1H, d, J= 3.6 Hz, 3’-OH), 6.18 (1H, dd, J= 3.9 and 7.5 
Hz, H-1’), 6.67 (1H, d, J= 8.2 Hz, CHNH), 7.20-7.35 (10H, m, 10 
arom H), 7.55 (1H, br s, N(5’)H), 7.75 (1H, s, H-6), 8.45 (1H, d, J= 
8.4 Hz, CHNH), 11.21 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.99 (5-CH3), 46.39 (C-2’), 49.28 (C-5’), 61.36 (CHNH), 71.61 (C-
3’), 85.36 (C-1’), 86.98 (C-4’), 109.60 (C-5), 127.66 (arom C), 127.70 (arom C), 127.88 (arom C), 
129.13 (arom C), 137.58 (C-6), 143.18 (arom C), 151.21 (C-4), 164.49 (C-2), 183.34 (C=S). 
 
Exact mass (ESI-MS) for C24H27N4O4S [M+H]+ found, 467.1757; calcd, 467.1752; Anal. 
(C24H26N4O4S) C, H, N, S. 
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N-Benzoyl-N’-(5’-deoxy-α-D-thymidin-5’-yl)thiourea (5.22) and 5’-benzoylamino-5’-
deoxy-α-D-thymidine (5.30) 
Treatment of amine 47 (140 mg, 0.58 mmol) and benzoyl isothiocyanate (114 mg, 0.70 
mmol) using the same procedure as described for the synthesis of 5.10, afforded, after 
purification by column chromatography (CH2Cl2/MeOH 97:3), the expected thiourea 5.22 
(120 mg, 51 %) as well as benzamide 5.30 (39 mg, 20%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.76 (3H, d, J= 0.9 Hz, 5-CH3), 
1.90-1.98 (1H, ddd, J= 2.9 and 14.5 Hz, H-2’), 2.56-2.67 (1H, m, 
H-2”), 3.63 (1H, m, H-5’), 3.82 (1H, m, H-5”), 4.23 (1H, m, H-3’), 
4.43 (1H, m, H-4’), 5.50 (1H, d, J= 3.3 Hz, 3’-OH), 6.20 (1H, dd, J= 
3.3 and 7.5, H-1’), 7.49 (2H, m, 2 arom H), 7.62 (1H, m, arom H), 
7.76 (1H, J = 0.9 Hz, H-6), 7.91 (2H, m, 2 arom H), 11.00 (1H, t, J= 5.1 Hz, N(5’)H), 11.23 (1H, br s, 
N(ar)H), 11.38 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 13.03 (5-CH3), 41.77 (C-2’), 47.17 (C-5’), 71.72 (C-3’), 85.59 and 
85.55 (C-1’ and C-4’), 109.57 (C-5), 129.10 (arom C), 129.25 (arom C), 132.84 (arom C), 133.71 
(arom C), 137.62 (C-6), 151.18 (C-4), 164.54 (C-2), 168.86 (C=O), 181.42 (C=S). 
 
Exact mass (ESI-MS) for C18H20N4O5SNa [M+Na]+ found, 427.1051; calcd, 427.1052; Anal. 
(C18H20N4O5S) C, H, N, S. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 1.2 Hz, 5-CH3), 1.87-
1.94 (1H, ddd, J= 2.5 and 14.4 Hz, H-2’), 2.51-2.62 (1H, m, H-2”), 3.30 
(2H, m, H-5’ and H-5”), 4.22-4.32 (2H, m, H-3’ and H-4’), 5.39 (1H, d, 
J= 3.3 Hz, 3’-OH), 6.16 (1H, dd, J= 2.8 and 7.8, H-1’), 7.42-7.52 (3H, 
m, 3 arom H), 7.75 (1H, J = 1.3 Hz, H-6), 7.84 (2H, m, 2 arom H), 8.57 
(1H, t, J= 5.9 Hz, N(5’)H), 11.20 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 13.04 (5-CH3), 41.96 (C-2’), 49.12 (C-5’), 71.72 (C-3’), 85.54 (C-1’), 
87.24 (C-4’), 109.33 (C-5), 127.91 (arom C), 128.99 (arom C), 131.97 (arom C), 134.91 (arom C), 
137.69 (C-6), 151.18 (C-4), 164.56 (C-2), 167.21 (C=O). 
 
Exact mass (ESI-MS) for C17H19N3O5Na [M+Na]+ found, 368.1224; calcd, 368.1222; Anal. 
(C17H19N3O5) C, H, N. 
 
 
N-(5’-Deoxy-α-D-thymidin-5’-yl)-N’-(3-trifluoromethyl-4-chlorobenzyl)thiourea (5.23) 
4-Chloro-3-trifluoromethylbenzylamine (65 mg, 0.31 mmol) was added at 0 °C to a stirred 
solution of 1,1’-thiocarbonyldiimidazole (61 mg, 0.34 mmol) and imidazole (6.3 mg, 0.09 
mmol) in 4 mL acetonitril.  After 10 minutes at 0 °C, the reaction was allowed to stir during 3 
hours at room temperature.  A solution of 5.47 (75 mg, 0.31 mmol) in 2 mL DMF was added 
and the reaction mixture was stirred at room temperature during overnight.  The reaction 
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mixture was evaporated to dryness and purified by column chromatography (CH2Cl2/MeOH 
99:1) to obtain compound 5.23 (114 mg, 75%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.77 (3H, d, J= 0.9 Hz, 5-
CH3), 1.87-1.95 (1H, ddd, J= 2.9 and 14.4 Hz, H-2’), 2.50-
2.60 (1H, m, H-2”), 3.47 (1H, m, H-5’), 3.55 (1H, m, H-5”), 
4.18 (1H, m, H-3’), 4.26 (1H, m, H-4’), 4.71 (2H, d, J= 4.8 Hz, 
CH2NH), 5.41 (1H, d, J= 3.0 Hz, 3’-OH), 6.14 (1H, dd, J= 3.2 
and 7.6 Hz, H-1’), 7.56 (1H, dd, J = 2.0 and 8.8 Hz, arom H), 7.65 (1H, d, J = 8.7 Hz, arom H), 7.73 
(2H, app s, arom H and H-6), 7.78 (1H, t, J = 4.7 Hz, N(5’)H), 8.14 (1H, d, J= 4.9 Hz, CH2NH), 11.20 
(1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 13.00 (5-CH3), 31.47 (CH2NH), 46.48 (C-2’), 46.58 (C-5’), 71.58 (C-
3’), 85.46 (C-1’), 86.98 (C-4’), 109.44 (C-5), 116.28 (CF3), 127.10 (arom C), 127.17 (arom C), 129.49 
(arom C), 132.14 (arom C), 133.57 (arom C), 137.58 (C-6), 140.54 (arom C), 151.19 (C-4), 164.52 (C-
2), 182.28 (C=S). 
 
Exact mass (ESI-MS) for C19H21N4O4SClF3 [M+H]+ found,; calcd, 493.0924; Anal. (C19H20N4O4SClF3) 
C, H, N, S. 
 
 
N-(5’-Deoxy-α-D-thymidin-5’-yl)-N’-(phenethyl)thiourea (5.24) 
Compound 5.24 was synthesized from 5.47 (108 mg, 0.45 mmol) and phenethyl 
isothiocyanate (130 mg, 0.54 mmol) using the same procedure as described for the 
synthesis of 5.10.  After purification by column chromatography (CH2Cl2/MeOH 97:3), 
compound 5.24 (137 mg, 76%) was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.77 (3H, d, J= 0.9 Hz, 5-
CH3), 1.87-1.95 (1H, ddd, J= 3.0 and 14.3 Hz, H-2’), 2.49-2.60 
(1H, m, H-2”), 2.80 (2H, t, J= 7.5 Hz, CH2Ph), 3.49 (1H, m, H-
5’), 3.60 (2H, m, H-5” and CH2NH), 4.19-4.29 (2H, m, H-3’ and 
H-4’), 5.39 (1H, d, J= 2.8 Hz, 3’-OH), 6.14 (1H, dd, J= 3.4 and 
7.7 Hz, H-1’), 7.16-7.31 (5H, m, 5 arom H), 7.52 (2H, m, N(5’)H and CH2NH), 7.74 (1H, d, J= 1.2 Hz, 
H-6), 11.20 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 13.01 (5-CH3), 35.47 (CH2Ph), 45.89 (CH2NH), 46.09 (C-2’), 47.82 
(C-5’), 71.56 (C-3’), 85.43 (C-1’), 87.10 (C-4’), 109.46 (C-5), 126.80 (arom C), 129.04 (arom C), 
129.34 (arom C), 137.63 (C-6), 140.01 (arom C), 151.20 (C-4), 164.51 (C-2), 184.28 (C=S). 
 
Exact mass (ESI-MS) for C19H25N4O4S [M+H]+ found, 405.1595; calcd, 405.1596; Anal. 
(C19H24N4O4S) C, H, N, S. 
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N-(3,4-Dichlorophenethyl)- N’-(5’-deoxy-α-D-thymidin-5’-yl)thiourea (5.25) 
3,4-dichlorophenethylamine (59 mg, 0.31 mmol) was added at 0 °C to a stirred solution of 
1,1’-thiocarbonyldiimidazole (61 mg, 0.34 mmol) and imidazole (6.3 mg, 0.09 mmol) in 4 mL 
acetonitril.  After 10 minutes at 0 °C, the reaction was allowed to stir during 3 hours at room 
temperature.  A solution of 5.47 (75 mg, 0.31 mmol) in 2 mL DMF was added and the 
reaction mixture was stirred at room temperature during overnight.  The mixture was 
evaporated and after purification by column chromatography (CH2Cl2/MeOH 97:3), 
compound 5.25 (120 mg, 82%) was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 0.9 Hz, 5-
CH3), 1.85-1.93 (1H, ddd, J= 3.0 and 14.7 Hz, H-2’), 2.48-
2.57 (1H, m, H-2”), 2.80 (2H, t, J= 7.1 Hz, CH2Ph), 3.49 
(1H, m, H-5’), 3.61 (2H, m, H-5” and CH2NH), 4.19-4.31 
(2H, m, H-3’ and H-4’), 5.40 (1H, d, J= 3.0 Hz, 3’-OH), 6.14 
(1H, dd, J= 3.2 and 7.6 Hz, H-1’), 7.21 (1H, dd, J = 2.1 and 8.1 Hz, arom H), 7.49 (1H, d, J = 1.8 Hz, 
arom H), 7.51-7.54 (1H, d, J = 8.2 Hz, arom H), 7.53 (2H, br s, CH2NH and N(5’)H), 7.74 (1H, d, J= 
1.2 Hz, H-6), 11.20 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 13.02 (5-CH3), 34.37 (CH2Ph), 45.19 (CH2NH), 46.13 (C-2’), 47.82 
(C-5’), 71.56 (C-3’), 85.42 (C-1’), 87.07 (C-4’), 109.46 (C-5), 129.44 (arom C), 129.91 (arom C), 
131.08 (arom C), 131.42 (arom C), 131.50 (arom C), 137.63 (C-6), 141.38 (arom C), 151.20 (C-4), 
164.51 (C-2), 183.65 (C=S).  
Exact mass (ESI-MS) for C19H23N4O4SCl2 [M+H]+ found, ; calcd, 473.0816; Anal. (C19H22N4O4SCl2) 
C, H, N, S. 
 
 
N-(3,4-Dichlorophenyl)-N’-(5’-deoxy-α-D-thymidin-5’-yl)urea (5.26) 
Compound 5.26 was synthesized from 5.47 (85 mg, 0.35 mmol) and 3,4-dichlorophenyl 
isocyanate (79 mg, 0.42 mmol) using the same procedure as described for the synthesis of 
5.10.  After purification by column chromatography (CH2Cl2/MeOH 97:3), compound 5.26 
(113 mg, 75%) was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.78 (3H, s, 5-CH3), 1.89-1.97 
(1H, ddd, J= 3.2 and 14.3 Hz, H-2’), 2.51-2.61 (1H, m, H-2”), 
3.09 (1H, m, H-5’), 3.21 (1H, m, H-5”), 4.16 (2H, m, H-3’ and H-
4’), 5.42 (1H, d, J= 3.3 Hz, 3’-OH), 6.15 (1H, dd, J= 3.6 and 7.8, 
H-1’), 6.44 (1H, t, J= 5.1 Hz, N(5’)H), 7.22 (1H, dd, J= 2.4 and 
9.0 Hz, arom H), 7.43 (1H, d, J= 9.0 Hz, arom H), 7.75 (1H, d, J= 0.9 Hz, H-6), 7.82 (1H, d, J= 2.4 Hz, 
arom H), 8.92 (1H, br s, N(ar)H), 11.24 (1H, br s, N(3)H). 
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13C NMR (75 MHz, DMSO-d6): δ 12.99 (5-CH3), 41.77 (C-2’), 49.28 (C-5’), 71.57 (C-3’), 85.35 (C-1’), 
87.32 (C-4’), 109.54 (C-5), 118.40 (arom C), 119.36 (arom C), 122.97 (arom C), 131.12 (arom C), 
131.61 (arom C), 137.60 (C-6), 141.33 (arom C), 151.21 (C-4), 155.56 (C=O), 164.51 (C-2). 
 
Exact mass (ESI-MS) for C17H18N4O5Cl2Na [M+Na]+ found, 451.0548; calcd, 451.0552; Anal. 
(C17H18N4O5Cl2) C, H, N. 
 
 
N-(5’-Deoxy-α-D-thymidin-5’-yl)-N’-(3-trifluoromethyl-4-chlorophenyl)urea (5.27) 
Compound 5.27 was synthesized from 5.47 (79 mg, 0.33 mmol) and 4-chloro-3-
trifluorophenyl isocyanate (88 mg, 0.40 mmol) using the same procedure as described for 
the synthesis of 5.10.  After purification by column chromatography (CH2Cl2/MeOH 97:3), 
compound 5.27 (120 mg, 79%) was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.78 (3H, d, J= 1.2 Hz, 5-CH3), 
1.89-1.97 (1H, ddd, J= 3.1 and 14.3 Hz, H-2’), 2.52-2.62 (1H, 
m, H-2”), 3.15 (1H, m, H-5’), 3.24 (1H, m, H-5”), 4.18 (2H, m, H-
3’ and H-4’), 5.44 (1H, d, J= 3.3 Hz, 3’-OH), 6.17 (1H, dd, J= 3.6 
and 7.8, H-1’), 6.53 (1H, t, J= 5.1 Hz, N(5’)H), 7.55 (2H, app s, 
2 arom H), 7.77 (1H, d, J= 1.2 Hz, H-6), 8.06 (1H, s, arom H), 9.14 (1H, br s, N(ar)H), 11.23 (1H, br s, 
N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 13.00 (5-CH3), 41.81 (C-2’), 49.35 (C-5’), 71.51 (C-3’), 85.31 (C-1’), 
87.26 (C-4’), 109.53 (C-5), 116.57 (CF3), 122.11 (arom C), 123.00 (arom C), 123.05 (arom C), 128.05 
(arom C), 132.56 (arom C), 137.60 (C-6), 140.66 (arom C), 151.20 (C-4), 155.57 (C=O), 164.51 (C-2). 
 
Exact mass (ESI-MS) for C18H19N4O5ClF3 [M+H]+ found, 463.0993; calcd, 463.0995; Anal. 
(C18H18N4O5ClF3) C, H, N. 
 
 
5’-Azido-5’-deoxy-α-D-thymidine 3’-methanesulfonate (5.48) 
Compound 5.46 (400 mg, 1.5 mmol) was dissolved in pyridine (5 mL) and 
methanesulphonylchloride (150 µL, 1.95 mmol) was added at 0 °C.  After 2h, the reaction 
was quenched by saturated NaHCO3-solution (5 mL) and extracted with CH2Cl2 (3x 10 mL).  
The combined organic layers were dried with MgSO4 and evaporated to dryness to obtain 
pure compound 5.48 (420 mg, 81%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.77 (3H, d, J= 1.0 Hz, 5-CH3), 2.32-2.40 
(1H, ddd, J= 3.6 and 15.0 Hz, H-2’), 2.81-2.91 (1H, m, H-2”), 3.27 (3H, s, 
SO2CH3), 3.52 (2H, d, J= 5.1 Hz, H-5’ and H-5”), 4.70 (1H, m, H-4’), 5.17 (1H, 
m, H-3’), 6.16 (1H, dd, J= 3.6 and 6.9, H-1’), 7.52 (1H, d, J= 1.1 Hz, H-6), 
11.31 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C11H15N5O6S [M+H]+ found, 346.0818; calcd, 346.0821. 
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5’-Azido-3’,5’-dideoxy-2’,3’-didehydro-α-D-thymidine (5.49) 
To a solution of compound 5.48 (420 mg, 1.21 mmol) in THF (15 mL) was added DBU (906 
µL, 6.07 mmol), and the reaction was refluxed at 80 °C during overnight.  After cooling down, 
the reaction was poured into NH4Cl (15 mL) solution, and extracted with CH2Cl2 (3 x 25 mL).  
The organic layers were dried over MgSO4, evaporated and purified by column 
chromatography (CH2Cl2/MeOH 99:1) to yield 290 mg (95%) pure compound 5.49. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.77 (3H, d, J= 1.0 Hz, 5-CH3), 3.36 (1H, dd, 
J= 4.8 and 13.2 Hz, H-5’), 3.62 (1H, dd, J= 3.3 and 13.2 Hz, H-5”), 5.32 (1H, 
m, H-4’), 6.03 (1H, dd, J= 1.5 and 5.7, H-1’), 6.40 (1H, dd, J= 1.5 and 6.0 Hz, 
H-2”), 6.89 (1H, dd, J= 1.5 and 5.4 Hz, H-3’), 7.52 (1H, d, J= 1.1 Hz, H-6), 
11.31 (1H, br s, N(3)H). 
 
Exact mass(ESI-MS) for C10H11N5O3Na [M+Na]+ found, 272.0761; calcd, 272.0759. 
 
 
5’-Amino-3’,5’-dideoxy-α-D-thymidine (5.50) 
To a solution of azide 5.49 (150 mg, 0.6 mmol) in methanol (4 mL) was added 10% Pd/C (15 
mg) and the reaction placed under a H2 atmosphere. After 5 hours, the reaction mixture was 
filtered through a plug of Celite, which was further washed with MeOH and the combined 
filtrates were evaporated to yield pure 5.50 as a white solid (128 mg, 95%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.70 (1H, m, H-3’), 1.77 (3H, d, J= 1.2 Hz, 
5-CH3), 1.89-2.06 (2H, m, H-2’ and H-3”), 2.27 (1H, m, H-2”), 2.56 (2H, d, J= 
5.1 Hz, H-5’ and H-5”), 4.27 (1H, m, H-4’), 5.98 (1H, dd, J= 5.1 and 6.6, H-
1’), 7.41 (1H, d, J= 1.1 Hz, H-6). 
 
Exact mass (ESI-MS) for C10H16N3O3 [M+H]+ found, 226.1188; calcd, 226.1191. 
 
 
N-(3-Trifluoromethyl-4-chlorophenyl)-N’-(3’,5’-dideoxy-α-D-thymidin-5’-yl)thiourea 
(5.28) 
Compound 5.28 was synthesized from 5.50 (78 mg, 0.35 mmol), and 4-chloro-3-
trifluoromethylphenyl isothiocyanate (100 mg, 0.42 mmol) using the same procedure 
described for the synthesis of 5.10.  After purification by column chromatography 
(CH2Cl2/MeOH 97:3), compound 5.28 (127 mg, 78%) was obtained. 
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1H NMR (300 MHz, DMSO-d6): δ 1.78 (3H, d, J= 1.2 Hz, 5-CH3), 
1.76 (1H, m, H-3’), 1.97-2.19 (2H, m, H-2’ and H-3”), 2.22-2.39 
(1H, m, H-2”), 3.52 (1H, m, H-5’), 3.67 (1H, m, H-5”), 4.57 (1H, 
m, H-4’), 6.10 (1H, dd, J= 5.4 and 6.0, H-1’), 7.48 (1H, d, J= 1.2 
Hz, arom H), 7.60 (1H, d, J= 8.7 Hz, arom H), 7.73 (1H, dd, J= 
2.4 and 8.7 Hz, arom H), 8.19 (1H, s, H-6), 8.32 (1H, br s, N(5’)H), 10.15 (1H, br s, N(ar)H), 11.21 
(1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ  12.76 (5-CH3), 27.99 (C-3’), 31.45 (C-2’), 48.26 (C-5’), 79.22 (C-4’), 
86.11 (C-1’), 110.17 (C-5), 117.86 (CF3), 121.02 (arom C), 125.21 (arom C), 127.32 (arom C), 128.28 
(arom C), 136.95 (C-6), 139.90 (arom C), 151.14 (C-4), 164.56 (C-2), 180.98 (C=S). 
 
Exact mass (ESI-MS) for C18H18N4O3SClF3Na [M+Na]+ found, 485.0641; calcd, 485.0638; Anal. 
(C18H18N4O3SClF3) C, H, N, S. 
 
 
5’-Amino-3’,5’-dideoxy-2’,3’-didehydro-α-D-thymidine (5.51) 
Compound 5.49 (80 mg, 0.32 mmol) was dissolved in dry pyridine (4 mL) and 
triphenylphospine (135 mg, 1.6 mmol) was added to the solution.  The reaction was stirred 
during 3 hours at room temperature, evaporated to dryness and purified by column 
chromatography (CH2Cl2/MeOH 90:10), yielding 65 mg pure compound 5.51 (92%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.69 (3H, d, J = 1.2 Hz, 5-CH3), 2.59 (1H, 
dd, J = 4.7 and 13.5 Hz, H-5’), 2.70 (1H, dd, J = 4.7 and 13.7 Hz, H-5”), 
4.99 (1H, m, H-4’), 5.83 (1H, app dt, J = 2.4 and 5.7, H-1’), 6.33 (1H, app 
dt, J = 1.5 and 6.0 Hz, H-2’), 6.81 (1H, app dt, J = 1.5 and 4.9 Hz, H-3’), 
7.10 (1H, d, J= 1.2, H-6). 
 
13C NMR (75 MHz, DMSO-d6): δ 11.96 (5-CH3), 45.68 (C-5’), 88.49 (C-1’), 89.41 (C-4’), 109.75 (C-5), 
125.37 (C-2’), 135.72 (C-3’), 137.42 (C-6), 150.53 (C-4), 163.75 (C-2). 
 
Exact mass (ESI-MS) for C10H14N3O3 [M+H]+ found, 224.1039; calcd, 224.1035. 
 
 
N-(3’,5’-dideoxy-2’,3’-didehydro-α-D-thymidin-5’-yl)-N-(3-trifluoromethyl-4-
chlorophenyl)thiourea (5.29) 
Compound 5.29 was synthesized from 5.51 (70 mg, 0.31 mmol) and 4-chloro-3-
trifluoromethylphenyl isothiocyanate (90 mg, 0.38 mmol) using the same procedure as 
described for the synthesis of 5.10.  After purification by column chromatography 
(CH2Cl2/MeOH 99:1), compound 5.29 (112 mg, 78%) was obtained. 
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1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 1.2 Hz, 5-
CH3), 3.73 (2H, m, H-5’ and H-5”), 4.29 (1H, m, H-4’), 5.97 (1H, 
dt, J= 2.4 and 6.0, H-1’), 6.45 (1H, dt, J= 1.8 and 6.0 Hz, H-2’), 
6.98 (1H, dt, J= 1.8 and 5.4 Hz, H-3’), 7.13 (1H, d, J= 1.2 Hz, 
arom H), 7.61 (1H, d, J= 9.0 Hz, arom H), 7.72 (1H, dd, J= 2.4 
and 8.4 Hz, arom H), 8.07 (1H, br s, N(5’)H), 8.17 (1H, s, H-6), 9.96 (1H, br s, N(ar)H), 11.30 (1H, br 
s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ  12.66 (5-CH3), 47.80 (C-5’), 85.82 (C-4’), 90.11 (C-1’), 110.71 (C-5), 
115.26 (CF3), 121.59 (arom C), 125.21 (arom C), 126.67 (arom C), 126.84 (C-2’), 127.07 (arom C), 
127.85 (arom C), 132.29 (C-3’), 135.44 (arom C), 136.42 (C-6), 139.87 (arom C), 151.34 (C-4), 
164.49 (C-2), 181.68 (C=S). 
 
Exact mass (ESI-MS) for C18H16N4O3SClF3Na [M+Na]+ found, ; calcd, 483.0481; Anal. 
(C18H16N4O3SClF3) C, H, N, S. 
 
 
1-[(2-Hydroxyethoxy)methyl]thymine (5.52)  
A mixture of thymine (400 mg, 3.17 mmol), HMDS (16 mL) and ammoniumsulphate (16 mg) 
was refluxed during 2 hours under nitrogen.  After cooling to room temperature, the mixture 
was evaporated to dryness and resolved in acetonitrile (32 mL).  At -45 °C 
trimethylsilyltriflate (602 µL, 3.33 mmol) was added dropwise, followed by the dropwise 
addition of dioxolane (470 mg, 6.34 mmol).  After 2 hours the reaction was allowed to warm 
to room temperature and stirred overnight.  To quench the reaction, a saturated aqueous 
NaHCO3-solution (20 mL) was added at -45 °C.  The resulting mixture was extracted three 
times with diethylether (25 mL).  The combined organic layers were dried over MgSO4 and 
evaporated to dryness.  The crude residue was purified by column chromatography 
(CH2Cl2/MeOH 95:5) to obtain 480 mg (76%) of pure compound 5.52. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 1.2 Hz, 5-CH3), 3.45 (4H, m, 
CH2CH2), 4.61 (1H, t, J=5.1 Hz, OH), 5.03 (2H, s, OCH2N), 7.54 (1H, d, J= 
1.2, H-6), 11.26 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C8H12N2O4 [M+Na]+ found, 223.0721; calcd, 223.0694. 
 
 
1-[(2-Azidoethoxy)methyl]thymine (5.53) 
Compound 5.52 (480 mg, 1.82 mmol) was dissolved in anhydrous pyridine (14 mL) and 
methanesulfonylchloride (183 µL, 2.36 mmol) was slowly added at 0 °C.  After 2 hours, the 
reaction was quenched with aqueous NaHCO3-solution (10 mL) and the mixture was 
extracted three times with ethylacetate (20 mL).  The combined organic layers were dried 
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over MgSO4 and evaporated to dryness.  The obtained residue was dissolved in DMF (40 
mL) and 1.46 g (22.5 mmol) of NaN3 was added.  The reaction mixture was heated at 60 °C 
during the night, evaporated and purified by column chromatography (CH2Cl2/MeOH 97:3), 
yielding 393 mg (96%) of 5.53. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 1.2 Hz, 5-CH3), 3.39 (2H, t, 
J= 4.8 Hz, CH2O), 4.64 (2H, t, J= 4.8 Hz, CH2N3), 5.07 (2H, s, OCH2N), 7.56 
(1H, d, J= 1.2 Hz, H-6), 11.30 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C8H12N5O3 [M+H]+ found, 226.0948; calcd, 226.0940. 
 
 
1-[(2-Aminoethoxy)methyl]thymine (5.54) 
To a solution of azide 5.53 (393 mg, 1.75 mmol) in methanol (15 mL) was slowly added 50 
mg of 10% Pd/C. The reaction mixture was submitted to a hydrogen atmosphere overnight. 
After filtration of the catalyst over a plug of celite and evaporation of the solvent in vacuo, 
resulting compound 5.54 (345 mg, 99%) was obtained and used without further purification. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.77 (3H, s, 5-CH3), 2.65 (2H, t, J= 5.7 Hz, 
CH2NH2), 3.43 (2H, t, J= 4.8 Hz, CH2O), 5.05 (2H, s, OCH2N), 7.48 (1H, s, H-
6). 
 
Exact mass (ESI-MS) for C8H14N3O3 [M+H]+ found, 200.1034; calcd, 200.1035. 
 
 
N-[(Thymin-1-yl)methoxyethyl]-N’-phenylthiourea (5.31) 
Compound 5.31 was synthesized from 5.54 (65 mg, 0.33 mmol) and phenyl isothiocyanate 
(57 mg, 0.42 mmol) in 2 mL DMF using the same procedure as described for the synthesis 
of 5.10. After purification by column chromatography (CH2Cl2/MeOH 99:1), thiourea 5.31 (94 
mg, 86%) was obtained as a white powder. 
  
1H NMR (300 MHz, DMSO-d6): δ 1.74 (3H, d, J= 0.9 Hz, 5-CH3), 
3.62 (4H, app s, CH2CH2), 5.06 (2H, s, OCH2N), 7.07 (1H, m, arom 
H), 7.28 (2H, m, 2 arom H), 7.37 (2H, d, J= 7.5 Hz, 2 arom H), 7.56 
(1H, d, J= 1.2 Hz, H-6), 7.76 (1H, br s, N(5’)H), 9.61 (1H, br s, 
N(ar)H), 11.28 (1H, br s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.56 (5-CH3), 44.10 (CH2NH’), 67.35 (CH2O), 76.84 (OCH2N), 
109.92 (C-5), 123.79 (arom C), 124.93 (arom C), 129.33 (arom C), 139.77 (C-6), 141.23 (arom C), 
151.78 (C-4), 164.98 (C-2), 181.18 (C=S). 
 
Exact mass (ESI-MS) for C15H19N4O3S [M+H]+ found, 335.1175; calcd, 335.1177. 
H
N
N
OO
O
N3
H
N
N
OO
O
H2N
H
N
N
OO
ONH
H
N
S
3 ’-branched-β -  and 5 ’-α-  subst i tu ted thymidine analogues 
  171 
N-[(Thymin-1-yl)methoxyethyl]-N’-(4-chloro-3-trifluoromethylphenyl)thiourea (5.32) 
Compound 5.32 was synthesized from 5.54 (97 mg, 0.49 mmol) and 4-chloro-3-
trifluoromethylphenyl isothiocyanate (138 mg, 0.58 mmol) in 3 mL DMF using the same 
procedure as described for the synthesis of 5.10. After purification by column 
chromatography (CH2Cl2/MeOH 99:1), compound 5.32 (178 mg, 83%) was obtained. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.76 (3H, d, J= 1.2 Hz, 5-
CH3), 3.65 (4H, app s, CH2CH2), 5.09 (2H, s, OCH2N), 7.58 
(1H, d, J= 1.2 Hz, arom H), 7.62 (1H, d, J= 8.7 Hz, arom H), 
7.73 (1H, dd, J= 2.4 and 8.7 Hz, arom H), 8.12 (2H, app d, J= 
1.2 Hz, H-6 and N(5’)H), 9.94 (1H, br s, N(ar)H), 11.29 (1H, br 
s, N(3)H). 
 
13C NMR (75 MHz, DMSO-d6): δ  12.52 (5-CH3), 44.15 (CH2NH’), 67.19 (CH2O), 76.87 (OCH2N), 
109.92 (C-5), 117.96 (CF3), 121.58 (arom C), 125.21 (arom C), 126.73 (arom C), 127.14 (arom C), 
132.26 (arom C), 139.86 (C-6), 141.14 (arom C), 151.78 (C-4), 164.90 (C-2), 181.33 (C=S). 
 
Exact mass (ESI-MS) for C16H17N4O3SF3Cl [M+H]+ found, 437.0659; calcd, 437.0661. 
 
 
2’,3’-Isopropylideneadenosine (5.54) 
Adenosine (1.00 g, 3.74 mmol) and p-toluenesulphonic acid (710 mg, 3.74 mmol) were 
suspended in acetone (25 mL) and dimethoxypropane (5 mL).  After 10 minutes the reaction 
mixture became clear and after 1 hour, the mixture was evaporated to dryness, resolved in 
aqueous NaHCO3 (25 mL) and extracted three times with ethyl acetate (25 mL).  The 
organic solvents were dried over MgSO4, evaporated to dryness and purified by column 
chromatography (CH2Cl2/MeOH 95:5) to yield 880 mg (77%) 5.54. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.33 (3H, s, CCH3), 1.55 (3H, s, CCH3), 
3.47-3.60 (2H, m, H-5’ and H-5”), 4.21 (1H, m, H-4’), 4.96 (1H, dd, J= 2.7 and 
6.0 Hz, H-3’), 5.23 (1H, d, J= 5.4 Hz, 5’-OH), 5.35 (1H, dd, J= 3.3 and 6.0 Hz, 
H-2’), 6.12 (1H, d, J= 3.3 Hz, H-1’), 7.34 (2H, s, NH2), 8.15 and 8.34 (2H, 2 x 
s, H-2 and H-8). 
 
 
Exact mass (ESI-MS) for C13H17N8O3 [M+H]+ found, 308.1353; calcd, 308.1359. 
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5’-Azido-5’-deoxy-2’,3’-isopropylideneadenosine (5.55) 
Compound 5.54 (880 mg, 2.87 mmol) was dissolved in pyridine (12 mL) and 
methanesulfonyl chloride was added at 0 °C.  After 1 hour the reaction was finished.  
Aqueous NaHCO3 solution (20 mL) was added and the reaction was extracted three times 
with ethyl acetate (20 mL).  The combined organic layers were dried over MgSO4 and 
evaporated to dryness.  The obtained residue was resolved in DMF (40 mL), NaN3 (1.527 g, 
23.5 mmol) was added, and the reaction was heated to 60 °C overnight.  The mixture was 
evaporated to dryness and purified by column chromatography (CH2Cl2/MeOH 98:2), 
yielding 677 mg (71%) of compound 5.55. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.34 (3H, s, CCH3), 1.54 (3H, s, CCH3), 3.57-
3.72 (2H, m, H-5’ and H-5”), 4.24 (1H, m, H-4’), 4.98 (1H, dd, J= 2.7 and 6.0 
Hz, H-3’), 5.35 (1H, dd, J= 3.3 and 6.0 Hz, H-2’), 6.11 (1H, d, J= 3.3 Hz, H-1’), 
7.38 (2H, s, NH2), 8.14 and 8.36 (2H, 2 x s, H-2 and H-8). 
 
Exact mass (ESI-MS) for C13H17N8O3 [M+H]+ found, 333.1419; calcd, 
333.1424. 
 
 
5’-Amino-5’-deoxy-2’,3’-isopropylideneadenosine (5.56) 
A solution of 5.55 (677 mg, 2.04 mmol) and Pd/C (68 mg) in MeOH (25 mL) was 
hydrogenated overnight.  The reaction mixture was filtered over celite, evaporated to 
dryness and used in the next reaction without further purification. 
 
 
N-(5’-Deoxy-2’,3’-O-isopropylidene-β-D-adenosin-5’-yl)-N’-(5’-deoxy-α-D-thymidin-5’-
yl)thiourea (5.57) 
5’-Amino-2’,3’-isopropylidene adenosine (5.56) (130 mg, 0.43 mmol), imidazole (6mg, 0.08 
mmol) and 1,1-thiocarbonyldiimidazole (83 mg, 0.47 mmol) were dissolved in DMF (7 mL) at 
0 °C and after 10 minutes the reaction was allowed to warm up to room temperature.  After 2 
hours, 5.47 (112 mg, 0.43 mmol) in 2 mL DMF was added.  After 3 hours, the reaction was 
finished and evaporated to dryness.  The obtained crude compound was purified by column 
chromatography (CH2Cl2/MeOH 95:5) to obtain 205 mg (82%) 5.57. 
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1H NMR (300 MHz, DMSO-d6): δ 1.32 (3H, s, CCH3 (A)), 
1.53 (3H, s, CCH3 (A)), 1.76 (3H, d, J= 0.9 Hz, 5-CH3 (T)), 
1.87-1.94 (2H, ddd, J= 2.6 and 14.2 Hz, H-2’ (T)), 2.49-2.59 
(1H, m, H-2” (T)), 3.41-3.67 (3H, m, H-5’(T), H-5” (T) and H-
5’ (A)), 3.78-3.90 (1H, m, H-5” (A)), 4.13-4.34 (3H, m, H-3’ 
(T), H-4’ (T) and H-4’ (A)), 5.01 (1H, dd, J= 3.4 and 6.2 Hz, 
H-3’ (A)), 5.41 (1H, d, J= 3.4 Hz, 3’-OH (T)), 5.46 (1H, dd, 
J= 2.8 and 6.3 Hz, H-2’ (A)), 6.15 (2H, m, H-1’ (T) and H-1’ 
(A)), 7.34 (2H, s, NH2), 7.55 and 7.64 (2H, 2 x br s, 2 x N(5’)H), 7.73 (1H, d, J= 1.2 Hz, H-6), 8.18 and 
8.33 (2H, 2 x s, H-2 and H-8 (A)), 11.24 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C24H32N9O7S [M+H]+ found, 390.2148; calcd, 390.2145. 
 
 
N-(5’-deoxy-β-D-adenosin-5’-yl)-N’-(5’-deoxy-α-D-thymidin-5’-yl)thiourea (5.33) 
Compound 5.58 (120 mg, 0.20 mmol) was dissolved in 50% trifluoroacetic acid in H2O (10 
mL) and stirred for 2 hours at room temperature. The reaction mixture was evaporated to 
dryness and purified by column chromatography (CH2Cl2/MeOH 93:7) to obtain 98 mg of the 
pure compound 5.33 (89%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.76 (3H, d, J= 1.2 Hz, 5-
CH3 (T)), 1.86-1.94 (2H, ddd, J= 2.6 and 14.6 Hz, H-2’ (T)), 
2.49-2.59 (1H, m, H-2” (T)), 3.41-3.67 (3H, m, H-5’(T), H-5” 
(T) and H-5’ (A)), 3.82-3.93 (1H, m, H-5” (A)), 4.01-4.29 
(4H, m, H-3’ (T), H-4’ (T), H-4’ (A) and H-3’ (A)), 4.70 (1H, t, 
J= 5.4 Hz, H-2’ (A)), 5.29 (1H, br s, 3’-OH (A), 5.43 (1H, br 
s, 3’-OH (T)), 5.49 (1H, br s, 2’-OH (A)), 5.88 (1H, d, J= 6.0 
Hz, H-1’ (A)), 6.14 (1H, dd, J= 3.0 and 7.5 Hz, H-1’ (T)), 
7.43 (2H, s, NH2), 7.59 (1H, br s, N(5’)H), 7.74 (2H, app d, J= 1.2 Hz, H-6 and N(5’(A)H)), 8.20 and 
8.38 (2H, 2 x s, H-2 and H-8 (A)), 11.25 (1H, br s, N(3)H). 
 
Exact mass (ESI-MS) for C21H28N9O7S [M+H]+ found, 550.1833; calcd, 550.1832. 
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6 EVALUATION OF THYMIDINE ANALOGUES ON OTHER THYMIDINE 
KINASES
 
 
Nucleosides (N) and deoxynucleosides (dN) form an important class of biological building 
blocks, which are essential for the synthesis of DNA and RNA, and thus for cell survival.  
Before being built in DNA or RNA, nucleosides require the activation into their triphosphates 
by different enzymes.  The nucleoside kinase (NK) is responsible for the first 
phosphorylation, followed by the phosphorylation by nucleoside monophosphate kinase 
(NMPK) to the nucleoside diphosphate (NDP), which is then converted to the nucleoside 
triphosphate (NTP) by nucleoside diphosphate kinase (NDPK).  Similar enzymes exist to 
convert the corresponding deoxynucleosides into their activated triphosphate forms. 
 
  NK  NMPK             NDPK  
N                              NMP                              NDP                              NTP 
 
Despite the structural differences found in bacterial and human TKs and TMPKs, 174,175,176,177 
all these enzymes catalyze very similar biochemical processes.  Both kinases possess a 
binding site for dT or dTMP embedded in the interior of the enzyme, an adenosine binding 
site located on the surface of the enzymes, and a bridging phosphate binding site which 
accommodates either three (TK) or four (TMPK) phosphate moieties.  Interestingly, herpes 
viruses use TKs which have both TK- and TMPK activity.178,179 
In this thesis a wide variety of thymidine derivatives was synthesized and evaluated for their 
activity against the mycobacterial thymidine monophosphate kinase.  Due to the high 
similarity between TKs and TMPKs, those compounds might also interfere with thymidine 
kinases.  After a description of the role, appearance and characteristics of the different 
deoxynucleoside kinases, the activities of selected analogues against different kinases will 
be reported. 
 
6.1 DEOXYNUCLEOSIDE KINASES 
In mammalian cells four different deoxynucleoside kinases can be found: thymidine kinase 1 
(TK-1), thymidine kinase 2 (TK-2), deoxycytidine kinase (dCK) and deoxyguanosine kinase 
(dGK).  
As explained before, the main role of deoxynucleoside kinases is the activation of 
deoxynucleosides to their monophosphates, which is essential for their conversion to DNA-
building blocks.  Deoxynucleoside kinases play also a fundamental role in the activation of 
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nucleoside drugs.  The anticancer agents Gemcitabine, Fludarabine, Clofarabine and 
Cladribine require activation by dCK before being biologically active.  The same activation is 
required for Zalcitabine (ddC), Lamivudine (3TC), didanosine (ddI), abacavir (ABC) and 
Emtricitabine ((-)-FTC), used for the treatment of HIV-infection.  Similarly, TK-1 is crucial for 
the activation of drugs used in HIV-infected patients, like Zidovudine (AZT) and Stavudine 
(d4T).180  
After further conversion to their triphosphates, these agents serve as alternative substrates 
in the reverse transcriptase reaction, where upon their incorporation they act obligatory as 
chain terminators. 
In contrast to these nucleoside reverse transcriptase inhibitors, nucleotide reverse 
transcriptase inhibitors such as adefovir (PMEA) and tenofovir (PMPA) already possess a 
phosphate mimicking phosphonate group.  Consequently, only two phosphorylation steps 
are required to convert these antivirals to the active metabolites. 
 
6.1.1 Thymidine kinase 1 and 2 
Among the different mammalian deoxynucleoside kinases, two enzymes phosphorylate 
thymidine, TK-1 and TK-2.  The main differences between the two kinases are demonstrated 
by their amino acid sequences, their substrate specificities, their location and their levels of 
expression during the different cell cycle phases. 181, 182 
 
Table 6.1 The most important features of TK-1 and TK-2 
 TK-1 TK-2 
Amino acid sequence Unique in its group Belongs to a larger group of nucleoside 
kinases: similar to dCK, dGK, Dm-dNKa 
(40% analogy), HSV-1 TK  
Substrate specificity: 
  
- Natural nucleosides Thymidine, 2’-deoxyuridine Thymidine, 2’-deoxyuridine, 2’-
deoxycytidine 
- Antiviral nucleoside 
analogues 
- AZT: excellent substrate 
 
 
- Ara-T: weak substrate 
AZT: poor substrate, but in non-dividing 
cells TK-2 phosphorylation becomes 
significant. 
- Ara-T: good substrate 
Location Cytosol Mitochondria 
Levels of expression Highest expression in S 
phase cells; very low 
activity in resting cells 
Constitutively expressed, physiologically 
active in non-proliferating and resting cells. 
a
 Dm-dNK: multisubstrate deoxynucleoside kinase of the fruitfly Drosophilia melanogaster 
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So far, no crystallographic determination of TK-2 has been reported.  The strong similarity 
with Dm-dNK (40% similarity in amino acid sequence and no long amino acid sequence 
insertions or deletions) allowed the construction of three-dimensional models of TK-2, using 
the Dm-dNK structure as a template.183,184 
 
6.1.2 The role of thymidine kinase 2 
6.1.2.1 TK-2 deficiency 
Throughout the whole cell cycle, mitochondrial DNA replication takes place, thus constantly 
requiring the production of dNTPs for mtDNA synthesis.  Being active in non-proliferating 
tissues, TK-2 provides the nucleotides for mitochondrial DNA (mtDNA) synthesis.  TK-2 
deficiency would therefore lead to mitochondrial disorders, designated as mtDNA depletion 
syndromes, mostly affecting skeletal muscles.185  Some of these disorders might be 
associated to mutations in mitochondrial dNKs.186  
 
6.1.2.2 Mitochondrial toxicity 
Next to the mitochondrial disorders associated to TK-2 deficiency, severe mitochondrial 
toxicity is also associated to long-term treatment with antiviral nucleoside analogues such as 
AZT.187,188  Although the mechanism by which these nucleoside analogues exert their 
mitochondrial toxicity is not fully understood,187 it has been suggested that after 
phosphorylation of the nucleoside analogues by TK-2, their triphosphates might accumulate 
in the mitochondria.  Although AZT is not an excellent substrate for TK-2, in non-replicating 
cells AZT phosphorylation by TK-2 is significant.  The accumulation of AZT-TP is suggested 
to affect DNA-polymerase-γ, resulting in mtDNA depletion.187,188 
In order to prevent this TK-2 related mitochondrial toxicity, TK-2 inhibitors might be useful to 
be given as a co-treatment with nucleoside analogues.  Additionally, the identification of TK-
2 inhibitors can be a valuable tool to answer the many open questions regarding the real 
contribution of TK-2 in the maintenance and homeostasis of mitochondrial dNTP pools and 
in the phosphorylation of certain antiviral drugs which is suggested to cause their 
mitochondrial toxicity. 
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6.1.3 Known thymidine kinase 2-inhibitors 
6.1.3.1 Ara-, ribo- and 2’-deoxyribo- nucleoside analogues 
In the past, several TK-2 inhibitors have been identified.  An interesting finding concerns the 
inhibitory activity of different ribofuranosyl nucleosides (e.g. 5-(E)-(2-bromovinyl)uridine 6.1; 
Ki = 10.4 µM), while their 2’-deoxy analogues are phosphorylated by the enzyme.189 
TK-2 can also be inhibited by certain nucleosides, including 3’-O-alkyl thymidine analogues 
and 3’-hexanoylamino-3’-deoxythymidine 6.2, a potent TK-2 inhibitor (Ki-value = 0.15 µM).190 
While Ara-T behaves as a good substrate for TK-2, the introduction of long chain acyl 
substituents at the 2’-OH affords TK-2 inhibitors (e.g. 6.3: Ki = 2.3 µM).  As these 2’-O-acyl 
derivatives are unstable in cell culture and readily converted to the parent nucleoside,191 they 
can not be used as tools to study TK-2 in intact cells. 
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Figure 6.1 Ara-, ribo- and 2’-deoxyribo- nucleoside analogues as TK-2 inhibitors. 
 
 
6.1.3.2 Acyclic nucleoside analogues 
The identification of 5’-O-trityl-thymidine as a moderately active inhibitor of TK-2 (IC50 = 33 
µM), encouraged Pérez-Pérez et al. to replace the sugar moiety by acyclic spacers, as the 
main role of the sugar moiety was suggested to be the correct positioning of the trityl 
substituent and the thymine base.192  This led to from the acyclic 1-[(Z)-4-(triphenylmethoxy)-
2-butenyl]thymine 6.4 (IC50 = 1.5 µM), which, after further optimisation efforts, resulted in 6.5 
with a IC50-value as low as 0.4 µM.193 
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Figure 6.2 Acyclic nucleoside analogues as TK-2 inhibitors. 
 
Enzyme kinetic analysis showed that these acyclic nucleoside derivatives are competing 
with the thymidine substrate for TK-2 binding, but behave as uncompetitive inhibitors with 
respect to ATP, the co-substrate of the TK-2 catalyzed reaction.  ATP-binding to the enzyme 
results in a conformational change.  Only after this conformational change, the inhibitors 
show their affinity for TK-2. 
Consequently, it can be concluded that the acyclic nucleoside derivatives bind to the 
thymidine-binding site of the enzyme, but only after ATP was bound to the enzyme.192 
 
 
6.2 ACTIVITIES OF SYNTHESIZED THYMIDINE DERIVATIVES 
Selected 2’,3’-bicyclic thymidine derivatives, 3’-branched β-thymidine analogues and 5’-
thiourea substituted α-thymidine derivatives were tested for their inhibitory activities against 
TK-1 and TK-2, the thymidine kinases of Herpes simplex virus and Varicella zoster virus, 
and the multifunctional 2’-deoxynucleoside kinase from Drosophilia melanogaster.  The 
activities are shown in Table 6.2. 
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Table 6.2 Kinase activity of synthesized thymidine derivatives (IC50 in µM)   
 TK-1 TK-2 HSV-1 TK VZV TK Dm dNK 
4.3 > 500 408 ± 20 > 500 ≥500  > 500 
4.6 > 500 8.2 ± 2.8 208 ± 31 37 ± 1 78 ± 8 
4.8 > 500 146 ± 66 > 500 237 ± 72 > 500 
4.9 > 500 > 500 ≥500  268 ± 19 > 500 
5.3 > 500 1.2 ± 1.1 400 ± 54 31 ± 5 84 ± 51 
5.4 > 500 3.1 ± 0.3 ≥500  77 ± 51 72 ± 33 
5.5 > 500 1.2 ± 0.1 444 ± 18 37 ± 2 38 ± 4 
5.10 > 500 405 ± 78 > 500 40 ± 3 > 500 
5.14 > 500 57 ± 20 422 ± 6 30 ± 7 258 ± 13 
5.17 > 500 31 ± 8 392 ± 8 45 ± 1 249 ± 24 
5.21 > 500 110 ± 13 > 500 95 ± 66 38 ± 5 
5.23 > 500 38 ± 1 472 ± 40 40 ± 4 266 ± 49 
5.24 > 500 99 ± 36 > 500 150 ± 38 474 ± 17 
5.25 > 500 41 ± 3 365 ± 22 45 ± 6 253 ± 5 
5.31 > 500 ≥500  ≥500  > 500 > 500 
5.32 > 500 176 ± 6 19 ± 0 282 ± 5 242 ± 15 
5.33 > 500 > 500 > 500 330 ± 2 > 500 
5.45 99 ± 51 46 ± 2 34 ± 3 47 ± 3 232 ± 4 
5.46 > 500 466 ± 47 > 500 284 ± 6 > 500 
5.49 > 500 490 ± 14 > 500 304 ± 0 ≥500  
5.53 > 500 > 500 > 500 > 500 > 500 
5.54 > 500 > 500 > 500 > 500 > 500 
 
 
While, with exception of the α-D-thymidine (5.45), the tested compounds were virtually not 
inhibitory active against TK-1, several analogues showed good inhibitory activity against TK-
2, resulting in selective TK-2 inhibition. 
Especially in the series of the 3’-C-branched thiourea-substituted β-thymidine derivatives, 
several analogues (5.3, 5.4 and 5.5) displayed potent and highly selective inhibitory activity 
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for TK-2 versus TK-1.  With IC50-values around 1 µM, these compounds approach the high 
activities found for some acyclic nucleoside analogues. 
Initial kinetic studies indicated that these compounds act as competitive inhibitors of the 
phosphorylation of thymidine to TMP, catalyzed by TK-2. 
In contrast to our observations on TMPKmt, the thiourea-substituted α-D-thymidine 
derivatives showed weaker activities compared to their analogous 3’-branched β-thymidine 
derivatives.   
In the series of 2’,3’-bicyclic derivatives, the five-membered thiocarbamate derivative 4.6 
with an IC50-value of 8.2 µM, appeared to be the most active TK-2 inhibitor. 
 
In order to determine the way of binding of those compounds to the enzyme, mor detailed 
enzyme kinetics will be performed.  These studies, combined with molecular modelling 
studies, should reveal if the identified hits bind the TK-2 enzyme in a similar way as 
TMPKmt. 
 
6.3 CONCLUSION 
With IC50-values in the low micromolar range, 3’-C-branched thiourea-substituted β-D-
thymidine derivatives (e.g. 5.3, 5.4 and 5.5) represent a new class of potent and selective 
TK-2 inhibitors.  This finding opens the way for further structure-based optimisation.  This 
approach may ultimately lead to the discovery of agents that are useful for studying the 
physiological role of the mitochondrial TK-2 enzyme.  Furthermore, new leads may be 
discovered that are capable to suppress the mitochondrial toxicity observed after prolonged 
treatment with nucleoside reverse transcriptase inhibitors, whilst maintaining cytosolic 
production of the active triphosphate metabolites.  
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7 A FLUORESCENT 3’-C-BRANCHED THYMIDINE DERIVED 
COMPOUND AS BUILDING BLOCK IN OLIGONUCLEOTIDE 
SYNTHESIS
 
 
 
7.1 INTRODUCTION 
3’-C-branched thymidine derivatives play a major role throughout this thesis.  A project in 
collaboration with the University of Southern Denmark (SDU, Odense, DK), raised the 
opportunity to use such a compound as modified building block for oligonucleotide synthesis, 
in this way illustrating the broad applicability of modified nucleosides in medicinal chemistry.  
This chapter describes the synthesis of a 3’-C-branched pyrene substituted thymidine 
derivative, its incorporation into different oligonucleotides and a study of the most important 
properties of the obtained oligonucleotides.  
 
7.1.1 Secondary and tertiary structure of DNA and RNA 
Genetic information in cells is carried by 2’-deoxyribonucleic acids (DNA) and ribonucleic 
acids (RNA).194,195 
Two complementary strands of DNA/RNA may self-assemble and coil around a common 
axis, forming a right-handed double stranded helix.  The nucleobases pair with each other 
following the Watson-Crick base pairing rules.  This pairing is determined by the formation of 
hydrogen bonds, i.e. two between adenosine (A) and thymidine or uridine (T/U), and three 
between guanosine (G) and cytidine (C) and is further stabilized by pi-pi stacking between the 
aromatic nucleobases.  The two polymers in the duplex are hybridized with each other in an 
antiparallel orientation of the polymers, bringing the 5’-end of one polymer opposite to the 3’-
end of the other polymer.194,195 
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Figure 7.1 Watson-Crick baseparing between adenine and thymine and between guanine and 
cytosine 
 
The nucleobase moieties are buried in the hydrophobic core of the duplex while the sugar 
moieties and the phosphate backbone are on the exterior of the duplex and therefore more 
exposed to the solvent.  Depending on the duplex type and environmental conditions, 
different helix geometries are observed, i.e. A-, B- or Z-type helices.  Their main differences 
are the amount of base-pairs per helical turn, and the wideness of their major and minor 
groove (see Figure 7.2). 
 
Minor groove
Major groove
 
Figure 7.2 Right-handed double stranded DNA helix196 
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Other structures than duplexes may be formed by nucleic acids, such as DNA triplexes.197  
In the formation of triplexes, two different motifs are known, depending on the base 
composition and the orientation of the third strand, i.e. the triplex forming oligonucleotide 
(TFO). 
A TFO consisting of only pyrimidines may bind to dsDNA (having a polypurine tract) via base 
triplets where a thymine (T) or protonated cytidine (C+) form weak hydrogen bonds with an 
AT- or GC-base-pair, respectively, called Hoogsteen bonds.  In this triplex, the TFO and the 
duplex purine strand are aligned in a parallel orientation.  As the cytidine of the TFO needs 
to be protonated for a strong interaction, these Hoogsteen bonds are clearly pH-dependent. 
In the antiparallel motif, a TFO consisting of only purines binds a dsDNA via reverse 
Hoogsteen bonding (G-GC and A-AT).  In both cases, the TFO is positioned in the major 
groove of the dsDNA.  
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Figure 7.3 Illustration of Hoogsteen and reverse Hoogsteen base triplets. 
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7.1.2 Nucleic acid diagnostics 
During the last decade, the sequencing of the human genome has led to a high need for the 
development of probes, able to detect specific sequences of nucleic acids in cytogenetic 
research and clinical diagnosis.198,199  The demand for such assays stems from a need of 
clinics to reduce time in the detection of diseases.  Two principle approaches to achieve this, 
consist of heterogenous or homogenous assays.  In heterogenous assays, a target is 
immobilized on a surface (e.g. gel or membrane) and a solution of various probes is poured 
over the surface.  Only complementary probes bind to the target, while non-complementary 
probes are removed by washing.  In order to detect hybridization, a reporter group (e.g. 
fluorescent or radioactive molecule, termed label) is attached to the probe, causing a signal 
upon hybridization.  The main disadvantages of these heterogenous assays are the very 
time-consuming and labor-intensive work and above this, the inability to investigate living 
organisms. 
In homogenous assays however, the excess of non-binding probes cannot be washed out, 
thus requiring a strategy in which a change in a spectral property (e.g. intensity, emission 
wavelength) is observed upon hybridization to the nucleic acid target, relative to other non-
binding probes.  The most popular homogeneous assays rely on fluorescence detection. 
 
7.1.2.1 Binding of small molecules to dsDNA 
The simplest design of homogenous fluorescence assays involves the binding of small 
molecules (e.g. ethidium bromide or cyanine dyes) to dsDNA in the minor groove or by 
intercalation.  Upon binding to dsDNA, these dyes become fluorescent.200  A main 
disadvantage of these molecules is the non-specific binding to dsDNA and moreover, they 
cannot detect single stranded probes. 
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Figure 7.4 The simplest homogenous fluorescence assay based on ethidium bromide 
 
7.1.2.2 Intercalating agents 
In order to obtain specific detection of single stranded nucleic acids, reporter groups have 
been connected to oligonucleotides,201,202 using the Watson-Crick mediated hybridisation.  
Intercalating agents have been attached to ON’s, which might lead to increases in 
fluorescence intensity upon hybridization to DNA/RNA complements.  However, very often 
these single stranded probes already show a high level of fluorescence, especially if the 
intercalating dye is attached to the ON via a long linker,203 in this way causing only a weak 
hybridization-induced fluorescence increase. 
 
A similar approach to facilitate detection of nucleic acids in solution is the attachment of a 
fluorophore-group giving a strong fluorescence signal when it is projected away from the 
nucleobase stacking in a nucleic acid duplex.  Partial success was achieved with ONs 
labelled with fluoresceins,204 dansyl205 or pyrenes.206,207  However, instead of hybridisation of 
the probe to its target, other substances might cause quenching of fluorescence.  Moreover, 
the highest decrease that can be obtained is maximum 100%, indicating that hybridization-
induced increase in fluorescence intensity is preferred. 
 
The change in the fluorescence intensity observed is mainly depending on the chemical 
nature of the fluorophore and on the position of the fluorescent label relative to the 
nucleobases before and after hybridization.  Nucleobase moieties in the close proximity of 
N
H2N
NH2
Et
Br-
dsDNA Dye molecule complex 
Ethidium bromide 
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the fluorophore can quench the fluorescence emitted by the fluorescent label.208  Both the 
increase and decrease of fluorescence intensity upon hybridization are based on this feature 
of fluorophores. 
 
 
7.2 TRIPLEX FORMATION OF PYRENE LABELLED PROBES FOR NUCLEIC ACID 
DETECTION IN FLUORESCENCE ASSAYS 
7.2.1 General requirements for nucleic acid detection 
A technique that requires the earlier described typical features is the combinatorial 
oligonucleotide fluorescence in situ hybridisation (COMBO-FISH) introduced by Hausmann 
et al. in 2003.209  COMBO-FISH uses oligonucleotides (ONs) that form triple helices with 
intact duplexes to label chromosomes in a cell nucleus under non-denaturing conditions.  
The triplex formation, upon binding of the triplex forming oligonucleotides (TFOs) to a 
homopurine/homopyrimidine DNA duplex, is highly specific.  It can be used for sequence-
specific recognition of dsDNA, without prior denaturation of it.210  As described above, one of 
the disadvantages is the use of nucleic acid probes possessing a fluorophore, which is not 
sensitive enough to changes in the microenvironment, especially after hybridization of the 
probe to the complement.  This leads to a high background signal and the requirement of 
washing out excess fluorescent probes which makes labelling very difficult.  To overcome 
these problems, novel fluorescent modified nucleic acids are needed.  Among the available 
fluorophores, pyrene and its derivatives are attractive fluorescent dyes due to their inherent 
chemical and photochemical characteristics, rather long fluorescence lifetimes and 
sensitivity to the microenvironment.211  The ideal ON probe should have the fluorophore 
incorporated in the middle of the sequence and display a very low fluorescence signal as 
single stranded ON.  Upon hybridisation a considerable increase of the fluorescence signal 
(positive signal) must indicate binding to the target. 
 
7.2.2 Pyrene in modified nucleoside building blocks 
In previous research, pyrene derivatives have been incorporated at different positions of the 
modified nucleoside building blocks.  The 2’-N-position of 2’-amino-DNA212 and –LNA213 or 
2’-O-position of RNA214 were substituted with pyrene via a short tether.  In both cases, 
increase of fluorescence upon hybridisation to RNA is strong and is much weaker in the 
case of binding to DNA.   
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Figure 7.5 Structures of 2’-amino DNA and LNA 
 
Incorporation of pyrene at an internal or 5’-terminal phosphorus via a relatively long linker (> 
4 carbons) resulted in considerable quenching of fluorescence upon hybridisation due to 
intercalation of pyrene,215 while incorporation at the 3’- or 5’-end via a relatively short linker 
(1 or 2 atoms) gave a slight increase of fluorescence.216  Bryld et al.217 describe the 
synthesis and evaluation of 4’-pyrene-substituted DNA via a piperazinomethyl linker.  They 
could not observe any difference in fluorescence upon hybridisation.  Finally the pyrene unit 
has been coupled to sugar moieties to intercalate as bulge in the middle of the TFO.218, 219  
None of the described probes are known to give increased fluorescence intensities upon 
triplex formation in which the single-stranded triplex-forming oligonucleotide (TFO) binds to 
dsDNA through specific major groove interactions.   
Since the 3’-position is needed as a part of the phosphate-backbone, this position has not 
been substituted with pyrene moieties, except at a 3’-end monomer. 
 
7.2.3 Objectives 
Obika et al.220  demonstrated that several 2’-5’-linkages in a 3’-5’ TFO strand led to 
stabilisation of triplexes.  As this change in the phosphate-backbone opens possibilities for 
the introduction of a pyrene unit at the 3’-position, we decided to synthesize a modified 
nucleoside with the fluorophore attached to the 3’-position via a short linker. 
A novel fluorescent pyrene-containing nucleoside was prepared by click chemistry between 
1-ethynylpyrene and 3’-azidomethyl-3’-deoxyribothymidine and incorporated into several 
ONs.   Thermal stabilities and fluorescence spectra of the different probes and their 
corresponding duplexes and triplexes with complementary ssDNA/RNA and dsDNA’s were 
examined.   Modelling was used as a tool to explain the results of thermal stability studies 
and the fluorescence properties observed. 
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7.2.4 Chemistry 
The synthesis of phosphoramidite 7.3 (Scheme 7.1) started from compound 4.26, which was 
obtained in 11 steps from 1,2-O-isopropylidine-α-D-xylofuranose with an overall yield of 
17%.221  The formation of the 1,4-triazol was performed in the microwave cavity at 125 °C 
during 15 minutes with Cu (I) as a catalyst in 79% yield. 5’-O-Dimethoxytrityl-protection 
followed by phosphytilation at the 2’-position were performed under standard conditions in 
59% yield over two steps.   
DNA-synthesis of ONs containing compound 7.3 was performed on a 0.2 µmol scale under 
standard conditions except for an increased coupling time (10 min) and an extended 
deprotection step (100 sec), using 4,5-dicyanoimidazole as an activator.  This resulted in a 
coupling efficiency of 98%.  The obtained ONs were purified by reverse-phase HPLC, their 
composition was verified by MALDI-TOF (Table S1) and the purity was found to be over 82% 
by ion-exchange HPLC. 
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Scheme 7.1, Reagents and conditions: a) 1-ethynylpyrene, CuSO4, ascorbic acid, DMF/H2O 19:1, 
125 °C, 15 min, microwave, 79%; b) DMT-Cl, pyridine, rt, 16h, 91%; c) NC(CH2)2OP(NPri2)2, 
diisopropylammonium tetrazolide, CH2Cl2, rt, 16h, 65%. 
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7.2.5 Homopyrimidine oligonucleotides 
7.2.5.1 Thermal stability 
The thermal stability of triplexes and duplexes (DNA/DNA and DNA/RNA) using synthesized 
oligonucleotides was determined by thermal denaturation studies.  The melting temperatures 
(Tm, °C) determined as the first derivatives of the melting curves at 260 nm are listed in 
Table 7.1, 7.3 and 7.4. 
For homopyrimidine sequences, pH-dependent Hoogsteen-type base-pairing was studied, 
by determining the thermal stability of parallel triplexes toward duplex D1 and of parallel 
duplexes toward ON15 (Table 7.1).  Tm values of Watson-Crick type antiparallel duplexes 
formed by ON1-10 and ON16 are also shown.  Since the latter type of duplexes can also be 
studied by mixed pyrimidine/purine sequences, mixed 9-mer sequences were used for 
hybridization with ssDNA and ssRNA (Table 7.4). 
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a
 C= 1.5 µM of ON1-10 and 1.0 µM of each strand of dsDNA (D1) in 20 mM sodium cacodylate, 
100 mM NaCl, 10 mM MgCl2, pH 5.0, 6.0 and 7.2; duplex Tm = 56.5 °C (pH 5.0), 58.5 (pH 6.0) 
and 57.0 (pH 7.2); b C= 1.0 µM of each strand in 20 mM sodium cacodylate, 100 mM NaCl, 10 
mM MgCl2, pH 5.0, 6.0 and 7.2; c Third strand and duplex melting overlaid. Tm was determined at 
350 nm; d Third strand and duplex melting overlaid; e n.d. not determined; p = TINA, TL = thymin-
1-yl α-L-LNA monomer, CL = 5-methylcytosin-1-yl α-L-LNA monomer. Structure of monomer X is 
shown in Scheme 1 as the 5’-DMT-2’-phosphoramidite-derivative 4, structures of p and α-L-LNA 
are shown in Figure 7.6. 
OO
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Figure 7.6 Structures of the incorporated triplex-stabilisators 
Table 7.1 Tm [°C] Data for Duplex Melting of ON1-10 and D1, ON15 and ON16, Taken from 
UV Melting Curves (λ = 260 nm)a 
  
Triplexa 
5’ 
GACGGGGAAAGAAAA
AA 3’ 
CTGCCCCTTTCTTTTTT 
(D1) 
Parallel duplexb 
5’ 
GACGGGGAAAGAAAA
AA 
(ON15) 
Antiparallel duplexb 
3’ GGGGAAAGAAAAAA 
(ON16) 
pH  5.0 6.0 7.2 5.0 6.0 7.2 5.0 6.0 7.2 
ON1 3' TTT TTT CTT TCC CC 55.0
d
 
28.0 <5.0 29.5 19.5 n.d. 47.5 48.5 47.0 
ON2 3' TTT TTT CTX TCC CC 55.0
 c
 
25.0 <5.0 20.0 <5.0 n.d. 45.0 47.5 45.5 
ON3 3' TTT TTT CXX TCC CC 33.0 19.5 n.d.
e
 
32.0 21.5 n.d. 36.0 38.0 n.d. 
ON4 3' TTT TTT CXX XCC CC 32.0 < 5.0 n.d. 31.5 24.0 n.d. 36.5 38.5 n.d. 
ON5 3' TTT TXT CTT TCC CC 55.5
 c
 
16.0 n.d. 23.5 <5.0 n.d. 39.5 43.0 n.d. 
ON6 3' TTT TTT CXT XCC CC 25.5 <5.0 n.d. 21.5 <5.0 n.d. 31.5 37.5 n.d. 
ON7 3' TTT TXT CTX TCC CC 27.0 <5.0 n.d. 22.5 <5.0 n.d. 34.5 39.5 n.d. 
ON8 3' TTT TTT CTpX TCC CC 54.0
 c
 
20.5 n.d. 27.5 16.5 n.d. 43.0 47.5 n.d. 
ON9 3' TTT TTT CTXp TCC CC 53.0
 
c
 
22.5 n.d. 29.0 20.0 n.d. 44.0 46.5 n.d. 
ON10 3' TT
LT TTLT CLTX 
TCLC CLC 65.5
 
d
 49.5c 35.5c 53.0 43.5 38.5 58.5 59.0 58.5 
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Obika et al.220 described the stabilising effect of the discontinuous replacement of 3’,5’-
phosphodiester linkages in TFOs by 2’,5’-linkages.  As demonstrated by the Tm values for 
the ON2/D1 and ON5/D1 triplexes at pH 6.0, insertion of the fluorophore positioned at 3’-
carbon via the triazole linker tends to destabilize parallel triplexes.  Introduction of a second 
2’-5’ thymidine with a pyrene residue led to further destabilization of the parallel triplexes 
(ON3, ON6, ON7 toward D1).  Destabilisation was found to be higher for triplexes formed 
with ON6 and ON7 having one or three nucleosides between two modified thymidine 
building blocks than observed for ON3, with two adjacent pyrene-containing thymidines.  
Moreover, it is interesting to mention that at pH 5.0 the Tm-value for the triplex with ON4, 
possessing three modified building blocks in the row, was higher than those for ON6 and 
ON7.  However, all these values were lower than the Tm-value for the unmodified triplex.  
Such behaviour can be explained by non-interrupted neighbouring 2’-5’-linkages in ON4 
compared to the separate 2’-5’-linkages in ON6 and ON7.  This can also be a reason for the 
surprising stabilization of parallel duplexes observed for ON3 and ON4 in comparison with 
the wild-type triplex ON1/ON15 at pH 5.0 and 6.0 (Table 7.1).  This is an interesting 
observation because both parallel triplexes and parallel duplexes are formed according to 
Hoogsteen base-pairing.  However, a duplex can easier accommodate repetitive insertions 
of 2’-5’ thymidine linkages with pyrene in the middle of one of the strands as it is a more 
flexible structure than a triplex.  Unfortunately, this was not the case with Watson-Crick type 
duplexes, where a drop in thermal stability was detected for ON2-ON7 toward ON16 as 
compared to ON1/ON16 at pH 5.0 and 6.0. 
 
7.2.5.2 Fluorescence 
A. Results 
The presence of the pyrene residue in ONs resulted in the formation of an additional band in 
the UV-spectra with λmax of 350 nm.  The single stranded probes containing a single 
incorporation of the monomer X exhibited a fluorescence emission with λmax ≈ 386 (band I) 
and 402 nm (band III) upon excitation at 350 nm.  This emission appears at a higher 
wavelength than the typical pyrene monomer emission with λmax ≈ 378 (band I) and 391 nm 
(band III), which can be explained by the conjugated triazole ring in the monomer X.  To our 
surprise a very low intensity of fluorescence was observed for single-stranded ONs.  
Strikingly, the formation of parallel triplexes caused a huge increase of intensity.  To study 
the fluorescence properties in more detail, we decided to determine fluorescence quantum 
yield (ΦF) for ssONs and corresponding complexes with complementary strands.  ΦF is 
defined as the ratio of the number of photons emitted by fluorescence at a certain 
wavelength to the number of photons absorbed at this wavelength.  In our study ΦF was 
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determined in the thermal denaturation buffer at 10 °C using equimolar quantities of each 
strand (1.0 µM) upon excitation at 350 nm relative to anthracene (ΦF = 0.36) and 9,10-
diphenylanthracene (ΦF =0.95) in cyclohexane222 following standard procedures (Table 
7.2).223,224 
 
a C = 1.0 µM of each strand in 20 mM sodium cacodylate, 100 mM NaCl, 10 mM MgCl2, pH 5.0, 6.0 
and 7.2; b n.d. not determined because of low thermal stability of triplexes; c exciplex band at 460 nm 
was observed. 
 
 
B. Discussion 
The fluorescence emitted by single stranded ON2 and ON5-ON7 was strongly quenched 
with ΦF in a range from 0.001 to 0.004, which was most probably a result of communication 
with neighbouring bases including electron transfer.225  Upon binding of these TFOs to the 
dsDNA (D1), an increase in fluorescence intensity was detected at pH 5.0.  As parallel 
triplexes are pH sensitive and more thermally stable complexes are formed at acidic 
conditions due to required protonation of cytosine, fluorescence quantum yields were higher 
at pH 5.0 than at pH 6.0.  For example, ΦF for ON2/D1 was almost three times higher at pH 
5.0 (0.179) than at pH 6.0 (0.061).  A correlation between thermal stability of parallel 
triplexes and fluorescence quantum yields can also be illustrated by comparison of ON2 and 
ON5.  Thus, Tm for ON5/D1 at pH 6.0 was 9.0 °C lower than the Tm-value for ON2/D1, which 
Table 7.2 Quantum Yields at λ = 350 nm for Single-Stranded Probes ON2, ON5-ON7 and ON10, and 
the Corresponding Parallel Triplexes, Parallel and Antiparallel Duplexes in Aerated Thermal 
Denaturation Buffer at 10 °C. 
  
SS strand Triplexa 
5’ GAC GGG GAA AGA 
AAA AA 
3’ CTG CCC CTT TCT 
TTT TT 
(D1) 
Parallel duplexa 
5’ GAC GGG GAA AGA 
AAA AA 
(ON 15) 
Antiparallel duplexa 
3’ GGG GAA AGA AAA 
AA 
(ON 16) 
pH  5.0 6.0 7.2 5.0 6.0 7.2 5.0 6.0 7.2 5.0 6.0 7.2 
ON 2 3' TTT TTT CTX TCC CC 0.001 0.004 n.d.
b
 0.179 0.061 n.d. 0.001 n.d. n.d. 0.032 0.036 n.d. 
ON 5 3' TTT TXT CTT TCC CC 0.001 0.003 n.d. 0.138 0.023 n.d. 0.005 n.d. n.d. 0.035 0.039 n.d. 
ON 6 3' TTT TTT CXT XCC CC 0.001 0.003 n.d. 0.036 n.d. n.d. 0.009 n.d. n.d. 0.005 0.008 n.d. 
ON 7 3' TTT TXT CTX TCC CC 0.002 0.003 n.d. 0.037 n.d. n.d. 0.009 n.d. n.d. 0.037 0.028 n.d. 
ON 10 3' TT
LT TTLT 
CLTX TCLC CLC 0.001 0.003 0.05 0.179 0.158 0.073
c
 0.008 0.032 0.081c 0.046 0.081 0.038c 
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resulted in a lower ΦF value (0.023 instead of 0.061).  Surprisingly, a large difference was 
observed in fluorescence quantum yields between parallel triplexes, parallel and antiparallel 
duplexes formed by the same ON.  Almost complete quenching of fluorescence was 
detected for all parallel duplexes, even at pH 5.0, when complexes were most stable.  
Despite the higher thermal stability, a lower ΦF value for antiparallel duplex ON2/ON16 was 
observed in comparison with triplex ON2/D1 at pH 6.0.  The contrary situation was observed 
for a different TFO with the single insertion of X (ON5) at the same pH, i.e. ΦF(ON5/ON16) > 
ΦF(ON5/D1), which was an outcome of low triplex thermal stability (Tm(ON5/D1) = 16.0 °C). With 
lowering the pH to 5.0, fluorescence intensities of triplexes were much higher than those for 
antiparallel duplexes (see ON2, ON5 and ON6 toward D1, Table 7.2).  All measurements of 
ΦF were performed at 10 °C. Because of partial melting of parallel triplexes, lower ΦF values 
were detected at 20 °C (results are not shown).  To ensure that these effects are not a 
consequence of interactions of the pyrene residue in the structure X with metal ions 
presented in cacodylate buffer solution, we performed measurements in medium salt sodium 
phosphate buffer at pH 5.0 and got the same tendency as described above in fluorescence 
spectra upon binding of ON2 to D1, ON15 and ON16 (results are not shown). 
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Figure 7.7. Steady-state fluorescence emission spectra of ON2 and the corresponding complexes 
with D1, ON15 and ON16 upon excitation at 350 nm.  Spectra of 1.0 µM solutions were recorded in 
thermal denaturation buffer at 10 °C at pH 5.0, emission slit 0.0 nm (Figure 7.7a) and pH 6.0, 
emission slit 2.5 nm (Figure 7.7b). 
 
C. The applicability of the modified oligonucleotides as nucleic acid diagnostics 
So far, the discrimination in fluorescence properties upon binding of ONs possessing pyrene 
residue to dsDNA and ssDNAs has never been reported.  The strong increase of 
fluorescence intensity upon binding to dsDNA is a very important feature and an advantage 
of the described probe, as it opens novel perspectives for the detection of nucleic acids 
using triplex formation.  Earlier described attempts were devoted to the development of 
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probes based on the principle of molecular beacons, i.e. a fluorophore and a quencher were 
placed separately at the 3’ and 5’-ends of the TFO, which was extended with a number of 
complementary bases in order to make a hairpin, thus placing a fluorophore and a quencher 
in a close proximity.226  No signal was observed for the probe alone, but the presence of 
dsDNA resulted in a probe hybridization followed by increase in fluorescence intensity.  
However, it is known that molecular beacons can sometimes open up in cell media after 
entering the cell in the absence of complementary targets, bringing false positives in the 
detection assays.227  Existing nucleic acids staining dyes, based on small molecules, like 
TOTO (Figure 7.8) and others,228 which are used nowadays for labelling of dsDNA, have two 
main disadvantages.  First, such staining dyes bind to dsDNA unspecifically or have 
preferences only to certain regions, which usually are repetitive in the genome.229  Second, 
these dyes have a very low affinity to triplexes as a consequence of not-fitting shape of 
molecules to the base triplet and due to electrostatic repulsion between C+•G-C triad and 
positively charged structure of dyes.230  For this reason, a combination of TFO and a free 
staining dye cannot be used for a sequence selective labelling of dsDNA.  Therefore, nucleic 
acids probes having one or several modified nucleotides with a fluorophore, which give a 
positive signal upon binding to complementary strands, are of high importance for any 
detection technique. 
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Figure 7.8 TOTO, a currently used quinolinium bichromophore nucleic acid stain 
 
The main drawback of the monomer X is its destabilizing effect upon triplex formation.  For 
this reason, attempts were made to develop a TFO, which can form stable triplexes at 
realistic cell pH’s 6.0 and 7.2, and at the same time shows the same favourable fluorescence 
intensity increase observed for the above described ONs. 
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C.1 The incorporation of TINA 
In ON8 and ON9, we used bulged insertions of TINA monomer (Figure 7.6), known to 
stabilize parallel triplexes with ∆Tm up to 19.0 °C for a single insertion of p.231  A 
disadvantage of TINA monomer in this particular case is the small difference between the 
excitation wavelengths for X and p, 350 and 373 nm respectively, meaning that irradiation of 
only one of these monomers is hardly achieved.  We assumed that by placing p as left or 
right bulged neighbour to the modification X in ON2, strong monomer fluorescence coming 
from TINA in a single-stranded state could be transferred to an excimer band appearing at 
longer wavelengths by interaction of two pyrenes.  In contrast to these considerations, 
further destabilization of parallel triplexes was observed (Table 1, ON8 and ON9 toward D1 
in comparison with ON2/D1 at pH 6.0).  Moreover, high monomer fluorescence was detected 
for ssON8 and ssON9 while only very small excimer band could be observed at 480 nm 
upon excitation at 350 nm.  This hampered the detection of binding of these probes to 
dsDNA by fluorescence.  However, these results do not exclude a use of TINA monomers in 
a combination with the monomer X in the future.  For this purpose, fluorescently orthogonal 
intercalators to pyrene X, like naphthalene derivative,231 should be used in TINA structure 
and could be placed three or four bases away from insertion of X in the TFO. 
 
 
C.2 The incorporation of α-L-LNA 
An alternative to intercalating nucleic acids is sugar modified nucleotides, which are 
fluorescently silent and give thermal stabilization upon insertion into TFOs.  We decided to 
use α-L-LNA (Figure 7.6), which stabilizes triplexes up to 5 °C per insertion.  As a general 
rule, every third or fourth nucleotide in the TFO should be substituted by α-L-LNA monomer 
to achieve high Tm values at neutral pH.232  A use of 5-methyl-cytosine derivative of α-L-LNA 
is also an advantage for parallel triplex formation, because 5-methyl-cytosine is easier 
protonated than cytosine.233 In the sequence ON10, five α-L-LNA nucleotides were 
incorporated leading to increased thermal stability in all cases (Table 7.1).  Thus, at pH 6.0 a 
triplex stabilisation of 5 °C per insertion of α-L-LNA was observed and at pH 7.2, triplex 
ON10/D1 melted at 35.5 °C.  Parallel and antiparallel duplexes formed by ON10 with ON15 
and ON16, respectively, were more thermally stable than the wild-type duplexes of ON1. 
Indeed at pH 7.2, the parallel duplex ON10/ON15 showed higher Tm than the corresponding 
triplex ON10/D1 with ∆Tm value of +3.0 ºC,  which questions the formation of the triplex. In 
order to prove triplex formation of ON10 with duplex D1 we recorded CD spectra at different 
pH (Figure 7.9).  The negative band at ~212 nm is considered to be a sign for a parallel 
homopyrimidine DNA triplex234 and it has also been observed for triplexes formed by α-L-
LNA modified TFOs.235  As can be seen from Figure 7.9, a negative band at ~212 nm was 
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presented in CD spectra at all pH, which thereby confirmed the formation of a triple helix for 
ON10. Melting of the triplexes at pH 7.2 and 6.0 was clearly seen on CD spectra recorded at 
40 and 55 °C, respectively. 
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Figure 7.9 CD spectra of 1.0 µM solutions of ON10/D1 were recorded in thermal denaturation buffer 
at 10 ºC at pH 5.0, pH 6.0 and pH 7.2. 
 
Concerning the fluorescence properties of ON10, a similar increase in fluorescence intensity 
was observed upon triplex formation at pH 5.0 and 6.0 caused by monomer X (Figure 7.10).  
Interestingly, triplexes formed by ON2 and ON10 at pH 5.0 showed the same fluorescence 
quantum yield (0.179) (Table 7.2).  A considerably lower decrease of ΦF was detected for 
ON10/D1 than for ON2/D1 upon changing pH from 5.0 to 6.0, which is clearly a 
consequence of higher triplex thermal stability for ON10.  Importantly, the fluorescence 
intensity for antiparallel duplex ON10/ON16 was lower than that for the corresponding triplex 
at pH 5.0 and 6.0, meaning that fluorescent discrimination caused by X in ON2 between 
triplex and antiparallel duplex remained after substitutions of some natural bases in TFO by 
α-L-LNA. 
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Figure 7.10 Steady-state fluorescence of ON10 and the corresponding complexes with D1, ON15 
and ON16 upon excitation at 350 nm. Spectra of 1.0 µM ON solutions were recorded in thermal 
denaturation buffer at 10 °C at pH 5.0 (Figure 7.10a) and pH 6.0 (Figure 7.10b). 
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At pH 7.2, parallel duplex and triplex with ON10 were less stable due to the deprotonation of 
cytosine (Table 7.1).  Under these conditions ON10 formed a triplex with Tm of 35.5 °C.  
However, deprotonation of cytosine had a large influence on the fluorescence properties of 
ON10 and its complexes at pH 7.2.  In the fluorescence spectra of ssON10 we observed a 
change in the ratio of band III/I (Figure 7.10), which was reversed in comparison with ssON2 
(Figure 7.7).  Moreover, fluorescence intensity of the probe alone was slightly increased 
upon changing the pH from 5.0 to 6.0 and then to 7.0 (ssON10, Figure 7.10 and Figure 
7.11).  It is known that the ratio of band III/I is affected by local environmental polarity236 and 
changes in fluorescence observed were associated with changing the pH and deprotonation 
of cytosine. Upon binding of ON10 to complementary dsDNA and ssDNAs, a new broad 
emission appeared at longer wavelength (460 nm, Figure 7.10).  However, it differed from an 
excimer emission band (480-500 nm), which usually is caused by interactions of at least two 
pyrene units positioned in a closed proximity. Similar results have been observed by 
Yamana et al.237 upon duplex formation of pyrene labeled oligonucleotides. The increased 
intensity ratio of band III/I was associated with a decrease in local environmental polarity. In 
our case the pyrene residue was most probably transferred into the more hydrophobic base-
pair pocket, which led to a new broad emission band around 460 nm. This emission can be 
ascribed to the exciplex of the pyrene and an adjacent base. This effect was observed upon 
triplex formation, but was even more obvious in the fluorescence spectrum for the parallel 
duplex at pH 7.2 (Figure 7.11). The latter, as we have already mentioned above, is less rigid 
than the triplex thus providing extra space for interaction of pyrene with neighboring bases. 
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Figure 7.11 Steady-state fluorescence of ssON10, corresponding triplexes with D1, and parallel and 
antiparallel duplexes with ON15 and ON16, respectively. Spectra were recorded in thermal 
denaturation buffer at pH 7.2 at 10 °C, using an excitation wavelength of 350 nm. 
 
The melting temperatures of the single mismatched triplexes formed by ON2 and ON10 with 
duplexes D2-D4 were determined at pH 5.0 and 6.0 and are shown in Table 7.3.  As 
expected, the mismatched triplexes formed with ON2 showed much lower thermal stability 
compared to matched triplexes (∆Tm > - 25.0 °C) and no changes in fluorescent spectra of 
ssON2 were observed upon its hybridization to mismatched dsDNAs.  The presence of α-L-
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LNA in ON10 resulted in formation of considerably more stable mismatched triplexes in 
comparison with ON2.  Thus at pH 5.0 the difference in Tm values for matched and 
mismatched triplexes was not exceeding 7.0 °C showing higher drop in Tm toward duplex 
D3.  Nevertheless, formation of mismatched triplexes with ON10 was proved by the 
presences of a negative band at ~212 nm in theirs CD spectra at 10 °and Tm-values 
obtained by UV at 260 nm were verified by monitoring changes in θ at 210 nm in CD against 
increased temperature (Table 3 and Supporting Information).  Interestingly that at pH 5.0 
despite of the high thermal stability of triplexes ON10/D2-D4, where thymidine X was not 
matching with bases of duplexes, we observed a ~20 fold decrease in fluorescence intensity 
for all three mismatched triplexes in comparison with the perfectly matched ON10/D1 (Figure 
6).  A high level of quenching in fluorescence and high thermal stability of mismatched 
triplexes with ON10 can be a result of the interaction of pyrene moiety with adjacent 
nucleobases which can be realized if pyrene moved from outside the triplex into the triplex 
interior.  The latter is possible because of imperfect base-pairing and consequent repulsion 
of thymine at mismatched positions making a room for pyrene intercalation.  The excellent 
discrimination in fluorescence for ON2 and ON10 observed between matched and 
mismatched triplexes can be used for detection of dsDNA via formation of perfectly matched 
parallel triplexes.  
 
 
For Tm measurement: C = 1.5 µM of ON2 or ON10 and 1.0 µM of each strand of mismatched 
dsDNA in 20 mM sodium cacodylate, 100 mM NaCl, 10 mM MgCl2, pH 5.0 and 6.0; for 
quantum yield measurement: C = 1.0 µM of each strand in the same buffer at pH 5.0; b Third 
strand and duplex melting overlaid. Tm was determined at 350 nm; c Values in brackets are 
determined with CD Tm measurements; d n.p. not possible to determine. 
Table 7.3 Tm [°C] Data for Mismatched Parallel Triplex of ON2, Taken from UV Melting 
Curves (λ= 260 nm)a and Fluorescence Quantum Yields at 350 nm (in brackets). 
 
3' TTT TTT CTX TCC CC (ON2) 3' TTLT TTLT CLTX TCLC CLC (ON10) 
 pH = 5.0 pH = 6.0 pH = 5.0 pH = 6.0 
3’ AAA AAA GAC AGG GGC AG 
5’ TTT TTT CTG TCC CCG TC 
28.0 (0.001) <5.0 62.0b [62.0]c 41.5b [42.0] 
3’ AAA AAA GAG AGG GGC AG 
5’ TTT TTT CTC TCC CCG TC 
21.0 (0.001) <5.0 58.5b [59.0] 34.5b [35.0] 
3’ AAA AAA GAT AGG GGC AG 
5’ TTT TTT CTA TCC CCG TC 
29.5 (0.001) <5.0 61.0b [n.p]d 40.5b [n.p] 
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Figure 7.12. Steady-state fluorescence of ON10 and the corresponding complexes with D1-D4 upon 
excitation at 350 nm. Spectra of 1.0 µM dsDNA with 1.5 µM of ON10 were recorded in thermal 
denaturation buffer at 10 °C at pH 5.0, emission slit 0.0 nm. 
 
Although the formation of the exciplex band was unexpected at pH 7.2 for complexes of 
ON10, it opens new possibilities for the use of this probe for diagnostic purposes. 
Fluorescence intensity upon hybridization to dsDNA at pH 7.2 was much lower (ca. 100 
arb.units, Figure 7.10) than at pH 6.0 (750 arb. units, Figure 7.7).  Such pH-depending 
fluorescence signal can be useful for dsDNA detection in cells with lower pH values.  Tumor 
cells have a natural tendency to overproduce acids, resulting in more acidic pH values in the 
tumor microenvironment, which can be down to 6.4 for human cancers, and down to 6.12 for 
mouse cancers, depending on the tumor type.238  Therefore, the described probe is an ideal 
platform to develop sequence-specific detectors for tumor cells. Moreover, as COMBO-FISH 
experiments are so far performed under conditions with pH-values around 6.0,209 probes 
based on the design of ON10 are suitable for such experiments. 
 
7.2.6  Mixed purine-pyrimidine oligonucleotides 
7.2.6.1 Thermal stability 
To study the influence of the monomer X on Watson–Crick base-pairing, a mixed sequence 
was synthesized with one, two or three neighbouring modified nucleotides incorporated.  
Table 7.4 shows the thermal stabilities of ON11-14 upon hybridization to ssDNA/ssRNA and 
the fluorescence quantum yields for ON12 and its complexes determined at 350 nm.  
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Table 7.4 Tm [°C] Data for Duplex Melting of ON11-14 and DNA/RNA Complements, 
taken from UV Melting Curves (λ= 260 nm)a and Fluorescence Quantum Yields for 
ON12 determined (in brackets). 
  
5' GTG AAA TGC 
DNA (ON17) 
5' GUG AAA UGC 
RNA (ON18) 
ON11 3' CAC TTT ACG 36.0 34.0 
ON12 3' CAC TXT ACG (0.02)b 20.0 (0.04) 19.0 (0.07) 
ON13 3' CAC TXX ACG < 5.0 13.5 
ON14 3' CAC XXX ACG < 5.0 < 5.0 
aThermal denaturation temperatures measured as the maximum of the first derivative of 
the melting curve (A260 vs temperature) recorded in high salt buffer (1400 mM NaCl, 20 
mM sodium phosphate, pH 7.0), using 1.0 µM concentrations of each complementary 
strands; b Fluorescence quantum yields were measured in the aerated thermal 
denaturation buffer at 10 °C, using 1.0 µM concentrations of each complementary 
strands at excitation wavelength of 350 nm. 
 
Earlier reports for 2’,5’-linked oligoribonucleotides showed a decrease of 1.3 °C for each 
2’,5’-linkage in ON in their thermal stability toward ssRNA and a much higher decrease 
toward ssDNA.239  As no transition in melting curves was observed in a medium salt 
phosphate buffer for duplexes with ON12-14, we used a high salt concentration for this 
study.  When adding a pyrene unit to the 3’-position of 2’,5’-linkages (structure X), a 
considerable decrease in antiparallel duplex thermal stability, more than 15 °C per 
modification, was observed in comparison with the wild-type duplex (ON11/ON17).  This 
indicates that pyrene could not stabilise duplexes by intercalation, but most probably was 
directed towards the outside of the duplex.   
 
7.2.6.2 Fluorescence 
The inability of pyrene to intercalate can also be seen in the steady-state fluorescence 
emission spectra of ON12 and the corresponding duplexes with ssDNA and ssRNA (Figure 
7.13).  Interesting to mention is that pyrene fluorescence was not quenched in ssON12 as 
much as we have already seen for single-stranded homopyrimidine sequences in Table 7.2.  
This can be a result of the presence of purines in the same sequence for ON12.  Upon 
hybridisation of ON12 with ssDNA a two-fold increase in fluorescence intensity was 
observed.  Binding to complementary ssRNA resulted in an approximately 3.5-fold increase 
in fluorescence intensity.  Similar results have previously been described for 2’-pyrene-
modified oligoribonucleotides.  The 2’-N-position of 2’-amino-DNA212 and –LNA213 or the 2’-
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O-position of RNA214 have been substituted with pyrene via a short tether.  In these cases 
the increase of fluorescence upon hybridisation to ssRNA was considerably stronger than in 
the case for binding to ssDNA. 
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Figure 7.13 Steady-state fluorescence emission spectra of ON12 and the corresponding duplexes 
with complementary ssDNA/RNA. Spectra were recorded in the thermal denaturation buffer at 10 °C 
using an excitation wavelength of 350 nm and an excitation slit of 4.0 nm and emission slit of 2.5 nm. 
 
This short study about the influence of X on Watson-Crick base pairing shows that a much 
larger decrease in stability is obtained, while a smaller increase in fluorescence signal upon 
binding can be observed.  Duplexes with RNA show a higher increase compared to duplexes 
with DNA, which is similar to previous reported analogue studies. 
 
7.2.7  Modelling 
Molecular modelling studies were performed on the complexation of a truncated dsDNA with 
ON2 (3’-TTC TXT CCC-5’) in order to visualize different conformations of the pyrene 
modified 2’,5’-thymidine (Structure X).  The parallel triplex was analysed with pyrene located 
either inside or outside the triplex.  As can be seen from comparing Figure 7.14a and 7.14b 
a larger distortion of the triplex structure is observed when the pyrene was intercalating with 
bases of the triplex (Figure 7.14a).  In agreement with our observation of very strong 
fluorescence signal for ON2/D1, Figure 7.14 b and 7.14c show the projected conformation of 
the pyrene modified 2’,5’-thymidine.  Despite of such a large distortion of the triplex structure 
upon intercalation of pyrene, this was most probably the case for triplex ON10/D1 at pH 7.2 
when exciplex band was observed in the fluorescence spectrum. 
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a)  b) 
 
 
 
c)  d) 
 
 
 
 e)  f) 
 
 
  
Figure 7.14 Representative truncated structures obtained by molecular modelling studies of the 
triplex, ssDNA and dsDNA. The modified nucleotide is shown in green and the TFO is shown in 
orange. a) Triplex formed by ON2 with dsDNA with the pyrene moiety inside the triplex. b), c) The 
triplex formed by ON2 with dsDNA with the pyrene moiety outside of the triplex, respectively sideview 
and topview. d) ssDNA, ON2, with the pyrene moiety placed between neighbouring nucleobases. e), 
f) The dsDNA formed by ON12 with complementary DNA, with the pyrene moiety placed respectively 
inside and outside the duplex. 
 
 
To explain the practically total quenching of fluorescence for ssONs possessing X, we 
performed molecular modelling analysis of the truncated single stranded ON2 (3’-TTC TXT 
CCC-5’).  Studies showed that rotation of the modified nucleotide, with the pyrene moiety 
placed between neighbouring nucleobases, resulted in stacking of pyrene with these 
nucleobases, giving a fluorescently silent oligonucleotide (Figure 7.14d).  Upon hybridization 
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to complementary dsDNA, pyrene would be forced outside the triplex, thereby explaining the 
increase in the fluorescence signal observed for complexes of ON2, ON5 and ON10 with 
matched duplexes. 
 
Modelling studies for the duplex formed between ON12 and complementary ssDNA showed 
serious distortions of the phosphate backbone and the Watson–Crick base-pairs upon 
positioning of the pyrene moiety between bases of dsDNA (Figure 7.14e).  The intercalation 
of pyrene led to a more stable duplex structure with an increase in stability of ~1966 kJ/mol 
compared to the duplex with the pyrene moiety placed outside the duplex (Figure 7.14f).  
However, the conformation with pyrene intercalated in the duplex can be rejected based on 
our experimental results. The formation of a less stable duplex, compared to an unmodified 
duplex and an increase of the fluorescence signal upon hybridization of ON12, indicates, in 
contradiction to what the modelling studies show, that the conformation of the duplex is one 
where the pyrene moiety is directed towards the outside of the duplex. 
 
7.2.8  Conclusion 
A novel 3’- substituted ribothymidine analogue possessing a pyrene moiety coupled to the 
sugar part via a triazolyl methyl linker, compound X, was synthesized and incorporated as a 
2’,5’-linker into different ONs.  Thermal stability studies showed that single incorporation of X 
in the middle of ONs instead of thymidine resulted in lowering Tm values for either Watson–
Crick or Hoogsteen type complexes.  While the single stranded homopyrimidine probes were 
fluorescently silent with the quantum yield (ΦF) of 0.001-0.004, formation of parallel triplexes 
with the complementary dsDNA led to the very strong increase of the fluorescence signal 
with the value of ΦF in a range from 0.023 to 0.179 depending on the site of insertion and 
thermal stability.  Lowering the pH resulted in higher thermal stability of Hoogsteen-type 
triplexes and higher fluorescence quantum yields.  Antiparallel duplexes of the same probes 
had lower values of ΦF than parallel triplexes under the similar conditions.  Molecular 
modelling of triplexes showed that the pyrene-containing residue at the 3’-position of 2’,5’-
ribothymidine prefers to be positioned outside the triplex since it caused minimal distortion of 
the complex. 
To compensate the low thermal stability induced by X, known triplex stabilizators were 
additionally incorporated into ONs.  In a first attempt phenylethynylpyrene glycerol (TINA) 
was incorporated as a neighbouring bulge to the modification X.  However, neither 
stabilisation nor the previously detected fluorescence enhancement was observed in 
triplexes formed by these ONs.  For this reason α-L-LNA, a non-fluorescent nucleotide, 
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monomer was used to stabilize triplexes.  As a result of five substitutions of native nucleic 
bases by α-L-LNA in the homopyrimidine sequence possessing X, enhancement in thermal 
stability and fluorescent quantum yield was observed at pH 6.0 and 5.0 upon parallel triplex 
formation.  This oligonucleotide had very low fluorescence signal as single stranded probe 
and marginal changes in fluorescence were observed upon formation of mismatched 
triplexes, in which thymidine X was not matching with bases of dsDNAs. The latter means 
that fluorescence discrimination between homopurine dsDNA stretches and sequences with 
single base pair inversion is feasible.  Moreover single mismatched triplexes showed an 
almost unchanged thermal stability, but with a high degree of quenching, which means that 
specific detection of matched dsDNA is possible. Upon binding to dsDNA at pH 6.0, a very 
specific 50-fold increase of the fluorescence signal was observed that was much stronger 
than that for antiparallel duplex formed by the same probe.  However, at pH 7.2 a lower 
increase in fluorescence in combination with a shift to a longer wavelength, known as 
exciplex, was observed.  This feature allows using that kind of probe to detect species of 
dsDNA in an environment of tumor cells, which are known to overproduce acids and have 
lower pH values than normal cells. 
For the first time, a pyrene labelled oligonucleotide probe was developed that explores the 
increase of fluorescence signal to discriminate between dsDNA over ssDNAs.  This is a 
promising platform for further development of fluorescent probes, which can bind a 
sequence selectively to dsDNA without prior denaturation of the target and give a positive 
signal upon hybridization.  A perspective for such probes is their use in fluorescence in vivo 
hybridization under vital conditions and in living cells. 
 
7.2.9  Experimental section 
General Synthesis Procedures 
NMR spectra were recorded on a Varian Gemini 2000 spectrometer at 300 MHz for 1H using 
TMS (δ: 0.00) as an internal standard and at 75 MHz for 13C using CDCl3 (δ: 77.0) or DMSO 
(δ: 39.44) as an internal standard.  Accurate ion mass determinations of the synthesized 
compounds were performed using the 4.7 T Ultima Fourier transform (FT) mass 
spectrometer (Ion Spec, Irvine, CA).  The [M + Na]+ ions were peak matched using ions 
derived from the 2,5-dihydroxybenzoic acid matrix.  MALDI-TOF mass spectra of isolated 
oligodeoxynucleotides (ONs) were determined on a Voyager Elite biospectrometry research 
station (PerSeptive Biosystems).  Thin-layer chromatography (TLC) analyses were carried 
out with use of TLC-plates 60 F254 purchased from Merck and were visualized in UV light 
(254 nm).  The silica gel (0.040-0.063 mm) used for column chromatography was purchased 
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from Merck.  Solvents used for column chromatography were distilled prior to use, while 
reagents were used as purchased. 
 
 
1-{3-[(4-(pyren-1-yl)-1H-1,2,3-triazol-1-yl)methylene]-3-deoxy-β-D-
ribofuranosyl}thymine (7.1) 
To a solution of compound 4.26 (420 mg, 1.41 mmol) in 8 mL of a DMF/H2O 19:1 mixture in 
a microwave tube, freshly prepared 1M aq. CuSO4 (283 µM, 0.28 mmol) was added.  The 
solution was bubbled with Ar for 1 minute.  Afterwards, a freshly prepared aqueous sodium 
ascorbate solution (424 µM, 0.42 mmol) and 1-ethynylpyrene (480 mg, 2.12 mmol, dissolved 
in 8 mL DMF/ H2O 19:1) were added.  The mixture was bubbled again with Ar for 3 minutes.  
The resulting mixture in a sealed microwave tube was placed in a microwave synthesiser 
Emrys Creator.  The heating temperature was set to 125 °C, with a 30 s premixing time.  
The reaction mixture was irradiated for 15 min followed by N2 cooling to 40 °C.  Water was 
added and the mixture was kept at 6 °C during 5 h for complete precipitation of the triazol 
and unreacted alkyn.  The precipitate was filtered off and washed with water to remove all 
catalysts.  The solid on the filter was washed with methanol to dissolve the triazol.  The 
collected organic phase was evaporated to dryness and the residue was purified by silica gel 
column chromatography (CH2Cl2/MeOH 95:5) to yield the pure triazol 7.1 (583 mg, 79%). 
 
 
1H NMR (300 MHz, DMSO): δ 1.79 (3H, s, 5-CH3), 2.96 (1H, m, H-3’), 3.51 
(1H, d, J = 12.3 Hz, H-5a’), 3.81 (1H, d, J = 12.6 Hz, H-5b’), 4.19 (1H, m, H-
4’), 4.32 (1H, m, H-2’), 4.67 (1H, dd, J = 6.0 and 14.1 Hz, H-6a’), 4.81 (1H, 
dd, J = 7.5 and 14.1 Hz, H-6b’), 5.33 (1H, br s, 5’-OH), 5.78 (1H, br s, 2’-OH), 
6.24 (1H, d, J = 5.1 Hz, H-1’), 8.04-8.41 (9H, m, pyrene-H and H-6), 8.77 
(1H, s, triazol-H), 8.91 (1H, d, J = 6.3 Hz, pyrene-H), 11.31 (1H, br s, NH). 
 
13C NMR (75 MHz, CDCl3): δ 12.24 (5-CH3), 41.17 (C-3’), 46.10 (C-6’), 60.12 
(C-5’), 74.80 (C-2’), 82.77 (C-4’), 90.87 (C-1’), 108.30 (C-5), 123.86, 124.24, 
124.89, 125.04, 125.10, 125.38, 125.46, 126.41, 127.01, 127.27, 127.43, 
127.61, 127.92, 130.31, 130.49, 130.87 (pyrene and triazol C-5), 136.14 (C-6), 146.03 (triazol C-4), 
150.39 (C-2), 163.80 (C-4). 
 
Exact mass (ESI-MS) for C29H25N5O5Na [M+Na]+ found, 546.1769; calcd, 546.1753. 
 
 
 
O
HO
N NH
O
O
N
N
N
OH
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1-{3-deoxy-5-O-(4,4’-dimethoxytriphenylmethyl-3-[(4-(pyren-1-yl)-1H-1,2,3-triazol-1-
yl)methylene]-β-D-ribofuranosyl}thymine (7.2) 
Compound 7.1 (530 mg, 1.01 mmol) was coevaporated three times with pyridine and 
dissolved in anhydrous pyridine (4 mL).  4,4’-Dimethoxytrityl chloride (461 mg, 1.36 mmol) 
was added under N2-atmosphere.  After 16 h, MeOH (0.5 mL) and EtOAc (20 mL) were 
added and the mixture was quenched with aqueous NaHCO3-solution (20 mL).  The water 
layer was extracted with EtOAc (2 x 20 mL).  The combined organic layers were dried over 
MgSO4, evaporated to dryness and purified by column chromatography (CH2Cl2/MeOH/ 
pyridine 97/2.5/0.5).  Compound 7.2 was obtained (760 mg, 91%) as a yellow foam. 
 
1H NMR (300 MHz, CDCl3): δ 1.42 (3H, s, 5-CH3), 3.10 (1H, m, H-3’), 3.29 
(2H, m, H-5a’ and H-5b’), 3.67 (6H, s, 2 × OCH3), 4.39 (3H, m, H-2’, H-6a’ 
and H-6b’), 4.71 (1H, m, H-4’), 5.71 (2H, m, H-1’ and 2’-OH), 6.79 (4H, d, J = 
8.7 Hz, DMT), 7.15-7.43 (10H, m, DMT and H-6), 7.72 (1H, s, triazol-H), 
7.89-8.10 (8H, m, pyrene-H), 8.61 (1H, d, J = 9.3 Hz, pyrene-H), 10.91 (1H, 
br s, NH). 
 
13C NMR (75 MHz, CDCl3): δ 12.06 (5-CH3), 42.86 (C-3’), 49.69 (C-6’), 55.11 
(OCH3), 72.57 (C-2’), 75.95 (C-5’), 82.01 (C-4’), 87.53 and 87.08 (C-1’ and 
C(Ar3)), 110.64 (C-5), 113.35, 124.93-131.28, 135.40 (pyrene, DMT and 
triazol C-5), 136.11 (C-6), 144.18 (triazol C-4), 146.55 (DMT), 150.58 (C-2), 158.70 (DMT), 164.55 (C-
4). 
 
HRMS (ESI-MS) for C50H43N5O7Na [M+Na]+ found, 848.3084; calcd, 848.3060. 
 
 
1-{2-O-[2-cyanoethoxy(diisopropylamino)phosphino]-3-deoxy-5-O-4,4’-dimethoxy-
triphenylmethyl-3-[(4-(pyren-1-yl)-1H-1,2,3-triazol-1-yl)methylene]-β-D-
ribofuranosyl}thymine (7.3) 
Compound 7.2 (510 mg, 0.62 mmol) was dissolved under N2-atmosphere in anhydrous 
CH2Cl2 (10 mL).  N,N-Diisopropylammonium tetrazolide (159 mg, 0.93 mmol) was added 
followed by the dropwise addition of 2-cyanoethyl tetraisopropylphosphordiamidite (223 mg, 
0.74 mmol) under external cooling with an ice-water bath.  After 16h the reaction was 
quenched with H2O (6 mL).  The layers were separated and the organic phase was washed 
with H2O (6 mL).  The water layers were washed with CH2Cl2 and the resulting organic 
phases were combined, dried over MgSO4 and filtered.  The solvent was removed under 
reduced pressure, and the residue was purified using silica gel column chromatography 
(CHCl3/MeOH/pyridine 99/0.5/0.5).  The purified compound 7.3 (412 mg, 65%) was obtained 
as a foam and was further used in DNA synthesis. 
O
DMTO
N NH
O
O
N
N
N
OH
  A f luorescent 3 ’-branched thymidine der ivat ive in o l igonuc leot ide synthesis 
  215 
 
 
 
31P NMR (CDCl3) δ 148.40, 150.34 in a ratio of 2:3. 
 
Exact mass (ESI-MS) for C59H61N7O8P [M+H]+ found, 1026.4338; calcd, 
1026.4318. 
 
 
 
 
 
Synthesis and Purification of Modified Oligonucleotides. 
DMT-on oligodeoxynucleotides were synthesized in a 0.2 µmol scale on CPG supports using 
Expedite Nucleic Acid Synthesis System Model 8909 (Applied Biosystems).  Standard 
procedures were used for phosphoramidite 7.3 with 4,5-dicyanoimidazole as an activator 
except for extended coupling time (10 min) and an increased deprotection time (100 s), 
resulting in step-wise coupling yields of 98% for monomer 7.3 and >99% for unmodified DNA 
phosphoramidites. 
The obtained DMT-on oligonucleotides bound to CPG-supports were treated with 32% 
aqueous ammonia (1.3 mL) at room temperature for 2 hours and then at 55 °C overnight.  
Purification of the 5’-O-DMT-on ONs was carried out by using a reverse-phase 
semipreparative HPLC on a Waters Xterra MS C18 column.  DMT groups were cleaved by 
treatment with 80% aq. AcOH (100 µL) for 20 minutes, followed by addition of H2O (100 µL) 
and 3 M aq NaOAc (50 µL).  The ONs were precipitated from 99% EtOH (600 µL).  The 
precipitate was washed with chilled 70% aqueous ethanol.  The purity of the obtained ONs 
was checked by ion-exchange chromatography on a LaChrom system (Merck Hitachi) using 
a GenPak-Fax column (Waters) and it was found to be >82% for all ONs. 
 
O
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N NH
O
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Fluorescence Measurements 
Fluorescence measurements were performed on a Perkin-Elmer luminescence spectrometer 
LS-55 fitted with a Julabo F25 temperature controller using quartz optical cells with a 
pathlength of 1.0 cm.  The spectra were recorded at 10 °C in the same buffer as for Tm 
studies using a 1.0 mM concentration of each ONs.  In all cases, absorption in the range 
from 360 to 600 nm of the solutions did not exceed 0.10, in order to avoid inner-filter effects, 
and was never less than 0.01, to avoid uncertainties.  Corrections were made for solvent 
background. 
Steady-state fluorescence emission spectra (360-600 nm) were obtained as an average of 
five scans using an excitation wavelength of 350 nm, excitation slit of 4.0 nm, emission slit of 
2.5 nm or 0.0 nm and scan speed of 120 nm/min.  The fluorescence quantum yield (ΦF) of 
anthracene (ANT) in cyclohexane in this experimental setting was measured to be 0.32 
relative to 9,10-diphenylanthracene in cyclohexane (ΦF =1.00), which is in excellent 
agreement with the reported value of 0.36.222  Emission quantum yields of pyrene-labeled 
ONs ΦF(ON) were determined according to following calculations: 223 
ΦF(ON) = ΦF(ANT) * [A (ON)/A350(ON)] * [1/α(ANT)] * [n(H2O)2/ n(Cyclohexane)2] 
In this equation ΦF(ANT) is the cross-calibrated value for the fluorescence emission quantum 
yield of anthracene in cyclohexane, A (ON) is the area of the fluorescence emission spectra 
Table 7.5 MALDI-MS of synthesized ONs 
Oligonucleotides  
m/z 
[M+H]+  
Calcd (Da) 
m/z 
[M+H]+ 
Found 
(Da) 
 
Purity 
ON 2 3'-TTT TTT CTX TC CCC-5' 4403.2 4404.5 100% 
ON 3 3'-TTT TTT CXX TC CCC-5' 4684.5 4684.8 100% 
ON 4 3'-TTT TTT CXX XC CCC-5' 4965.8 4966.8 100% 
ON 5 3'-TTT TXT CTT TC CCC-5' 4403.2 4404.3 100% 
ON 6 3'-TTT TTT CXT XC CCC-5' 4684.5 4682.5 100% 
ON 7 3'-TTT TXT CXT TC CCC-5' 4684.5 4683.0 100% 
ON 8 3'-TTT TTT CTpX TC CCC-5' 4870.6 4871.1 100% 
ON 9 3'-TTT TTT CTXp TC CCC-5' 4870.6 4871.1 100% 
ON 10 3' TTLT TTLT CLTX TCLC CLC 4585.2 4584.9 100% 
ON 12 3'-CAC TXT ACG-5' 2955.2 2953.6 100% 
ON 13 3'-CAC TXX ACG-5' 3236.5 3236.9 100% 
ON 14 3'-CAC XXX ACG-5' 3517.8 3518.0 82% 
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of the sample from 360 to 600 nm, A350 (ON) is the absorbance of the sample at the 
excitation wavelength (350 nm), α(ANT) is the slope of the fluorescence emission area vs. 
A350 calibration curve for ANT, and n(H2O) and n(Cyclohexane) are the refractive indexes 
of water (1.3328) and cyclohexane (1,4266), respectively.   
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Figure 7.15 Area vs. A350 curves of anthracene in cyclohexane for calibration of emission 
quantum yield measurement (upper panel) and of triplex ON10/D1 in thermal denaturation 
buffer (lower panel) for determination of emission quantum yield. ‘Area’ refers to the area 
under the emission spectra (360-600 nm) using an excitation wavelength of 350 nm. 
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Melting Temperature Measurements 
Melting profiles were measured on a Perkin-Elmer UV-vis spectrometer Lambda 35 fitted 
with a PTP-6 temperature programmer.  The triplexes were formed by first mixing the two 
strands of the Watson–Crick duplex, each at a concentration of 1.0 µM, followed by the 
addition of the TFO at a concentration of 1.5 µM in the corresponding buffer solution.  The 
solution was heated to 80 °C for 5 min and afterward cooled to 15 °C and kept at this 
temperature for 30 minutes.  The duplexes were formed by mixing the two strands, each at a 
concentration of 1.0 mM in the corresponding buffer solution followed by heating to 80 °C for 
5 minutes and then cooling to room temperature.  The absorbance of both triplexes and 
duplexes was measured at 260 nm from 5 to 70 °C with a heating rate of 1.0 °C/min.  Lower 
heating rate (0.5 °C/min) resulted in the same melting curves.  Control experiments were 
also performed at 343 nm for ON2.  The melting temperatures (Tm, °C) were determined as 
the maximum of the first derivative plots of the melting curves.  All melting temperatures are 
within the uncertainty + 0.5 °C as determined by repetitive experiments. 
 
Molecular Modelling 
Molecular modelling experiments were performed with Maestro v7.5 from Schrödinger.  All 
calculations were conducted with AMBER* force field and the GB/SA water model.  The 
dynamics simulations were performed with stochastic dynamics, a SHAKE algoritm to 
constrain bonds to hydrogen, time step 1.5 fs and simulation temperature of 300 K.  
Simulation for 0.5 ns with an equilibration time of 150 ps generated 250 structures, which all 
were minimized using the PRCG method with convergence threshold of 0.05 kJ/mol.  The 
minimized structures were examined with Xcluster from Schrödinger, and representative 
low-energy structures were selected.  The starting structures were generated with Insight II 
v97.2 from MSI, followed by incorporation of the modified nucleoside building block.   
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